<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2402210549
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rozitta
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        44.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAR ALDAWA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Rozitta</strong><sup>&Ograve;</sup> belongs to a group of medicines called statins.</p><p dir="ltr">You have been prescribed <strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>because:</p><ul dir="ltr"><li>You have a high cholesterol level. This means you are at risk from a heart attack or stroke.</li></ul><p dir="ltr"><strong>Rozitta</strong><sup>&reg;</sup> is used in adults, adolescents and children 6 years or older to treat high cholesterol.</p><p dir="ltr">You have been advised to take a statin, because changing your diet and taking more exercise were not enough to correct your cholesterol levels. You should continue with your cholesterol-lowering diet and exercise while you are taking <strong>Rozitta</strong><sup>&Ograve;</sup>.</p><p dir="ltr">Or</p><ul dir="ltr"><li>You have other factors that increase your risk of having a heart attack, stroke or related health problems.</li></ul><p dir="ltr">Heart attack, stroke and other problems can be caused by a disease called atherosclerosis. Atherosclerosis is due to buildup of fatty deposits in your arteries.</p><p dir="ltr"><strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>is used to correct the levels of fatty substances in the blood called lipids, the most common of which is cholesterol.</p><p dir="ltr">There are different types of cholesterol found in the blood &ndash; &lsquo;bad&rsquo; cholesterol (LDL-C) and &lsquo;good&rsquo; cholesterol (HDL-C).</p><ul dir="ltr"><li><strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>can reduce the &lsquo;bad&rsquo; cholesterol and increase the &lsquo;good&rsquo; cholesterol.</li></ul><ul dir="ltr"><li>It works by helping to block your body&rsquo;s production of &lsquo;bad&rsquo; cholesterol. It also improves your body&rsquo;s ability to remove it from your blood.</li></ul><p dir="ltr">For most people, high cholesterol does not affect the way they feel because it does not produce any symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your blood vessels causing them to narrow.</p><p dir="ltr">Sometimes, these narrowed blood vessels can get blocked which can cut off the blood supply to the heart or brain leading to a heart attack or a stroke. By lowering your cholesterol levels, you can reduce your risk of having a heart attack, a stroke or related health problems.</p><p dir="ltr">You need to keep taking <strong>Rozitta</strong><sup>&Ograve;</sup>, even if it has got your cholesterol to the right level, because it prevents your cholesterol levels from creeping up again<strong> </strong>and causing buildup of fatty deposits. However, you should stop if your doctor tells you to do so, or you have become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Rozitta</strong><sup>&Ograve;</sup><strong>:</strong></p><ul dir="ltr"><li>If you have ever had an allergic reaction to <strong>Rozitta</strong><sup>&Ograve;</sup>, or to any of its ingredients.</li><li>If you are pregnant or breast-feeding. If you become pregnant while taking <strong>Rozitta</strong><sup>&Ograve;</sup> stop taking it immediately and tell your doctor. Women should avoid becoming pregnant while taking <strong>Rozitta</strong><sup>&Ograve;</sup><strong> </strong>by using suitable contraception.</li><li>If you have liver disease.</li><li>If you have severe kidney problems.</li><li>If you have repeated or unexplained muscle aches or pains.</li><li>If you take a drug called ciclosporin (used, for example, after organ transplants)</li></ul><p dir="ltr">If any of the above applies to you (or you are in doubt), please go back and see your doctor.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>In addition, do not take </strong><strong>Rozitta</strong><sup>&Ograve;</sup><strong> </strong><strong>40 mg (the highest dose): </strong></p><ul dir="ltr"><li>If you have moderate kidney problems (if in doubt, please ask your doctor).</li><li>If your thyroid gland is not working properly.</li><li>If you have had any repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines.</li><li>If you regularly drink large amounts of alcohol.</li><li>If you are of Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</li><li>If you take other medicines called fibrates to lower your cholesterol.</li></ul><p dir="ltr">If any of the above applies to you (or you are in doubt), please go back and see your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Take special care with Rozitta</strong><sup>&Ograve;</sup></p><p dir="ltr">Talk to your doctor or pharmacist before taking <strong>Rozitta</strong><sup>&Ograve;</sup>.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have problems with your kidneys.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have problems with your liver.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had repeated or unexplained muscle aches or pains, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines. Tell your doctor immediately if you have unexplained muscle aches or pains especially if you feel unwell or have a fever. Also tell your doctor or pharmacist if you have a muscle weakness that is constant.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you regularly drink large amounts of alcohol.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your thyroid gland is not working properly.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take other medicines called fibrates to lower your cholesterol. Please read this leaflet carefully, even if you have taken other medicines for high cholesterol before.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take medicines used to treat the HIV infection e.g. ritonavir with lopinavir and/or atazanavir.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking or have taken in the last 7 days a medicine called fusidic acid (a medicine for bacterial infection), orally or by injection. The combination of fusidic acid and Rozitta<sup>&reg;</sup> can lead to serious muscle problems (rhabdomyolysis).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are over 70 (as your doctor needs to choose the right start dose of <strong>Rozitta</strong><sup>&Ograve;</sup><strong> </strong>to suit you)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe respiratory failure.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are of Asian origin &ndash; that is Japanese, Chinese, Filipino, Vietnamese, Korean and Indian. Your doctor needs to choose the right start dose of <strong>Rozitta</strong><sup>&Ograve;</sup><strong> </strong>to suit you. &nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">If any of the above applies to you (or if you are not sure):</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take<strong> Rozitta</strong><sup>&Ograve;</sup><strong> </strong>40 mg (the highest dose) and check with your doctor or pharmacist before you actually start taking any dose of<strong> Rozitta</strong><sup>&Ograve;</sup><strong>. </strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">In a small number of people, statins can affect the liver. This is identified by a simple test which looks for increased levels of liver enzymes in the blood. For this reason, your doctor will usually carry out this blood test (liver function test) before and during treatment with <strong>Rozitta</strong><sup>&Ograve;</sup>.</p><p dir="ltr">While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Children and adolescents: </u></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the patient is under 6 years old: <strong>Rozitta</strong><sup>&Ograve;</sup><strong> </strong>should not be given to children younger than 6 years.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the patient is below 18 years of age: <strong>Rozitta</strong><sup>&Ograve;</sup><strong> </strong>40 mg tablet is not suitable for use in children and adolescents below 18 years of age.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Taking other medicines, herbal or dietary supplements</strong></p><p dir="ltr">Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p dir="ltr">Tell your doctor if you are taking any of the following:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin (used for example, after organ transplants)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;warfarin or clopidogrel (or any other drug used for thinning the blood)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;fibrates (such as gemfibrozil, fenofibrate) or any other medicine used to lower cholesterol (such as ezetimibe)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;indigestion remedies (used to neutralise acid in your stomach)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;erythromycin (an antibiotic)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;an oral contraceptive (the pill), hormone replacement therapy</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fucidic acid (an antibiotic)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-viral medicines such as ritonavir with lopinavir and/or atazanavir or simeprevir (used to treat infections, including HIV or hepatitis C infection).</p><p dir="ltr">The effects of these medicines could be changed by <strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>or they could change the effects of <strong>Rozitta</strong><sup>&Ograve;</sup>.</p><p dir="ltr">If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart <strong>Rozitta</strong><sup>&reg;</sup>. Taking <strong>Rozitta</strong><sup>&reg;</sup> with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breastfeeding </strong></p><p dir="ltr">Do not take <strong>Rozitta</strong><sup>&Ograve;</sup> if you are pregnant or breast-feeding. If you become pregnant while taking <strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>stop taking it immediately<strong> </strong>and tell your doctor. Women should avoid becoming pregnant while taking <strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>by using suitable contraception.</p><p dir="ltr">Ask your doctor or pharmacist for advice before taking any medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Driving and using machines<u> </u></strong></p><p dir="ltr">Most people can drive a car and operate machinery while using <strong>Rozitta</strong><strong><sup>&Ograve;</sup></strong>&ndash; it will not affect their ability. However, some people feel dizzy during treatment with <strong>Rozitta</strong><strong><sup>&Ograve;</sup></strong>. If you feel dizzy, consult your doctor before attempting to drive or use machines.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Important information about some of the ingredients of </strong><strong>Rozitta</strong><strong><sup>&Ograve;</sup></strong><strong> </strong></p><p dir="ltr"><strong>Rozitta</strong><strong><sup>&Ograve;</sup></strong> tablets contain lactose, if you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr"><u>Usual doses in adults </u></p><p dir="ltr"><strong>If you are taking Rozitta</strong><sup>&Ograve;</sup><sup> </sup><strong>for high cholesterol: </strong></p><p dir="ltr"><strong><em>Starting dose </em></strong></p><p dir="ltr">Your treatment with rosuvastatin<sup> </sup>must start with the 5 mg or the 10 mg dose, even if you have taken a higher dose of a different statin before. The choice of your start dose will depend upon:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your cholesterol level.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The level of risk you have of experiencing a heart attack or stroke.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weather you have a factor that may make you more sensitive to possible side effects.</p><p dir="ltr">Please check with your doctor or pharmacist which start dose of <strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>will best suit you.</p><p dir="ltr">Your doctor may decide to give you the lowest dose of rosuvastatin (5 mg) if:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are of Asian origin<strong> </strong>(Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are over 70 years<strong> </strong>of age.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have moderate kidney problems.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are at risk of muscle aches and pains (myopathy).</p><p dir="ltr"><strong><em>Increasing the dose and maximum daily dose </em></strong></p><p dir="ltr">Your doctor may decide to increase your dose. This is so that you are taking the amount of rosuvastatin<sup> </sup>that is right for you. If you started with a 5 mg rosuvastatin, your doctor may decide to double this to 10 mg, then 20 mg and then 40 mg if necessary. If you started on 10 mg, your doctor may decide to double this to 20 mg and then 40 mg if necessary. There will be a gap of four weeks between every dose adjustment.</p><p dir="ltr">The maximum daily dose of <strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>is 40 mg. It is only for patients with high cholesterol levels and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough with 20 mg.</p><p dir="ltr"><strong>If you are taking Rozitta</strong><sup>&Ograve;</sup><sup> </sup><strong>to reduce your risk of having a heart attack, stroke or related health problems: </strong></p><p dir="ltr">The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if you have any of the factors mentioned above.</p><p dir="ltr"><u>Use in children and adolescents aged </u><u>6</u><u>-17 years </u></p><p dir="ltr">The dose range in children and adolescents aged 6 to 17 years is 5 to 20 mg once daily. The usual start dose is 5 mg per day, and your doctor may gradually increase your dose to find the right amount of <strong>Rozitta</strong><sup>&reg;</sup> for you. The maximum daily dose of <strong>Rozitta</strong><sup>&reg;</sup> is 10 or 20 mg for children aged 6 to 17 years depending on your underlying condition being treated. Take your dose once a day. <strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>40 mg<strong> </strong>tablet should not<strong> </strong>be used by children.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Taking your tablets </strong></p><p dir="ltr">Swallow each tablet whole with a drink of water.</p><p dir="ltr">Take<strong> Rozitta</strong><sup>&Ograve;</sup><sup> </sup>once daily. You can take it at any time of the day with or without food.</p><p dir="ltr">Try to take your tablet at the same time every day to help you to remember it.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Regular cholesterol checks </strong></p><p dir="ltr">It is important to go back to your doctor for regular cholesterol checks, to make sure your cholesterol has reached and is staying at the correct level.</p><p dir="ltr">Your doctor may decide to increase your dose so that you are taking the amount of <strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>that is right for you.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you take more Rozitta</strong><sup>&Ograve;</sup><strong> than you should </strong></p><p dir="ltr">Contact your doctor or nearest hospital for advice.</p><p dir="ltr">If you go into hospital or receive treatment for another condition, tell the medical staff that you&rsquo;re taking <strong>Rozitta</strong><sup>&Ograve;</sup>.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you forget to take Rozitta</strong><sup>&Ograve;</sup><strong> </strong></p><p dir="ltr">Don&rsquo;t worry; just take your next scheduled dose at the correct time. Do not take a double dose to make up for a forgotten dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you stop taking Rozitta</strong><sup>&Ograve;</sup><strong> </strong></p><p dir="ltr">Talk to your doctor if you want to stop taking <strong>Rozitta</strong><sup>&Ograve;</sup>. Your cholesterol levels might increase again if you stop taking <strong>Rozitta</strong><sup>&Ograve;</sup>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, <strong>Rozitta</strong><sup>&Ograve;</sup> can cause side effects, although not everybody gets them.</p><p dir="ltr">It is important that you are aware of what these side effects may be. They are usually mild and disappear after a short time.</p><p dir="ltr"><strong>Stop </strong>taking <strong>Rozitta</strong><sup>&Ograve;</sup><sup> </sup>and seek medical help immediately<strong> </strong>if you have any of the following allergic reactions:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue and/or throat, which may cause difficulty in swallowing</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe itching of the skin (with raised lumps).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Also,<strong> stop </strong>taking<strong> </strong><strong>Rozitta</strong><sup>&Ograve;</sup><strong> </strong>and talk to your doctor immediately if you have any unusual aches or pains in your muscles which go on for longer than you might expect. Muscle symptoms are more common in children and adolescents than in adults. As with other statins, a very small number of people have experienced unpleasant muscle effects and rarely these have gone on to become a potentially life threatening muscle damage known as <em>rhabdomyolysis</em>.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><em>Common possible side effects (these may affect between 1 in 10 and 1 in 100 patients): </em></strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling weak</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your <strong>Rozitta</strong><sup>&Ograve;</sup> tablets (only <strong>Rozitta</strong><sup>&Ograve;</sup> 40 mg)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.</p><p dir="ltr"><strong><em>Uncommon possible side effects (these may affect between 1 in 100 and 1 in 1,000 patients): </em></strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itching or other skin reactions</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your rosuvastatin (only rosuvastatin 5mg, 10 mg and 20 mg).</p><p dir="ltr"><strong><em>Rare possible side effects (these may affect between 1 in 1,000 and 1 in 10,000 patients): </em></strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction &ndash; signs include swelling of the face, lips, tongue and/or throat, difficulty in swallowing and breathing, a severe itching of the skin (with raised lumps). If you think you are having an allergic reaction, then stop taking <strong>Rozitta</strong><sup>&Ograve;</sup><strong> </strong>and seek medical help immediately</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle damage in adults &ndash; as a precaution, stop<strong> </strong>taking<strong> </strong><strong>Rozitta</strong><sup>&Ograve;</sup> and talk to your doctor immediately if you have any unusual aches or pains<strong> </strong>in your muscles which go on for longer than expected</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A severe stomach pain (inflamed pancreas)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in liver enzymes in the blood</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding or bruising more easily than normal due to low level of blood platelets.</p><p dir="ltr"><strong><em>Very rare possible side effects (these may affect less than 1 in 10,000 patients): </em></strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice (yellowing of the skin and eyes)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis (an inflamed liver)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Traces of blood in your urine</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to the nerves of your legs and arms (such as numbness)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Memory loss</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast enlargement in men (gynaecomastia)</p><p dir="ltr"><strong><em>Side effects of unknown frequency may include: </em></strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea (loose stools)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome (serious blistering condition of the skin, mouth, eyes and genitals)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Edema (swelling)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep disturbances, including insomnia and nightmares</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual difficulties</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing problems, including persistent cough and / or shortness of breath or fever</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tendon injury</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness that is constant</p><p dir="ltr">If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg; C.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use <strong>Rozitta</strong><sup>&Ograve;</sup> after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance in<strong> Rozitta</strong><sup>&Ograve;</sup> is rosuvastatin. <strong>Rozitta</strong><sup>&Ograve;</sup> film coated tablets contain rosuvastatin calcium equivalent to 10 mg, 20 mg or 40 mg of rosuvastatin.</p><p dir="ltr">The other ingredients are: Lactose, microcrystalline cellulose, crospovidone, tribasic calcium phosphate, magnesium stearate, red iron oxide (E172), hypromellose, triacetin, titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rozitta 10 mg film coated tablets: Pink round biconvex film coated tablets, coded with C14 on one side and plain on the other side.
Rozitta 20 mg film coated tablet: Pink round biconvex film coated tablets coded with C113 on one side and plain on the other side. 
Rozitta 40 mg film coated tablets: Pink oval biconvex film coated tablets coded with C126 on one side and plain on the other side. 

Rozitta10, 20 and 40 are available in aluminum strips in packs of 30 (3 blisters of 10).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Dar Al Dawa Development &amp; Investment Co Ltd (Na&rsquo;ur &ndash; Jordan).</p><p dir="ltr">Tel. (+962 6) 57 27 132</p><p dir="ltr">Fax. (+962 6) 57 27 776</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي <strong>روزيتا</strong> إلى مجموعة الأدوية تسمى الستاتينات.</p><p dir="RTL">يصف لك الطبيب <strong>روزيتا </strong>اذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مستويات مرتفعة من الكوليستيرول. وهذا يجعلك عرضة لخطر الاصابة بنوبة قلبية او سكتة دماغية.</p><p dir="RTL">يستخدم <strong>روزيتا</strong> للبالغين، المراهقين والاطفال الذين تزيد اعمارهم عن 6 سنوات لعلاج ارتفاع كوليستيرول.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوصى بتناول الستاتينات عند عدم نجاح تغيير الحمية الغذائية و ممارسة الرياضة خفض مستويات الكوليستيرول لديك. يجب أن تحافظ على حمية غذائية منخفضة الكوليستيرول وممارسة الرياضة خلال فترة العلاج ب <strong>روزيتا</strong>.</p><p dir="RTL">أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك عوامل اخرى قد تزيد من خطر الاصابة بنوبة قلبية، سكتة دماغية أو أي مشاكل صحية متعلقة بذلك.</p><p dir="RTL">قد يؤدي مرض تصلب الشرايين الى حدوث نوبة قلبية، سكتة دماغية و مشاكل اخرى.</p><p dir="RTL">ينتج مرض تصلب الشرايين من تراكم الترسبات الدهنية في الشرايين.</p><p dir="RTL">يستخدم<strong> روزيتا </strong>لخفض مستويات مواد دهنية في الدم تسمى الدهنيات، و يعد الكوليستيرول اكثرها شيوعا.</p><p dir="RTL">يوجد انواع مختلفة من الكوليستيرول في الدم- الكوليستيرول &quot;السيء&quot; (البروتين الدهني منخفض الكثافة) والكوليستيرول &quot;الجيد&quot; ( البروتين الدهني مرتفع الكثافة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعمل <strong>روزيتا </strong>على خفض<strong> </strong>الكوليستيرول &quot;السيء&quot; و زيادة الكوليستيرول &quot;الجيد&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يساعد <strong>روزيتا </strong>على منع جسمك من إنتاج الكوليستيرول &quot;السيء&quot;. كما يزيد من قدرة الجسم على إزالته من الدم.</p><p dir="RTL">في معظم الناس، لا يؤثر الكوليستيرول المرتفع على الحالة التي يشعرون بها لأنه لا ينتج عنه أي أعراض. على الرغم من ذلك، اذا بقي بدون علاج، فإن الترسبات الدهنية قد تتراكم على جدران الاوعية الدموية مما يؤدي الى تضيقها.</p><p dir="RTL">في بعض الاحيان، قد يتم سد هذه الاوعية الدموية المتضيقة والذي قد يؤدي الى قطع تدفق الدم الى القلب او الدماغ مما يؤدي الى نوبة قلبية او سكتة دماغية. قد يتم تقليل خطر حدوث نوبة قلبية، سكتة دماغية أو أي مشاكل صحية مرتبطة بذلك عن طريق خفض مستويات الكوليستيرول.</p><p dir="RTL">يجب عليك أن تستمر في تناول <strong>روزيتا، </strong>حتى في حال عادت مستويات الكوليستيرول لديك الى مستواها الطبيعي، لأن ذلك يمنع مستويات الكوليستيرول من الارتفاع مرة اخرى والتسبب بتراكم الترسبات الدهنية. على الرغم من ذلك، عليك ان تتوقف عن تناول الدواء في حال نصحك الطبيب بذلك او اذا اصبحت حامل.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع</strong><strong> </strong><strong>استعمال روزيتا: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق حدوث تحسس لديك عند تناولك دواء <strong>روزيتا</strong> او اي من مكوناته.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حامل أو مرضع. اذا اصبحتِ حامل أثناء تناول <strong>روزيتا</strong>، توقفي عن تناوله على الفور وأخبري طبيبك بذلك. ينبغي على النساء الامتناع عن الحمل أثناء تناول <strong>روزيتا</strong> عن طريق استخدام وسائل منع حمل مناسبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تعاني من مشاكل شديدة في الكلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق حدوث آلام في العضلات متكررة أو غير معروفة السبب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تتناول دواء يدعى سيكلوسبورين ( يستخدم، على سبيل المثال، بعد زراعة الاعضاء)</p><p dir="RTL">اذا انطبق عليك اي من الحالات السابقة ( او في حال الشك)، يجب عليك مراجعة الطبيب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بالاضافة الى ذلك، لا تتناول </strong><strong>روزيتا 40 ملغم ( الجرعة القصوى):</strong><strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تعاني من مشاكل متوسطة في الكلى ( إسأل الطبيب اذا لم تكن متأكدا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كانت الغدة الدرقية لا تعمل بشكل سليم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق حدوث آلام في العضلات متكررة او غير معروفة السبب، لديك تاريخ شخصي او عائلي لحدوث مشاكل في العضلات او سبق وعانيت من مشاكل في العضلات خلال فترة العلاج بأدوية أخرى خافضة الكوليستيرول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول كميات كبيرة من الكحول بشكل منتظم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت من أصول آسيوية (اليابان، الصين، الفيليبين، فيتنام، كوريا و الهند)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى تسمى الفايبريت لخفض مستوى الكوليستيرول</p><p dir="RTL">اذا انطبق عليك اي من الحالات السابقة ( او كنت شاكا بذلك)، يجب عليك مراجعة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>استعمال روزيتا</strong></p><p dir="RTL">تحدث الى الطبيب او الصيدلي قبل تناول <strong>روزيتا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تعاني من مشاكل في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق حدوث آلام في العضلات متكررة او غير معروفة السبب، لديك تاريخ شخصي او عائلي في حدوث مشاكل في العضلات او سبق وعانيت من مشاكل في العضلات خلال فترة العلاج بأدوية أخرى خافضة للكوليستيرول. أخبر طبيبك على الفور في حال عانيت من آلام في العضلات متكررة او غير معروفة السبب خاصة اذا كنت تشعر بتوعك او كان لديك حمى. أخبر طبيبك او الصيدلي أيضا اذا كان لديك ضعف في العضلات على نحو ثابت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول كميات كبيرة من الكحول بشكل منتظم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كانت الغدة الدرقية لا تعمل بشكل سليم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى تسمى الفايبريت لخفض مستوى الكوليستيرول. يرجى قراءة هذه النشرة بحذر، حتى لو كنت تتناول ادوية اخرى من قبل لخفض الكوليستيرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تتناول ادوية لعلاج العدوى بفيروس نقص المناعة البشرية مثل ريتونافير مع لوبينافير و / او اتازانافير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تتناول أو تناولت في آخر سبعة أيام مضت دواء يسمى حمض الفوسيديك (دواء يستخدم للعدوى البكتيرية)، عن طريق الفم أو الحقن. قد يؤدي المزيج من حمض الفوسيديك و<strong>روزيتا</strong> الى مشاكل خطيرة في العضلات (انحلال الريبدات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك يزيد عن 70 عام (لأن الطبيب يحتاج أن يختار الجرعة الابتدائية الصحيحة التي تناسبك من <strong>روزيتا</strong>).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تعاني من قصور شديد في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت من أصول آسيوية - اليابان، الصين، الفيليبين، فيتنام، كوريا و الهند. يحتاج الطبيب أن يختار الجرعة الابتدائية الصحيحة التي تناسبك من <strong>روزيتا</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اذا انطبقت عليك اي من الحالات السابقة ( أو لم تكن متأكدا):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول <strong>روزيتا</strong> 40 ملغم ( الجرعة القصوى) و تحقق من الطبيب او الصيدلي قبل بدء تناول اي جرعة من <strong>روزيتا</strong>.</p><p dir="RTL">في عدد قليل من الناس، قد تؤثر الستاتينات على الكبد. يتم تحديد ذلك عن طريق فحص بسيط للكشف عن ارتفاع مستويات انزيمات الكبد في الدم. لهذا السبب، قد يطلب منك الطبيب القيام بهذا الفحص ( فحص وظائف الكبد) قبل و خلال العلاج ب <strong>روزيتا.</strong></p><p dir="RTL">سيقوم طبيبك بمراقبة حالتك بحذر أثناء تناول هذا الدواء إذا كنت تعاني من مرض السكري أو وجود خطر لحدوث مرض السكري لديك. ستكون عرضة لحدوث مرض السكري في حال كنت تعاني من إرتفاع السكر أو الدهون في الدم، زيادة الوزن و إرتفاع ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الاطفال و اليافعين: </u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كان المريض دون سن 6 أعوام: لا ينبغي استخدام <strong>روزيتا </strong>في الاطفال دون سن 6 أعوام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كان المريض دون سن 18 سنة: إن <strong>روزيتا</strong> 40 ملغم غير مناسب للاستخدام في الاطفال و اليافعين دون سن 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات</strong><strong> </strong><strong>الدوائية</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أخذ</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>المستحضر</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أعشاب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مكملات</strong><strong> </strong><strong>غذائية</strong></p><p dir="RTL">يرجى إخبار طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL">أخبر طبيبك اذا كنت تتناول أي من الادوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين ( يستخدم على سبيل المثال بعد زراعة الاعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الورفارين او الكلوبيدوجريل ( او أي ادوية أخرى تستخدم في ترقيق الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفايبريت ( مثل جيمفيبروزيل، فينوفايبريت) أو أي ادوية أخرى تستخدم في خفض الكوليستيرول (مثل ازيتيميب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ادوية عسر الهضم ( تستخدم لمعادلة الحمض في المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاريثروميسين ( مضاد حيوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية منع الحمل التي تؤخذ عن طريق الفم ( الاقراص)، العلاج بالهرمونات البديلة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض فيوسيديك (مضاد حيوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للفيروسات مثل ريتونافير مع لوبينافير و/او اتازانافير أو سيميبريفير (تستخدم لعلاج العدوى، ويتضمن فيروس نقص المناعة البشرية أو التهاب الكبد ج)</p><p dir="RTL">من الممكن أن تؤثر بعض الأدوية على تأثير <strong>روزيتا</strong> أو من الممكن أن يؤثر <strong>روزيتا</strong> عليها. &nbsp;</p><p dir="RTL">اذا كنت بحاجة الى تناول حمض فيوسيديك لعلاج عدوى بكتيرية سوف تحتاج الى التوقف عن هذا الدواء مؤقتاً. سوف يخبرك الطبيب الوقت الآمن لاعادة البدة ب <strong>روزيتا</strong>. نادراً ما يؤدي تناول <strong>روزيتا</strong> بالتزامن مع حمض فيوسيديك الى ضعف في العضلات أو طراوة أو ألم (انحلال الربيدات).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong></p><p dir="RTL">لا تتناولي<strong> روزيتا</strong><strong> </strong>إذا كنت حاملا او مرضعة. اذا اصبحتِ حامل اثناء تناول دواء <strong>روزيتا</strong><strong> </strong>توقفي عن تناوله على الفور وأخبري طبيبك بذلك. ينبغي على النساء الامتناع عن الحمل أثناء تناول <strong>روزيتا</strong> عن طريق استخدام وسائل منع حمل مناسبة.</p><p dir="RTL">إستشر طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير روزيتا على القيادة وإستخدام الآلات</strong></p><p dir="RTL">قد يقوم معظم الناس من قيادة السيارات و تشغيل الآلات اثناء تناول <strong>روزيتا</strong><strong> </strong><strong>- </strong>لا يؤثر هذا الدواء على قدرتك. على الرغم من ذلك، قد يشعر بعض الناس بالدوار اثناء العلاج ب <strong>روزيتا</strong>. استشر طبيبك قبل ان تحاول قيادة السيارات او تشغيل الآلات في حال شعرت بالدوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات روزيتا</strong></p><p dir="RTL">تحتوي أقراص <strong>روزيتا</strong><strong> </strong>على اللاكتوز، في حال أخبرك طبيبك بانك تعاني من عدم القدرة على تحمل بعض أنواع السكر, اتصل بطبيبك قبل البدء بتناول هذا المستحضر الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائما كما أخبرك الطبيب. تحقق من الطبيب او الصيدلي اذا لم تكن متأكدا.</p><p dir="RTL"><u>الجرعات الاعتيادية في البالغين</u></p><p dir="RTL"><strong>اذا كنت تتناول روزيتا لعلاج ارتفاع </strong><strong>الكوليستيرول</strong><strong>:</strong></p><p dir="RTL"><em>الجرعة الابتدائية:</em></p><p dir="RTL">يجب ان تكون الجرعة الإبتدائية من روزوڤاستاتين 5 او 10 ملغم، حتى في حال كنت تتناول جرعة أعلى من نوع آخر من الستاتينات مسبقا. يتم اختيار الجرعة الابتدائية لك اعتمادا على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستوى الكوليستيرول لديك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; درجة خطورة الاصابة بنوبة قلبية او سكتة دماغية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال كان لديك سبب يجعلك اكثر حساسية لحدوث أعراض جانبية محتملة</p><p dir="RTL">يرجى التحقق من الطبيب او الصيدلي حول الجرعة الابتدائية المناسبة لك من <strong>روزيتا</strong>.</p><p dir="RTL">قد يقرر الطبيب إعطائك الجرعة الادنى من روزوڤاستاتين ( 5 ملغم) في الحالات التالية:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>اذا كنت من أصول آسيوية (اليابان، الصين، الفيليبين، فيتنام، كوريا و الهند)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان عمرك يزيد عن 70 عام</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>اذا كنت تعاني من مشاكل متوسطة في الكلية</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>اذا كنت عرضة لحدوث آلام في العضلات ( اعتلال عضلي)</p><p dir="RTL"><em>زيادة الجرعة و الجرعة اليومية القصوى</em></p><p dir="RTL">من الممكن زيادة الجرعة من قبل الطبيب حتى تأخذ الجرعة المناسبة لك من <strong>روزيتا. </strong>اذا كانت جرعتك الابتدائية 5 ملغم روزوڤاستاتين ، فإن طبيبك قد يقوم بمضاعفة الجرعة الى 10 ملغم ثم 20 ملغم و ثم 40 ملغم اذا اقتضت الحاجة. اذا كانت جرعتك الابتدائية 10 ملغم روزوڤاستاتين ، فإن طبيبك قد يقوم بمضاعفة الجرعة الى 20 ملغم ثم 40 ملغم اذا اقتضت الحاجة. &nbsp;سوف يقوم طبيبك بتعديل الجرعة على فترات بفارق 4 أسابيع.</p><p dir="RTL">الجرعة اليومية القصوى من <strong>روزيتا</strong> هي 40 ملغم. يتم إعطاء هذه الجرعة فقط في المرضى الذين لديهم مستويات مرتفعة من الكوليستيرول يصاحبها خطر لحدوث نوبات قلبية او سكتة دماغية والذين لم تنخفض لديهم مستويات الكوليستيرول بشكل كافٍ أثناء تناولهم جرعة 20 ملغم.</p><p dir="RTL"><strong>اذا كنت تتناول روزيتا لتقليل</strong><strong> خطر الاصابة بالنوبة القلبية او السكتة الدماغية او المشاكل الصحية المتعلقة بذلك:</strong></p><p dir="RTL">الجرعة الموصى بها هي 20 ملغم يوميا. على الرغم من ذلك، قد يقرر طبيبك تخفيض جرعتك اذا كان لديك اي من الاسباب التي تم ذكرها سابقا.</p><p dir="RTL"><u>الاستخدام في الاطفال واليافعين الذين تتراوح اعمارهم 6-17 سنة</u></p><p dir="RTL">تتراوح الجرعة في الأطفال واليافعين الذين تتراوح أعمارهم 6-17 سنة من 5 الى 20 ملغم مرة واحدة يومياً.&nbsp; الجرعة الابتدائية الاعتيادية هي 5 ملغم في اليوم من روزوڤاستاتين. من الممكن زيادة الجرعة من قبل الطبيب حتى تأخذ الجرعة المناسبة من <strong>روزيتا. </strong>الجرعة اليومية القصوى من<strong> روزيتا </strong>هي 10 أو20 ملغم للأطفال الذين أعمارهم من 6 الى 17 سنة ويعتمد على حالتك التي يتم علاجها. تناول الجرعة مرة واحدة يوميا. يمنع استخدام<strong> روزيتا </strong>40 ملغم في الاطفال.</p><p dir="RTL"><strong>تناول الاقراص</strong></p><p dir="RTL">يجب بلع القرص كاملا مع الماء.</p><p dir="RTL">تناول <strong>روزيتا</strong> مرة واحدة يوميا. يمكن تناول هذه الأقراص بأي وقت خلال اليوم مع أو بدون الطعام.</p><p dir="RTL">حاول أن تأخذ الأقراص في نفس الوقت يوميا مما يساعدك على تذكر ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فحوصات </strong><strong>الكوليستيرول المنتظمة</strong></p><p dir="RTL">من المهم ان تراجع طبيبك وتقوم بفحوصات منتظمة للتحقق من الكوليستيرول ، للتأكد من ان نسبة الكوليستيرول وصلت الى المستوى الصحيح و ثبتت على هذا المستوى.</p><p dir="RTL">من الممكن زيادة الجرعة من قبل الطبيب حتى تأخذ الجرعة المناسبة لك من <strong>روزيتا.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong><strong> </strong><strong>الزائدة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>روزيتا</strong></p><p dir="RTL">تحدث إلى طبيبك أو قم بزيارة أقرب مستشفى للحصول على النصيحة.</p><p dir="RTL">اذا تم إدخالك المستشفى او تلقيت دواء لعلاج مرض آخر، أخبر الطاقم الطبي بأنك تتناول <strong>روزيتا</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نسيان</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>روزيتا</strong></p><p dir="RTL">لا تقلق؛ فقط تناول الجرعة التالية في الوقت الصحيح. لا تقم بمضاعفة الجرعة للتعويض عن الجرعة الفائتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول روزيتا</strong></p><p dir="RTL">تحدث الى الطبيب إذا كنت تنوي التوقف عن تناول <strong>روزيتا</strong>. قد تعود مستويات الكوليستيرول للارتفاع مرة اخرى اذا توقفت عن تناول <strong>روزيتا.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">اذا كان لديك أي أسئلة اضافية حول استخدام هذا الدواء، إسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن الأدوية الأخرى، من الممكن أن يسبب <strong>روزيتا</strong> أعراض جانبية الا أنها لا تحدث مع جميع المرضى.</p><p dir="RTL">من المهم بان تكون على وعي بهذه الآثار الجانبية والتي تكون عادة طفيفة و تختفي بعد فترة قصيرة من الزمن.</p><p dir="RTL">توقف عن تناول <strong>روزيتا</strong> و اطلب العناية الطبية على الفور<strong> </strong>إذا حدثت لك أي من تفاعلات الحساسية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس، مع او بدون إنتفاخ في الوجه، الشفاه، اللسان و/أو الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنتفاخ في في الوجه، الشفاه، اللسان و/أو الحلق والتي قد تسبب صعوبة في البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة شديدة في الجلد ( مع نتوءات بارزة)</p><p dir="RTL">&nbsp;</p><p dir="RTL">أيضا، توقف عن تناول <strong>روزيتا </strong>وتحدث الى طبيبك على الفور اذا عانيت من آلام غير اعتيادية في العضلات والتي استمرت لفترة أطول من المتوقع. إن الاعراض في العضلات شائعة في الاطفال واليافعين أكثر من البالغين. شأنه شأن جميع الستاتينات الاخرى، تكونت لدى عدد قليل من الناس آثار جانبية مزعجة في العضلات والتي قد تتطور بشكل نادر لتسبب تلف في العضلات مهدد للحياة يعرف <em>بانحلال الريبيدات</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>أعراض جانبية شائعة (قد تؤثر على 1 من كل 10 الى 1 من كل 100 مريض):</em></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة كمية البروتينات في البول &ndash; والتي قد تعود الى وضعها الطبيعي عادة بدون الحاجة الى وقف تناول أقراص <strong>روزيتا </strong>( فقط في <strong>روزيتا</strong> 40 ملغم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكري. يزيد احتمال ذلك في حال وجود ارتفاع في مستوى السكر والدهون في الدم, وفي حال زيادة الوزن وارتفاع ضغط الدم. سوف يقوم طبيبك بمراقبتك خلال تناول هذا الدواء.</p><p dir="RTL"><strong><em>أعراض جانبية غير شائعة (قد تؤثر على 1 من كل 100 الى 1 من كل 1000 مريض):</em></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح، حكة او أي تفاعلات جلدية أخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة كمية البروتينات في البول &ndash; والتي قد تعود الى وضعها الطبيعي عادة بدون الحاجة الى وقف تناول روزوڤاستاتين ( فقط في جرعات 5 ملغم، و10 ملغم و20 ملغم من روزوڤاستاتين).</p><p dir="RTL"><strong><em>أعراض جانبية نادرة (قد تؤثر على 1 من كل 1000 الى 1 من كل 10000 مريض):</em></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة &ndash; تشمل العلامات إنتفاخ في الوجه، الشفاه، اللسان و/أو الحلق، صعوبة في البلع و التنفس، حكة شديدة في الجلد ( مع نتوءات بارزة). اذا كنت تعتقد بأنك تعاني من تفاعل حساسية، توقف عن تناول <strong>روزيتا </strong>واطلب العناية الطبية على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف العضلات في البالغين- كإجراء احترازي، توقف عن تناول <strong>روزيتا </strong>و تحدث الى الطبيب على الفور في حال كنت تعاني من آلام في العضلات والتي قد تستمر لفترة أطول من المتوقع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في المعدة ( التهاب البنكرياس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع انزيمات الكبد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف أو كدمات أكثر سهولة من المعتاد بسبب انخفاض مستوى الصفائح الدموية.</p><p dir="RTL"><strong><em>أعراض جانبية نادرة جدا (قد تؤثر على أقل من 1 من كل 10000 مريض):</em></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرقان ( اصفرار الجلد و العينين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كميات قليلة جدا من الدم في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الاعصاب في الساقين و اليدين ( مثل الخدران)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي في الرجال ( تثدي الرجال)</p><p dir="RTL"><strong><em>أعراض جانبية بمعدل تكرار غير معروف:</em></strong></p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>إسهال (براز رخو)</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>متلازمة ستيفنز جونسون (تقشر شديد في الجلد، الفم، العينين و الاعضاء التناسلية)</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>السعال</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة (انتفاخ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في النوم، تشمل أرق و كوابيس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات جنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفس، تشمل سعال مستمر و / او ضيق التنفس او حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة في الاوتار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في العضلات على نحو ثابت</p><p dir="RTL">إذا أي من الأعراض الجانبية أصبحت خطيرة، أو إذا لاحظت أي أعراض جانبية غير مذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ <strong>روزيتا</strong><strong> </strong>بعيدا عن متناول ايدي الاطفال ونظرهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ دون 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم <strong>روزيتا</strong><strong> </strong>بعد تاريخ الانتهاء المذكور على العبوة الخارجية. يدل تاريخ الانتهاء على اخر يوم في الشهر المذكور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في المياه العادمة أو النفايات المنزلية. إسأل الصيدلي حول الطريقة السليمة للتخلص من الأدوية التي لم تعد بحاجة إليها. سيساعد هذا في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة في<strong> </strong><strong>روزيتا</strong> هي روزوڤاستاتين. أقراص <strong>روزيتا </strong>المغلفة تحتوي على روزوڤاستاتين كالسيوم مكافئة ل 10، 20 او 40 ملغم من روزوڤاستاتين.</p><p dir="RTL">المواد غير الفعالة الأخرى: لاكتوز، سيليلوز دقيق البلورية، كروس بوفيدون، فوسفات الكالسيوم ثلاثي القاعدة، ستيارات المغنيسيوم، لون أحمر (E172)، هيبروميلوز، ثلاثي الأستين، ثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أقراص روزيتا</strong> <strong>10 ملغم المغلفة:</strong> أقراص مغلفة وردية اللون مستديرة الشكل محدبة الوجهين، مرمزة بالرمز &nbsp;14 Cعلى جهة واحدة &nbsp;وملساء على الجهة الاخرى.</p><p dir="RTL"><strong>أقراص روزيتا</strong> <strong>20 ملغم المغلفة:</strong> أقراص مغلفة وردية اللون مستديرة الشكل محدبة الوجهين، مرمزة بالرمز 113 &nbsp;Cعلى جهة واحدة &nbsp;وملساء على الجهة الاخرى.</p><p dir="RTL"><strong>أقراص روزيتا</strong> <strong>40 ملغم المغلفة:</strong> أقراص مغلفة وردية اللون بيضاوية الشكل محدبة الوجهين، مرمزة بالرمز 126 C على جهة واحدة &nbsp;وملساء على الجهة الاخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اقراص<strong> روزيتا </strong>10، 20 و 40 ملغم<strong> </strong>متوافرة<strong> </strong>في اشرطة من الالومنيوم في عبوات من30 (3 أشرطة، يحتوي كل شريط على 10 اقراص).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة دار الدواء للتنمية والإستثمار المساهمة المحدودة (ناعور &ndash; الأردن)</p><p dir="RTL">هاتف. 132 27 57 (6 962 +)</p><p dir="RTL">فاكس.776 27 57 (6 962 +)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            02/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rozitta® 10 mg film coated tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 10 mg Rosuvastatin (as rosuvastatin calcium). Each tablet contains 89.95 mg lactose monohydrate.
For a full list of excipients see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablets 
Rozitta® 10 mg tablets are Pink round biconvex film coated tablets, coded with C14 on one side and plain on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Treatment of hypercholesterolaemia</strong></p><p dir="ltr">Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.</p><p dir="ltr">Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.</p><p dir="ltr"><strong>Prevention of Cardiovascular Events</strong></p><p dir="ltr">Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event (see Section 5.1), as an adjunct to correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines.</p><p dir="ltr">Rozitta<sup>&reg;</sup> may be given at any time of day, with or without food.</p><p dir="ltr"><strong>Treatment of hypercholesterolaemia</strong></p><p dir="ltr">The recommended start dose is 5 or 10 mg orally once daily in both statin na&iuml;ve and patients switched from another HMG CoA reductase inhibitor. The choice of start dose should take into account the individual patient&#39;s cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below). A dose adjustment to the next dose level can be made after 4 weeks, if necessary (see Section 5.1). In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses (see Section 4.8), a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolaemia at high cardiovascular risk (in particular those with familial hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow-up will be performed (see Section 4.4). Specialist supervision is recommended when the 40 mg dose is initiated.</p><p dir="ltr"><strong>Prevention of cardiovascular events</strong></p><p dir="ltr">In the cardiovascular events risk reduction study, the dose used was 20 mg daily (see Section 5.1).</p><p dir="ltr"><strong>Paediatric population</strong></p><p dir="ltr">Paediatric use should only be carried out by specialists.</p><p dir="ltr"><u>Children and adolescents 6 to 17 years of age (Tanner Stage &lt;II-V)</u></p><p dir="ltr">In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose is 5 mg daily.</p><p dir="ltr">&bull; In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have not been studied in this population.</p><p dir="ltr">&bull; In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have not been studied in this population.</p><p dir="ltr">Titration should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see Section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p dir="ltr">Experience in children with homozygous familial hypercholesterolaemia is limited to a small number of children aged between 8 and 17 years.</p><p dir="ltr">The 40 mg tablet is not suitable for use in paediatric patients.</p><p dir="ltr"><u>Children younger than 6 years</u></p><p dir="ltr">The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, Rozitta<sup>&reg;</sup> is not recommended for use in children younger than 6 years.</p><p dir="ltr"><strong>Use in the elderly</strong></p><p dir="ltr">A start dose of 5 mg is recommended in patients &gt;70 years (see Section 4.4). No other dose adjustment is necessary in relation to age.</p><p dir="ltr"><strong>Dosage in patients with renal insufficiency</strong></p><p dir="ltr">No dose adjustment is necessary in patients with mild to moderate renal impairment. The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance of &lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal impairment. The use of Rosuvastatin in patients with severe renal impairment is contraindicated for all doses (See Section 4.3 and Section 5.2).</p><p dir="ltr"><strong>Dosage in patients with hepatic impairment</strong></p><p dir="ltr">There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child-Pugh scores of 8 and 9 (see Section 5.2). In these patients an assessment of renal function should be considered (see Section 4.4). There is no experience in subjects with Child-Pugh scores above 9. Rosuvastatin is contraindicated in patients with active liver disease (see Section 4.3).</p><p dir="ltr"><strong>Race</strong></p><p dir="ltr">Increased systemic exposure has been seen in Asian subjects (see Section 4.3, Section 4.4 and Section 5.2). The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients.</p><p dir="ltr"><strong>Genetic polymorphisms</strong></p><p dir="ltr">Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin exposure (see Section 5.2). For patients who are known to have such specific types of polymorphisms, a lower daily dose of Rosuvastatin is recommended.</p><p dir="ltr"><strong>Dosage in patients with pre-disposing factors to myopathy</strong></p><p dir="ltr">The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see Section 4.4).</p><p dir="ltr">The 40 mg dose is contraindicated in some of these patients (see Section 4.3).</p><p dir="ltr"><strong>Concomitant therapy</strong></p><p dir="ltr">Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when rosuvastatin is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease inhibitors including combinations of ritonavir with atazanavir, lopinavir, and/or tipranavir; see Sections 4.4 and 4.5). Whenever possible, alternative medications should be considered, and, if necessary, consider temporarily discontinuing Rozitta<sup>&reg;</sup> therapy. In situations where co-administration of these medicinal products with Rozitta<sup>&reg;</sup> is unavoidable, the benefit and the risk of concurrent treatment and Rozitta<sup>&reg;</sup> dosing adjustments should be carefully considered (see Section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rozitta® is contraindicated: 
	in patients with hypersensitivity to rosuvastatin or to any of the excipients. 
	in patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 times the upper limit of normal (ULN). 
	in patients with severe renal impairment (creatinine clearance <30 ml/min). 
	in patients with myopathy. 
	in patients receiving concomitant ciclosporin. 
	during pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures. 
The 40 mg dose is contraindicated in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include: 
	moderate renal impairment (creatinine clearance < 60 ml/min) 
	hypothyroidism 
	personal or family history of hereditary muscular disorders 
	previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate 
	alcohol abuse 
	situations where an increase in plasma levels may occur 
	Asian patients 
	concomitant use of fibrates. (see Sections 4.4, 4.5 and 5.2) 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Renal Effects</u></p><p dir="ltr">Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of Rozitta<sup>&reg;</sup>, in particular 40 mg, where it was transient or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease (see Section 4.8). The reporting rate for serious renal events in post-marketing use is higher at the 40 mg dose. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg.</p><p dir="ltr"><u>Skeletal Muscle Effects</u></p><p dir="ltr">Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported in rosuvastatin-treated patients with all doses and in particular with doses &gt; 20 mg. Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction cannot be excluded (see Section 4.5) and caution should be exercised with their combined use.</p><p dir="ltr">As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated with rosuvastatin in post-marketing use is higher at the 40 mg dose.</p><p dir="ltr"><em>Creatine Kinase Measurement</em></p><p dir="ltr">Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. If CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried out within 5 &ndash; 7 days. If the repeat test confirms a baseline CK &gt;5xULN, treatment should not be started.</p><p dir="ltr"><em>Before Treatment</em></p><p dir="ltr">Rosuvastatin, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:</p><p dir="ltr">&bull; renal impairment</p><p dir="ltr">&bull; hypothyroidism</p><p dir="ltr">&bull; personal or family history of hereditary muscular disorders</p><p dir="ltr">&bull; previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate</p><p dir="ltr">&bull; alcohol abuse</p><p dir="ltr">&bull; age &gt;70 years</p><p dir="ltr">&bull; situations where an increase in plasma levels may occur (see Sections 4.2, 4.5 and 5.2)</p><p dir="ltr">&bull; concomitant use of fibrates.</p><p dir="ltr">In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN) treatment should not be started.</p><p dir="ltr"><em>Whilst on Treatment</em></p><p dir="ltr">Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately, particularly if associated with malaise or fever. CK levels should be measured in these patients. Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are &le; 5x ULN). If symptoms resolve and CK levels return to normal, then consideration should be given to re-introducing Rosuvastatin or an alternative HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted. There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with statins, including rosuvastatin. IMNM is clinically characterised by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p dir="ltr">In clinical trials there was no evidence of increased skeletal muscle effects in the small number of patients dosed with Rosuvastatin and concomitant therapy. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG-CoA reductase inhibitors. Therefore, the combination of Rosuvastatin and gemfibrozil is not recommended. The benefit of further alterations in lipid levels by the combined use of Rosuvastatin with fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose is contraindicated with concomitant use of a fibrate (see Section 4.5 and Section 4.8).</p><p dir="ltr">Rozitta<sup>&reg;</sup> must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). Patients should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness. Statin therapy may be re-introduced seven days after the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment of severe infections, the need for co-administration of Rozitta<sup>&reg;</sup> and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p dir="ltr">Rosuvastatin should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).</p><p dir="ltr"><u>Liver Effects</u></p><p dir="ltr">As with other HMG-CoA reductase inhibitors, Rosuvastatin should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.</p><p dir="ltr">It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. Rosuvastatin should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events (consisting mainly of increased hepatic transaminases) in post-marketing use is higher at the 40 mg dose.</p><p dir="ltr">In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with Rosuvastatin.</p><p dir="ltr"><u>Race</u></p><p dir="ltr">Pharmacokinetic studies show an increase in exposure in Asian subjects compared with Caucasians (see Section 4.2, Section 4.3 and Section 5.2).</p><p dir="ltr"><u>Protease inhibitors</u></p><p dir="ltr">Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir. Consideration should be given both to the benefit of lipid lowering by use of Rosuvastatin in HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma concentrations when initiating and up titrating Rosuvastatin doses in patients treated with protease inhibitors. The concomitant use with certain protease inhibitors is not recommended unless the dose of Rosuvastatin is adjusted (see Sections 4.2 and 4.5).</p><p dir="ltr"><u>Lactose intolerance</u></p><p dir="ltr">Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p dir="ltr"><u>Interstitial lung disease</u></p><p dir="ltr">Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see Section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p dir="ltr"><u>Diabetes Mellitus</u></p><p dir="ltr">Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/l, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p dir="ltr">In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/l.</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">The evaluation of linear growth (height), weight, BMI (body mass index), and secondary characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years of age taking rosuvastatin is limited to a two-year period. After two years of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see Section 5.1).</p><p dir="ltr">In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently compared to observations in clinical trials in adults (see Section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Effect of co-administered medicinal products on rosuvastatin</u></p><p dir="ltr"><strong>Transporter protein inhibitors:</strong> Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of rosuvastatin with medicinal products that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy (see Sections 4.2, 4.4 and 4.5 Table 1).</p><p dir="ltr"><em>Ciclosporin</em><strong>:</strong> During concomitant treatment with rosuvastatin and ciclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Table 1). Rozitta<sup>&reg;</sup> is contraindicated in patients receiving concomitant ciclosporin (see Section 4.3).</p><p dir="ltr">Concomitant administration did not affect plasma concentrations of ciclosporin.</p><p dir="ltr"><em>Protease inhibitors</em>: Although the exact mechanism of interaction is unknown, concomitant protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). For instance, in a pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product of two protease inhibitors (300 mg atazanavir / 100 mg ritonavir) in healthy volunteers was associated with an approximately three-fold and seven-fold increase in rosuvastatin AUC and C<sub>max</sub> respectively. The concomitant use of Rozitta<sup>&reg;</sup> and some protease inhibitor combinations may be considered after careful consideration of Rozitta<sup>&reg;</sup> dose adjustments based on the expected increase in rosuvastatin exposure (see Sections 4.2, 4.4 and 4.5 Table 1).</p><p dir="ltr"><strong>Gemfibrozil and other lipid-lowering products</strong>: Concomitant use of rosuvastatin and gemfibrozil resulted in a 2-fold increase in rosuvastatin C <sub>max</sub> and AUC (see Section 4.4).</p><p dir="ltr">Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is contraindicated with concomitant use of a fibrate (see Sections 4.3 and 4.4). These patients should also start with the 5 mg dose.</p><p dir="ltr"><strong>Ezetimibe: </strong>Concomitant use of 10 mg rosuvastatin and 10 mg ezetimibe resulted in a 1.2 fold increase in AUC of rosuvastatin in hypercholesterolaemic subjects (Table 1). A pharmacodynamic interaction, in terms of adverse effects, between rosuvastatin and ezetimibe cannot be ruled out (see Section 4.4).</p><p dir="ltr"><strong>Antacid</strong>: The simultaneous dosing of rosuvastatin with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.</p><p dir="ltr"><strong>Erythromycin:</strong> Concomitant use of rosuvastatin and erythromycin resulted in a 20% decrease in AUC and a 30% decrease in C<sub>max</sub> of rosuvastatin. This interaction may be caused by the increase in gut motility caused by erythromycin.</p><p dir="ltr"><strong>Cytochrome P450 enzymes:</strong> Results from <em>in vitro</em> and <em>in vivo</em> studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected. No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4).</p><p dir="ltr"><strong>Interactions requiring rosuvastatin dose adjustments (see also Table 1):</strong> When it is necessary to co-administer Rosuvastatin with other medicinal products known to increase exposure to rosuvastatin, doses of Rosuvastatin should be adjusted. Start with a 5 mg once daily dose of Rosuvastatin if the expected increase in exposure (AUC) is approximately 2-fold or higher. The maximum daily dose of Rosuvastatin should be adjusted so that the expected rosuvastatin exposure would not likely exceed that of a 40 mg daily dose of Rosuvastatin taken without interacting medicinal products, for example a 20 mg dose of Rosuvastatin with gemfibrozil (1.9-fold increase), and a 10 mg dose of Rosuvastatin with combination ritonavir/atazanavir (3.1-fold increase).</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:0px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1 Effect of co-administered medicinal products on rosuvastatin exposure (AUC; in order of decreasing magnitude) from published clinical trials</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change in rosuvastatin AUC<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin 75 mg BID to 200 mg BID, 6 months</p></td><td style="vertical-align:top"><p>10 mg OD, 10 days</p></td><td style="vertical-align:top"><p>7.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir 300 mg/ritonavir 100 mg OD, 8 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>3.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Simeprevir 150 mg OD, 7 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.8-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir 400 mg/ritonavir 100 mg BID, 17 days</p></td><td style="vertical-align:top"><p>20 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Clopidogrel 300 mg loading, followed by 75 mg at 24 hours</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Gemfibrozil 600 mg BID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>1.9-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Eltrombopag 75 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.6-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir 600 mg/ritonavir 100 mg BID, 7 days</p></td><td style="vertical-align:top"><p>10 mg OD, 7 days</p></td><td style="vertical-align:top"><p>1.5-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir 500 mg/ritonavir 200 mg BID, 11 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Dronedarone 400 mg BID</p></td><td style="vertical-align:top"><p>Not available</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole 200 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p><sup>**</sup>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ezetimibe 10 mg OD, 14 days</p></td><td style="vertical-align:top"><p>10 mg, OD, 14 days</p></td><td style="vertical-align:top"><p><sup>**</sup>1.2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir 700 mg/ritonavir 100 mg BID, 8 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Aleglitazar 0.3 mg, 7 days</p></td><td style="vertical-align:top"><p>40 mg, 7 days</p></td><td style="vertical-align:top"><p>&harr;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Silymarin 140 mg TID, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fenofibrate 67 mg TID, 7 days</p></td><td style="vertical-align:top"><p>10 mg, 7 days</p></td><td style="vertical-align:top"><p>&harr;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rifampin 450 mg OD, 7 days</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole 200 mg BID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole 200 mg OD, 11 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin 500 mg QID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>20% &darr;</p></td></tr><tr><td style="vertical-align:top"><p>Baicalin 50 mg TID, 14 days</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>47% &darr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>Data given as x-fold change represent a simple ratio between co-administration and rosuvastatin alone. Data given as % change represent % difference relative to rosuvastatin alone.</p><p>Increase is indicated as &ldquo;&uarr;&ldquo;, no change as <strong>&ldquo;</strong>&harr;&rdquo;, decrease as &ldquo;&darr;&rdquo;.</p><p><sup>**</sup>Several interaction studies have been performed at different Rosuvastatin dosages, the table shows the most significant ratio</p><p>OD = once daily; BID = twice daily; TID = three times daily; QID = four times daily</p></td></tr></tbody></table><p dir="ltr"><u>Effect of rosuvastatin on co-administered medicinal products</u></p><p dir="ltr"><strong>Vitamin K antagonists: </strong>As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of Rosuvastatin in patients treated concomitantly with vitamin K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in International Normalised Ratio (INR). Discontinuation or down-titration of Rosuvastatin may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.</p><p dir="ltr"><strong>Oral contraceptive/hormone replacement therapy (HRT): </strong>Concomitant use of Rosuvastatin and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses. There are no pharmacokinetic data available in subjects taking concomitant Rosuvastatin and HRT and therefore a similar effect cannot be excluded. However, the combination has been extensively used in women in clinical trials and was well tolerated.</p><p dir="ltr"><strong>Other medicinal products:</strong></p><p dir="ltr"><strong>Digoxin:</strong> Based on data from specific interaction studies no clinically relevant interaction with digoxin is expected.</p><p dir="ltr"><strong>Fusidic Acid:</strong> Interaction studies with rosuvastatin and fusidic acid have not been conducted. The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.</p><p dir="ltr">If treatment with systemic fusidic acid is necessary, Rozitta<sup>&reg;</sup> treatment should be discontinued throughout the duration of the fusidic acid treatment.&nbsp;<strong>Also see section 4.4.</strong></p><p dir="ltr"><strong>Paediatric population: </strong>Interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Rozitta<sup>&reg;</sup> is contraindicated in pregnancy and lactation.</p><p dir="ltr">Women of child bearing potential should use appropriate contraceptive measures.</p><p dir="ltr">Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. Animal studies provide limited evidence of reproductive toxicity (see Section 5.3). If a patient becomes pregnant during use of this product, treatment should be discontinued immediately.</p><p dir="ltr">Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans (see Section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Studies to determine the effect of rosuvastatin on the ability to drive and use machines have not been conducted. However, based on its pharmacodynamic properties, rosuvastatin is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The adverse reactions seen with rosuvastatin are generally mild and transient. In controlled clinical trials, less than 4% of rosuvastatin-treated patients were withdrawn due to adverse reactions.</p><p dir="ltr"><u>Tabulated list of adverse reactions</u></p><p dir="ltr">Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC).</p><p dir="ltr">The frequencies of adverse reactions are ranked according to the following convention: Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p dir="ltr"><strong>Table 2. Adverse reactions based on data from clinical studies and post-marketing experience</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including angioedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Endocrine disorders</em></p></td><td style="vertical-align:top"><p>Diabetes mellitus<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Polyneuropathy</p><p>Memory loss</p></td><td style="vertical-align:top"><p>Peripheral neuropathy</p><p>Sleep disturbances (including insomnia and nightmares)</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cough</p><p>Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastro-intestinal disorders</em></p></td><td style="vertical-align:top"><p>Constipation</p><p>Nausea</p><p>Abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased hepatic transaminases</p></td><td style="vertical-align:top"><p>Jaundice</p><p>Hepatitis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritis</p><p>Rash</p><p>Urticaria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculo-skeletal and connective tissue disorders </em></p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myopathy (including myositis)</p><p>Rhabdomyolysis</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Tendon disorders, sometimes complicated by rupture</p><p>Immune-mediated necrotising myopathy</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Oedema</p></td></tr></tbody></table><p dir="ltr"><sup>1 </sup>Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, history of hypertension).</p><p dir="ltr">As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.</p><p dir="ltr"><strong>Renal effects: </strong>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with Rosuvastatin. Shifts in urine protein from none or trace to ++ or more were seen in &lt;1% of patients at some time during treatment with 10 and 20 mg, and in approximately 3% of patients treated with 40 mg. A minor increase in shift from none or trace to + was observed with the 20 mg dose. In most cases, proteinuria decreases or disappears spontaneously on continued therapy. Review of data from clinical trials and post-marketing experience to date has not identified a causal association between proteinuria and acute or progressive renal disease.</p><p dir="ltr">Haematuria has been observed in patients treated with Rosuvastatin <sup>&nbsp;</sup>and clinical trial data show that the occurrence is low.</p><p dir="ltr"><strong>Skeletal muscle effects: </strong>Effects on skeletal muscle e.g. myalgia, myopathy (including myositis) and, rarely, rhabdomyolysis with and without acute renal failure have been reported in Rosuvastatin -treated patients with all doses and in particular with doses &gt; 20 mg.</p><p dir="ltr">A dose-related increase in CK levels has been observed in patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (&gt;5xULN), treatment should be discontinued (see Section 4.4).</p><p dir="ltr"><strong>Liver effects: </strong>As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient.</p><p dir="ltr">The following adverse events have been reported with some statins:</p><p dir="ltr">Sexual dysfunction.</p><p dir="ltr">Exceptional cases of interstitial lung disease, especially with long term therapy (see Section 4.4).</p><p dir="ltr">The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events (consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose.</p><p dir="ltr"><strong>Paediatric population:</strong> Creatine kinase elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently in a 52-week clinical trial of children and adolescents compared to adults (see Section 4.4). In other respects, the safety profile of rosuvastatin was similar in children and adolescents compared to adults.</p><p dir="ltr"><strong>To report any side effects:&nbsp; </strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia </strong></p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: + 966 112057662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at + 966 112038222, Exts: 2317-2356-2353-2354-2334-2340</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>United Arab Emirates</strong></p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp; Pharmacovigilance and Medical Device Section</p><p>o&nbsp;&nbsp; Drug Department</p><p>o&nbsp;&nbsp; UAE Ministry of Health &amp; Prevention</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hotline: 80011111</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: pv@moh.gov.ae</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box: 1853 Dubai UAE</p></td></tr></tbody></table><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other countries</strong></p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: HMG-CoA reductase inhibitors</p><p dir="ltr">ATC code: C10A A07</p><p dir="ltr">Mechanism of action</p><p dir="ltr">Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering.</p><p dir="ltr">Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.</p><p dir="ltr"><strong>Pharmacodynamic effects</strong></p><table border="0" cellpadding="0" dir="ltr"><tbody><tr><td><p>Rozitta<sup>&reg; </sup>reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases HDL-cholesterol. It also lowers ApoB, nonHDL-C, VLDL-C, VLDL-TG and increases ApoA-I (see Table 3). Rozitta<sup>&reg; </sup>also lowers the LDL-C/HDL-C, total C/HDL-C and nonHDL-C/HDL-C and the ApoB/ApoA-I ratios.</p><p><strong>Table 3 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb) (adjusted mean percent change from baseline)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p></td><td style="vertical-align:top"><p><strong>Total-C</strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p></td><td style="vertical-align:top"><p><strong>TG</strong></p></td><td style="vertical-align:top"><p><strong>nonHDL-C</strong></p></td><td style="vertical-align:top"><p><strong>ApoB</strong></p></td><td style="vertical-align:top"><p><strong>ApoA-I</strong></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-5</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-45</p></td><td style="vertical-align:top"><p>-33</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-35</p></td><td style="vertical-align:top"><p>-44</p></td><td style="vertical-align:top"><p>-38</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-52</p></td><td style="vertical-align:top"><p>-36</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>-10</p></td><td style="vertical-align:top"><p>-48</p></td><td style="vertical-align:top"><p>-42</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-55</p></td><td style="vertical-align:top"><p>-40</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>-23</p></td><td style="vertical-align:top"><p>-51</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>-63</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>-28</p></td><td style="vertical-align:top"><p>-60</p></td><td style="vertical-align:top"><p>-54</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>A therapeutic effect is obtained within 1 week following treatment initiation and 90% of maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.</p><p><strong>Clinical efficacy and safety</strong></p><p>Rozitta<sup>&reg; </sup>is effective in adults with hypercholesterolaemia, with and without hypertriglyceridaemia, regardless of race, sex, or age and in special populations such as diabetics, or patients with familial hypercholesterolaemia.</p><p>From pooled phase III data, Rosuvastatin <sup>&nbsp;</sup>has been shown to be effective at treating the majority of patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8 mmol/l) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/l).</p><p>In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given Rosuvastatin from 20 mg to 80 mg in a force-titration design. All doses showed a beneficial effect on lipid parameters and treatment to target goals. Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C was reduced by 53%. 33% of patients reached EAS guidelines for LDL-C levels (&lt;3 mmol/l).</p><p>In a force-titration, open label trial, 42 patients with homozygous familial hypercholesterolaemia were evaluated for their response to Rosuvastatin <sup>&nbsp;</sup>20 - 40 mg. In the overall population, the mean LDL-C reduction was 22%.</p><p>In clinical studies with a limited number of patients, Rosuvastatin <sup>&nbsp;</sup>has been shown to have additive efficacy in lowering triglycerides when used in combination with fenofibrate and in increasing HDL-C levels when used in combination with niacin (see Section 4.4).</p><p>In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients between 45 and 70 years of age and at low risk for coronary heart disease (defined as Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/l (154.5 mg/dL), but with subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were randomised to 40 mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin significantly slowed the rate of progression of the maximum CIMT for the 12 carotid artery sites compared to placebo by -0.0145 mm/year [95% confidence interval -0.0196, -0.0093; p&lt;0.0001]. The change from baseline was -0.0014 mm/year (-0.12%/year (non-significant)) for rosuvastatin compared to a progression of +0.0131 mm/year (1.12%/year (p&lt;0.0001)) for placebo. No direct correlation between CIMT decrease and reduction of the risk of cardiovascular events has yet been demonstrated. The population studied in METEOR is low risk for coronary heart disease and does not represent the target population of Rosuvastatin 40mg. The 40mg dose should only be prescribed in patients with severe hypercholesterolaemia at high cardiovascular risk (see Section 4.2).</p><p>In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;50 years) and women (&ge;60 years).</p><p>Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily (n=8901) and were followed for a mean duration of 2 years.</p><p>LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group compared to the placebo group.</p><p>In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk score &gt;20% (1558 subjects) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate per 1000 patient-years was 8.8. Total mortality was unchanged in this high risk group (p=0.193). In a post-hoc analysis of a high-risk subgroup of subjects (9302 subjects total) with a baseline SCORE risk &ge;5% (extrapolated to include subjects above 65 yrs) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.0003) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate was 5.1 per 1000 patient-years. Total mortality was unchanged in this high risk group (p=0.076).</p><p>In the JUPITER trial there were 6.6% of rosuvastatin and 6.2% of placebo subjects who discontinued use of study medication due to an adverse event. The most common adverse events that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo), abdominal pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03% placebo). The most common adverse events at a rate greater than or equal to placebo were urinary tract infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin, 7.2% placebo), back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin, 6.6% placebo).</p><p><strong>Paediatric population</strong></p><p>In a double-blind, randomized, multi-centre, placebo-controlled, 12-week study (n=176, 97 male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label, rosuvastatin dose-titration phase, patients 10-17 years of age (Tanner stage II-V, females at least 1 year post-menarche) with heterozygous familial hypercholesterolaemia received rosuvastatin 5, 10 or 20 mg or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks. At study entry, approximately 30% of the patients were 10-13 years and approximately 17%, 18%, 40%, and 25% were Tanner stage II, III, IV, and V, respectively.</p><p>LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively, compared to 0.7% for placebo.</p><p>At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/l.</p><p>After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see Section 4.4). This trial (n=176) was not suited for comparison of rare adverse drug events.</p><p>Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with heterozygous familial hypercholesterolaemia aged 6 to 17 years (88 male and 110 female, Tanner stage &lt;II-V). The starting dose for all patients was 5 mg rosuvastatin once daily. Patients aged 6 to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged 10 to 17 years (n=134) to a maximum dose of 20 mg once daily.</p><p>After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the baseline value in LDL-C was -43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL). For each age group, the LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234 mg/dL, Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, 124 mg/dL), and -35% (Baseline: 241 mg/dL, Month 24: 153 mg/dL) in the 6 to &lt;10, 10 to &lt;14, and 14 to &lt;18 age groups, respectively.</p><p>Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, TG/HDL-C, non HDL C/HDL-C, ApoB, ApoB/ApoA-1. These changes were each in the direction of improved lipid responses and were sustained over 2 years.</p><p>No effect on growth, weight, BMI or sexual maturation was detected after 24 months of treatment (see section 4.4).</p><p>Rosuvastatin was studied in a randomised, double-blind, placebo-controlled, multicenter, cross-over study with 20 mg once daily versus placebo in 14 children and adolescents (aged from 6 to 17 years) with homozygous familial hypercholesterolaemia. The study included an active 4-week dietary lead-in phase during which patients were treated with rosuvastatin 10 mg, a cross-over phase that consisted of a 6-week treatment period with rosuvastatin 20 mg preceded or followed by a 6-week placebo treatment period, and a 12-week maintenance phase during which all patients were treated with rosuvastatin 20 mg. Patients who entered the study on ezetimibe or apheresis therapy continued the treatment throughout the entire study.</p><p>A statistically significant (p=0.005) reduction in LDL-C (22.3%, 85.4 mg/dL or 2.2 mmol/L) was observed following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. Statistically significant reductions in Total-C (20.1%, p=0.003), nonHDL-C (22.9%, p=0.003), and ApoB (17.1%, p=0.024) were observed. Reductions were also seen in TG, LDL-C/HDL-C, Total-C/HDL-C, nonHDL-C/HDL-C, and ApoB/ApoA-1 following 6 weeks of treatment with rosuvastatin 20 mg versus placebo. The reduction in LDL-C after 6 weeks of treatment with rosuvastatin 20 mg following 6 weeks of treatment with placebo was maintained over 12 weeks of continuous therapy.</p><p>In the 7 evaluable children and adolescent patients (aged from 8 to 17 years) from the force-titration open label study with homozygous familial hypercholesterolaemia (see above), the percent reduction in LDL-C (21.0%), Total-C (19.2%), and non-HDL-C (21.0%) from baseline following 6 weeks of treatment with rosuvastatin 20 mg was consistent with that observed in the aforementioned study in children and adolescents with homozygous familial hypercholesterolaemia.</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with rosuvastatin in all subsets of the paediatric population in the treatment of homozygous familial hypercholesterolaemia, primary combined (mixed) dyslipidaemia and in the prevention of cardiovascular events (see section 4.2 for information on paediatric use).</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Absorption:</strong> Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral administration. The absolute bioavailability is approximately 20%.</p><p dir="ltr"><strong>Distribution</strong>: Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.</p><p dir="ltr"><strong>Metabolism:</strong> Rosuvastatin undergoes limited metabolism (approximately 10%). <em>In vitro</em> metabolism studies using human hepatocytes indicate that rosuvastatin is a poor substrate for cytochrome P450-based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to a lesser extent. The main metabolites identified are the N-desmethyl and lactone metabolites. The N-desmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive. Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.</p><p dir="ltr"><strong>Excretion:</strong> Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of absorbed and non-absorbed active substance) and the remaining part is excreted in urine. Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is approximately 19 hours. The elimination half-life does not increase at higher doses. The geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%). As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane transporter OATP-C. This transporter is important in the hepatic elimination of rosuvastatin.</p><p dir="ltr"><strong>Linearity:</strong> Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in pharmacokinetic parameters following multiple daily doses.</p><p dir="ltr"><strong>Special populations:</strong></p><p dir="ltr"><strong>Age and sex: </strong>There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin in adults. The pharmacokinetics of rosuvastatin in children and adolescents with heterozygous familial hypercholesterolaemia was similar to that of adult volunteers (see &ldquo;Paediatric population&rdquo; below).</p><p dir="ltr"><strong>Race:</strong> Pharmacokinetic studies show an approximate 2-fold elevation in median AUC and C<sub>max</sub> in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with Caucasians; Asian-Indians show an approximate 1.3-fold elevation in median AUC and Cmax. A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups.</p><p dir="ltr"><strong>Renal insufficiency:</strong> In a study in subjects with varying degrees of renal impairment, mild to moderate renal disease had no influence on plasma concentration of rosuvastatin or the N-desmethyl metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold increase in plasma concentration and a 9-fold increase in the N-desmethyl metabolite concentration compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects undergoing haemodialysis were approximately 50% greater compared to healthy volunteers.</p><p dir="ltr"><strong>Hepatic insufficiency:</strong> In a study with subjects with varying degrees of hepatic impairment there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There is no experience in subjects with Child-Pugh scores above 9.</p><p dir="ltr"><strong>Genetic polymorphisms:</strong> Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a higher rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes. This specific genotyping is not established in clinical practice, but for patients who are known to have these types of polymorphisms, a lower daily dose of Rozitta<sup>&reg;</sup> is recommended.</p><p dir="ltr"><strong>Paediatric population:</strong>&nbsp;Two pharmacokinetic studies with rosuvastatin (given as tablets) in paediatric patients with heterozygous familial hypercholesterolaemia 10-17 or 6-17 years of age (total of 214 patients) demonstrated that exposure in paediatric patients appears comparable to or lower than that in adult patients. Rosuvastatin exposure was predictable with respect to dose and time over a 2-year period.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG have not been evaluated. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels were as follows: In repeated-dose toxicity studies histopathologic liver changes likely due to the pharmacologic action of rosuvastatin were observed in mouse, rat, and to a lesser extent with effects in the gall bladder in dogs, but not in monkeys. In addition, testicular toxicity was observed in monkeys and dogs at higher dosages. Reproductive toxicity was evident in rats, with reduced litter sizes, litter weight and pup survival observed at maternally toxic doses, where systemic exposures were several times above the therapeutic exposure level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Core: Lactose, crospovidone, tribasic calcium phosphate, microcrystalline cellulose, magnesium stearate.</p><p dir="ltr">Coat: &nbsp;red ferric oxide (E172), hypromellose, triacetin, titanium dioxide.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>Immediate packaging</strong></p></td><td style="vertical-align:top"><p><strong>Outer packaging </strong></p></td></tr><tr><td style="vertical-align:top"><p>Laminated Aluminum Strip for formpack</p><p>Aluminum foil</p></td><td style="vertical-align:top"><p>Cardboard box</p><p>Leaflet</p></td></tr></tbody></table><p dir="ltr">Rozitta<sup>&reg;</sup> 10 mg tablets are available in packs of 30 (3 blisters of 10).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Medicines should not be disposed of via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dar Al Dawa Development & Investment Co. Ltd.
P.O.Box 9364 
Na’ur - Jordan  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/02/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/png; base64,iVBORw0KGgoAAAANSUhEUgAABAAAAAQACAYAAAB/HSuDAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAAyZpVFh0WE1MOmNvbS5hZG9iZS54bXAAAAAAADw/eHBhY2tldCBiZWdpbj0i77u/IiBpZD0iVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkIj8&#x2B;IDx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iIHg6eG1wdGs9IkFkb2JlIFhNUCBDb3JlIDcuMC1jMDAwIDc5LmRhYmFjYmIsIDIwMjEvMDQvMTQtMDA6Mzk6NDQgICAgICAgICI&#x2B;IDxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI&#x2B;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&#x2B;IDwvcmRmOlJERj4gPC94OnhtcG1ldGE&#x2B;IDw/eHBhY2tldCBlbmQ9InIiPz4CH1RLAAIOi0lEQVR42uzdCXiddZ03/F&#x2B;SJm3Tfd93ui&#x2B;0tAWmtBRk32UrKDKK4O7oq&#x2B;NyXaOPOi&#x2B;g8zg8oziOL8LoOINLRVHcWKUs0oJsLbQspVCgLV0pbem&#x2B;JHnv&#x2B;2B5Qjjn5JwsbdJ&#x2B;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&#x2B;kJKSEv8aAAAAHJJqamoO&#x2B;tdgAgAAAAAOAwoAAAAAUAAAAAAAh4I2vgUAALQgB2NjqBrfdkABAAAArTvcN8XXpSAAFAAAANDKwn5T/b8oBQAFAAAAwn4L/Bw1zfz1KAQABQAAAAJ/E9xXYz5nTTT/mH&#x2B;JIgBQAAAAIPDnv4&#x2B;SA/C5axpQENQ08v9TGQAoAAAAOCwDf0kzfK5CA3exnydbKVDTwK9NEQAoAAAAOCQCfyHBvqQRX0djlwnU1HNdIfffmELAVACgAAAAoNWF/aYI/CVF3ldTfr01da6raWApUBMNO8JvKgBQAAAA0GoDf0PCfkkjPl&#x2B;haor4f6uppxQoyRP&#x2B;G3KE31QAoAAAAKDFBf5Cj&#x2B;4XE/ZLGnD/TfG9yBbua7J8PTVZXq&#x2B;p5&#x2B;trbBmgCAAUAAAANFvgb8w4f6GBP9v7ir3PYv5/awq8riRLEZDra6ppRBlgKgBoGX8wampaxu&#x2B;WkpIS/xoAAM0b9psj8Oe7v5ImLgTqu76mAdfVFHBdTY6Pr&#x2B;/99b2vEIoAOES0hOxtAgAA4PAO/MWu329M4C/0/YX&#x2B;v&#x2B;dal19fkM42&#x2B;l/3ulzvq6nz9WabDDAVALRICgAAgEM78Ddkd/5CxvkbEvYbMhnQ2O9LTZ7Qny/cZzu6X5Ln9rk&#x2B;b65NBu0VACgAAAAE/kZ9fHOt3y8k8Gd7X1MWAYV&#x2B;z&#x2B;ob8S80&#x2B;Ne9PlsZUJPl6zMVACgAAACE/RYV&#x2B;Bs6zl9sqG&#x2B;OIqBu4M5XBGQL/7nW/ucL/oVc1xRTATUN&#x2B;JlQBAAKAAAAgb/ZA3&#x2B;h1xdzP8WUAMWG/7ohvm6AjzphviZH8M92RoB8SwdKcpQHhfx/FPOzogwAFAAAAK0s8DfX&#x2B;v36bl9s4C/J8/GFlgCNmQLIF5prGhH&#x2B;s31MtrezLQcoidxTAflOJ2gqAFAAAAAI/PWG4qbesK/Q64u5rphioKEFQET9p/crpADI93Z15D6in21SoL69AkwFAAoAAIBDJPC3lHH&#x2B;bAG8oYG92Osaujyg0CKg0M3/ig37&#x2B;ZYG5JocqK8cMBUAKAAAAA6BsN&#x2B;SAn9Trt8vNtwXept8X0t934N8RUB9G/3Vvq66gAKg7vuq8xQF1TmCf7ZyoG4JUMhUQGNPJagMAAUAAIDA30yBv7Hr9&#x2B;sL/M25fr&#x2B;QcJ8r8Bf7MYUUG4UqZuS/NEfIr1sOVNcJ4LkKgtICgn9jpgJylQGmAgAFAABAMwf&#x2B;5tqw70Cs388V7qORYb6hhUC2sqLQf7tCdv2vb8y/7pH9bOP31XluX53nfvMF&#x2B;3xTAVFkEVBMsFcEgAIAAEDgz/PxB3PDvmJG/Qs96t/UYb4x0wDFfN/ylQDFbvS3P6CXxruP9Nd9vXZgz7bjfyFTAfnG/evepu7ygGLKAMsDAAUAACDsH6DAf6is3y/m7dIiPzaiuLMDFFICFHMqv7rLAHK9nq0AqH3ZXxwUMhVQ374ApgIABUBzqqnxOw4AWlXaTxwCgb&#x2B;h6/cbE/iLHfHP93ZD31fo11vvv8PZZ5/d/T3vec&#x2B;AWbNmTVm2bNmLX/rSlx5dtWrV3gKKgHyXumG&#x2B;dhmQqwAoieKmAuorJyLHfR7wqYAaT5RbXYbZf336srS0NPbs2ZP&#x2B;zoyqqqrMdfv27Yvy8vJo06bNO65Lb1td/daPf/qyoqIidu/eHW3bts3cbufOnW9fv2vXrsx1Xbp0ydwmlb69//Omt0vvb/916edv3759bN26NTp16hQ7duzIvD&#x2B;9bNu2Lbp16xavv/565mV6m/1f35tvvvn2&#x2B;9Lb1v08&#x2B;/&#x2B;/0pfp59x/3eTJk/2AKAAAAIG/QWG/vpBeSKAvJPA3dv1&#x2B;RMN2429oiC9tgmIgXxnwrpeXX3553xkzZgxILlP79OkzPAkGo5Mw0jV937Rp0&#x2B;Kss85a9tRTT931wx/&#x2B;8IGf/exn66Lw3f2zBf/SPNfV/biSKGwqoLqeryUi&#x2B;zKDgzYVsP&#x2B;xpwgABQAAwKEY&#x2B;FvT&#x2B;v2IA7NeP9v7Sgu4XaOWBHz6058efPTRRw&#x2B;aOnXqUWng79Kly7A2bdp0zPUP3rlz55GzZs0aeeyxx17&#x2B;z//8zw/dfffd85KXT69bt25vFH70v7TO23WDf2me92UrBfLtG9BqpgJqPyaVAaAAAAA4mIG/pazfjyj89HaNGedvrsBfmuN9pUWG/6KLgG7dupV/8pOfHJ6E/cETJkyY3KtXrxGdOnUaUFZW1rbYH4by8vIuI0aMOOsTn/jEWZdeeunSJ5544p4f/ehHD8&#x2B;dO3dtZB/xrxv485UB2YJ/3bMEFLNXgKkAQAEAAAj7rSDwHw7r9/OF/0Jez3q/o0aNqvzQhz50xFFHHTU8eX1C7969R1RWVvZOfjya9Llqukzg5JNPHn388cdf9rWvfW3&#x2B;Pffc85fPfvazT&#x2B;YI/dlKgNplQHXknwYoCVMBgAIAABD4mzXwN9X6/fpuX2zgb6r1&#x2B;w0J/PUddS92hL&#x2B;Y1991Oe6447q8733vG3nkkUeOGjp06JiePXuOaNeuXbdomjM41KuioqLb2LFjz04vl1566dMLFy78yzXXXPPAQw89tDnefWS&#x2B;2JfZyoFCNwQsZCqg7j4DEU17BoFcpz0sugxQBIACAAAQ&#x2B;Bsb&#x2B;A/m&#x2B;v2Ixm3Y11Tr9yMatst&#x2B;oe9rskunTp3K3/Oe93Q/77zzRk2cOHHsoEGDjujevfuI8vLyDi3hZ7R3796TTjvttEmzZs2as2LFiiduvvnm2//P//k/y3bv3l3dwBKgOt69DCDfkoFipwLqvh3RtFMBuR5PpgJAAQAA0KSBvyWv3y8k8BdaArSU9fuNuWQb8y9NAn7bM844o28S&#x2B;kcmgT8d5x&#x2B;WBP6hpaWlFS35Z7eysrLXmDFjTr/66qtP&#x2B;dznPvfCfffdd8cNN9zw&#x2B;Lx5897IEfKzLQUorXO7uiG72KmAXJMATTEVUF/YjzAVAAoAAIAmCvstKfAfyPX7Ec27I3&#x2B;hu/UXsnlf1pBf&#x2B;zbjx4/vcO655w469thjj5gwYcKkJOwP7tq16&#x2B;A4QOP8Ta20tLSsZ8&#x2B;eYy&#x2B;&#x2B;&#x2B;OKxZ5999hvPPffcA7fddttDV1999XN1wn&#x2B;2UiDb0f6qyL9JYLZCoDpLYM8W6Bs7FRA5CgJTAaAAAAAE/mYP/CUFfmxDA39Trd8vJvA3xRH/0iLLgIZs3lfw&#x2B;v3zzz9/xJFHHjli7NixR3bp0qV/x44d&#x2B;x2KP/Pt27fvftRRR50/ZcqU937kIx957PHHH3/k29/&#x2B;9oJHHnlkS57wn2s6IFfgz7ehYLZSINsSg2xh/2BNBdQU&#x2B;ztFEQAKAADg0Az8hR7dry&#x2B;kFxLoCwn8xazfj2j4bvz13aaQgJ8tyBcb/gsK&#x2B;bUupWeddVaPJPCPHjNmzLCRI0dO7tSpU98kGPc43B4LgwYNOjq9nHLKKXOWLVv21//5n/&#x2B;597vf/e6LOcJ/vqmA6si9SWCuMwnU1Pl3r8lTEDT3VEBNAY/dKKYMMBUACgAAoPUF/qYe529s4G&#x2B;t6/cLHeFvqsvbEwB9&#x2B;vSpOOmkk3q9973vHTdixIhhiUkdOnToXVFR0ckj5C0dO3bsO2XKlPOOPPLIMz7/&#x2B;c8/vWDBgge/8Y1vLHj&#x2B;&#x2B;ed3xFvj/oVMBdS3bCDXngER&#x2B;acC8p0&#x2B;MNuygmxvR&#x2B;SfCsh3KkFTAaAAAAAOwbDfHIG/pa/fb47AX1rE&#x2B;xoT/rOO&#x2B;afr90844YTeZ5555qQhQ4YMHTx48ITKysqeZWVl7TxK8ks3NRw0aNC0Sy65ZFry/bvkueeee/hHP/rRvBtvvPGVKG4qoPYeAblOIRhR&#x2B;FRAttMKZts3oJipgFynEjQVAAoAAEDgb5bA39D1&#x2B;w0N/A09RV9TbNhXyJr9otfyz549u9vMmTP7nHLKKVOS8Dq0T58&#x2B;Y9LAn/x4lHqUNFynTp0GHH300RdNnTr17K997WvP3Zn4/ve/v3DRokXbIvtUQLbQX98pBhs7FZBtSUChUwElWcoCUwGgAAAADuHA31zr95s68Be6fj8KCO&#x2B;F3KaQgJ8tsDd0zf67gn2OS&#x2B;mFF17Y&#x2B;5hjjhmQBP8j&#x2B;/XrN7x3794j2rZt280jpHmkkxMDBgyYcuWVV0655JJL1jzxxBP3/va3v/3r9ddf/1KdQJ9vKUAhpxgsdiqg9iRAoVMB1VmCf7ZyoG4JUMhUQKNOJagMAAUAAAj8By/wt6b1&#x2B;xHNs16/kDKgWdfvp29fddVV6en4Bk2bNi0N/CPS0/FVVFR09Ag58NIzI8yePfsDM2fOvPgzn/nMYw8&#x2B;&#x2B;OBD3/zmNx9ftmzZ9hzhvyoK3yOg2KmA2oVBoVMBZdF8UwG5ygBTAaAAAACaIfC3lPX7xQT&#x2B;lrZ&#x2B;P9/u/c2xfv8dgb9Tp05tPvrRjw6bPn360EmTJk1MAv8Raehs06aN9fstSFlZWdvhw4fPTC/nnXfe8qVLlz76n//5n/f/6Ec/WpEj/BezR0C&#x2B;MwlkC/qNmQqorifY55sKiCKLgILLAEUAKAAAQNhvuYH/QK7fj2jeI/rNsX4/21r&#x2B;zGXEiBHtP/jBD46YNm3ayNGjR4/p3bv3yHT9fmlpablHSevQrVu34ccee&#x2B;zwqVOnnvtP//RPi26//fa7r7nmmkXr1q3bHU03FZBvWUB1FD8VUFOrWKhbDBQ6FVC3gCimDLA8ABQAACDwNzLwN3b9fn2B/2Cv329I4C&#x2B;NA7t&#x2B;/10hv9alNAmKnefMmTPiqKOOGjNs2LDRvXr1GtmuXbuuTfTzwUFUXl5eOXz48Bmf/vSnZ1x22WWvPP3003/5wQ9&#x2B;cP8tt9yyJppuKqB2cdDYqYDqLMG&#x2B;mFMJRpbro8gioOgyQBEACgAAOFwCf3Nt2FfSgPeXFHF9vnAfRYT5hgT8Qm5bbPgv6NK2bduyM888s&#x2B;cZZ5wxMgn849MN&#x2B;5LAPyIJitbvH&#x2B;K6des2dPbs2UNnzJhx/je/&#x2B;c1Ft912213XX3/9kpUrV&#x2B;6K&#x2B;jcILHQaoDpPAZBtDX&#x2B;hUwHFnEqw7v2ZCgAFAAAI/A0I&#x2B;8UE/ta0YV9zr98/aBv29enTp&#x2B;K8887rd/zxx4&#x2B;YMmXKpCTsD&#x2B;nRo8fw9Nzyh9NjYevWrbFy5Yp45ZVXon379snLV2P79m2xd&#x2B;/e2LRpUyTfk9i4cWN07tw5qqqq0vX00b1792jTpk3yskd06dI5uXTNXJfeNr2P1iote0aMGDHzH//xH2deeeWVryxYsOCuuXPnPnHzzTevince&#x2B;W/ImQMKOZNAfVMB1fHO/QCyhf9cUwG5zhAQdW4bRRYBRZcBigAUAABASw77zRH4D7f1&#x2B;xGFHdFvaPivd/3&#x2B;yJEjK&#x2B;fMmTN42rRpwydNmjQ5CawDu3TpMiT58Sg9XB4LK1asiKeeWhSLFz8d69dviD179sS2bdti69Y3Y&#x2B;jQYdGrV68k5FfHkUdOSq7fHsOGDY927dqmgS19HEV1dXXs3Lkz9u3bl3n/Cy8sjS1bNsfmzVti7949mW91RUV5VFZ2TO5vaIwZMzpGjDgiBgwY0Oq&#x2B;V127dh165plnfuyUU07Z/uUvf/nB&#x2B;&#x2B;6779EvfOELj&#x2B;7evbs0T/gvdo&#x2B;AQqYCqiP3EfyaMBUACgAAEPibPfCXFPixDQ38DV2/35jA3xRH/EsLuG1TbtiXc8x/&#x2B;vTpnS&#x2B;55JIjJkyYMGz8&#x2B;PGTk0DXv2PHjv0Pt8fDhg3r4957743f/vY38dprq6Nfv34xderUOPnkkzMBv3fv3png3xTSSYHXX98QK1asjOeeezb&#x2B;8Ic/xM6dO2LPnr0xfPjwmDXr&#x2B;BgxYkT07NkzM0HQGpSXl3dIfn7OSC8XX3zxc4sXL3743/7t3x644447NhQQ/ptiKiBX0DcVAK31eUpL&#x2B;XlvKfvZePwD0AIC/6G2fj8KCO&#x2B;F3KaQHfmzhfqGrt/PG/L3X8oSJ510Urc5c&#x2B;aMGTVq1NDkMrlTp079Kisrexyuj4u1a9fGt7/9L5ng37t3n3j/&#x2B;y&#x2B;Lc889N3Ok/0A951u7dk0sWLAgfvnLX8add94RAwcOjDPPPDM&#x2B;/vFPZCYDWqvdu3dvWr58&#x2B;WO33nrrvG984xuLq9KxiXefOaAmGjcVUF0n7NfkebvQSxT4dmQpBGpyvMwW&#x2B;GuKLQLqZIFWGQZyfdn7r09flpaWZiZv0sdguqQmvS6dqCkvL8&#x2B;UYrWvS2&#x2B;bTt1kmp3kZUVFRfqzF23bts3cLp3G2X/9rl27Mtd16dIlc5tU&#x2B;vb&#x2B;z5veLr2//delnz9drpMuAUp&#x2B;V8aOHTsy708v6VRQt27d4vXXX8&#x2B;8TG&#x2B;z/&#x2B;t78803335fetu6n2f//9f&#x2B;iaH9102ePLnF/zsdSCYAAKD1BH7r9wsrA5p9/f6sWbN6XHTRRRNGjBgxNLlM6tChQ5/kiXAnj5CI3/3utvjCF76QhIKd8e1v/2tceOFFmZDQnNJlBEkojieeeDKefvqpePnl5Zmg07dv35g5c1Z88YtfjAkTJkS7du3/dvutsXjx4sztTjvttOjZs1er&#x2B;f4mAazb2LFjT/3KV75yykc&#x2B;8pHnFi5c&#x2B;NC11177wEMPPbQp3n1EP9cpBYudCsh16r9ipwLqbi4Y0bRnEKjJ8XrBZYCpAA51CgAAOLBhv7GBv6Hr9yPyj&#x2B;1H5D8iX2i4b67An2u8v7QJw39plvssHT9&#x2B;fIeZM2f2OueccyYNHTp02MCBA8d37Nixd1lZWVuPkne6664748orr4xu3brG7bffERMnTmqWz/PGG2/EM88sicceezR5&#x2B;UysXr0ms0Hg0KFD4qijpsYVV3w4Jk2a9Pa0wZYtW2LBgofj4YcXxLPPPhvr1q2L5N8wduzYHldffXV86Utfig996Iq3jyq2lt9Pffr0GXf66aePmz179oXLly9/9Gc/&#x2B;9mfv//977&#x2B;wdevWfXnCf31H/avqhPe6L2uXA8XuFVD37Yim3Ssg1&#x2B;9SewWAAgAADunAf6DX70c03xH95ly/X/v1zGXWrFldZ8yY0efUU0&#x2B;dPHjw4GH9&#x2B;vUbXVlZ2ftw2rCvIdLR3&#x2B;9//98zYfvb3/52k4f/NPTPnfuL&#x2B;OMf/xBr1qyJMWPGxoQJE&#x2B;Pcc8&#x2B;LI4&#x2B;cnNn4b790w8Fbb/11EvgfjuXLX44339ySOUtAWg5ccsmlceyxx2SWJqRTAt/5znfiH/7h03HvvfPi&#x2B;uuvz&#x2B;wR0Nq0b9&#x2B;&#x2B;R7pPwLXXXnvq5z//&#x2B;RfnzZt3x4033vj4vffe&#x2B;0bkP21gvqmAuiG72KmAXJMATTEVUFPnsW8qABQAAHBQAn9zrd&#x2B;v7/bFBv6mWr/fkMBfGsUf7S92zX7ekF/rUnreeef1SgL/gJkzZ05KAv8RSVAclgYqj5DipNlo&#x2B;/btUV7eJpLvY4PvJ72PdIf/p556OrP296yzzoyuXbtlTvWX/DtlTg/4xz/&#x2B;MbNOef/mfq&#x2B;99lr88Ic/jEcf/WusWbM2qqr2xcCBg&#x2B;Loo4&#x2B;O88&#x2B;/IAn&#x2B;R0VlZeW7Ple6NOHLX/5y9O/fL6688sOxe/fO&#x2B;K//&#x2B;kl06tS5tf5OK&#x2B;vZs&#x2B;foOXPmjD7nnHM2LlmyJN0w8JGvf/3rSyL/koB80wD5NgnMVghUZwns2QJ9Y6cC6t6HqQAo5OfYJoDv/uMFgMDfDIG/OdbvRzRuw75irjtQ6/eb4/KOCYArrrhiwPTp0wcdc8wxEwcOHDiqa9euA5Mg2MUjpPHSCYDPfOYz8elPfzq&#x2B;971/L&#x2B;hjNmzYEM8&#x2B;&#x2B;0wsWrQos34/PbqfBv8BAwZmNv1Kj/wfffQxccEFF2TG&#x2B;lPpBmT33Xdf3HLLLzO7/nfq1DGOOGJk/N3f/V2MHTsmxo&#x2B;fUPTXfuGF52f2L/jv/745LrvsA4dSMVO9evXqhY888sj8733ve3998MEHN8U7NwrMd0rB&#x2B;jYRzHVdttvULg4ism8mGHVuX18xkO&#x2B;6bC8jy9uHxKaBNgG0CWChTAAAIPAXHvYbG/ibcv1&#x2B;IYG/pWzYV&#x2B;j6/SYL&#x2B;fvvv7Kysuyqq64aOmPGjGETJkwYN2DAgNEdO3bsmzyZrPQIaXrpDvvLlr0QN9xwQ2Yk//Of/8d3vH/fvr2ZwJ4G/aeeeipzur70iH4aHEaOHBXnnHNuTJs2PbNj/37p0f6vfe1/xf/&#x2B;39&#x2B;KM844M3PE/phjjs3s6J9e0jDQFGP76cRAmiWWLVt2qP0eLE1&#x2B;7qdeeOGFU0877bR1zz///Pxf/vKXD1x33XXLsgT/&#x2B;kJ/3VML1l0ikGsqoO64fq6pgaaaCog612dbYlBvViv274ypAFoDBQAAwn7LC/wHcv1&#x2B;xIE/oh&#x2B;Rf51&#x2B;USG/9m0GDRrU9oMf/ODwY489dmRiTP/&#x2B;/cek4/xlZWUVHiUH4Illmzbxne9cn4T/4XHddd/OhPx0Q75Vq1ZkduhPd91PjxD26dM3xo8fH5/85Kdi8uQp0bnzWyP36dG7hQsXZo7Ep7v0v/TSS5ly4KSTTorPfOazmQmA2mv9U00R/tNSYt68e5Ovo0PmrAGHqo4dO/aZNm3aBVOmTDn7M5/5zFN//etf53/5y1/&#x2B;y/Lly3dG/VMBpVHYVECuPQMiR&#x2B;ivjtxnFqg9LRDRuL0CchUF9e0VUHCot1cAreL5kiUA7&#x2B;TxCiDwFxD2Iwpbv19f4G/O9fuFhPeGBv7SIt/XkM37Clm/X5IE/S4XXHDBsKOPPnpcEgxH9O7de0y7du262rDv4Et32//3f78&#x2B;XnzxxRg79q0N&#x2B;9Ij9xMnTnx7fDc9&#x2B;v/YY49ldudPj7yna/nTQD9ixIhMMXDMMcdE//79M2PHzSWdWPjIRz4Sf/3rI3H11dfEF77wxcPq32nr1q2rly5d&#x2B;shNN9305xtvvPGVyL8kINseAfnOKFB39D/fsoBcpxUsZklAvimBXEsEsj35b3VLBCwBsARAAaAAABD46w/8zbVh34FYvx/R&#x2B;N34GxLwGzPCnyvY5w35UWfDvlNPPTUN/JOSYDi0V69eo5Inhx09QlquNEykT95Tq1evzqzdX7gwnQZ4OfO&#x2B;/v0HxKhRo2LixAkxZcpRmd36D4S0mPj5z38eP/zhDdG3b9/4&#x2B;te/Eeeee&#x2B;5h&#x2B;&#x2B;&#x2B;UBKdd69ate&#x2B;7222&#x2B;/43vf&#x2B;96ixYsXb4vsUwHZQn99pxbMtWdAFFkK1J0KKLQIyHddxCGwV4ACQAFQKEsAADhUA39Tj/M3NvC31vX7hY7wN/WGfaXJE73yOXPmDJgxY8aQadOmTe7Zs&#x2B;egJBweUVZW1tYjpKnC&#x2B;d5Yt259bNy4Mfr16x&#x2B;9er1znD598p0&#x2B;6V65ckXm9H7pUf30yX76pH3EiCMyY/z17fi/P/ynNmxYH0uWLIlHHnkkCRA7MqfwO&#x2B;644zK79Hfv3rzBPz27QLqk4NFHH427774rli17MQkTXeJb3/pWXHLJ&#x2B;5Jgc3ivEkkeV&#x2B;369&#x2B;8/5aqrrppy6aWXrlm4cOG8n//85/NvuOGGV&#x2B;qE9nxLAeouFyiN7HsGRBS&#x2B;V0CuSYDIE/6r450j/PmWDNS&#x2B;vpC9Ahp1KsEDUQZA3p9FEwAtr5UBEPZbROBv6ev3myPwF3JEv6Hhv6D1&#x2B;x/4wAeGJWFwSHI5qlu3bgO6du06zDh/81m5cmX8x398P&#x2B;bOnZs8B6qOs88&#x2B;J5J/g8xGfOlRt9tv/1Ncd911SVhemlm3P3Dg4ORl78zO/IsWLczcx6RJR2Y&#x2B;7oQTZsfgwUPSIFnQ516&#x2B;fHnmPpYseSbWrl2TKQrat2&#x2B;XOeVfOvafbsqXHu3r3r1bcn1lpnRIb5Ne9h/92//cLf0Vkh45rKgoT762TbF&#x2B;/brMEcq0tEj3HliyZHHs2LEz&#x2B;dpKY9iw4XH00dNjypQpmTMHkFtVVdXuV1555dH777//oeuvv37h4sWLt&#x2B;YI/6YCDvJUgAkAEwAKAAUAgMDfvIG/oev3Gxr4m/oUfcW8r5A1&#x2B;0Wv5Z80aVLHyy&#x2B;/fOS4ceOGTJw48agk7PdLngwO9Ag58NLN&#x2B;X73u9/FT396cyxdujSzTn/OnEsyp95Lw/fmzZuiQ4eOmaP26Wn7Hn/88fjVr26JJ598MvPEvF&#x2B;/fnHqqafFJz7xyRg9enSDvoa0VEj3AFi3bm2sWrUyM5WwadPmt8NGWlCkn2v37r2ZEFJTU5UElerM9ZWVlZkyY9iwYcn/yyuZI/s9e/aKLVs2x5AhwzJhf/jw4fVOK5Dbli1bVj399NP3//SnP11QZ6&#x2B;AqijszAGFlgG5yoFC9gfItVdAdY5gX8heATV5An4hJcEBKQIUAAoABYACAOBQD/zNtX6/qQN/oev3o4DwXshtCgn42UJ9Q9fsvyvY57iUzp49u&#x2B;tll102btSoUUPGjBkzOXni1y8Jbj09QppOeuR76dIXIn3ETZ06NRPec0mfWN9222/jzjvvil69esQHPnB5Et7HZHbu/8lP/iv&#x2B;9Kc/Zm538smnxOWX/330798vCf2/iltvvTUTAtL7nz59emYCYOTII6Jz5y7vGPdvSumT&#x2B;TQkpMEkLSFS&#x2B;/ZVvf28LQ0I6eRBx44dM9d16NDBD0Mz2bt37450KuDBBx98&#x2B;Atf&#x2B;MIjmzdv3hNNPxVQ3wRAoVMBxW4amO&#x2B;6QgP/QZkKUAAoABQACgCAwzXwt6b1&#x2B;xHNs16/kDKgWdfv9&#x2B;zZs3zWrFnd5syZM/GII44YmpjUuXPnfsmTxU4eIU0jfSL/2mur4qWXlke/fn1j7NhxkYSy&#x2B;Ld/uy7mz1&#x2B;QCewXXzwnzj//gswR/SxBLnOqvT/96U/x29/&#x2B;JrM&#x2B;fsKECfHBD34wzjnnnOQJd3n8&#x2B;te/Si6/zgSCv//7v4/LL788eUK&#x2B;LfOkP33izuFt48aNLz7//PN//f73v3/f3LlzV0dhUwGFnDmguacCCjlbQKuaClAAKAAUAAoAgNYU&#x2B;FvK&#x2B;v2I/GP7EcWfeq/Q65ri7Vy795c2YfjPOuY/ZsyYyhkzZvQ877zzJo0YMWL4gAEDxiVP7PrasK/5pKfQu/HGG&#x2B;OnP/3vWLFiVcyceVx86ENXZM5jv2bNmkx4/&#x2B;Uv52aeLB9//Ox43/veH6effnp07979XfeVPuG///774jvf&#x2B;U7Mm3dvJP9&#x2B;8dnPfi7&#x2B;4R/&#x2B;4e33N9fRfQ6JMmrbqlWrFv3&#x2B;97&#x2B;/&#x2B;9prr30q&#x2B;ZnbE7k3CGzoNEChBcBhORWgAFAAKAAUAAAtNey3pMB/INfvRzTvEf0Dun7/uOOO6zJz5sy&#x2B;J5988qShQ4ce0bdv3yM6dOjQ14Z9B97Gja9njuLfcsuv4qGHHsycRu/CCy/KXAYOHBCLFi2K//zP/4wHH7w/eYLeNU477fQ477z3xrHHHhtdu3Z9x32lY/&#x2B;XXnpJbN&#x2B;&#x2B;I7Oe/oEHHkzuw7YMFFVMvfTEE0888N3vfvfB5OdyfdQ/FdDQMiAaUArUff2QmQpQACgAFAAKAIDWFPgbu36/vsB/sNfvNyTwl0bxR/sbs37/XSG/1qX0nHPO6Tljxoz&#x2B;s2bNmjhkyJDR3bt3H1JZWdnLI&#x2B;TASMf109PYpUf9003y0ifPaXjv339g8uT4/x6Zf/XVV&#x2B;I3v/lNEvhvitWrV2c2v0vDfnrkP32S/oc//CEeeeThGDNmbFxxxYczp/GrLV3/f889d8Vrr63OLAWYPHmKbz4NkgTBLStXrlw4d&#x2B;7cO2&#x2B;88calyeu74sBOBRQzCVDsVEC2QiDiIE4FKAAUAIUyywXAgQj8B3P9fhQQ7IsN/MWu368vqDfF0f5CioCCx/wvu&#x2B;yyfknYHzJ16tTxgwcPHpM8sRuYPPHr4hFyYC1btix&#x2B;/OMfx4IF8zOntEufPKanuks390vLgJ49e2Y24zv33HMzT8TTo/0vvLA02rVrF5WV7TO3eeCBB5L3tY0PfehD8dWv5n8ifOSRR2Yu0Fjp74sjjjjihK9&#x2B;9asnfPzjH1&#x2B;2YMGCu3/xi18srLVXQL7wv/9SWuDLmlq/72q/nS3gN2QqIOrcX0mWz1H3b1C2gJ/tb19NnesLSoj7/1bXOHpJsU/QTAC0vFYGoJUF/pa8fr&#x2B;QwF/ohn3NvX6/0BH&#x2B;Jt&#x2B;wL3miXnrVVVcNmTlz5vDx48ePGzRo0NgOHTr0Li8vt5X6AfDWZnxPx&#x2B;rVazK796e72ffp0zeGDh2a2dX&#x2B;&#x2B;eeXxvz5f8kcXUt33E&#x2B;PmK1duzZuvfXX8d///ZNYt25DdOvWObp37xG9evWKcePGxzHHHBPTpk3P3Ee2Nf9wkH7Wtz3//PN/ueuuu&#x2B;Z/9atfXbh79&#x2B;66RUBTnDngsJ0KqK6ursmVbUwAtAwmAABobWG/JQX&#x2B;1rp&#x2B;v9BQH5F/nX5Rm/TVvk0SCttdcsklQ44//vgxI0aMGDlgwICxyZOxHjbsa1rpE&#x2B;Tbb789fvWrWzJP&#x2B;i6&#x2B;&#x2B;OI48cT3ZNbo73fLLb&#x2B;Mq6&#x2B;&#x2B;OjZsWB&#x2B;zZ8&#x2B;OgQMHZQqB5cuXpzusZ85bf&#x2B;qpp8Z5550X/fr1j3nz5sVXvvJP8dxzz2aO8s&#x2B;YMTN5cntkZvf&#x2B;8eMnZG6fPrGGligJch0nTpx4Rnr5wAc&#x2B;sPjJJ59c8IMf/ODhWnsFlEbuUwoWOg1QdyqgdlBvzFRAdbz7iH&#x2B;2CYCGTgXU5Hi94DIgCcUluYoAUAAACPxNFfhLCvzYhgb&#x2B;hq7fb0zgb4oj/qUF3LbQNftFb9IXdTbsO/PMMwcnLycmAXF43759xybhsUvy41HmUdJ80iA&#x2B;Y8aM2L59W8yd&#x2B;4u46qqrMiP7733ve&#x2B;Oiiy6K6dOPzhw5S49wbd68OQYNGhxXXnllJsSn4/5p2P/Upz6Z2dxv6NBBcfnlH4yPfezj8c///M&#x2B;ZcmD06NGZUmD/kTBoTZLfQxOT30sTTzjhhIteeumlR3/3u9898L/&#x2B;1/96up7w39ipgNr3U5Ml2JfkKQvqvh2Rf&#x2B;PAXPdZ9/psgT/qhP&#x2B;ShhQBqaqqKmUA73zCZQlAnUeYJQCAwN/Q9fv1hfRCAn0hgb&#x2B;x6/ejwDAf0fg1&#x2B;tmCfDFr9gsO&#x2B;bUupRdeeGHv448/fnASPif369dvSK9evUZXVFR09Ag5sN54Y2Pcf//90aZNWYwbNyEJ&#x2B;m/GbbfdFrff/qd4&#x2B;eWXY9So0UmovzwJ8mPihRdeiPnzH4o1a1ZHu3btM2OxaXGwb19VZqO&#x2B;3//&#x2B;d8ltXoyvfOUrcc011/jmcshJnoNXr1u37plFixY9/LWvfW3eY4899ma8cz&#x2B;AumG&#x2B;Kk/Yz7ccoJBlAbkmAbJNBUQ0/FSCEfnPIJBvSUBRoWXfvn01lgDImikTAACHd&#x2B;Bv6nH&#x2B;xgb&#x2B;Q239fqFj&#x2B;w1ev19ZWVmWhMhBRx999KBjjz32qB49egzq2bPnEcb5D677778vPv7xj8XatWuirKw8Ce3Xxic&#x2B;8fEYO3ZcnHPOOUmYXxbz5v05vvWtbyZPqNvF5Zf/fVx77TejX79&#x2B;maP/aWlQVVWdWS7wgx98P1MEnHzySXHGGWf65nKo/j0rTacCTj/99IkzZ84879VXX11000033X7DDTe8mGOvgNLIPw1Qd3Kg7iaB2ZYJVNf6fZ3tyH/d0N7QqYC699HsUwFJgH77vpLvpyOeh/NjzQRAy2tlAJop7DdH4G/p6/ebI/CXFvG&#x2B;xoT/rGP&#x2B;/fv3b3vFFVcMmzhx4qCpiSQgDujSpcuw0tJS4/wtyGOPPRaf/ew/ZHbkT3fsP/nkk5Mn3XvimWeWZI5onXTSyfHJT34qCfx946WXlmeCfrphX7quv670iNbrr2&#x2B;Inj17ZTYIhMNF8rO/&#x2B;4033lh&#x2B;1113/fHHP/7xovvuu29TvPPIf75TCta3XKDQqYB8&#x2B;wNkC/uNnQo4YJsGbt&#x2B;&#x2B;vcYEwOGXNRUACgBA4G/OwH&#x2B;w1u9HNN8R/UJ36y8t4vWcY/5jxoyp/PCHPzxq/PjxQ5LQf1TXrl37J0&#x2B;YBnqEtHzz5t0b11xzdaxatSpzZH/cuHGZdf9HHTU183b6RDZ98gzULwmJG5955pkHbrnllgeuu&#x2B;66ZVmCf32hv74yIF9JkCv05wr8zXEGgWwhpcnKgD179tQoABQACgCA1h/4m2v9flMH/qZav9&#x2B;UAT9bYG/omv28IX//pSwxY8aMzpdddtnY0aNHD0kuk5MnVAMqKyt7eoS0TumT5PTJanp6vmxH94HiJMFu35o1a56aN2/evT/4wQ&#x2B;efOSRR9K9AppqKiDXdEAUWQrUDuzVRRQB&#x2B;a7L9rLJi4AkjNcoAA7trGkPAIDDM/A3x/r9iOI27Ct0/X5E86zXL6YMaI71&#x2B;yXJE5mKmTNndr3kkksmjBw5cnhiQufOnQckT6g6eYQcGtInuYMGDfKNgCaSBL82AwYMmHr55ZdPveCCC9YtXLhw3u233/7ot771raX1hP98ewTkOoVgRPa9Amr/nahvKiAKDP/1nV6w9vXZTkdYb/Ys5PtbWVn59n0lgduR0UOQAgCg9QT&#x2B;lrJ&#x2B;P6LwDfta2vr9fKfnK3a3/oJCfq3XS5OQXzlr1qye55xzzoQRiYEDB45JA78N&#x2B;wCK16FDhz4zZ85834wZM&#x2B;Z89KMf/euCxL/8y788unjx4m2RfSogW&#x2B;ivbxpgf9jOVg5k20CwOvKfTjAi&#x2B;2aDkSfY12QpH2rfPnJ8TK7XC5L8fcp8zObNmxUBCgAAmjnst6TAfyDX70cc&#x2B;CP62cJ/rrH/QtfyZy7Tp0/vfMIJJ/Q56aSTJiZ5f3SfPn2Gd&#x2B;zYcUBJS1n3BnAISDdBHTp06Iz0ctZZZ6145pln5t98881/ueGGG16pE&#x2B;hLI/dUQHVknwZozFRA7UmAQqcCqrME/2zlQN0SoJCpgLoFQkHBvmvXrm9/TLpEwE&#x2B;cAgBA4D8wgb&#x2B;x6/frC/ytbf1&#x2B;tuDe2PX7RW/SV/ty6qmn9kgC/4AZM2ZMGD58&#x2B;Jju3bsP6dChQ2&#x2B;PEIADo0uXLoOT38GDp0&#x2B;ffu4Xv/jFp&#x2B;bPn//QV77ylYdXrly5K0f4r6qnGGjMVEDtwqDQqYCyaL6pgFxlQMGhfv8SgfXr1ysCFAAAAn8jA39zbdjXHOv3Cwn8xa7fb0jAb8wIf8HBPsel9OKLL&#x2B;5z4oknDps6deqYoUOHju/UqVP/9u3bd/MIATi4ysvLOwwfPnxGejnnnHNeWbp06ePf/e5375w7d&#x2B;7qHOE/35kD6psK2F8G1OQI&#x2B;o2ZCqiuJ9jnmwqIIouAgsuA3r17v/0xq1evVga0puewzgJQ5xHgLABA8wT&#x2B;ph7nb2zgL2bUv5gN&#x2B;5p7/X6&#x2B;8f76jvY3Zi1/aWVlZdn73//&#x2B;AUngHzlu3LhRQ4YMGZ&#x2B;uP62oqOjoEQLQ8u3du3fba6&#x2B;9tvi2226747vf/e6SV199dWfkngoo9swBhZ5CsNAzCBR7KsF812V7GTnKh6KKgNrSTQOdBaDlZ00FgAIAaPqw3xyB/3Bbvx9R2BH9hob/etfvjxgxov2555474OSTTx4/bNiw4YMGDZrQrl277smTEOdyA2jltmzZsuLJJ5&#x2B;876abbnroF7/4xWs5wn&#x2B;2MwcUWwLkOr1grrMG5Hq9vmIg6rku3/VRRElQrw0bNtQoABQACgBA4G/ewN/Q9fuNCfxNeYq&#x2B;ptqwr6hN&#x2B;mpfjjvuuC6nnHLKgBNOOOHIJOwP7du37/gk8HdNN5fyKAE4NO3du3f7ihUrnrztttvu/vd///dnak0FFHNKwWKnAnIVAIfcVMCaNWtqFAAKAAUAcCgG/kNt/X4UEN4LuU0hAT9bqC9mzX6u1/NOAJx//vm9Zs6cOej4448/qk&#x2B;fPoOSy5iKiopOHiEAh6fNmze/umDBgjvmzp375M0337wq6p8KaGgZEA0oBeq&#x2B;3qqmAtIiQAGgAFAAAIdD4G9N6/cjmme9fiFlQLOu3y8rKyu98sorB02bNm3gjBkzpvbs2XNgjx49jkieULT3CAGgtn379u1YunTpg/fee&#x2B;8jX//61xdu3rx5TxzYqYBiJgGKnQrIVghEHMCpgNdee61GAaAAUAAALSnwt5T1&#x2B;xH5x/ajnjBfXwnQ3Bv2leZ4X2kThv&#x2B;sp&#x2B;lLniCUf/SjHx2e/NEfmIT&#x2B;qcnbg5LLkOQJQ7lHCACFWrdu3TOLFi16&#x2B;Kabbnr41ltvXVNA&#x2B;G&#x2B;KqYBcBcAhNRXw6quv1igAFAD&#x2B;UYADHfZbUuC3fj//6znH/NMN&#x2B;6666qpR48ePHzxp0qSjunbtOrBz584DSlrKHxcAWrXdu3dvevHFFx&#x2B;55557Hv7c5z73eDTPmQMO26mA9FSCCgAFgAIAOFiBv6nW79d3&#x2B;2IDf1Ot329I4C&#x2B;N4o/2N2b9/rtCfq1L6fTp0zt96EMfGjd27Niho0ePnpQE/kGVlZU9PUIAaO64sHbt2meeeuqpR775zW/e/&#x2B;CDD74R&#x2B;acCij1zQCFnEih2KqC6wCIgomFTAfnCf1Hh6sUXX6xRACgAFAAg8Dd14D&#x2B;Y6/cjGrdhX1Ot348ofIO&#x2B;hhztb6r1&#x2B;yXJH/uKGTNmdJkzZ86EMWPGDB86dOj4NPDbsA&#x2B;g9avauSd2rtsYGx5&#x2B;JnZv3BL9Tz0mOo8a2Cq&#x2B;9u3bt29YsWLFop///Od3fetb33ouCZ/VYSqgyaYC1q9fX6MAUAAoAEDgLzbsNzbwN&#x2B;X6/UICf6ElQEtZv98kIb/W66XpOP&#x2B;sWbN6nnPOOeNGJ/r37z&#x2B;yc&#x2B;fOg8vKyio8QgBaueSp9obHnomVv/tLbH3xtXhzycrY&#x2B;sqa2LtjW/Kuqmjfs2cMOO3YGHrpe6LfydOirF3L/9WfhM2qDRs2PP/II4/cf&#x2B;211/7lscceezPeORVQN8znmwrIF/wLKQByTQI0xVRAtrDf7FMBK1asqFEAKAAUACDst7TAfyDX70c07478he7WX8jmffnW8mcuU6dO7XTCCSf0fc973jN&#x2B;1KhRY3r16jUsCfyDrN8HOBQLgJrY8Ogz8fyNt8baPz0ZW9a9GuVRGW2ifZQkoS7J0kk63pX8gSiL7pNHxtBLTorBF82Ozke0mqmA9cuXL3/iJz/5yZ033HDDSzt27KiK3FMBuY72ZysIIuqfDog4xKcC1q1bV6MAUAAoAEDgL3b9fmMCf1Ot3y8m8DfFEf/SIsuAhmzeV8j6/ZIk6Hc75ZRTBh9zzDFjR44cOb5bt24DO3To0NcjBODwsmfLtnjl1/Ni1Z/mx2t3/DWqd&#x2B;1J/nhURNnfTtiyr3p3kmb3Rrvu3aL/KdNj&#x2B;OWnRd8Tjoo2Hdq1&#x2B;P&#x2B;3JIju2bhx44v33nvvHTfddNOT991336Y84T9XGVDIcoB8UwH59gfIFu4bOxXQ0CKg6DLgueeeq1EAKAAUAHB4BP5Cj&#x2B;7XF9ILCfSFBP5i1u/ne199YT6aIOBnC/LFhv&#x2B;CQn6tS&#x2B;n555/fKwn8I4488shRI0aMmNi5c&#x2B;e&#x2B;7du37&#x2B;ERAtB67du&#x2B;KwnibWPfjj3RprJto&#x2B;9v45NLY&#x2B;UfHooXf/qn2PHi&#x2B;iQN1kSbaBclpWVRU70v9sWu5I9OWXSdeEQMnnN8DLv45Og8elCr&#x2B;F7t3Llz45IlSx6YO3fuA9dff/2LdfYKqC4g9NdXBjR0KiBb4G&#x2B;OqYB8pxKsrxioV/K9rVEAKAAUANA6A39Tj/M3NvC31vX7hY7wN/WGfaWdOnVqkwT&#x2B;vmeeeeaYkSNHjhg2bNikDh069KyoqOjsEQLQulTv3Rdbnl8RW5a8EpsXvxxbl69OfutXx/YV62PvG9uiTaf2sefNbdG2a5coaVMSbft2jcr&#x2B;PaPTsAHRefzg6DpmaHQY1Cd/VV/H7jfejLX3PRnLfvyH2PDgkti1bXO0ibZRVtI2cz9V1bujKvZE&#x2B;y49os8pU2LE5adH/1OnR1m7ti3/&#x2B;1ldvXfNmjWL77nnnrv/53/&#x2B;Z3ETTwXkmg6IaNhSgdq3KaQIyHddtpfNUgQoABQACgBouWG/OQJ/S1&#x2B;/3xyBv7SI9zUm/Gcd809CfuUZZ5zR77TTTpswNDF48OCJ7dq169GmTZt2HiUAjbdv&#x2B;85Y/8jieOPpZbH15dXRsXcSqNuWRNfRQ6LH1HFROaDpz4CaBvCXb/5zvL7g2di6cnXs3bEjs0FfTWYgf0fmSHxpEsurk&#x2B;tKMn8WajJvl/ztT0TJ3/5stO/RIzqPGhA9ZoyJAWf&#x2B;XfSaPj7KO1UW/HVsef6VePGXd8bqXz8cG5e8kLnfzF4BZWVRXfXWVED6OXtMHxmjPvzeGHzB7GjXu2ur&#x2B;HdNzyDw5JNP3p1YeM011zxbT/gvZhPBfHsGFDsVUOiSgBY3FbBo0aIaBYACQAEAAn9D1&#x2B;83NPA39BR9TbFhXyFr9oteyz9r1qyus2fP7nfqqadO6dev3&#x2B;D&#x2B;/ftPSAJ/l9LS0jYeJQBN7&#x2B;lrfxLzv/rNJHJXJL&#x2B;Qy2uF7Ig2XdrHrP/4egy77OQm&#x2B;Vxbnn01nvjS/xev3f5wVNXs&#x2B;dvnfOvXe1Wb3dFl&#x2B;NDocvTQ6D11QhIiyqJq957YtXlLbH95TWx9bnVsW7Emdm3ZlPnq0o9N/4SklUF6xL4s2kaXsYNj0LnHxZCLTowe08YU/HVV7dwdK&#x2B;98KFNKrL7z0diXvF1e2v6tv0zVNbGv5q29ArqOHhGTv/bhGPr&#x2B;k1rNv2&#x2B;SPapfffXVRxYk/vVf//XRJLhui&#x2B;xTAY05peBhOxWQFgEKAAWAAgAOXuBvrvX7TR34m3L9fiG3KSTgZwvsDV2z/65gn&#x2B;NSeuGFF/aePn16vxNPPHFq3759ByeX0RUVFV08QgAOjB2vvR6v/uq&#x2B;2LBgSea0eTW7q2L3li3Rrnf36HLUkBj70Yujx9FjGv15dq19I&#x2B;4&#x2B;6f&#x2B;Jjc8&#x2B;n0T3zlFS9tafi3RX/vLO7ePYH30hCe&#x2B;zorQ8e99bvWdfbH1ldaxf8HSsvevxWPfAU7F1zeq3xvdL22Z2/6&#x2B;qScuAJLy37xB9j58cQy89OQaee1y07V74KrGNjz8fT1/zk1j5h/mZPQLe/qtWk24auDNqSmti&#x2B;rf/IcZ&#x2B;7pIoKW1dJ5PZvHnzimeffXbBLbfcMv/6669/KQqfCii0DIho3qmA6jzBP9cpAw/YVEADP0YBoAAAgb8ZAn9rWr8f0Tzr9QspA5pz/X7m9Y997GODpkyZMmDGjBnTevXqNahnz54j2rRpU&#x2B;kRAnDwpSE7la67b9ez/lH3PZu3RkXXTgXd95tLV8XtMz4Se9K1/WXt385K6ah9edf2ceIf/nf0njmx4K81Xcu/8rYH4uVb7ot1856KkqrS2P9Mo6aqOlMEpP/tPGxgDL7ohBj76Yujw&#x2B;DehQXlxcvj9pkfi5o3qzLLAf7vH&#x2B;/S2FO1NTr26xdnL/6vaNujdW4/s2/fvh0rVqxYtGDBgvn/9E//tGDlypW7coR/UwGtrAhQACgAoDUH/payfr&#x2B;YwN/S1u/n272/2N36Cw75&#x2B;&#x2B;&#x2B;/srKy7FOf&#x2B;tTwSZMmDTj66KOn9ejRY3DXrl2HlJWVVXiEALSiYmBvVezZsjW2vbg6trz4amx44JnY&#x2B;PTzsWfjthhw2jExZM6J0evvJkRpRf7VWi/c9Pt47HPfi73bt2fW2peWlmX&#x2B;cqQlQJtu7TL3M&#x2B;TCE6L7lFF5C4iq3bvjzWUr443Fy2LVb&#x2B;bH6t8/FtX7qt6a2K9ON2kri5LSt/YOqKpKpwJ2RWXv3jHp638fo656b9avM32Ovuf1N2P9/Kdi8b/&#x2B;LDY&#x2B;/EKU1V59Vp28v2Z7lJaVxdRrPhnjvnhplJSVtvp/202bNr383HPPPXr99dfffcstt6zJEf6LPXNAQ04hmG8SINdUQHXk3xcg31RATZ6wXkhJ0CLLAAWAAgBaS9hvSYH/QK7fj2jeI/rNsX4/21r&#x2B;zGXQoEFtP/7xj4&#x2B;aMGHCkIkTJ07u3r37kE6dOvUrzTzDA6BVSp66rv3z4/HUv/13rLnz8dgb25LwXpkZvU//DKRH2tu0aR/dp42KYZeelBnj7zisb8672/j40njmup/H6nsejV1vbM4cVX9r74H426n4yqPjkL7RecjAaDeke5R37hgVPTrEjuXro7xj&#x2B;9i6Yl1sevGl2Pny67F37/bMHgKlUZF8mfsyH9uuV7eo2VsVe9/ckTw/&#x2B;b9/uqqq9iS32BFHfunDMeWbH31XeN/9&#x2B;pZ46v/9cSz/n7tj25a1yT1V/m2fgZrM15XuPdv3PUclwf990f/k6YfcP/OePXu2rlq1avEdd9zx52984xtPvP7663ui6acCCi0A6psKKHbTwHzXFRr4W8VUgAJAAQCtOfA3dv1&#x2B;fYH/YK/fb0jgL42mXb9f9CZ9tS6lU6ZM6XDFFVeMGT9&#x2B;/PBRo0ZNTAL/0MrKyp4eIQANt2/HziTAVkdp&#x2B;/Ioq2g5A1M7126KdQ8uilfm3hNr710Uu97cnNmtv01J27dSYc2uzC7&#x2B;7Xv0jH6nTYth7zs5E5jbVGY/acvWF1fF6j8/HmvueTw2L04C/YpNsW/3jiRd7s1suFedxO6aTA4syZwh4K3NCUsz&#x2B;TNdm59u&#x2B;temrDKzf0BaOHQ/amT0mnVk9D3&#x2B;yHj40/8aq/40P8rLOtbKXSWxr2pHtO/XK859&#x2B;ifRtuc7t5upqU4&#x2B;y85dsWvd5lj70MJY9ccFsXH&#x2B;c1HeoUMMed/sGPjemdHjyFHJl1ByyP8Mbtq06aUlS5Y88p3vfOfe3/72t2ujsKmAQs4cUMhUQKH7A2SbCijkbAEHeyqgWcOgAkABAC058DfXhn0lDXh/SRHX5wv3UUSYb0jAb8wIf6HBPuulU6dO5ccdd1zXOXPmjEsC/xFDhgwZ061bt2EVFRUdPUIAGvsEMeLZ782NlX&#x2B;eH9ueWhNtKtpGtC2Ntv06R89J42LguTOiz8xJUdKm8QNV6ZHxbavWxusPPRO7t74Zg86cGV3GDinqPt58YVW8&#x2B;qt5sfL3f4mNjz6fJL99mVCenrClunpfZiogDezdk8A8&#x2B;L2zYtAFx0e3SSNyf01btsf2VRti2yurY8fK9Zmvr3rnvti5fmOUlbeN3Zs2JyG/X&#x2B;xZvy3aDeoWXUcOjbL2bTNH&#x2B;zuNHBCVA3u9fUT/hRt&#x2B;H0988T&#x2B;iese&#x2B;WhMAb&#x2B;0LsCu2xNgPXhTH3viFepcrpHat3xxtKttGm47tD8sfy127dm1Zs2bNc7feeusfr7vuuiXr1q3bHfVvEFjsNEChBYCpAAWAAgBacOBv6nH&#x2B;xgb&#x2B;5tqwr7nX7x&#x2B;sDftK03H&#x2B;2bNn9zr77LPHjBs3bmy/fv2OSAL/UOv3ARou3bjuzZdXZnaar&#x2B;jUKcralkfHwf2jff/usfCrN8YLP/ldJhNU/&#x2B;2Id3p6u/RIeM/h4&#x2B;OM&#x2B;38QlYN6Nejzbpj/TLzyyz/HpmXLY9viNbFjw8ao2rMzc9&#x2B;VnXtG7/ccGcMuPTn6nTK9qB3za/ZVxZo/Px4rbv1LrPzDX2L7ug2ZrztdHpCG76qa3Zn/h7YdukSfEyfH8PefGv1POzoqundq0u9rTVVVrL7j0Xjm&#x2B;rmx9s9PZpYClJa1yZwZIN0TIN0DoKyyIkZ/9MKY/M9XRnlne88WmVtq3njjjVefeOKJe//jP/7jL7///e/XR/1TAQ0tA6IBpUDd1wspBiIaNxXQIosABYACAA5E2G&#x2B;OwH&#x2B;4rd&#x2B;PKOyIfkPDf73r98ePH9/h9NNP73/88cePTgL/hJ49ew7p0qXLkJKW8ssToIXate6NKG1bERVd8w9EbV78ctx9xmfjzddWZEbn05Ca/gpuE8nHDuyUOd3ewPNmxuYlL8eO1Ruietfe2Lt7R/SYPCa6TRwRnUcOjGjgr&#x2B;Qtz7waq&#x2B;99NF766R2x6emXYt/unZlN&#x2B;MpKK6Kmujqzxj29545H9I8h554QQy45MXpMG1vUae62r1gXq&#x2B;9&#x2B;LJbffGdsfOyF2LPzzbemAsrKM0ff98XO5HOURcfhfWPIBSfE8A&#x2B;dEd3GD29g4K&#x2B;O3Ru3xBtPLosNf1kcK&#x2B;54KDYvfClJUTVvLUmoqc4sJUi1Hdg5Bp86O0Z96rzocdRoP7BFZpb0ZfpUIH2Z2Shxz543X3nllSd&#x2B;/etf33XTTTctrXUGgQM9FVBT5CUKfLtu8M93fbb3NybY1zTVv5sCQAEAh1rgb&#x2B;j6/cYE/qY44l9awG2bcsO&#x2B;nGP&#x2B;xx13XJezzjpryLRp00aNGTNmUrdu3QZ07Nixv0cIQHbVe/fF7vWbY8drG&#x2B;LNF1fFxoVLY9MTL8Xm5S9HeXn7GHxhEpwvnJ0E5zFZ/6rt2bQtlv3kT7Hmzsdi60urYt&#x2B;WHVG1e2/UlNRE&#x2B;2HdYshZJ8aUaz/a7P8fbyxZFst/ene89seHY/MzL2dCc3kS1EtKy6K6em&#x2B;mDKio6BDdjx4dQ993Ugw&#x2B;5/jiJg&#x2B;S57rpRn8v33JvrPzNQ/Hm8lcyZUdZWbu/HZF/63O07dolhl70nhj7mTnRdeKw4p5P76uK1&#x2B;58NJ793i9i/bynY3fV1r9t2PfWqfra9u0UvSZPzNx//7OPjvZ9evgBbmBuqZtdal1Xs3HjxuXz58&#x2B;/42c/&#x2B;9nC3/zmN2sKCP8HeyqgusAiIN91hQT&#x2B;xhQBNY39N1MAKAAQ&#x2B;K3fb/yGfcUe8T9Q6/fzhvxal9Ik7Pc499xzR40dOzbdsG9yp06d&#x2B;tiwD6BwVbv2xCu/mBfP/OAX8frjS5IQuyeJnB0zR7lrMmP7e6K8bYfo&#x2B;XdjYvB7T4iB5x0XHYdm3w0/LQP2bk0LgD1RUlYSnYYPqPfz71i1PjYveTU2PvV8bHn61eg9a0IMumBWtO/dsHC7d9uOWDvviXjpl3fGunsWxo4NbyQhujzalLz1//PWpn5VUdm7Vww46&#x2B;9i8EUnRN8TpuTc1C&#x2B;bdMnDilsfiBd&#x2B;&#x2B;Lt444llmYmDt/56lURNVfod3BHte3WLY77zjzHs/ScVPeGQbty37eU1mQ3/0mUO6VKKvidOie5TR0eHAb390DZBZqmdXeoWArWmArYuXbr0/rvuuuvhdK&#x2B;ATZs27Y0DOxXQkImA/5&#x2B;994CS47zORL/OOU1PzgEzyEMMMkgwiARJSRQpkiIlUiIlW&#x2B;KRvCs/7ZHXx/b67L41Je96V36r57UlP0k&#x2B;tsKSShYlWZZEkRYJJpEEGJBzmsFgcujpnLvff291DxqDjhNADPB/OIXurq6qrq7qqfq/79773ULCAFBeycBVKQRIAUAKABKS8F9pwi/r98sTA5a0fl&#x2B;Qe60g/LUf/vCHV69YsaKjq6trgyD7NQaDwS7/QiQkJCQWBiLv468eQP8PX8To7n0IjI5yIzsNjDxmJwM8SkA3uwVx/uA2tH7kVjTcvglaW&#x2B;VGcsHBCRz96vcx9OwehC5MIBFU6vYplZ4&#x2B;ydrShPrbN2DFp&#x2B;5Bzfa1bIw3HwQHxzDwzEuCSL&#x2B;OyTePAuH07G0rlVRM/eh1VW83CwFtD9wK57ryo/bJSBzP3vQHmH73BLQa0yW330QyDK3JiA/u&#x2B;Sac6zuv299VJBLBD3/wA&#x2B;YsK1etQlNjI&#x2B;rq66F/jzpBFBIACj1mn4&#x2B;Pjx998803X/znf/7n/WIaLkH&#x2B;K&#x2B;0cUE4ngbnzUOB9oLBvQLHXCxUCllQEkAKAFAAkJNmfD9lfKOGfb/0&#x2B;UDxtHygekS&#x2B;X3C8V4S&#x2B;U3q9eRPKft01fd3e3&#x2B;fbbb6&#x2B;97777bmhpaWltb2/vNZlMbi01ZpaQkJCQWDKEhyYx&#x2B;IvXMPCTl1kUiMcj1BgPGpUeqTR540dZGrCvakXrvTsFeX4fqresKp43l4NEIAzP0XMYef5tDP78FXjePYNEOsxig0atY8d97lGvMsDe24rOR&#x2B;9C0z3b4Vq3Yn5CwMAoTv7TL3H6G/&#x2B;K6ISPXf2zNITM9BIIcS2/HjY03LkZq/7gI2j60I6ijvqpWAIDP38Zb3/x7xAd8V7cJmcBkLTgQ9WKFbjrxf8Nc8u1HbXP1tPnPU6pFPbv24eBgQHMzMwgEAhAq9HAYrVizdq1WL16NSwWy3smAJQSAubOI6&#x2B;AI0eOvPzKK6&#x2B;89Wd/9mdvl0n&#x2B;FyMroFTXgFQB8l9ueUApIWCxzQLT8zlvUgCQAoCEJPxXI&#x2B;G/0vX7wNJF9Jeyfj/3OU8333yzc8eOHbUf&#x2B;MAHNjY2NrY2NzevMxqNLvXFUZWEhISExBXG1FvHBUl/FYP/8ho8R85xL3s2wVNpkEzH2Q1fpzOjducNaL7/RrQ9cEtFhDedSGHizcM4&#x2B;8PnMfzrvfCfuwDFRNAo/lfx9klwMDqc/Bkdj96Bprt3wFB9efIXpc5HRqfhP32B93Vm/xlMHz2F4KlxxEJBpIMJJvyUZUDFDbR9vckGU5MbzjXtcPZ2wtbTDNf6TvG8a9YsMO4LIhmOQW3QQmPQY1Ick8P/43sYePYl9gHQwSKWVSOZirJwodNY0fzANmz88r9jkeRqRjwex75338W0x4Pamhps6OuDuO8WF3ASCbzxxhvY8&#x2B;abHMmn5R0Oh/gd6FAtttHe1oZWMeWL8pMgEAwGMTo6iqNHj2Lvnj248667sHPnTmi1S3u7LzfqX2zZ3PnDw8MHDh069MbXvva1373wwgtTuDQrYC6ZL5YVUIr4F/MMKEcUWKy2gsDiZgOk53PupAAgBQAJSfhLEXmUQeRLiQWLadi3WPX78yH8alQe7a&#x2B;0Zr8oyc&#x2B;Z1A888EDN5s2bG3bt2rWprq6upb6&#x2B;fpXBYHDKvxAJCQmJqw/JUBQjL76D8z95CUO/fhOhiUk2ptNASc/Ptvaz1NWi7rY&#x2B;bo1Xd9uGilrTkQP&#x2B;8G/ewsBPd2Pk395G1O8T5NoElUbLUXWK0tNtxdJcg45H7kTtTevgPT0A/5EhpCJJhEYnEDg7jND5SbE3QeYX9I8a&#x2B;NGtR6c2wdRQDVt3I1w3rIB7cw8c6zrgWtcJlfZy0ju55xgOfuU7mD5wCuqwBjBqoLXooTdZoK&#x2B;zw97dgmkyTXz3DKJeP5wrO9AkiH/rfbeiZse6ZXFeY7EY3n33XZw5fZpJ&#x2B;/bt25nIE8kvRMinpqbw5S99iXnIY489hsamJl5&#x2B;xuPB2Pg4BgcHMToygubmZmzZuhUre3pYILns&#x2B;E5O4kt/8ReY8Xrx&#x2B;OOPsxBwJfhKuT4A&#x2B;d7LJwYEg8GxM2fOvPXss8/&#x2B;7stf/vIBFM8KKBTtLyQQpHHlPAPmKwSkSwgCCxYBpAAgBQAJSfjLeV1KFHgvDfsqmXel6veXYrokA&#x2B;DTn/5086ZNmxp37ty5qba2ts3tdneJQYZF/oVISEhILC9wa7zf7MXAj3dj4vXDiIZ9LARoVDqkuFVdlOv5nSvb0PzATWh98FZUb1ol7gTlDwd8JwfR/8&#x2B;7cfJvf4bohJfd/LN0gRz3SWwgUMRdaY2XFjTfwD4FBthZeNDbbDDWu9iM0L1tFarFZO1sgKkxxys2mcbk/mOYeOsw1DEt0qY0TE4XnGs64DszjLf&#x2B;6G/gPzPE26XPJF&#x2B;EOEIw6J247an/hraHb4P36ACbGVb19cBQ41iScXYymVzyCHku9u7di5d272Zy39HRgRZB5ql232BQBJ9Dhw7h&#x2B;eeew1ZB8Nva2&#x2B;ER5H9CkP/JqSmcO3sWExMTeOCBBzDQ34/RsTF8/BOfQENDA86dO8fLnjp5EoI0swhAmQIfeegh3taV4ivzIfyFBICccxQfGxs7fODAgTf/8i//cvfBgwcDRch/ITFgscoDSmUHlCMElCoPWKxsgHQl504KAFIAkLg2Cf/VXL9fDuG/Wgz7yq3fXzSSn92&#x2B;GCCo//AP/7Brw4YNTZs3b95YU1PT7nQ6WzTcL0lCQkJC4lrB9L7TGPjJixj82e/gPdbPZJyI&#x2B;MUSgSin2VdvXo32j9&#x2B;Bxru3wtrRUHK75BMwc7gfe/79VznKrtEYsoNOHncqXgQh1K5bj&#x2B;aP3ARLRx2S3hh0dWY4utuhEURV77TCWO0QNyVdYaL7h/8b&#x2B;77&#x2B;TRYsdDBzJgOLGeJbVG9dg21/&#x2B;0VAo8bM8XPic8W3Gw9C22hE9fq1cK7qyJs5sNh46623IMgk9Dod7r3vPgxduMCp9C6XC80tLZULOMEgjEYjR/9Npvy2Op6ZGfQLsj48NITp6WlehzIDqHZ/3dq1WLd&#x2B;Pe8Dkf2RkRGcFcu6q6qgE2TebDaju7ubz9MzP/kJXn75Zdx&#x2B;&#x2B;&#x2B;34zBNP4NixY9BotfB7vSwo0H6QAOB2L31Lw0rr/8sl/vmWCQQCIwMDA/u&#x2B;//3v/&#x2B;ZrX/va6TzEvxjpn4&#x2B;JIIqIBJUKAfNtJzhfEUAKAFIAkLjOyP7VRPivZP0&#x2B;cOUj&#x2B;kDxOv1SxD5fLT9PdXV1&#x2B;s9//vM9vb297evXr&#x2B;8VhL/DYrHUy/p9CQkJiesDRNjHXj6AgZ&#x2B;&#x2B;jKFfvY7Q2ASytfyAUiJAtfemmirU3trHnQTc67thqHNyfT21I/TsO4Pp/Scwc2QAvuMDCI1MUoifa/Up&#x2B;p7tFKDVGmFuq0HTfdux5j98DJa2unnvt/fYAM4&#x2B;/Rym3j6GwNlxqAWhj3mC0DTqUL91Mzb8l89wG773EmScR9H2I0ePsos&#x2B;pdurNRom2bfeemvZ26HU/J/8&#x2B;MdM7u12O8yC/GsFqbfZbKitrUU7RfpbWgo69NN&#x2B;jI&#x2B;P46fPPINwOIxHHn2U92H2NyD2izIDKKp/4sQJhEMh5ipWqxV37Np1ybLvFVcpJ&#x2B;pfivgXEwDmLiOOSXRiYuL43r17X/zKV77yxpEjRwplBSymeeB8hIBcv4Bi3gFA8cyAJREBpAAgBQCJa5/wL7R&#x2B;vxThX8r6/XLI&#x2B;3wJv7rC9&#x2B;Zj3ldO/b6qr6/P&#x2B;slPfnKlIPwrxA19tdvtXmEymapUV8tFSUJCQkLiPUNocBxDz&#x2B;1B/w93Y2rPMUQCHvYLIMO8rBhAMBhsUFk0UKe1LADEwv5MOj94ea7bhwF6hx32la1w9nagakM3XBu64FjbzhH&#x2B;xUTcH&#x2B;LPTIYj0LusUOt0V/S4nTx1CocOHsSWLVvQ2nqpeSCRaorCk5P&#x2B;DTfcwPP279/PU1IQb7r91tTUMNmmyDrV3xPJz8VLL72Eb33jG7jnQx/iiQQAIvJkyNc/MMBeAD6fD1s2b8b69evR3dOTdz&#x2B;ffvpp/OqXv0R7ezv&#x2B;5E//FE6nYt8TjUZ5/ygDgPbJarNBo9FcFXylkuh/KeJfTnZAvuehUGjk1KlTb3/3u999Vkz9KF4SsJjCwGKVCwDllQfMRwSQAoAUACSuccJfbnS/XMJ/Jev3gfm78ZdaRl2mGFBpCn8hYl&#x2B;U5GcncSPX7ty50/nQQw&#x2B;tEoOOlS0tLT3V1dVUv2&#x2B;VfyESEhISEsXgPdKPkZfewdjL&#x2B;zFzoB/hsUkk/BFu9ZdiIUDDkX0N9NAZTNBZLDDVu&#x2B;DIuPI71rShqq&#x2B;bOwuodZpr&#x2B;lhRhJ5S5sfHxlDldmPb9u3o6&#x2B;tjUj8XVGP/pSefREqMwcX9mck/&#x2B;QT4vF6O0h8/fhxVVVVYuWoV1q1bxxF&#x2B;ev93v/sdTp44gc1btjD5HxPk3&#x2B;/3s3kfmfjR8mQE&#x2B;NT/&#x2B;T9sCvjxj3&#x2B;cif3xY8d4mdOnTnEmAHUPWLNmDR548MGCZQRXExaa9j&#x2B;X1JcjDhTKKojFYpHJycnjzz///K&#x2B;/&#x2B;c1v7jt58mSgDPL/XvoHzH1eTkYAULitYMUigBQApAAgcXUT/sVO518o4V&#x2B;u9fvlpvAvtmGfmtL577777tq77rqrRxD&#x2B;teJ1pxhEdGhmCzAlJCQkJCQqRzIcRXBwHOHRKcS8QcSm/dCaTYh5/LD1NEJnNfNEKf0a0/V7yyGX/bf27sW&#x2B;/fvh9/mwevVqNshb0d3NEfUs3nnnHTbqu&#x2B;197&#x2B;OxOBn0kQDQ39&#x2B;PCxcusHkfmfhRDT615vvoxz7GdfxE6Mmlf1AsEwmH4aqqgloM/8wWC5cDHBCf&#x2B;&#x2B;tf/xpesa0/&#x2B;ZM/QX1DA0WvkU6lmKGRmR9tY26GwXIUAOb7ej5ZAPnmBQKB4ZMnT776ve99b/f3v//98yXIf7mCwFJlCJTKDFioCCAFACkASCwDsr8UhP9qr99fCsJfTkR/vuS/ZP1&#x2B;d3e3&#x2B;f7772&#x2B;68cYbu9etW9frdrtbnE5nh0znl5CQkJCQuPIgc75sHT6R&#x2B;T1vvIFjx4/DZDajt7cXGzduRF3dRd8DSuEfGR5GLB7nUoFEMsmEniL7RPTHxsY4Xf&#x2B;Tn/oULJbLm&#x2B;8MDQ1xZJ&#x2B;yCkg4sDscLDRQzf7mzZsLegIsN/JfTAAoN0OgWDZA7vxKMgMoM0NMYXH8j1JWwFNPPXX40KFDvhLkv5AIUI4QkER5JoLz6SCwJCKAFACkACBxfRP&#x2B;&#x2B;dbvz5fwL3aLvkreK6dmv&#x2B;Ja/i1bttgfeuihDjGI6Fy7dm2fIPsNNputWf6FSEhISEhIvLcgI71v/9M/cRZAnyD6lI7vEIScxtrkD0A1/1PT06hyuThdn96bEqSfnPgp9Z/eo2Wpvp9EAjL2Wy2Wq6mtLfiZFM2nFoM0mtdqrr0yi0rN/ip9nM&#x2B;8Ys&#x2B;DweDYwYMHn//pT3/6&#x2B;tNPPz1QhPxXIg6U6i5QaVZAKY8AIH/XACkASAFAYhkS/qWq319swl9u/T7KIO/lLFMOwc9H6udbs38ZsS8wqW&#x2B;//XbnRz/60VUCHWLqE2S/1mw218q/EAkJCQkJifce0UgEe/bu5Vp9qtun1PsTx4/jgCD8lNJP8zZt3sylANkUfmrPR5H/QDDIYkG9IPs0GidDvrbWVjhdLqjVanlwUXnUfyHdAcqN/BcTCXI6CERGRkb2vfDCC8/96Ec/Onrw4EFfDpHPR&#x2B;pLCQWF5pXberBSEWA&#x2B;WQBSAJACgMQyIvzLqX4fWJp6/XLEgCWt33e5XDpB&#x2B;Ksefvjh9R0dHa3d3d19guzXGAwGh/wLkZCQkJCQKA0yuBNkiyPo5KZfCOfOnePIOUXe9737Ls8j93wy76sElKpPpnuUir9t2zZO89cbDLgwOMgp/QcPHMB&#x2B;Md39/vfj937v9&#x2B;QJWgTyn&#x2B;&#x2B;9cgh&#x2B;JSJAofcKbSeVShUUBEKh0PC&#x2B;fft&#x2B;s3v37ne/9a1vnclD&#x2B;Mt5Xk72QDGjwTTKKw0oJgJIAUAKABLvMeG/Wur3geJp&#x2B;0DlrffKnbcYrwu596sXkfznTfOn&#x2B;v2bb765&#x2B;sEHH7yhtbW1TaBXEH63GJCY5V&#x2B;IhISEhIRE5UjE4/jHf/xHnDlzBk3NzWzAt6GvDyaj8eIyiQR&#x2B;/atf4YIg7UTcPviBD2Da40FLSwvcbjcLA4Xwr7/4Bdf5337HHVyTT&#x2B;39KJr/k5/8BIcPHsQtt9yCmro6hMR8EiAikQi0Oh277s9tDyhRmQBQzmM&#x2B;sr4YxL&#x2B;cdQtlCmSnZDIZO3/&#x2B;/GvvvPPOa9/4xjf2nz59OpiH8OeS&#x2B;1SRqVg2QSExYCEiwLyzAKQAIAUASfaXP&#x2B;G/kvX7wNJG9K9o/b4g&#x2B;04xEKn54Ac/uFEMClqamprWmUwmt1qt1sq/EgkJCQkJicpArfCIfJODPtXX9587B3FvxR27dnG7u3fefhsHDhzg5SgFf&#x2B;OmTVx7X2xQ9qMf/hCCmOFD997L0fzcIRyl9&#x2B;9580089dRT7NJP6f0kBpCgYDab0dXVhVtvu43d&#x2B;CUWl59UWv8/X5JfTECohPiXEgR8Pt&#x2B;5o0eP/pvAvm9/&#x2B;9tnS5D/SoSBFEpnBACVdwoA5pkFIAUAKQBIwr94hH&#x2B;h9fulCP97Xb8/H8KvRuXR/oXU719G8nMm9b333lstCH/9rl27NjY0NLTV1tauEoTfJf9CJCQkJCQkFo7z58/j5z//OQsATY2N7HwfF2R8xYoVMOZE/M&#x2B;ePYs9e/bg2NGj7JK/ZvVqbN&#x2B;xgwn8XJBw8Nxzz3GLPnLfp9p&#x2B;Su/3i/me6WlEBeEnE79bBNFfIQg/tdMjAUDc3&#x2B;UJWSJ&#x2B;UqnLf6H55Ub5F8MYsNR7OVkBoXPnzr1y9OjRt5988sk3vF5vtAD5L/S6lFBQTllAPmEAmF8WgBQApAAgCf8CCP97Wb&#x2B;PMoh9pYS/0vr9UkR9MaL95QgBZaf5//7v/35TX19f486dOzfW1dW1V1dXd&#x2B;r1ehkGkJCQkJCQuMLCwA9&#x2B;8ANO&#x2B;6e&#x2B;9zfedBNnBlDLNqrJ37dvH9f&#x2B;u6qquFUevRcKhTA9NcXrjon3Dh86xD4C7//AB5BOpXhZEhqI6Iv7uzTpu4IcpZJU/kIEv9x1F9oFIB/RzyLXJyDfsh6P51h/f/8bP/7xj1955plnLpRB/pMVCAKFRIBiBoFA&#x2B;Z0CpAAgBQBJ&#x2B;Csk&#x2B;wsl/ItZv18O4S/XsG&#x2B;p6/ffM8M&#x2B;ev2FL3yhc8uWLS0bN268QQwSuhwOR7NWq5UhAAkJCQkJiSsEIvUUtaeWelmQEeDQhQs4deoUewFQnX5jYyPWrV/PEX0axtE6TPZHRzmNn6L8Go0GBqOR3fo7Ozs5o8BqtcqDfBWQf3qk81YusV8s4j&#x2B;XpJeaX0mJwFxBgCaaJ36/3tHR0df37dv3xp/&#x2B;6Z/&#x2B;rgjZT5YpEpTbLaDUhAJCgBQApAAgyf5VTPiXa/3&#x2B;LOmeB/kvRwgoVsvPkxg4GD7zmc90bdq0qXPt2rVrBOHvpnZ8YrCgl38lEhISEhIS7w2oXv9b3/wm199Tu71Vq1ZdQtrJhO/YsWN47ZVX8OaePfjIRz6CB8UksfwEgNz3KjUIXIz3FqP&#x2B;f&#x2B;57&#x2B;d4nESAnK&#x2B;DghQsX9v7DP/zDb1544YWJOaR&#x2B;rgCQRHllA/nMAistBSg7C0AKAFIAkIS/ONlfLMK/WPX7lRD&#x2B;xYj4q8tYttya/YpN&#x2B;nKn3t5e62OPPbZCEP4eMahYWVtbu9JoNDrFz0Mj/0okJCQkJCSWBmNjY3j22Wc5in/zzp1YtXo1z/f5fPj5z37GBnur16xBVBD7c/39eOedd2DQ67mmn6L98ViM0/7pfWrDNzExwUymUcxrbWvD&#x2B;nXr0N7RIQ/0MhEACpH0QkS9EiGglMlfKUJf7vxKRYC5r0kQiMViE&#x2B;L3vO/111//zZNPPvl2DvlPFiD/pcoDCmUBlNshYK4QIAUAKQBc94S/3Oh&#x2B;KZJeDqEvh/AvtH4fZZJ5YOE1&#x2B;vmIfCU1&#x2B;2WT/OykEbjzzjur7r333hWbN29e3dTUtKKmpqZb1u9LSEhISEhcWRDxPz8wgJQYn5LBHtXhE6LRKN584w0m&#x2B;ZS6Tyn7NIaltnv3338/m/uxUOD1YmpqCjMzM6itrWXTvphYl4Z7HZ2dEPd2eZCXEfkvJACUygiYb/r/Qsl&#x2B;MaFhoaJAZkp5vd7D4m/g1b//&#x2B;7//1euvv&#x2B;7JIwQUEwHKKQmY2y4QuDQ7AMjfJUAKAFIAkIS/xHqLRfhl/X6F9fsul0snyH7dHXfc0dXX19crBhdtbre7W6bzS0hISEhIvPcgQz5qq1cIJAaMjIxgcHAQZ06fZrGgo70dN&#x2B;3cOUvwSSDY/eKLXA7g9/sRFNskwz&#x2B;aJJaPCFCO2d98HxfT7K9SQaBU&#x2B;n/u9nK9AnJfi7&#x2B;DMY/Hs2/37t3PfP3rXz8UCATiFQgBxbIBSmUCAMXLAKQAIAWAa47sL5TwL1X9PlA8al8uuV8Kwq&#x2B;u4L2FkP&#x2B;8af4tLS2GRx55pHXr1q0dGzZs6HO5XM1VVVWd4uchLXwlJCQkJCSuMrz26quc2k&#x2B;R/TZB7AuBiNDJkyfx9FNPcVbAH//xH2N9by&#x2B;/RyZ//f39bOjX0dEhI//LnPzneyyX4Bd7vdgt/4oJAJW0Byy1Xq4YIKZ4OBw&#x2B;cfbs2V9997vf/bfdu3dPonB5QDmtApFHFADy&#x2B;wJIAUAKAJLwX0HCv5iGfZW26FuMFnylyH&#x2B;p5wXT/Kl&#x2B;/9FHH&#x2B;0Sj&#x2B;3r16/fZLfb6x0OR4u8pUpISEhISCwPAvj2W2/htdde49T&#x2B;qqoqbr1HLv06rRZnzp7FyPAwxqm&#x2B;P5nEypUrsWXrVvT09HCrPonlT/7zPZ9v5H&#x2B;pjP8qFQfmU/8/d97cbIDsvOzreDw&#x2B;Mj4&#x2B;/vz999//1QIiQK4QkM55XakfAFC4DOCqEwC08k/r2sEyq98vtfxCDfvmW7&#x2B;/mAQ/H2Gfb81&#x2B;UZKfM6lvvvlmxyc&#x2B;8YnV3d3drWvXrt1ktVrrLBZLrfwLkZCQkJCQKIxoKom/OvwqQvEY7mzqxlpHNRpNC7e/&#x2B;VH/YZwLemHRaFFjssKk1uCW&#x2B;na4dMZyx3dM6Ps2bcJZqvkfGMDo6CgS8Th7BNTU1KDa7YZbTJQhQAKBxLUvCBQi/6VEgUK/sXKJaaUEttB&#x2B;FdtWqWXyCAGJNBkCpFKhZDLpV6vVpkQi4dHr9bU2m61NLKbJQ8rTuDRrNpXneT5useyjxVIAkIT/aqrfBxZm2FfJvCtVv78U06yg4HK59Dt37nQ&#x2B;8sgjvZ2dnS2C9G8UhL/GYDA45V&#x2B;IhISEhIRE&#x2B;UgKIvHi2ABeHTyOvz70CkxGE95X247bG1fgtpoWbKhqgKbCoVdKcIWXR87gH88ehFqjRSQehVVnwHO7HseN1c2VDdo1Go7q0yRxfRP/xY4iz80oyEey84kGc2v0yxEbCn127rpzBYk5af5JSvOn2eFw2KPVag3idZTmG41Gl1jXptFozIL8u7PLZwSAUpH7fGPudM5jLg9JFxEEVFe7SCBLAEr8gV1jhP9qSeefS87LJfxXQ/1&#x2B;sfZ8lbr1l0Xyc56rBcE3b9u2rerhhx/e0Nra2tLR0XGDxWKpERc/s7w9SkhISEhILAzBRBzHvBPYMzWMNyYv4Hdj/ej3T/PteLWzBh9uWYX7WlZjq7uxLDGARpVxwT988RjCyTiiyQQSZNJndcKglp10JcrjJeW6/Rd6nG9pQO5jvnT7clP8565fbvp/ikL7iUSU/gAjkYifNiPokD6ZTAYp2EX&#x2B;VdS9Ssw3FNr38fHxF&#x2B;&#x2B;&#x2B;&#x2B;&#x2B;7/JF4mcGm7wGJtA&#x2B;caAuaWBQDllQPMvRRcNVxTCgBXqQAg6/fnTe6BKx/Rz0f&#x2B;1fN8fklq//bt2x1iqr7nnns2trS0tDU1Na01m83VarVaZu9ISEhISEgsMYi0H/dO4c2pIfx66CT2Tg5hOhLCSrsbT6zow2d6tsCm1ckDJbFkvGQ&#x2B;PgAL9QQo9l4p079CQkE5r6PRaJjWFwSfjPyCRqPREo/HI3q93qDT6SjYlRZjYH0l/gdjY2O777777j8vIgAkSwgA&#x2B;ToDpDBPHwDpASBxpQn/Quv3SxH&#x2B;pazfL4e8z5fwqyt8bz7kv5z6fdW9995bs3nz5to77rhjY3Nzc0dNTU2PIPxu&#x2B;RciISEhISFx5WHS6NBXVc/Tv&#x2B;veBE8sggOeUfxq8CS&#x2B;fvJt/PLCSfz5hvfh9to2ebAkrqgwUOx1JeuWu0wx8aHYfhUSMGICgvDHKILv8/n8BgFB7lUU9RdjX6sg/2bxWiPWsZfapyyNyi0fyCkjyI7Hc8sAUrg88zad81iqHKBQecCygBQAri3Cv1SGfVeifh9YuBv/fAj&#x2B;QlL4yyb2BSb1Jz7xiYZt27Y133jjjRuampq6qqqq2vR6vUP&#x2B;hUhISEhISAD9AS/&#x2B;r72/QrPBhI929eHGmmYYNOUNX88GZ3BgagTvzoyjRm9ELJ1Cp8WJOpMVnVYXGsRjpXCJ7dxW187Tf9&#x2B;0C29ODsEgk/IkrgDJvxKiQbHIerF9yp2fW7&#x2B;fEQDSyWQy5ff7wzqdThMKhaKJRCJltVpNNJ&#x2B;If3V1dQ2tR/wonx/A3M/KJflz&#x2B;FVeD4Ec8p81&#x2B;FPj8gj&#x2B;fPjGshQB5BVr&#x2B;RD&#x2B;xU7nXyjhX4z6fWDxo/kLSe8vFe1fSC0/iwOf//zn27du3drW19e3vrGxscdutzeIi6FF/oVISEhISEhcjolIEOOxMH554QS&#x2B;ceItrHQ34sG2NXiodQ02VtUXXI9G&#x2B;J9585d4qf8wYDDBbbRirc2FtCDrulQSCTEss&#x2B;sMuMFVi0c7erHWUVPxvulUatxcI7vqSlwZEWC&#x2B;BD4fMa9UeChXjCBiT8sGAoGIIPdMjum5w&#x2B;EwU72&#x2B;mDRut9uZ3abZbDbNFRryEf5i5L4I6c9ua&#x2B;64PEv&#x2B;U0XG7ekS/GvZGf9dsrPSA2B&#x2B;P/AlJvtLQfiv9vr9pSD85UT050v&#x2B;S9bv19XV6T/96U93bt&#x2B;&#x2B;vWvVqlWrGxoaVlM6v0ajkU15JSQkJCSue4xHQxyWS4mhl02nh1athlalzrvsMe8knh0&#x2B;iafPHca7k0NiwJbCjbVteLhtDe5tXY0uq&#x2B;uydX4zfAaffePnIAex7930ILf1GwjM4KBnDK&#x2B;PnMFT548BYh&#x2B;0Rgt&#x2B;ctsj&#x2B;HDzSnlSJK4qPlKs/j/7WMogcCGmgMXej8ViSXqMRCKJYDAY0&#x2B;v1Or/fHzWZTDqDwaClyL94bijnO1X63Qotl2/&#x2B;yMjIK&#x2B;9///v/K5T6/kTOlERpT4D5eAFc9R4AUgBYBAHgGiH8863fny/hX&#x2B;wWfVfKsK9gmn9fX5/14Ycf7ty2bdvqjo6OFXV1dauNRqOT6pfkrUxCQkJCQuJS/NcDL&#x2B;H7Zw8wmW&#x2B;1VeE7Oz&#x2B;ClkxafjSV5BFzNBnHuYBXzLfBbVQa3rzrGcG/XjiNnw8ew/4pJQX/HkHeH2xdjZtrW&#x2B;DQm9hpfyjkxZOHXsNPzx2E02zHrXVt8It5e6fHUG&#x2B;2wagzwq7RYJ34zAdW9OH9jd3ypEhcVSJAJQaA8zH&#x2B;K0X2s88F2U9lovvpqampiBjf6jICQNputxszqfw6quGvlNCXu/&#x2B;lyH6h94eHh0kA&#x2B;JJ4Gc8h/nNFgAQKdwTI7QCQzCMAIOc1cualpQBwDQkAsn6/4PqVuvGXs0w5BD8fqa&#x2B;kZr/Q86IZAPfcc4/7rrvu6ti&#x2B;fTul83cIwr9Kp9NZISEhISEhIVES09EQwskEPLEwZuIxTIjHAxSdnxzC&#x2B;eAM4mLeSDQMQzqFNc4adNtr8LnujdiRk3Z/yDuB757Zj2&#x2B;cegfBWARbalqhE3fpgHh&#x2B;2DcJs1qLuEYLqrX7/7Z/CPc3r4I/HoFFZ&#x2B;AhuUGjFjd1lTwZElcd&#x2B;S9GoMsl&#x2B;qUIeL73BNFPh0KhhEajUc3MzMQolV&#x2B;Qe6rdTzgcDjbqE5NajHnVpUSI&#x2B;RD4ha4z93FoaOjVjACQQP4MgHzZACkUzgRIF3nMkv301SwASA&#x2B;A8sSJ95LwL6f6fWBp6vXLEQOWtH7fbDZrHnnkkaYbb7yxdevWrX21tbUt1dXVPTKdX0JCQkJCYn6oMpjxrmcUP&#x2B;o/jOdGzjL5RyKOZpsLK511uLm5AeurGrjW/3RgBnf&#x2B;5p&#x2B;wb2YcP731YZzzTeGtqWHxegJnvJMIJsU4PZnABxtX4PGOdZiKkqgQQYvFgah4r9poRrPJxp/rNpjlwZdYloJAuXX8xcjmXDIdCATi1HqPovxerzdGJJ/Ivslk0jqdTiMtQ2RfPL9s3bnu&#x2B;4We56vvn2viV8DB/5L1Kl1nThcA9ZznqSLcAUX4SLoAX1s2HgBSAFgawn&#x2B;11O8DxdP2gcpb7wFXzrCvkHu/ehHJf942fVS//6lPfaq9r6&#x2B;vZfPmzVtcLldjVVVVFxmYyL8QCQkJCQmJxcEp/zS&#x2B;cvg1Qd6TaHFUQ6fWYmt1I9w6IzyJhJIRMDGIp88c4PH1Qc8I1v/L1zhzgGAUZL7NYseDLauwsaoOH2lZjS5blZjksZVY3mQ/H4Ev93WhFHsi9oLwJ/V6vWpiYiJmtVq1xHuS4u9PEH&#x2B;9xWLRU&#x2B;SfnueLqM8l8/kEhhIt&#x2B;Yrxr7zr5NteMYPDAmJBLvlP5RECSgUdlx3JlwJABWR9ntz/ejPsW&#x2B;71&#x2B;7nPeeru7jY/8cQT3atWrWoRpH8zufOLi1&#x2B;r/POQkJCQkJCoHAMhH3aPnMVLgryrKIKoUqPL6kCX3Y12q0uQdgdqBHn/WOsatH7wszg&#x2B;M44dNc044p3ES2P9eFVMB8YGkc2sbXbV479v&#x2B;YB4mUSryYp2Ry1MGi3ceiPqjBYYNXJIK3FtCgGFWuzlW5beT6VS1HaPHfk9Hk9ckH2N3&#x2B;/nKL8Y3&#x2B;roPa1Aa2urfu42i5H0fGS&#x2B;EGkvl9iXu2y5&#x2B;5L5/nOPVW7QT1WAS&#x2B;SKAmmUlwU9twXgshEIrser5ZUw7Fus&#x2B;v1Sy1dK&#x2B;Berfn8&#x2B;hF&#x2B;NyqP9C6nfv4zk514Atm/fbv/kJz&#x2B;5RhD/5nXr1m2x2Wy1FoulTt5uJCQkJCQk5g9PLIK/O7EXXz/1LsYFqYcg6CsE6V9rq8L5oBc/PX8Mk2KZuBgnd1iccBCBN5hxPuTDf9r/AsbCAU7lh06Pztpm3FbTig83rcBNNS0ydV9CCgJ5nlPqPv/tCbJP5J9q9GdmZhJut1sveL5ao9GoGxoazNl1xHi34HZzo&#x2B;el5pVqM1gsE6CcKP/c93Lfn/u6jHKBuRkA5ZQBzOU9y47oX&#x2B;8CwFKn9C8nw77FqN8v9YeyGNH&#x2B;RZsEudft2LHDIQh/b0dHR0tPT89GIvwGg8Elbydl33XoiopUPIF0MoV0KoVUTAzfSGEORfn9RCQmLqMp8TrCy9G8uD8EjUGPqMcHrdWEhHit0mqQDEehUqv5DKViCWj0WiTFo1o80jbp4zR6HX&#x2B;OxqDjzwS1hzIZeNtai4m3QwtqrWaoyMRJ7B/PF8/pM&#x2B;lRLZZRaTRQ67TKMvyZ0uxJQkJCYilAzvsPv/LPeGHgCJprmrGloQMDIT/&#x2B;n013YbOrHkdmxrBn4gJ&#x2B;O3wKr4ydx6BnDO9rXYMaXRJ2cX2&#x2B;p2U1jGoNum1VuFGsv1I8OnTSakfi&#x2B;iT5lxEKMX6JRCJkSkep/Emfz5egFP7p6em4eKTWexqKfguCr6U6/rnbLUWoS5H&#x2B;UqS&#x2B;nHXnmwlQSohQi&#x2B;tHvtKAOVyjlMl3MS6nqoD7SQHgGiL9lab0X&#x2B;2GfUtdv19uCv&#x2B;iG/Z1dXWZtmzZ4nrkkUc2tLW1tba3t/eKC2OdVqu97kMHRNrpaCUCEcSDIZ4XODckCLIOwQtjTNiJbIdGJpk8hy6MMykPnh8VjzrEZvxIEekPRviiG/cHmVQno3HlopxI8MWXSLoqIxjQ&#x2B;/yoUV98nUjya2r&#x2B;PHuBFzctmpdO5V7oSXjIZGNlUrv4PUHq6XtwuhcRe/GaxQKxjyoi&#x2B;&#x2B;Iz1DpB/A16Fgl0dguLABqDAVqzARqzkZfVu&#x2B;wsMGhMRhYPdDYxWc08acU6tB6JDlrxvpqWE&#x2B;vQcZCQkJCQuBwacU2&#x2B;sbYVLwweQ61Wj491rMdo0I/Xxgbw7NApHJsextlQgAXdTncD&#x2B;owW/PH6W7C9VlbcSUjMBUX2s9F9qtc3m83aaDSaIpLvdDp1guSrifSLMe5l9fpzyXKp2v25okAhwl&#x2B;I/Odbf25Z9dzlis0vR2DIt26RUm51ERFgrg9AKXFgWaf/X6sCgGoR1ytH6Vkswn8l6/eBpXXkL9etvxzzvmK1/DwJsm/funWr&#x2B;957790oCH97U1PTakrnV6vV11WJC5HzRDDM5Np/Zghxb4BJvufwGb4g0nv&#x2B;s0N8fQqPTTNZJ&#x2B;JO85lAC3KeSiqZUByFT2UuuuI5RdtJGFCxwpqavc6RJyIRbxILWIEVJJsufxqK1Ivt62xmsZ4g4A4b121qjAZeTmPUi8&#x2B;OMelOiX2g5elzmOTTvoh1iXAnQ1HeZjbrgAaNKbEe7yOJB5n9VB5TvP/pUATpWELshviXUObzFE/yPBYd6LupMzeWbAsotWo2S4C/h3ik/eRJkH4SA0hA0NnN0Nut4jtZoXeKSXw3ntx2GKud4rkVWvG9tWaTIjYY9HIUIyEhcV2A7gx/0XsL2sx2fOf0Pvzf&#x2B;15AWlzXm80OrLJX486mHmytbsIKmxudVqc8YBISGVDrvWAwSK331B6Ph1rvUSRf4/P5klVVVXq3222g9wTxV&#x2B;Uz&#x2B;MuXSp&#x2B;P7M8lyKWi73O3X2ibhVz&#x2B;526vVNlAvn0oJAaU813neABUkr1cjMOl8/CsZVUSoLoaehGWUGyuNPEvRfrLMe1bCsJfadR/sSP&#x2B;6grFgPmY95VTv6&#x2B;666673DfddFP9&#x2B;973vg2tra1dNTU1XWazufZavzlQ2nygf5hT7Im0e0/0Y&#x2B;bQGb7iRKe9CAyMcGQ&#x2B;GY4g5g0qpDxDnDnqLm4mnFZPRDtzmJkQpxURk5bNptvrXDbOlFdptDDWucSdKQVDjRisCXJOJJfS&#x2B;YlAm1rqmMCbm2pYTKD3KMpvrKtCUuyjrsrO61I0PRWPsxBABJ4IcjIcg8ZiEF9MIfYsLhDxF/tI26DMg5Qg7XzSxWclxfpqDZUKxC9&#x2B;J7EtEhiY/EeivO&#x2B;0LgkH9H3T4v1EJI5ULMaCA2U40P4mxbIkkCT8QS5hoNIEmkfHOB6K8CMvJ9bhUgfx2SnxPbgUIauyQ0k5Y9EiW2ogHknMINGAswcsJhhcdhYFjNUumOrdMIhjRI8kIBhcNn6PluWsBgkJCYlrCOTw/&#x2B;70CHaTqd/4IE77JhAT1/l2iwN/sHo7vrhqG/Rqee2TuL5A3EsQ&#x2B;zg9CqKfptp9Ivnkzk&#x2B;k32g0cgBLq9Wqirn6L&#x2B;bzYvOKLVPuNsrd3mI9Zp/TdP78&#x2B;Tfe//73f4V0FjHF5zzmTsnMlPucptSc57lTOs9j7jS7O/mO3XuFayFCqlqEdRab9C8F4Z&#x2B;vYV&#x2B;5Nf7lEPx8RL5S8l8Wyc&#x2B;Z1B/72Mfqd&#x2B;zY0SSmXkH4VzocjhaTyXRN1u/HM0Q0PDLJ0XrvyQGER6cQGZ9GcHAMoaEJFsuYmFIaPbP0zMHU6TK1&#x2B;mAiSgSYD6JGqYvSO21MsPUOF4wN1QpJFQTV0tkoCKwW1q4mTomnbVjaGpSaerNRIfGURk/Rekqz1&#x2B;ouyXvKlT2JFKty1GJannZRqeFXRIZsuj&#x2B;JAMi9CPLG9PxI0X9&#x2B;zKbb03OTkZ9oSHzILp4VDnPKAxTlQpXzg1cV/GPmLAHKDqCbhDg25EeQjMSQJBFATPFAiEWVRCiM2JSPsyxi0&#x2B;Jx2ouYL4i4x89lEInMcrQOCTQxbwDh4Qn&#x2B;ekrmhCqT3aAIHSQY0Hej8gLOHnDZYKh2wFDlgKmuCpaWepgba2BwO1gwIBGBzpeEhITEcgLV8tP0sba1fJ09FfDg7alhPD98Bt89&#x2B;TbUYt4X1&#x2B;yAVnbYlbg2iT4PcqhePxgMJgWxV4&#x2B;Pj8fIiT87ZqHnVL9PrfjoMXd9ZQxVOrJfTmu&#x2B;S8ZBJZYplt6fT4Qo1R0AQNk1/&#x2B;XsS74of4kShrk8Byht&#x2B;FduADVdgDde1RkBy10AUC1w&#x2B;XKJ/2I68VdC&#x2B;K&#x2B;2&#x2B;v1y0/bnXb9Prz/72c&#x2B;23nTTTR033HDDGkH4KZ2/Xq/XW6&#x2B;1GwMRTaq/9506j&#x2B;lDp&#x2B;E5dAbRyRlBHv1MNClCnSXAbF4nSCS95gsdRZyZXUJJjScCqxUk32XlenUijbbOZmjtZuhsFjjWd8EkCCUSSRhrXNBW23mbOoNxDolPZ246yYx2mVbIO8mhlHqfqetf0A1xMW6qi7itnLsEH1/yDSBCziUBGTFBlfmJqnI&#x2B;N40UZwlQFgJlZMR9QSTEFBXnLjoxg&#x2B;jYNCLifEYnPWJeALGJGRYGEsGQkqEgzn8kEEaEyjGyNy/yRaDnGZGASD8JBJQhYHQ7YKx3w9xUC2trPWddGKpdsIjzqnNYlN&#x2B;IhISExNU6YBPXuB5bFU8fb1&#x2B;HmLjPBBIxSFtWiWsB5L6fbb83PT1N9fqUvs8DJqrXJ4JP9frt7e2WfES1CHkti8gXItq58/J9ZiliXamQUKhsoBBhr6T8oJTfQCHvgRyoUVn6/3x4qWwDeBWR/0qI/0LS9xfDnO9KE351Be8thPznTfOvq6vTP/bYY2233HJLT3d3d09zc/Mak8lUrdVqjdfMTUEQZiJ5M8fPcZq&#x2B;79QgQhfG2FgvPD4tiH5QMbTTaqHWqGcjxRSxpyi/kuaeRJqM9cVrio4T&#x2B;TO31cNUX82GdXZB9m1rOzg6bqCIcpUdGr0&#x2B;h9ynM7X7SkRaKQMA4uFwhcy7guuaKjdHIGdW9kk6Z5nZ10t5dc18QDo9h8rPWSRNxwd8vC95I11ANCCSTqJLbVUm0q&#x2B;GOueL0LHnsgQSCfwhxH0BRMY9iI5NITw6LaZJ/n1Qpkd0ysvZBFyCINYhUWH296FWxIF0ViDQaaEzGzlrgwQLc0M1LK31nD1gaa0Tj3ViXo3SJUEth9gSEhJXFyj1v0pvkgdCYtmB7sNkzqfRaDA1NRXnjEmtVkWEv7q6Wi/GsRqdTqduamoyZZc3m815SWshIaAUGS5HcKtEHCjWDaCUC38hAaNcsaDYZ5YSKnK3U&#x2B;h4itdzzf/UKB0ALYdLLtu2gMtVAJgv&#x2B;Z8v8a&#x2B;01V65JL/c9nvlLLPYhn3l1OxXXMu/adMm23333de6c&#x2B;fOda2trZ2NjY1rjUaj41oy7KMob1AQ/fE3DsF77Bw8B08hPOHhVHFKMc&#x2B;SOW5RJyaK0KfTSn05EfysYz6l31MauK27BaamWq6vN9VXwdHbDWODm4m/SqebJZspZIzyMqZ4FZP7skl9zgVXlXthvnjWKWZ&#x2B;8YYBNudj071ExsgvEmOjPfIBoGOQoraA4jEhHtXZNoHifVqO34/GlfVTqYt8nLsGaBSTwoxRIP/ItGreF7VWMfdLs7iiyRj9qfl9Likgoz&#x2B;V4i/A9ffpzK&#x2B;VlsmKEhz9z5QUqItIEJeIBmkk05cfNrU4n0arSZzLGjjWdinbzWoOYmXKCmDC7w9x&#x2B;UBkZBKhoXGEBsU0PI7I6DRiMz7u4EB&#x2B;CulYXAxA4lyKAPF7m95/Yta4kfwTyHDR4HZyGYG1owHWtkZY2xtg62iCpbmODQxlRwMJCQkJCYniyLbeE48pv9&#x2B;fcDgc2pmZmTil79tsNi3dd4n0u1wufT4yXKrtXrkp/MVc9csVFUp9RrHPLdbqr1QKfzHCX8nnzN1OdvuljA4r4GvFBIFKsgSualFgOZIu1TyWWyjxf6&#x2B;i94tJ8PMR9vnW7ANl1u/fc8897ltvvbVVTBvq6upaGxoa1mTS&#x2B;a&#x2B;ZkCQRNv&#x2B;ZCxh75V1MHzjJE0V4yayO/vYpJZ970wuyRY7w7FqfSrIYQCZ1ajKPsxhhqnNz1NaxrhOOle2wrW5noka18iq1ZvaAJcW6s673ZFy3GGYi2WtjltPnXjxVmai5OtO2L9PCjwz66Dm9F/P4mUwSgU2GFOEhOj7DxDwkyKxGPEanfexvQEQ9NjXDpJvmERGnNHmNxcTb0RppOyEm7bQ8eweQcEIXeBUfAP78pJjHYkE0wS3/iFBT6YI202mA6&#x2B;zFfNpnSuvPGvWR0SFnWuh00JkNinmfXq&#x2B;Y95n0fI64TaB45Dp9cW6ITFM6vlosw2UCYp95Mur4/LGAoM50EuBJnSkhUI5rxmYxc&#x2B;5zRIyMZwIvJfaVjBYNtS7Ye1ovEQhSsSjiwQjiHh8iQ5PcspEySMgXItg/guiEh0sPSDihY0UiEh1n8iMInh/B1DvHMqUFlLFg4C4G5DVg7SBRoBH2ribYV3XAJD6bRANu0SghISEhIXGdgdrsZaP71HqPyD7No9u0IPg6quM3GAxqIv&#x2B;lCOxcUlyKlOcj9cUIfanlyiHpZbXqy7ZqLiMjoZBvQKnPLfT55bQknPu5RY6zGuW3&#x2B;cM85y0LEeBabZO2UKf&#x2B;K9lOr5JtXM31&#x2B;4IDaTSf/OQnG7ds2dJy8803b3a73U21tbUrxWzjtfYDo9ruiT2HMP67A5h48xACA6Psvs9/VCaj0jpOkEVk2ugRUea0bkEAKW2bovm2FS2wCdJlX9nKzykybCTypdXygSUyS630WEhIxxbtL0O5aKpmL0uKSaDS&#x2B;k9pkSc4djSqXEAFyQ&#x2B;TmBFRiCWVLtB3IeIeEgSUIs1kUEgElEhwZGKGt0PHIiHWIZf8eDDMhDvbYpCEA&#x2B;LKaXVOVD0T0afk&#x2B;VSm3SC3GdRqMhUCqov7r1GxI7/SblAvCLoe8VBSIeBi/8MT4nhRZ4B4ij9LMUZUiDmLCNkrcoYQZwUOIuf8WZQhQGZ9qmxrQC2LN0T4&#x2B;dySQGAxKs&#x2B;tJuhtFhZpKJOD5rNhn8XEGRpam4nFBzL7o0eNOF4kitB3uCgaqGf/migTgE0eMyUaubcN6ihAXgCWzmZUZ&#x2B;QB8iEgLwnOGhia4PNDRpH&#x2B;k&#x2B;c5C4UyCEhUobKCdDIjQ8QT3DUiOj0Dz6HTnH2i4paHBi47ofISW2cTbF3NcIrfJ5lDmtk00iBHhhISEhIS1wyo9V4gEEjo9Xr1zMxMjOr0yYWfDPvIlb&#x2B;xsdEoxrDiFllZHV2x9Pu5pLWUMFCI/JaTMl&#x2B;MIJdDoOk5jbOS4ThU1KFJjEfLMfArFbWfT9u/coSQfEJCzroqVO7tVoi3LXssNwFAVeEylTr2X2mTvXyv1Vic9nyVuvWXRfJznqtJCX3iiSfae3t7m7YKiItlo5i6rqV0/iyIvHtPDGDyrSOC&#x2B;B&#x2B;B58hpJlpEhjmiTNFgmyV71WESy7X75J4viKCptQbO9SvguqEHjrUdTK50gmxRX3mOA9M6RPbFhHh8Ef5SMtHnrCN&#x2B;KnMxJ7JPYgRlDkTiHE2PeXxci04u&#x2B;BTBJ/JIpJ6WCw5PIO7xKvXo3gC/TwIFtdXL8Oqs&#x2B;qNEmImwqzIRcCKySDJh5uz7NGUsJGFpccPY6IBWkGFHTQ3/rGg7YaqNDwQQIzf9YEyQ1igSwZiS2q9RZboIpJH0RplYO9bVi2Ouh8VmQ1VNPUxWC3smRMJhTI&#x2B;OIED7Lb5j3BcR&#x2B;x4W24oqn6XJtk2gzAKxT&#x2B;LGlk6oYKixQF8nJocJJrtN8HIN3zRi4QgiYt/ifrENvx&#x2B;h4fBsKYeio6hmxYSseR8dIw1nCBgyxNoq9tmiuP1XOWad/&#x2B;k3oHdYuCUgEXxaXq3XcEcHlVYRH1gsyDEIzPo3zAoE4nN1YvvURcC1YeXsG1QmQOQ/MjKF4OAoAmeG4BO/4WD/sOI9Me1DgtssKtun7ZIwQOd&#x2B;8q2js78XFh2aa5VMge5WONd0skBA2Sq0zxISEhISElczMqQxTTX6GZGdn7vdbj1F&#x2B;/V6vaq&#x2B;vp6DVUT280X3Kx&#x2B;GqYrW0pfzXqWp&#x2B;qXEgGLL5yPrKjFOO/F3P8OZnzyPtV94FC0f3sldqAqJBXmOeUExIp&#x2B;YUUhIKCaalGkmqCqT&#x2B;1VC9Jdd3f9yFQAWk/zPJ4V/Ia3zyl12MVrwAcXr9EsR&#x2B;3y1/Dy1t7cbP/vZz/asXr26ua&#x2B;vb6vD4ah3Op2t15IiNhczR89i&#x2B;Pk3Mfxvb8JztJ&#x2B;JryrjFk9R3dkLE5HqqBKlp/fIrd11QzeqNq1m0m/rbmaSp1ZpuFZ/NkV7Eer0Z6PYyLkU0YUvQ/QTgbDS1i4YRojSx8&#x2B;PMDEkQh8Qz8MXxpUIsbhQ8iOl9eeY82Wj8FqLQRB3l7ghqGe7m9L3SMUFQaesASppSKQuRtyzNfRi8YRPkNGxICwd1bCva&#x2B;C0fYPRhLqWNpitNmgEYY4Lwjo1Nozh8&#x2B;cyEfmU2O8YYlNBRKcC4rskEBsRJFzMs/bUQ19rQTwQ5Sg/x8OTxJF1sDtNiEXEdw0FoDXroHdbeL9iMyFERv1cXsA&#x2B;BDMxxCfDHJF339gKY7OdhRutVoeWFSthq3KJ53oxUEjA7/Vg8PQJRMX54m1NhxAemVFUcZ1yfLJiAp1TygBROciHQMWEPh6YRirqE8dgGJ5IBHHyPkiq2DOAyjuIwJMgoHfaYRREnh711P6PxAIx6ZwW6CxmqE06pQRBnyljILFBrZhGJrn&#x2B;/9IODToSHGqccIrfYNYMMhGOIDbhYdHHd7yfBR/qRBEcGOUuFKlk7KJPRcaHgcQvz5GzLCTR52mtJpjrq2HtaIKrtxvOtR1w9LSx6SC3cJSQkJCQkHgPQE789BgOh5PUfo9q8ycnJ2MZJ35eRjzX00SvrVbrknGh&#x2B;TjrlyMWXEK0FfZbXETILDkbsChAonPnqU16TLxyCO/8yd8jlg5A9T&#x2B;Blvt3XiwLrWBf85Jz&#x2B;oxMJiRlFpTyCagke6JAGUIx7leIUxYrJy9kALgshIFrKVJbivyXG/VfKhO9hS5XTqQ&#x2B;3/YqMunLnXp7e62f&#x2B;9zn1nZ3dzevXbt2MxF&#x2B;asl3rd88yKl/6Ne/w8hL73CKdGTSw2SfU7/15tkrLl2waBJXMK6nplZ7RIaqNq&#x2B;Cvacd&#x2B;hqHIKSCQKUVYz/uL7/wu8kcwp9WavHJQDCupN7HZ4JK&#x2B;rcg9hT5jYxO8RQameAe9so&#x2B;K4Z8lO7ONexa5WfApnBzjOGS/hgs7W6YO6t42cb2TpgsVrELasSiEQS9M5gaHWUDPyL2ySCZ2YUF6Y3xPkGQ4FQowSZ5CV9EEEqq2VcjEgrhxP63odXrodPpKRUPyUT8kos5iQ5amxHGRiciI17ER8L84wyemoSpycYEPxwK4tyJIxyxp3Wp7IDS2vl1MqNUiJUMbitPkXEfAifFsRgLs3mfucMOU7tDHDuFPCeiUZw5ehB6gwE6vYH78KaSSf6uSomAON8NgqBXmRHsnxTHNoCEJ8bHSWs1wL6&#x2B;QeyvHRpB1ulz9QYjmju6YXM4&#x2B;bzF41F4JicwOnAO8VCExYTQ&#x2B;QmOzCunNDVrUshCk9kIXSZjgNo7UhtHQ00Vm/sZa6tmswsoTU8RB7QsCJAwoZgkUor/RWGA9t/YVAtTaz3cW9fx8aTjHpv0cicCvyD73qPn4D87iMDZIfazoHPGXgoZ7wMSibijxelBDP3mdaVrhcvOppXOtZ1wUbbL2i72MqCyAgkJCQkJicUGRfIz7ffg8XhiYoyqpZR&#x2B;In5izKqjWn0SANrb281XHWkp00Sv0HvsU5TxGErEorMmwEx8NUqghjtH8ZhAwwEAGoeiTLd9Kn2cOSzGKYL8q6GBublGyXJEtolT6bT7glF5jZqDGJEJH2ce8rbJwDmVLvvYFWv/V8QLoBzzdlUJIeDaIM3pdPqq&#x2B;kMok&#x2B;AvBvnP9yOYL2kvJ9q&#x2B;UPJe6foVGfbZbDbdtm3b7I8//nhvV1dXS09Pz0a73V4nLp6u60IxFgSdavn7n3mRI/4xj1dJ486YxymMP82p34pDvQaWtgbU3rwB9XduE6SnSxB&#x2B;JzQareLGT5HxZKqytnl5f9WqS&#x2B;rUmfCLfUiQY7w3hOjENPecD54fQ3h4jM0Ig&#x2B;eGue6enPWVtnEppV0dtY2zmZBSpZnUqlVqJrZUL08RfK6rT6VnnfEp5TzpjyM6FICjrxHOjY1M8J2uajjc1TAYFGuHSCSM4YGz4gYUU246bGCQRoLS7z1iH6eCiM&#x2B;EER8NcxTfWGeHc0sj9NVmJuiUtq9crMGiQqHrg0qnRmjAg5m9Q1waoHMY4exrgKHFwTcSEjT4epYufkzpOITOT8Pz6iCLJ1qbHu7bOnh/UrGL54wyENK4eFOZu28U2Q8P&#x2B;zH1whkm2VqbAdW7VkDnNLLwoXgKKNkQlO1AogkJCrSDiXgcM9OTilAhbnoJcZx9J0aQEseXfQFm9WMlLS/bupEzLDJfhCLt5ENAZQSm2ipxXKtgEBOZSRrFZKiyM/lWzA0NiveAVvkdKOKAOuO1kNki3djZ&#x2B;0AxnEwlE5wREB6bwsz&#x2B;U5wl4D18RskUEDdsrgXM7Ee2BIT2M8lKvjgeZhMMbnGuV7Yrwlhvj3hcAVO9&#x2B;1KTSQkJCQkJiRIQ98I0mfFRTb4g&#x2B;3ES&#x2B;6nVHrnyU&#x2B;s9EgOolp/mXYX7XvR17rxiy/LzzBjLf3oIHkHQiaS3PnwbZ&#x2B;JRlirdk6nDEo1B9XYLZ/Ad&#x2B;G/fgbOnE6u&#x2B;&#x2B;JFZQ79Sn0tjBvqMVx99kpe/8Tt/Due6djEOjOdfN9PCOmsizFmhyeRl&#x2B;0&#x2B;Biul9p3D0qz&#x2B;E9&#x2B;R59k&#x2B;65cdPspdSOpHMuz9znxd6ne/Y0XTu3Lm9d91119&#x2B;IWfE8U6LAlCwypQpM6QITch5xNXDv5ZIBsFDyX2l6/0Kc7&#x2B;dbU79UJn35PldN6fybN292Pfroo72dnZ0dbW1t62w2W4NWqzVfTzcUMk8bEoT/5D/8DN4jZxTVU5B&#x2B;nd168QIiyDy3pxOkyS7ITNXGVajevg7VOzfAVO1SVNWE4rzO0fUF/MoV47nMaSICSjXv4Si3fqPofWhQcX/3nx7kR&#x2B;4hP&#x2B;HhbgBK&#x2B;0ANX1zZ7V2v5QsykVpDtQXWrmpWWJ3VtbDanXwtoih80OtFyOsT3zHG6fUUwaf6e7rIq3QqaIw6&#x2B;PaPMLmzranFjHcC05OjYEv&#x2B;rOqqVmfqyC/eVMjNX9vkZMIf84jPMU0hNhpCdNyP8WdPwbyiChYx6VwmaLLKL5kQZohvLpFnIi6OBUXWje0&#x2B;xKciSHiimHzpHAy1Vpi7BOGtJxM&#x2B;PWcX8OoZweRSQUD5U9YYtdA3mREfD4vfgNjOi2fh2NQIU6uTiX2aRRFVfkEhc57oJpeYDimmhbRNmwE6h0ExHsyq2BmiGwkFEQr6cdE4QRxXIs0sPqVYhNCa9YiKY85iRuZYUFYC&#x2B;SbwTVWrVUoKxLHSWHXKb06dQGRqEsGhYXHjVIQcqrmgzgWUGUAZAqb6apgaa7iVJGWqUJcBrdWslClwloFGiSRQlwMqZ6D7XuYc6KrsvHxVr&#x2B;ItkIiI3&#x2B;GUF/5Tg/AeFwOPg2fgOznA2SYJf5D3mwYf6owXRHTKh5Hdb2P43/bwZ3FLwrZG1Gxbi6obelgYMIv9UqmlICAhISEhcRGUwk/3WiL9FNWnFH6v18ut98iZn&#x2B;52FOGnSP9VT2LKNMkrp0UgeQR5j/Xjt3f8MQJjI2wGXHtzL9S9KziDM3B2FG98&#x2B;n8iHg7ipu/&#x2B;Z7zzR3&#x2B;Ps889BxPcqL&#x2B;jD&#x2B;6tq5RMABRw/M&#x2B;OuwSBt3U14s7n/xcHhLR2M5cE5pLYbKyCg2XiPh7kMtMxHgdQ&#x2B;2Eah1A3oqwBMxMQMTb1Hh3AwK92My1xdXdygOWyPPoSpofKMDl1yeu8QkbhgEOhiH8p3olFWF4KAEsgEiyE/BckzGW&#x2B;X8myS07yc/dp06ZNth07dtTcc889vR0dHSsaGhp6rFZro5rypK9DRAWJGXjmRZz&#x2B;zi8QEKRacTo1XBKZTEaU&#x2B;nIyV2v44E1ou/82ODevgt5h5wObiMfEBTa80LvCLPkh8pzibgFhpSe8x4dA/wgCpy&#x2B;wF0FocJTN26gXPLfiUylO8kz6iRzqdJea/1FdlSCQ0YEATNV2jlDTa4pGUzo61bqrasQF2&#x2B;fD4JkT4k5KadzmDClNCkIX4bp5EgBio0H4D44hfG4Glm43TG0O3p4qoySnWfeco7xmSCyn39dY2a3frxNE0aVHMphAuH8aobPT0LqMgqhaoRfL6OxERJV0tWwmAivVYjMkUESGZjgDQiPu9xq7jlPTE94YZt65wKRTazdwar7WaRAkmVr6ZdLhVYpekYol2RAwOhlgLwN9swWagNjGTBTTrw1A5xqHqdkBY4ON1ydyPJuBkVHdWZSJC&#x2B;I9EUA8FBZkWnwfsQ3yF/AdHoNtdS1vm6P2mePCLvtQX3rec0waI2M&#x2B;xMXxTsfT4ryTX0OcCb3ebRLE3cnfSUfHW5B/lUEDo8UMV3UtDGYz/w6jwRB80x6EpmfEOQuLffOzMEQp/dP7TygXATo&#x2B;ZqMg9FVMusnQzyomc2M1dE4HCwuU7ULnm0wWqRUi&#x2B;0dS1ksqlhF6VEqWgVi/7rbNHOmnbJPgOTIYPI/pd45h5uBpbk9IQgF3dhDEn44lHQPyo5h69xgm9x7mz9I7rHCsbENV30pUb17DooCpoVqOfCUkJCSupzFZNJqMxWJpiu5PTU1x6714PJ6mKD9lqFIaP0X3KcV/2ZKUOcS&#x2B;VFZAodR2ZYyW4PupoOXQaPRKLT3YwBCH/&#x2B;opXHj1dcrPw9lvPyfI9nnoYWPirdHryhYpuDORGGvqHBYljM3mx6qLXZQy&#x2B;6SzmsRn9OP4136KoWf3inu/nyP/jt52bPjSE6i5pZcDWVmfAlV2PAKTUkqg0cx&#x2B;YKlOAfmEgUsEiQLiiZhKmfyV6wtQiuwvG2PA5S4AlNPKrxj5L5Ryry5B3Bcyb76iQEW1/Lfffrvrlltuabj11luJ8K&#x2B;srq5uvx7q90uByMrgv7yEY3/7IyYplApNpChLyijqnlUrq7evR8vDu1CzoxfmtnpOdxZ3qAUb9&#x2B;XW8FNKN7cHZLf6EELDkxxRnRGkjVKuI6OTSCXigrTZuB7e1lEFo62F0/WpVj0WiXDSEaWOU3o&#x2B;bYcfKQpN6eKUkS/IqHf/CKBRMXkfHerH6GC/kr4tLrxEIJW6LhUrybyPVNNdZeEp2ZRAtMHH6feJmZgguaPwHxvj9ygir68xce27msi2&#x2B;mLv&#x2B;ksEAWrZZ9bzMghFBek3CLKt5&#x2B;wEinCHh2cQGvSwCkwCABF3tVHDy3ObOq1K8Rcg0z3KbtBl6v2tWuhoPJBt&#x2B;xcW2xqbAcb4TqiQWk53p1R19WyZA3seZPZVYxOfZdHw8UqGEgicn0Kgf5L3gTo8aB0G/jy1WexLLKmII5G44qEgNkOZBMmAOO7&#x2B;BGdKhAe9sLS5oKeMBEGm&#x2B;fOzZD9zMCjqT&#x2B;lxlGlBggQZHcanxe/Ap3SC0LvNcGxogKHexhkNs9kRUNo1UukG3UCNRmo16EDalYbRYsFwOi6Oq1mQdLs4RyOZbgUXDSIpPZ&#x2B;8BgJnBjH&#x2B;8jtQmwycJeDoaYdzQw&#x2B;LAiQQ0A2cjo/GauQyAvJhoN8I7QeXt8QTs38zRPAda7vgWt&#x2B;D1od2ISl&#x2B;k&#x2B;HhKS4XmDl0CtPvnkDg7AVEJ71cVkBiFbVJZOPCSIw7Doy/fpAFAe5kILbl3rQGNdvXcccBEgkkJCQkJK4NJBIJiugnKXpPEX1y3TebzRoSASjK39DQQK33iLypyiRd14QgUCwr4DLiQ/debhmtumR&#x2B;Mpnijj&#x2B;K4Z9ajGNXizHNKAJjQ&#x2B;j5woNw9nYq44IC&#x2B;3DZPlKtPpX5UecEsV4qGueMzOx61Alo6Nd78Mbnv4Lg0Kj4RLGsoJb0/uQ7R/D67/8V7vjNX8PS2cCfO/s5qjknNVvpmuf45JL7UiJJsdaLBX5L8/1dFfIKWDZdAZaDAKCax3LF6v/LTe1X53leiOSXeq/QaxUWKbvggQceqLntttvatm7duqa9vX2tw&#x2B;FoNJlMbnmruYiR3&#x2B;7F4f/3aUy9c4xN/cjJPEti2JHfH2Bi0vbRO9H4oZ2o3bkBGr2eDdLIXG&#x2B;BV3olmk010lSbReQvKIjfpI8N&#x2B;2aILB05jcC5IURGJpXldQqxNTdUwd5Tz0S/fcVqTuGnyCqlPk2Nj2Do3CmkZs1fUuxGTy3&#x2B;qO0dTaT4Rob88Ow5j9AZD2zraphYUsSflicH/suMV9LpjIGeUutuaali/4DAuUmOuhPZTgRi8B0bBY6AiTpF&#x2B;EkI0AiizG71OqUunH61tL8xXxgJb0RRlalGnjeu4nR2DXfcybQrzHYAoEh7MK6URCQUoYD229zqEudPx&#x2B;Z6RrOFL/DRUAhhn1/53oEIdwcgsYAN8FQXWwiyQEHkn/wcAgqJ1zlM0NdZobXroRPn32g1K&#x2B;dHkGVq/0d&#x2B;A0mxveh4IFNmodTOz6atk7hBKfxiUko2SESYhHrYoxwXFkcUAx424onH2QtBMW9UMiRSQfF500qbQp0g2zW3dymZBXTDjSXn/JTIfDGKwVMnWe3PdltgXwduQ6gW51yp8U/PDhay4lO27l83e57DwxP8Gxz57RvcccC5bgWqd/TyI20gKH6jaqNO6VLgtvNgYNbfIFNfRx0wZvdSHBdzWx2snU1ovu8WJMX3DQ&#x2B;Nc9nK1BuHMb3/pHh&#x2B;HtFpH58fikrQ3yJnCPhDGH35XYy88BbPt7TUc1ZA3S0bOUPA1tUkL2QSEhISywBkzkf3J2q3R/cmukdRvX5VVZWe6vnpvbq6OoPC15bWjf9qI/7z6QxwKeG5lPhnOS4FdVZ89l4EJybQeu/NaLn/ZtTe0os1f/wxcU/vmB1jXUL8SUzIjBeQU4NPQYbIpBdTbx2HZ/8ZxCMh9P7n35vtJEClhpNvHsFrj38JURo/w8Btr6mMNEUtsDUWBMcn0P/D3Vj/F59STKGz4&#x2B;G5TFp1MTBWqo3hXMJfLFNizvqVRvav6drE5fzHVqpXY6UO&#x2B;sUIu7qEKJCPsM9XJCgmCvCkEXjssccadu3a1b1mzZqVmfr9Wr1eb5e3nMtBJmZH/tfTOPuD3zDJyI0ocus7b4CN1Lp&#x2B;/160fHQXqvpWM6tLUAnAQqL92fT&#x2B;rHFfJIaEIMGRMQ98J/rFRfUIfMfPITQ8zqSVluN0abMpUyuu7J/v4CinhdvW1WHgzHGMjQxCrzNAReTM71Oi2sBFwzpBvHWCABKx5WizIJCJFVFBwrycwj/1cj/XqxsbrDA2OjjNXGPUzhq3zEbvs7X4GZdZivjrKLU8FGPxQGfMZE6klIg2EdroTADwpFmsUKLsUKLvRi1nMOjcZsXplcodKEWe9j2RVgg&#x2B;GRKmFALJJDVzV6P0eipBMNY74FjbwFkKVL7QvKIH9io3mxkmU0l4JsZw4ewppGtsiqBDLQQnlRaCdPyzBoUUrU9MRPgrurY0wdTu5M&#x2B;k7bR09XBqvTrz&#x2B;cFAAP0njnANfzqa5G1FxgKsgmePV/YYpDN/2SRoqFQKwab9iPvFb8iXY1qT08lBlTH8U5soKq7j0gg6jnFPmEUU/oxU&#x2B;jIvAi5Z0WkvkdFZyKHv7YsgODjN358V9exxRkZeV19U25WUO/Vs/R61gaTMgPFX3oWlrR5179sqps3QG/UIXZjk3y6JAIY6F69D2QiXj/rSSocMxGe/r6m5Fpb2RjTs2s5ZNKGhcU4ZnPjdfnj2neBSl/iMX2k9SB4Cmayc0PAE/OeGMPCz3WxqaO9pQ/0tfajdcQO32SQfAwkJCQmJ9xaJRIIJfSQSSVLtPkX0p6en41SfT2n99J4Yp2qz9fr0/vV8vErV&#x2B;RfyC1DNIc/Z8dns7TceR8eju9D8wR3QUc2&#x2B;IPSUxVe9xclCPQVXcrdP93G6R5PHFHld0f09u32d2YyTz/wCb/zRXzPpd6zowA3/9dOK1w95IImxzbv/8RuI&#x2B;f2ghP4Vv3cPuj//YTYO3PMHX0XcFxTDDTUmXj&#x2B;keAfMbR84R9BQFSH6ud9/7vv5jl/u8gXElYWk&#x2B;UsB4CoUA&#x2B;aS/fmQ/8V8RJkiQqGsA16/sbHR8NBDDzXfcccdq7u6ujpbW1t7TSaT63oz7JsPRne/jX1/8U14j/cLQmy95OLBJijiZdvDu9D5qQ&#x2B;havMadvBfeIq/OtPXVBDX6SBSREQFufEePcvT9L7jHA1NhiJMYCjSaax3cso5RZ014nWK07xTfEmk2u/IsCCez/ugqzYJ0m5TItYWfcYcTn3RPG82KjtL5ZVaa0rnd1tgWVGN4NkpREd8iIz4ET4/wyqvxqyDzmXkVG9K1aeyAYrgZ/OZuN4sFOX6cv5&#x2B;qYvbV5z1KRdefZm7ezIUFzcfM2xr6nhfa5ta4KyuRiKuRNgD3hl4xseQEIQ6FY6xIR&#x2B;lxRN5vbSFYIpvXnRMKLodF8/PHDkInV6pfeP0NHHjo5tddp90VgP0dqqhdyA8NIPwqI&#x2B;PTWIswt/H0GiHpadaibBTN4J0EudPHsfoQD&#x2B;3JhR/X9z6LybOkyqtuN2bW6pgrLHDf2ZcyWZQqy6V4OnYi&#x2B;0l4yneJmcAiPNH1WdkqEj/UlmxIyN8cGaCRsWlBOTRQCLA9NuDMDUqXgRap1E5FxpVpkwjc1Nj4SXBn0mZAiQaREcC/JujUgY1G0Jq2DOAOhOoNVo&#x2B;Zxq7nn&#x2B;bJDooPgUZ5/6Y2C4fP0WYIJJ&#x2B;5h9/huHnX0fHI&#x2B;9H7S0beb3w0BRiUz5B6qthqHHOejQURFrZz9yyAXNrPawdzWi&#x2B;ZyfiwRAbWk6/fQxTbxziDIHwyAT/fdJvlzodcLmAOOdTbx/F&#x2B;Gv72ejS1OBG7Y5eNN29A3W3buTIg4SEhITE0pN9iu4TsZqZmYlR5J5S&#x2B;iltP1OvD6rZb25u1sqjVZkoUE5LwFzWo0I2GyCHGIt7LWVsKi2AVbPtgHMzPVWZ8r3zP3tVTK9g&#x2B;vBJ1It7/Oa/&#x2B;YKS5s8Gf2Kb8cw4FEboKDiVGRVSFu3Zn76C8bcO8bzme27E1m98kccn7s09GHn&#x2B;bZz89r&#x2B;wR0FodIK7VumcFiX7YM7&#x2B;XiwDUBUVSeYep2IlApeJJpV1mivXeF4KAO8h4S/Uq7ESw79CkfpCxF2zxEKBasuWLY5du3Y13nnnnb0tLS3tjY2N641Go0OtVuvkJbJ8kLP/oa98j4kD9SjPOrCTqQm5/1dt7MHq//g46ndt4wvaQg39sn1XSfVMBiKspoYHxzBz5AxGX9gL34kBNhZkozXq106ZCOKCbF9VD63LBIPOiIaWdujFzTMei7JDv2dyDOFAAI714JT76FgQ0SEfgqemoSbSbjdyvbjelYni6zSzUeXLFFLxT&#x2B;8wQb2yliO0GkdSccuPp5hsRwVxjIwH&#x2B;FhkRQy&#x2B;cOrVTF75F5rObEmTMVZBJtqf1QOyOeeUch9LIXrez63vqBaeiG9EkL2YOQqD&#x2B;I56vYmJsN/rEQSZ2sZZoa&#x2B;2Kq0BI3FEPUGO4KftKSbGsckQu/W7tjXzd&#x2B;boeiynp23uRT7TBSCdSjJ5tnZW87EJDUxzO0HEVYhPhxET35fElFQ0yStRiiJH&#x2B;4OB2T636kxXBj6WgrTTcabteQ8NK10P6LxT6n&#x2B;AMjxi3CDG2GxnM0HaT7rK2l0uuBuaoNXpEY9G&#x2B;Nx6JycQmJ5B0hdlQ0EqWVBbdJwJQDdqEqL8Z8OK/0AmpZ88DVJJRX0n3wdezhtlbwYq96BzbGxyCnJtgY7MEMnIUPxO2DyQjolK8RKoqmtAXVOrkr6fiCMU8GNiaBjBaQ8LCZExrziFOjaWjI5N49hXn8L0u8fR/bmHxHky8N9U8OwIZ65YWmvFdlXlt7xMX5ohQOfFtrINztWd6Hz8HkQnPdy2iAwFx1/dB9&#x2B;xfm47yJ4L1MrSaeW2h9aOJhirnZfc7CUkJCQkFg/E8iORSEqn06kE2Y9TNF&#x2B;r1aqCwWCSUvnJkZ/a7uWa81FtvzxyiysIXCYQ5GFFufOY/IuxJpWcBgYuKCV1rXWz7f84GVC8f&#x2B;7p3&#x2B;L0v/yK51Wt7&#x2B;bxTiq3kl09G5u/WGpAJYdiHH3hl69TyAwalR4rPvshHp/EfCHebtXGbuDbmXaAoTiPffUqa3YIeVkn4OzrfJ0QCqX6z30v3/IVkP5rnvBfKwJAuScnX81/MfJfjOzPFQcWTSy47777am688cbGO&#x2B;64Y3NNTU1zQ0PDWnFBtankqHbe2P&#x2B;lb&#x2B;HEN54RZM3ISmU2pT4VjfGFreffP4RVX/gYdC4HtzbDAnpy0kWWRAWKinL9OZn5DY5ibPdbnErNrv2CdJGfABmm5P46iTAGjkzCvrEeaacB8XiU09uNBkHqdUaEfF6EUn5WcCmKS27wtlXVSno7EdipMMIDM/AfHWMSqjHpOL1fS4Z8esVEj2vBiQwLksulCGQ6mE5eDODrFKM8teVyojabAsBtD9L8&#x2B;fpqQS4tRo6&#x2B;601GJMQ2qQY/FowoZoSCyCbF/iUEwdOY9PCfnuC6e8cNDfD5pzEzPa5Y8kPxBshG8HNbCNL3MFtcMNU5WJgImacRnxDfdyKI8V&#x2B;dhLnTxW0EaX/YJC&#x2B;dvjQLAhf3W9F9VDC4rYgMe6GrMwKTKiT9MUz89iycmxthbnfx8brYijCdN6qdTd0n0WR2&#x2B;&#x2B;K4xkbDLFJQJkXVre2cpZFV3DktP57gzgEGvZGFDvIuIPPFSCwCvcMMQ60dwXOTiE4F2awxS4yzwgqT/ex3y5JtsVxiLMoCAMFYa4Njc5PYliVzbC9&#x2B;l1nPhcwN0j85xYTaYrNDp9NDo9aK86Di7A9DlYVT&#x2B;8PiWLHoQK7BYp2R3&#x2B;5h4r/mjx7nGzwJNZGRaV7G3FI77762fJySMSWphEoZHBZU39SL2ps2YMUffIRFtOk3D7M/BokErt4V7A1QLP1/IhrCcGAGToMJbVaXvCBKSEhIlIFQKJQkEhiPx1NE8ongU91&#x2B;Nn2f7qVarVZNkX55tBaH5Gfvy8Ve55LbkttTKff/Q3/5PSbpvrODWPsfHsX6//IpZbybHd9RO2Jqew0zl1byWLYMckX3fAqiTe09zhF&#x2B;g9MGW0eD0jo6M5YjcV4Dxfsom5majcRn5YRsRuMlAgdKl0OU4wFwvZL6a0kAqCQNo1C0v9DzYuR/LsnXFHlPXYZgcMm6TzzxRMvGjRubbr755i1VVVXNtbW1K8UF1SR/jotE/p/8Fo59/cfQ260X67Sp9pvqmxw2rP/y59D64fdx5HMh6f7sik4GdBNexD1kFhdB6MIoLvziZUztOcwmf3RBVWmIhGci0sn0xRQoCqpbtAiPeRF51set9fytkxzNJ3dXpSY&#x2B;rUSgeV3M1lxTOrqpWQ9zq1MhmTFBQj0hhM57EJ30I5pN0WfSqFJ&#x2B;meQJq1Nx6rdKo7rI8VU5bHnuX5VyNUbSKwhaMAnXpjaxvgYGnQmdK9fCbLfz58cFmR0bGsDYhfNcU66k7McRb4sg3D&#x2B;D4Kkp8eiBtacG5g4nO&#x2B;vzcrTvWUO53I/NthAUX91UZ4POSkLCuCCHSsu90OAMdyXQ2o1MeA01Fk61J68BLkdQZbIUEkoWQMwv9mPEq6ji1P6v0YRkUIfkTAzTr5&#x2B;H/&#x2B;gER&#x2B;055Z62QxF3rTpHRFCOZZK7NdB5nlGUdKqD8yjkn25k/z973wEnWVVmfyrnqs45To7ADFmcQQkCioiKYEDW1RUVAXfZxVWU/66KrK4rBkzggvpbRSQoQRHJkgcmzzChZ3q6p3Oo6urKuep/v&#x2B;&#x2B;&#x2B;V11dU9XdA4gzPe/Cm6quevXye/ee7zvfORSYsLa4&#x2B;O/CDisWCeNg1&#x2B;5pQjd8HukaSmd5ffaOKtYL4Hp9XVFpQWHHllMK&#x2B;WlRFr0M8IjrwtbmEdeEm0UISx3Twu1JJOh4DGB8WLWhlKwPnVh15OCEuIYiiljgVHieKPbel7Zh5OllaDr/beyWQRTCxNikOP4ecezN8py9niBAPqtBNyoFV9Is/mg2mWBd2IpKMZVrKXF&#x2B;94f86An58PhYP/b7R7E56MVQJIA6ix1vq2vF&#x2B;5sX4&#x2B;ymRWi2azIpWtOa1rRGTbXeo&#x2B;z&#x2B;xMREkhT4xd9ZyvJTRt9msxkp23&#x2B;s1&#x2B;u/VYGAcnX/pcGPrjwgUuyZ&#x2B;x94HqNbtrEbAI99ZgBSumnr1eUV&#x2B;XUlAww6ZvGlY3Gu8acSQiob4HEr6S2JvpushCXkyUzxB6ZWUga&#x2B;ze14zMYEKPeqBQSOrgDAbCdqLj6Oc2EBlAP/c5lmDBDQQ/Taa69dtHLlyubTRCN1fgH6F2l0/r9No6z/3tt&#x2B;z0J/eQDD4D8Ja0M1TvrBv6H2tOOQisdev1kHg0s9UoEIZ0Apuxofm8DAw39lqn8mGhOAzgyDVfq2S3V8K1O7WTFePCRJYJAywpT2zAnQmfYnkBiPCJAc4Cyyuc7OivfmSrsA3Lr8vuQz00owQc2a03qsjQLANnsQPeBFZMDPwYdDWn5&#x2B;g7TX0&#x2B;uUGm5FWCarrqOAVm&#x2B;QdP50MMGChBVrm5DIxbBn60ZYrHbpPyt&#x2B;nKRjyolxuQ6jzczCf&#x2B;Rj714dR7jLh9DeMWkhWO0U2yr2TwHuBqth&#x2B;j4WUNAoXGJwWBhsQpeCsdLMEwFl0gdIjAVltlon7QGp5t1oJSE5maXOsjOCzKBLUUa5XHYfEBMvR4Dm2PAkawWwKr04V2xHKM4FlDhAjtgN8RSL9KnOAnI5RmRCKfLfYV0Fyshz3T9l3RVATPtm0OvLBJJkVJzsAPMlBcp5JptEOvbyj6ll8d/M2jDAZLXx9ofFeSerRApkkJMA0/71Jbh2fJ5zMFIZAekVRBXHCNJfiCS5Iy/ZSStZBcrETytAzGbzg4u53lKFdXlqmYU6zRbBH4yF0B2cwNaJYTzj7UdvwIedkUmkErGpbSa9A6MJY&#x2B;kEHujbgwcO7kKdAP9vq2nBB9pX4JzGTjRaNXtBrWlNa/O7KUAplxH9UzgcTlNtPlH5CfTTe/F5jgB&#x2B;Q0ODlVin4n3&#x2B;t3q9xuT/ewYBij&#x2B;b9n2JGgBdwTsdj8EslJ&#x2B;XWXbdlMjeoYC4qCZfnWcGbExgn4STKbiQogTH/c&#x2B;ics1imJw2HtuGDwwX5fentnD6EhXmqskoQZTiFjHb8ZjLd4dRCnBMtqNdA6Bc&#x2B;Giudf9zAf&#x2B;GwwkI1NfXm6&#x2B;//vqVS5YsaTn&#x2B;&#x2B;OMJ8De73e52HaU7tfY3baPPbcGO//4VP/QKs5cUkTS67Dj5h19Ezamr3lCtPy2XMvOx/jEk/WEG1GPPb0Hvbx9FfHRCAEYBZm1SwZxAkUFvgmdVEz8E6xtbUNvQLLCJiTPm4WAAQwcPcE24rlM&#x2B;qAiMUa17YjwsgPIY08s5muq2MN2dLeVsRraVIxBPtO2cTlLpc5GUVPyPpZC31Js&#x2B;EoDJbeMgAYFcm8MBm8vJtfmpRALRUIjrugjgUg2&#x2B;rNtKcSbfUGXm/SHwTnZ47lX1DDRjyUie6s6dTiFdLTsFWqkWveLkZjiXViO0Z4xr78PiNbcHEnBbTdJKj/bPamAgL3C7&#x2B;E7PnUk6HOMABANaFQgTZd1tnrZ/6jozWQFqQ8l8tJqBpv5QEJxfjli3waXEHZg2n&#x2B;UgTTqRzFPl1Lq1YvV/vdMEc4sOaX&#x2B;S6&#x2B;fHH93Hjg2WJhd3bMy2KIOMuTyA9A5Gg4iPiOMfy0ibyFhKqvPbjfKaojp&#x2B;Mb&#x2B;JtB7EMukaNNrNHLgx2czIZNKIByMM4imIERHnkOrx2L9XCQSwcq9RbGcsrbgD5PIBDQLx0BU4E5TaVmUez4rOPNSn0heDuLeIjl&#x2B;KcFDY&#x2B;ZYC/LOJ8yTFfm2bHMN&#x2B;AfJf8A5gk38YveFJjMRCYpsz5HkEPrH0araWumHFQZPXyFgyjgf6d/PU5KzE&#x2B;Y2duKx9Fc6oa4XDoMVjtaY1rR39jQA9PVvJeo8y&#x2B;VTDT1T&#x2B;yspKs/rMVaz3uFEQQDtqR09gYKq/1JW3QtNNfyMNf0oBfJnpLwbq&#x2B;f66aHH5pdFY0mmHe0kLIqNjMOpt2HPLvQjs7IG9vQ7B3f3wvrhLdL9inErjDjHG41JCTDEIMtEEVOEoshimcQ4xGUvV8xfu/0wAv1RgYA5BgGM2OjAfbABR8ho9FPzPpsZfCPh1BcDfUOZ7fr927VrX1VdfvXrhwoXtAvSfKsB&#x2B;s91ub9IeWW9xpxdLYPt//YJpSUZSA8/XgedYEXXVDf&#x2B;IWgH&#x2B;k28E/AvATbYnkd4RBv5kmdZ954Nc50/12kx5KrRqE0Ax1h8UYK6XAeGESYDneBwWixV6nYFBXE5RgVevRGYLuCxwLKyS4FCAWAoGJAQ4DHWNKYrxekXZVS8vdgXcSVWXHJcVUF0/g3LV&#x2B;pRwcyqLTDAN80oHg9K61jbU1DfBQNlS8b1vdIRp6qrKvAri1YBAqjWO5GiY98n71wMwVdi5dp7sBEmfQCce8jqVLp/JTbkI0hIpoCsAJFkTupbUIpDNTIHttLSpS4aiSAYi&#x2B;Uw9T6RPYNAp1oBFt7xaE68EBSSV3sgW95T1531QjosMDCigv3hZBboBqkAN0c91UM4NpHge0eOlmV4uL3SoroOCMmYxIWVlBf7QnlF2WyAFfzqfLMZnNcr1k6I9uRwI8EwAnFwPkuMxZMMZ1hag&#x2B;eztFbB1VEn1fquBN4xBvMoMENeOu7IabYuWwkIMAHFsE/EoxgeJ1j&#x2B;ETCSJaJ&#x2B;PHQFKcPigkvu4L6ZjoZ9hDMguA5Lh0PqBc1B7&#x2B;vFM/6fO2ui0wd7ZwNditkDDQe20DYq&#x2B;g/o6E9jPiHM2FA3hlYlh7BOg/2nvILoD4zgYDyOdiMvtpu2kyfg67P9Y2FKOe4diIdzZtQl3dm/FCk8dLm5dhkvbluP4ynrtYao1rWntqGikxs&#x2B;B0mSSrPeyTqczb71HwnwE&#x2B;K1Wq1Gt19fE&#x2B;Y4usD9XAHQIeFeyFSr1PlciA1GqL9YVAP9c4XChaPhA4zlKQHR85BwMPbdRGWdn0ffHZ/NlAwaYWbuKlkRjRbPHkRcgJNZodMgHOaLKwdFYx8LYqWimLONhJmBfskzi8HUBtADAUQb6C0F&#x2B;OdBfKjgwU9a/HPg3CHBvXLduXeUnP/nJtZ2dnYva29vXigduu9ls1lSm/s6t74FnMLGtS1qBFTwMSPCu8dxT0XbpuZxpf90XnnhgJSdCiHYPQWcxIz7qw67//hWC3f3iQSjlG9T6/sInpanGgoQ3jPjjIVganLC2umGqlllcneI9r1dE&#x2B;lTl&#x2B;rynPGTm3OipgWNhNQsMUu17ajLKtHgo1H165SyvxciZa75q88r8OgnG6UFp1Inf&#x2B;5H0ReFaWYuDAniODvXBZDTztieT8QKF2Kn9oGy8ga3kBNhrroBreUrsfxjRHh8zAgjsSvE4O89jcFskhZ4CArRdqhc9MxySiI0GOYCSUzPDJmllqLeqXcdcZGimjjGVAZDyvmNRNcw1YhusFrYaNJpJoDCBRDSGkG9CdC4JZMQ&#x2B;p0JxZjcwbd1QQJHXS0BMjgBkxUf6AtY6G6vo07ZzvT6p7pMdIbkGJKkkQK23V8CtOMakU0ATncdsNo2kPyWm3NR6clO7xvZ2k0lk/En&#x2B;iEoiqt/RwZ2rqhnBgoOHHBUdghMT2LdtMyw2B4zMBjEhFg0zK8QozkU6GGVbxdIZ/dk7RDo&#x2B;FFCj7Xa01qP9w&#x2B;eh5vTjOBhEmhaWumpYG6o4&#x2B;EX7SiD/cKj8k8kYdgW8eMU3hN3&#x2B;UTzrG8ZIZBKTKXGfZtKSxq9m&#x2B;C1vskQKMwbk4GRXYBy7JoZxy56XcXZdGz7csRrvaV6MylKMAq1pTWta&#x2B;zuBfcru03PV7/enaDxKgn1Kvb6B6PtiLGpobGzUMvrzIAjAffAsNoA6XQnwoyvd3&#x2B;tQPmtacniQKzFvXsMox2PrhZefB9&#x2B;G3ej61UPKPHouAdXDAnOFi4UCxagPrpZmMSa0srUvAX3Syxp7lrQJ6FLNoPrEJYrbAPIigOr&#x2B;H44IYDnBxNwbEPnWAgBHRxCgOBhQCuwX2&#x2B;7NFAgwrFy50n722WfXXnzxxSe1trYura&#x2B;vP8Fut3eIB65mOH0ENapZ7rnnMQE6ivo9cdOTwumCT1zIdfepVOp1gn89kpNhhPcPiYeXkcH/zpvvYO9yYhvoCchbjQID5VjMjYGlToJvcl0zuqwygz4RR2BjiAGNmRT9Bdgz19q5XpuF&#x2B;Uz6ggcW8nXgalDBXOlgb1f/tgEGslwrLoCXqdYFR1sVP0A91dWwOZwCPwngGY8jEgoKwJpANiWZEJmOFFsJhvaMA7vHmVJOtfhsGWc3ye2n1SkicqoeQC4zBUHJ0s/ZWcVZahIdJMo5gdREIIq4d8pGUG&#x2B;QtxftGy2DxAOlNV92mjijzMrruQwgk84gR373eTo/ZABDLSfQTSnxs4uCL46kN4aKE5vhXCzdEaxOJ6oammB3uPKWNVRqMTbYD32tVOenMokkiSWOh2VNP9nrhcU5mpRlA57jGmBrq&#x2B;AnpMPlYXtGi93OAZtELIqxoUH4R0dYcI&#x2B;y7BTkYfEbtX5fvXb0U1oB5QIYepcRxqRFliwY9FMdnCr4f0isf4rWl6QARzymmirw8ZKWiWGxb6GydP5Dnp6KWwFl9akMhH5ndDrgWbUIDWefgopVC2GucnOwydpSA2utB0aLRSFC6GbN7gdTCYzHwnjRO4it/hE5TY7DnxADBAL7LI5hkll6yu6/ngz/6&#x2B;1OKNAgpng2gz8NdIlpHxa7q3BZxyp8WEwrPbXaQ1ZrWtPaWzemyWZziUSCrfcCgUCahPhoisVimYqKCjOJ9ak1/OpvxN/agZvHgYDZRAGn9b&#x2B;6KTcAddzAIr&#x2B;Q2XcWp1bgt16pvS&#x2B;Q4Z227ikwNTX&#x2B;4mRXRjoVnfyjfxZjhBMx&#x2B;NgGTk7ZGqpRf&#x2B;bx2PfzP2Hk2c2cTKpbfxyvk8pzaZyx/Wu/xNiG7dJBwO1Gw1lrefxUDPDLgf5ikF/OCaDwb40FMD8CAOUAf6nPy02F9P9pFP/bbrtt5dtFq66uXuZ2u5dZrdYOceFoEdUjuAX39yOwt4/rnad1ogLw2tsbBIhZyJZrr&#x2B;tC08tapWjPMD9AqNRg7613I9I/yrX&#x2B;BN5di&#x2B;v46qmqrYe7sooi9UgJYBYOTCIaDkuRtJwEWGTnlg4n2b4vORFFjNTkk1lWc2fBFhLEs5uZ9k0PTIP4nGr0WXRwIiZrttPpPKikx1vaGwfadJw1dldXo6qmnq0EqU2MjaBv/x5xbOgBaOErnrL49ABnv/ehIKL7/eLhOy4z/R4rLNV2mNykNWDK&#x2B;8&#x2B;r0dn8HUZ9AdWfi/2PG6USPWXK8xtVICQoKf16yU5QBBTVuzSbyIp10TGs5QBIRU2t2Ica3sdELI7wpB/RyQDS4rhlY0mkggkWrOPOgn4fl9nxxFiEs/K0D5FgAF1bN7HWgmRZ6MQ5SUkqXEZSI0wOs9j2Wljr3RzEIGZFeiTOpQNVp7XBsUxsA2X30zlEgyGMDfTDZnfCbLWIc5tEJinPgUmcL5M4ZrYmN7Mr4uPh6R1vvv5dKXfI5PKlD4VPLFOdOO&#x2B;VJuTEOn0v9cLa4JL1/nQtKMdXahnIzLwU180xA4EOMIF2EvAjF4E8u0GvLxMulcchJ44xX5MC9FOgjBwybI01cC5sgXtJOxydzXAuaIJFAH&#x2B;K2hvE/UXXqGEOwlA94Un0hf14cqwPe/2j2ERUfvFZmsA&#x2B;izvopzL8hiOkG2K9AFkisE9s603bnsEP97yCC5oW4jNLTsL6unYYtEGE1rSmtTe5KZl8ovLnCOR7PB4jver1&#x2B;rz1nqrMzwN3o1F7EB3jQQEUgyDd9O8LBY9VFwBKUpGmU6x3BJG&#x2B;Ufi3dsP3yl4xlDGL7&#x2B;IFqYUCCkDeJYquO&#x2B;neJCMBOS5jpPV0fuwcdFx2FoN9s9mK135yP0Zf3MLz2Spr0Pret7EWgHfTHuy4&#x2B;TcYeOQlGMU6k7kIVvzTpXAva2Odp2LAP1ca/1yDAFo7egIAutcxf2nNipkV/wu/M9TX19eIh2xDbW3tO8UFY9HA/5HfQt39SEdjDFIKG6mwk1&#x2B;4yePkYMDraQTXYgNeZhmYPA703v0MJrfuhdEtvdYpEx8X4NHS6mFfdqvDwQ9Aak6nB/0H9iFJIn8EkAnQW82ydr61Mu/PzjXgvigHBOLeEAcJFGM2zoRDKREgQTwWADRPXZKUuU754xh/bB9n5OMjQQzXOmGyWiUoFGBVZROotH41tkpZf1OtA66sFB/kgID4fXDnsBKUkOsiUE3bTutnVoNYJ4FNAsHiDpGfc8RFWX62kK5VWHI&#x2B;PUKdE&#x2B;A/fjAEy2qxvVU2rp232hxwON3M2DAKYBgJB9G7d5fYb7GuagdsRKtPpvmYJfxR3h4SPqRz4H18P9xrm7gMgDjqrO6fJgJa0cM/X2qRYTaDa0kd0iGx/8NR3rBUIK6wDRTAnc1i0jsOf24s3y/qFJq7ykygKLpzYR2vLzUZEZ/pWHOB7QETGcULVxwrcUwN5M5ANH23hUG8zir1IAwu2XnR&#x2B;U&#x2B;IZdC1wAlq0jVQ9B641l7pdKV&#x2B;hKJKoJRuqCJ&#x2B;04QKIe0js&#x2B;xKkFXEIB2wNFTD0dEE16JWuBa3iWuyHo6WOphcDpjItcJiltn9We4RXyKG7tAEdk6O4umxfhwQYH&#x2B;bAP&#x2B;ReGRqJj3tA9Xvm4&#x2B;Oh4rCCghm0/hd7078rm8PzqprxWeXnIwLW5bAZjBqD16taU1rcx9LKACFrPdSqRRb75Eav9vtNmUyGYHNcjqq4Sc6v&#x2B;hbdBaLRRt7am0awD0EIKlSV0q/zl2XQV42kXE/wgLoU5adxPj23/4wRp7ciEQ0jEjXGJIk&#x2B;ixGR3qYoBf9GZcb5tX3lcQNjXHjCYZHNJJydjQwszNbMI6k8U86moDRbhVjnSS2fO1ObPv6nQLwi7Epojju6isEwG9FOpbEzpvvwsFHnoQZbgH&#x2B;o2g7dz1WfukjyMaT5fdzjk4AcwkCaO3oCQDMJSCgmwHsz5UBMK3W/&#x2B;KLL94gXjf6/f6lLpdrZTqdDosbypLNZjNGo9EhLiiKxmqhpCOoRYd9DAoJsEwH72QvYmHKU/Z10P8JSFGtUioYYXZB0h/C6DMbBRjNC&#x2B;iy&#x2B;Fpovxfh/RMIVg9jqL4L1joBYK3GvJ0dgee8330RCOcscoUNpkoBfOkRG0shPhZkpX1VxI8V/nOYEoLLZKeo5iTG4jEja00j0udDeJ8PBodZgDsB8OqcnJ0mYUHkAaFCq89T7LOSfU2Wd81uDiKQKn3wtWGmpEuLNwG4KeMdzyn&#x2B;sgR4KeMva/fznVBaahHQslQbl7zSbA55t4B8AEABt6HXRjiI4FxWg5HhgxgZ6OUoM5V0ZDLS0YAf6mnloS7AtrnaxFaCtuZKxOr8iO6X3vVjf9kHq9gP0kyw1DvE8g1ym4vKKXJqSb5Sh29psCMxYkUmkER49zhrA7hXN7DbAu&#x2B;v2iOWHdxBZurF&#x2B;UmNx5GNZpiRQO4ClnonLE1OdmCgY8OsBLIrNEow76qsREV1PbMLxMgQYf8kAj4vov4g71PSF&#x2B;Zsfb5T1qlihFP6BdMAv8IIYEVduobE9U9ZfGtDjQD6raIz7hQdeRPsjeIY1VZyx22izD5pNig0wZkGsa8FvegO&#x2B;PCSbxCviKkn5EdvNCjr9nWSqcAA2mSZByMvhRUg9vup0V48NdKLtdWNuHbJKfhAxwq4jGbtAaw1rWntkOckFOu9SCSStlqtBrLgo8y9eK&#x2B;n70mkr66uzqoMJw2F4EZrWpu1ayIqv0FCl0wuidGnNsO9qAXBfYNi6kPPb55AbGhcjH/NPBaIDolx6tCoAnwMzAogKJ8FCfpKPRwaC&#x2B;St&#x2B;vQsgwzfS3vF3CYB/1OoOmmx&#x2B;JxgY2KKaUAaQGLcMPrMFuz6n7sx8OeXOKhA4L/t3HVYcd2lHCAgTShXRxOvJ6tLYvHlF&#x2B;LE/74KRpuVRYbLWfgdDuAvFTTQ7qf5EQAoB/jLvS/WACgVBChr8Sce1C4B/G00iQuJ0sexZDIZFMAmS7Qs0azi1aLX67Uo7ZHQ2ZaqixKgKDHul0Jmh&#x2B;VSnn&#x2B;KIEWq9GR1ZjXDv30f4iM&#x2B;6Udf8KAxVpg5C50UYC0&#x2B;GETQMCoeaiYW&#x2B;yPQR5leEv1j6z7DlC3dIVd2Tsc2eC53HSDAbmwkyJlivVWA3Qo7Z2V1AtCSaj8FNzLplGQG6CS9i&#x2B;3vqMQgkEBqMs51/qyMT3ZybrP4vVSjNyhWe0S5Z59fg8wmU5AgGYwhE1GOl0E&#x2B;3HWq8YWuCPGq8YycFPJzLqjh4IOjwgO708VgMi0AbSwcRjwS4WOUZeG8FAc6yO6OQHNyNIqJjf2IHpiAY0WtAPVu6KwK6wGGKfBesG5Vnd8oADWVYFAZQaTHx&#x2B;J9Kb9Y3gshzu7TOTBX2mGkQAjpLFhkvZvOrFcsD7NI&#x2B;sV5GwvBXGdDRhynzEQCoZ2jiPUF2OXA0ujiQAqdv3KXEWXXg13jCG4ekfaPYj2Vp7bAvqCSz5l6nNQAiMr&#x2B;oNdEJIa0IwaTOK/kEIGKSiRT4hxmU7DUOBHu0iE2HBA7q8&#x2B;TKKadCgrSpKey&#x2B;warBdb6Ktib6&#x2B;Fa2ArX0g442&#x2B;tha6qFpdItWSg2s/TxNcxM5x&#x2B;PR7BxYgQHguN4cnyA6fy9sTCiiajydDVM0fnnc1acBR4l2N88MYxPvPgAfrD3ZXxh2Wn4UMdK2DUbQa1p7Zgdf6jWewTyFes9KPX6JgL9lJWtrq7ORwstFot24LR2mF3Q9DEjqepTX04DC4Pegte&#x2B;fTf23v4gEqMBpAVAJ9BOn6czKU4AJCeCJN0nmaXiX4vHA9eiFniWt6FidSc8qxag6oRFYowmdZDMZgv6n3gVw09uZEBvMFpQe/pqCmvlATYl3Uae2owd3/41xl7cKcZ2cZ43LcB/67ln4PQ7/53HI5lEkhNnjrY61J&#x2B;wBiu//DG0XnQGl3qWYucW1/nPBfAX35NzdVPQAgDz5P4oMxUHAYoV/0t9ThHaXMHFRYDfRRP9nU6nY&#x2B;Jrsl3xUzBALyMCNnrR2AFvfbPVVnC9fHHTm0wIHxhEtH8Ujs5Grn063JYlH3iuWzfIYAABbbNuKoPO1H7xyLObkHXnWC0fyRyL7lGtetIbzSv7c1bbomdAzyUBShaYhfdSsmabIqEpX4zpUsZKqQRva6oQk4fBYUvHYjhdFQz&#x2B;47EYxocH4B8flfXeyl2ga1FoT2JbKSCQCSeZ1k4aAuQ1T8vm7eGMtZxUbbksC7LpeN15sZfcoSYzU8lnRYyPdAha9RzssDodqGtpg83h4J/GwiH0de9FVLwSUFdBNNekkTAhCfKNhwWADwjgfpA7NWuTC9YGJwslGuxTXvb5hzsKOgOqO/PYETMJkOwQDzW3SdLZkhmk4wmk&#x2B;&#x2B;PIHVTsE4mhQIEYs55/RwEAZkEoFnvklGCst8AgxmrZeAaRgz5ED06wHgLV&#x2B;xvEROfL4DBKCr7Ynow4z6lwgtkDzGwg2xsqrVhdL8sQUgphLle6Uyf7voGe7jx9X&#x2B;JqeT1TYCIZiHGQRu68AvgzmTxdz&#x2B;iww9JYA3tbE1wLmuEmOn9LPezNtTC7HTDaLVy7rzfop66TEi2aTqIrOIFXJoYE0B/D075BDIUmMJoU51Z8l7fgo2Ucywr5SiBgy&#x2B;QYPvHCH/CjPRvwpdXr8cG25drDWGtam&#x2B;dNjP&#x2B;YgEXWeyTUZ7fbjYFAgKz3jGSzp6jx651OJ4&#x2B;vKdOvHTWtvdnNKsa9jo4GBIf6xZDUyWPI5GiQM/tGmJGh/7IhNJ1xCk69/V8R7B5EYFcvJ2GcYjxcc9oK2JprYLJZ8yAoq04CmPf8/q/YcPX3WPcqgySa15&#x2B;OWvEbAvPq2EVvNMG3aS/6n3pOrNHFQxwaGy2/6gqsvuEKMXazcKKH5k1HYuj8&#x2B;LlY&#x2B;MkLYKp0Mrt2quRAV1bosJQjwFwtALUgwPwOAOhmedUXvS8F&#x2B;g2lJqrHKnvQBNhXHuzObDabJlZALBYLExtA/C4rHv5E6zIYVSU2rf1Nm3tRmwBndqnmXqB6zgwAbwDDT76KJVd&#x2B;gClMh90KAJNKkWbwLN4726o4o251O1l5X5xvVmWPRcIsBJh3fcvIbG8mkWE3AFKgzyhidiTiRg/ILNXcU2yWau4JYHqMqs4KIge8SAwGORtMtHxXbRXM4qFNpQWquGEum5vuZa9uvthOQ42RywEYnGZkvVbSF&#x2B;FgANfxF9jSGQyWvLsA2xi6LHxHkDo/2xVmFfJ5VqH0pxSBQ7EQ71P7YW&#x2B;vRGJRmGvmzVQTRkJ1FOWlunVVhK/g7iVhOQL8ROd3LKqVwoh9k8ykiA8H&#x2B;XwSe4LEEfUOEqEzi/klrZ8CKOmoOKd60fFNRtkBgPcxJR/8BOYNJtOhSvg5NQOfZetCOq6kmUAqyuSckAzHkYrGpeBiMsPnjhqVI6QnknJ5BMhJj4BE&#x2B;Ax6Zhfo3UbRmdqQJRZCKIqJ53thE8eD2ANTAQydfOqomgjkiKATv9WLZdHxTGY4aJMgu0KxT6lgLM9wIZ0A&#x2B;g2Beou4Bkikjyj9lOV3EOBvqOb7gAG/1TKjA0A8k4YvHsGGiWFs8Q1j2&#x2B;QINvpH4YtFkKSyCzrP9PgiCjwFIzTjk0MbZf3FtNE/gkv&#x2B;eg/Ob1qIL69ex2KBWtOa1uYF2M9b7wWDwZTL5SJxvixl&#x2B;UmBXzQ9gf66ujotpa&#x2B;1txb8iHHH6hsvh/fDu5EIhJjQz&#x2B;DfZIVzYRsqVnWi/tw1WPDRc2F22lG5ogN47xn5MSKNDhKUIEkmYTSbMfLiduy&#x2B;9T50vP8sjG7Yht233Ac1W2Nxu7Dm5n/ipFomVminnYVzQQPPZ3TZsOB967Dk8xdzcIG0A8j2T6ckV2iManLbeV5V8K&#x2B;c3d9cGABzzfrnSxW03Oy8CgDM5ASgQ3lrwHIMgOKgwBzxITMA4HQ6zTnZiBlADIGk6DiConNgZoBZNO1y&#x2B;9s0ojG5BBjy7&#x2B;xWKFEF58dkRN/dj6Hlfethqa44bC0A1VmAIqK25jroBQAlQEjifKrFm83lRMuCRTCTV7l4yMWjUfTv70JwckJS7AnICyBusojbjVT2Fb95abMHJUufYPo90delwr1umnBeKhJHQoD2wK4RDhJQ4IG1A9xiEu&#x2B;ZTUCTXjdNqb/44UjfUzkBZcxzyRyig37oFJu&#x2B;/PwkTCcArmdlEwvUkShfTWOLwIF60WFIa8HQpJ8jwdIrPsOZfBIjJODuf7EfersB5jonq9mbxXbqldp3GaiY2ve8LkJG3n2WWvkbsucLd3ulcF06y5n8nDgGcQq&#x2B;6GWYmsUQBcinbD6VRzg73eIYS&#x2B;CbFAA&#x2B;nUixoB5PyXQ&#x2B;&#x2B;MDCieMJPjeuMxpE52dCY0s73FU1rFLvGx6CV0wEgilAkxTnJOENMVOB1ykWk55McADB1lrBDgBGjwXuihp4aqqRiMXgGxhCcGAc4V6vfKhYpaOC3jClm5DTSaFKOscUGKJ9JccH6jSJ0k/rp&#x2B;uPBPuofp/U&#x2B;T1LOwXgb4ajrQG2uir21jXZrbNS&#x2B;YdiIQyGA3h6vB&#x2B;7BWDdODmG/aEJxCmzT4EFlcZfoISvtbn2opKG&#x2B;ejQfjwx0osrF6/FjavXo8Hm1I6N1rR2lLQC6z19KBRKGY1GPQH9ZDKZJeBPdH76u1CcT1Pj19rfq9HIqfn8U3DBkz/G0KMbWOjP0V4P5&#x2B;ImVKzs5HGBhOjUxWemgWkSWR596TVsuOoWMX5uxtpvfxYv/OPNGO96DZM7e9hymrL&#x2B;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&#x2B;HAA0cFJJAeinKmvPrMTtnaPYu&#x2B;XRVaXQTwRhdFihsljg9NaK7YvzUGbdChe9NRSy0hkGYR6TRqdNtibagTAb4ST6Pwk2NfeCEdrPdfxsVifZWZiUVhce90hP/YGxvHUWB&#x2B;r8m8M&#x2B;uCPhqDQH6Ys&#x2B;Ai8aoL2b04XZbIgLY7tT/a8jL8M7MW31pyDD3auhjbs0JrWjrymWO/piNIfj8ezbrfbSGCfQL1qvUcDOrvdbphh3HnENZ/Ph&#x2B;7u/Vi4cBHpDhzy/cTEBF55ZQPOP/8C7SI4unscHhNVn7iEp&#x2B;LgQFYdbxbT6UncOhbHput&#x2B;grGt2xHYcZDr/yPdozDDyUk0d0crhp7biJbz1mPtTVei&#x2B;qRlSMfjhwbNKAAgQH/lV/9BaiolUofQ&#x2B;otBfLmsfylwX/x9qeWUCiSUW57Wjs4AQCmAXxwMmMkFoBj068oECApFAd9wo5IAs5k92yxWqzVHpQKig0mKjieWSqXSFouFiAGkL6BpB7zB1nnpudj/i4cFyItOE&#x2B;lTAwTddzyIqjVL0XrheiRjsbnh/6xURaV6peTYJPQuB5rfsw7&#x2B;bV3yAcQ&#x2B;q1l&#x2B;mKYORBHcO8qgnQE9&#x2B;bcL0EsBCVKiJ/s3ArFEHVeBvbR0k770ZMNHqvFkxRftmoTOpoepxjpF68/kZGmA3SgAsU4AagtjYALQVJbAZQZsCydt5Ph9Oo1kKMEPZVoPLZ9V/SETveYmK3QWmdEu7j3IbjDc60O0bxKhVhcmGodYTI/E7agcgOdR7AmnIhxqsMIAW4sH9tYKXi/tEwn0RQb9QF&#x2B;W18dBBaPUQJAe9/J3lKknWj05DOjtMqBBGgAsCCjmo6w&#x2B;AXq5r9JeLzUWhe&#x2B;ZXrhX12N/JMosANY/SKWkoq0eEsg7LbDVuyXFviGM6D4fAtuGEe0PwLmoCpYGF6&#x2B;TtQLUDkP2pHzsHQtqOPjCAQD6mFgFiqgfnYNwKIBQcFLe&#x2B;wYpsJhKZxUlfl2&#x2B;w&#x2B;Ttzsk6fzOr81cLsN/Ctftu0Zk6mutgb6xhOj8HkWZ5NHSH/TgQnMAG3xBe8g7gQGgCeyJiO1LJKR9GVuXXSEh/&#x2B;15KHGuzeN7EwvjQ87/HJf178N2T3oU2u0c7NlrT2lvc1IE/AXsC&#x2B;lSbT9Z7BPAVxiaohl9MRPMn4H/EJWYiok9zOOZegnXbbT/D8PAQvvzlr6Crq4sDAqeffnr&#x2B;&#x2B;z179uDnP79dCwDMlyBACSA9U7acklaUDIn0jPASqE6/8ey16H/oWUzu6cHKf/4wLDUeNF1wKtovfSfrX6ngvyQgJxHMWEJd8YwA/3As/WYKEhza7R7e/FpTjtuRcqBKDHJno/WrD2p9EbA3oLzKv2GWyahOopO4TXQGS/6W&#x2B;xyLyWKaaDSaJHYAsQJsNptZHAu9Fg84/Lbnx/dg69d/DnOF85BYEYE1k8eBU376ZdSefpykMs3luhQgn2r0g7v7FEq2GV0//h2GH3tJAEr7FEiESmmXIJxAKmsSUDI5rRiqcpV/VqmFl5&#x2B;RQJxegENSr2dqOP1vNcDoMgtwrlrs6eDoqJJq9mL9FbW17ASQJiHAaIRLDjhrna91mn77qCKEHKEV4Jpq5SkjTeJyTEFXa/7VYINq1Uc2MLE0Z&#x2B;RzKQmizTV2MZG9oEVuI5UdKNl4tbY&#x2B;HxBQUvacvRev4f1jiA8G8vXz0ndWsSVELr/9qvUe&#x2B;chWnNwCq9uBtgVLYTSZkIjHMHKwF2G/XwDcLGsAUJ18rD/IjAbaLmuLB9Z6FwxUGmE2THUOyjYxwKcyASqpeG2YRRKpbp/2hYIE5mpxnF1WGKg0gjQIyNJR8bolNX46hploGlkxmWscLFZILAG2w2HdhhxSEamzkPCFmM7PgSGblcE&#x2B;ZfdZfXdpJ5ydTQz2LdUeGKlMwDBz9VEolcBm/ygOBLx42tuPnROj6IkGMRkPK6wFvVK3r6X1j4iWjGORw4NbT3kPzm9dqh0PrWntbwf2GdAT40yMqdJUo0&#x2B;q/ETpJ&#x2B;BP9fz02ZE6tiKa9u7du7F06VLWo6F2883fxJo1a3HBBRfMGugg3SH6ndhn/iyVSuE//uNGbNq0CR0dnWhqasKll16GVatW4Utf&#x2B;iJ&#x2B;8INbtYtmHga7Sn027TuFwr/j6/&#x2B;HrnsfwsrPfwzLr/oAwoPjSE6G4V7exgkNUhQgfYBygYXDef9mzjvTZzN9t2/fvlfPPPPMH1CvLCZSu04pU7rEa0Z5LXyfUaZswWvh&#x2B;1yJ18IJBa9HRJDiaA0AFKv6F78Wg/7i13LAP//e7/f/rKKiYvFbtf/iYS2e/xkSE0wSa4A6MdFZEQ1Np5ULzK2lo3E8d8V/YPyl7SxIUqy6TrXV5ko3TvnZl1B32nFibB6bkzOgFBMMInJgCAaziZX6d3ztdgT39DCoI4o61dXrmQqfg8FuzusDGDjDbVCArqSKy&#x2B;x8VixHCsxx1pteSSiQLAuVEoG8iJv4w1rnhKXBDavLgabOhfBUV0M6UOowNtCHgZ79Um8gVz5UrFOywVInQMeZaP&#x2B;mQS43MNgkk4ABPTEV9JIKT4CU68vTOQbbBJYpWAGxH7RflDGnDD2VARB4ZqaDWc8Zb5WZkIkkkQ4LoB6NSQ2GOQzA6HfJwSicS2vhWlUHu8cNs8kMo9HM&#x2B;gPxWETRV1DAvQDZFNCI9vq59IAj2ySA6LDA5DKL7TQxM4SCC6RZQPtIKrQJb5j3leMXrGeQVez5INkDJj0zOHIKdV49dlAdCWjejBJ8yal0frkPltpKOFob4FrSykKV7qUdrMxvq6vk7D4d25kORVKcn97IJGf29wXG8NT4APqCE&#x2B;gnC75UfLoqv057RByZIXYdMzGoU/n31evw/1afCbNeO1da09obBTs0XiIKv2K9x9KqVMPvdrtNlPEn0E/fH1FjFAHSCaCLseUh3/X29uI73/k2br31xxD7IcD7/yPmAm666ZukMTVt3uHhYXzzmzfhM5/5LFasWIErrrgcVqsNd9xxJ/bv34/nn38O73//&#x2B;/mz8fFxfO5zn8Ho6CiuvPIz8Pm8cLncuOqqz2sX0jwPApT9WxkHpgJRthMkoWZiYNKYh5iTcwHsZQMMRZ8XZuTnAtTfrMBB8d/ivnh1/fr1WgCgoM23NJGuTMCgnEWgHqUtAt/yTsNkMhloslqtJhKjIbpaLBZL0ftUKkVWM&#x2B;Qnq5YUaK3UxWy3Yu1Nn8Ozl9&#x2B;I&#x2B;PgEg/PCen&#x2B;i4ycnAnj5k9/Aid/5Alre83YkRUer1iyVB6NZAeY8rAMQ6xvjkoIVX/wH7Pj67Qj3DKLyxE5Yqh3sm1rf0g6L2cp2elHR0fu9o4iFI5zln16sopt&#x2B;lSkZcbIqTAcFMPVHBWiOK0rxOcRGgogLsBoWoHZ8Sy8sTjvrDZgcVuR0WUkx16EA4E8F1jj4QFe1UiYgLilmNSRHI0j0hZgO5l4rgOqyOgbt1fUNMLHNm1hvJCImMY84Topyoax5J7X6WJrr6dMhmlICTEeQjUkxO5qPqGY5CgTQ6qmO32WcpmvAWX4KNOhyeYcCBvXUDYmr3FxvZdZApHcC1mYXT6ZKG2fKCdznnQ9ysqTAWufiibL0VHJAzItMSmzbeFyxM5TzcQTRrJRj6BU2gtIpEvsCqigiph7ZusLHieIgQEEHOs8cLTebxDVSy9l9z4pOeJZ1wCMAP4F9qt03zlK3n85l4U/EsMU/gs2&#x2B;EVblf9k3jPFYCBGxD2JFUnVeBfsWTZX/KBmRsZsCnd9vbnsGewNe3H7ae1F5LNsoak1rh9loDETJEHolcE91&#x2B;aFQKE3ifCTKR/0GjY/E5zw/ZfqPtH3Ytm0bvve9W3DSSSfh6quvOeR7YgDQftDrf/7nfzCw/8Qn/vGQ&#x2B;UKhIL71rZt5vp6eHni9XlxyyYfwwgsvYGhoEJs2bcRLL72EJUuW4tVXX&#x2B;G/v/jFf0dE9OXf//73cdxxx&#x2B;FTn/on7aKah202wbz8e9YfArNiCfzzEDSVLrmcudTklwO1xd&#x2B;Xsvsrp&#x2B;5fTtBvLvtZar81VnWJ6&#x2B;UoZADMBOJLZf5no/8bcSgDwDQxMfHjysrKRUfCsSG/WUWohiLdxAjQqQEDvV6vXdVFbeiJDXjx0zdJT1KLeTqYI8X1RJJB2/LrPoZFn79EZn4TyVkz0wReo4NexPvHYXDYBOD1Y9f//J8AqANwtNdwJLWyvh4VDbVs00fNPz7KivI6VdW/CBsUi9rxg4oyzgKo&#x2B;/7aw1ltY6WZAT5T5jPStz6bVhgFWVnTRQMHtijUS7BNInqstkp19fE0Z7yz0ZSiFSDp7BQQ4Dp7AXgt9Q7YmirEPtjQsKgTVTUNMJnMbD0X8HnR393F1Mo83Z8gsX4q4MC7xhn0NDKRlNjuKJITEa63V1Xvp&#x2B;2/&#x2B;J29rQqWChvc1TVwuNxiQJPG5Pg4YuGwwpLIsJ4BifUlvVHWSaBzQAJ7JreV6f560lowSWV92i&#x2B;9Rc&#x2B;WgBQAmB4SVGsUiuOwcwNxLL6YlswHKQ5oYzq/q7MF7uWdqBATCUTa6qu4BGW229IrwP5INIhnvf3YNTGCV/xj2C3AYTgdpzSR3F7Vhu9o6LhyygnmcpPs1MWdVRwG8he7yqA4RlkLiSjOrO/Ar9d/CC12t/aw1prWippqvSfGOWS9xyBfjH0yquUe8fxJof9o26/R0RH4/X40N7dA7NMh3x88eBA//vGPcN111&#x2B;Gss87CO995Fm666RuorKyaBoAeeeRPnM3/5Cc/xQyBO&#x2B;&#x2B;8Ey0tLXjmmafx2ms7US36U3HcEA5HsGrVSnz84x/HySefwr&#x2B;nz&#x2B;&#x2B;7714OGlx//Rc1UDSP21wy97P9PddlzPR&#x2B;ptKEUus6nEx/uXUUzqu&#x2B;JwbAunXrNAbAPAoAlKr/L3xvmCEAYCzxmp8mJiZ&#x2B;dKQEAAobdYzECiB2AEXEKTBgtVrZj1ZjB0y13vufxKv/cgsD4GJRQL75BLAlr/a2D5yF4276HKzVFUiR0MlsYiMCgMZH/Yj1j0tP1EQC&#x2B;267HyNPboDBapVZZKLGkyI/&#x2B;dfbpHc92/RRll4Zt&#x2B;iUbD0BXQKvVGvP&#x2B;gEkaueLIzEcQmwgKG37mqm8QGaZCfjmjPJ&#x2B;Ieo9gX&#x2B;aR6/TK2r0SpkBZahJCI&#x2B;E6lJZVsFXLfs4300UfqqPN8rIKDMDkhRcEMtymmCpcsBWLUXx2PpOj6kafxXwFbzNHx&#x2B;FfUDHiY4xAfHYcPBQT3p2JrDA0VmF2sWtqKir52MyIQZJk&#x2B;NjvF&#x2B;YpvKa5WNEzIj4UFAco2j&#x2B;fNB&#x2B;U&#x2B;kBi/XZJF1f9wbjYrTtpJmgWtmYPU5YG2vgWdIOjwD7npUL4OpogrW2Im&#x2B;3UzaAJ0BwT3gS&#x2B;4NePDnWjwOTY3hFgP2RaEAsP6PU7hsUG77iR98R3MhaKJtmMG80mFBhsaNB7EOzsxK1Nidi6SSWiPcDsRAqzFaMCvAbSSUxEo&#x2B;gKziBUCIi99VoPLaCAYkYVtc04d51H8JSd7X2sNbaMdtU6z0C9pTRN5lMOsV6L&#x2B;d0OrkUkpIc8wGo0r5cf/2/oaOjA9dcc&#x2B;0h3/f19eFHP7oV3/jGTQzkf/WrX2Fy0o&#x2B;f/OSncDicrN5P9H5q11zzeS4j&#x2B;Pa3v8NBgB/&#x2B;8AcM6teuXYNPferTWLhwIeJiPGO1Tu&#x2B;botEYnnjicSxYsIC1ALR2bAQA5gKiZ/tbzciTzkRKKRN4M2v/Dxf8H64mAGkAaAGA6W0&#x2B;lQDoDiN4oMfsLIIjshUwACzKRZQLh8MsIDA5OZmgUgG6SUnZlnrNmeg66kU41871cOb9e7eOD57N2/rq9d/n7L7eapmGVKl&#x2B;3VzhQv&#x2B;Dz2By536s/NI/ouk9Z4hOWlqZlAeGWVgbqmCwWRA5MCxwmxHLv/BRrvXuu/8JAbQTbGuXjgrgHYgiRvXmyu2v00lwSoCaQDln&#x2B;hNpDgpkQinWD&#x2B;CsPjkDmPQwNVhZgI6uSgLkzkV1DHir6xvhcHrYajCVTLDVXSQUQqGQ3iGWc5guBJgKJ9jfnsoMcorlHdHfOdMdEcsk5f4946wJoBfbYLSaWfSPaulVVwNVwZ8DG7SPJBpIgQXa/0gKqUAcsZ6gwIkpZjHk3QaURDEFYHwbgpjY2gdThZ3LKDi77xTnyqSbBobF1rHQntFjhbOjigMBoX1jXIqQ98PJ7&#x2B;1hXqM5eVyIccAMC7FP1poK2JvrULFqISpWLIBHTM42suLzSE2EGdpgNITesB8bJ4bw7NgAekI&#x2B;7Aj5kU7Gps4PgX11OtpaSpaDLK1swDn17VhT1ciU9gS5G4j7JySA/suTo3CIzwZiYfjFfsfF5yQq1O7w4N0NnVjgqUF/JIhHhvbj5fE&#x2B;jETDijXhMRAIsNiwY2IElz13P/501kfQbHNpo1WtzXswQv1xLBZTrfdyxGwUIN&#x2B;kJDVANnxymKKDxWJRxzvz5hg8&#x2B;uif0djYiI0bN2JgYICz9tMG48TWE8eB9n3t2hNRX9&#x2B;AL3/5SxgbG0NnpxObN2/m&#x2B;c455xz88Y&#x2B;P4LbbfspU/wsvvJA/e/XVV/GNb3wzf8yKwT81u92Giy66SLsgj4E2kxp&#x2B;MYV&#x2B;Lsr5annKc88&#x2B;i9XHHce6FHS9lvqdGiggzQv6TfE6y5UVzPb&#x2B;cD/THAHmZwCgFMAvBfjLBQHKfZ4PAogLW3eU3OQ6l8vF/l4Oh8Oslgv4fL4E0eTopiUxQaVT0M0G7MvdzOWiVuUCArMFHuYaVChXB1RcL1SqtX/gLBZbe/na/xFANwqjw3oI9dvkdiLSN4oNn70Zbe9/J1b82&#x2B;WwtzUKsJaQYLDUNgmgaHI74F7Whmj/GFKTYbRfei4qjluE7jsfRGDXAfZSNVXYYHRbYCDfe4tkIjBlXwHMrPhOm6&#x2B;o7udp9PRQpRr7RJoz9yyiJ6bogJ8BcsIehdPlgbuyCjq9ARarDdFIhOvRpyvwY&#x2B;pVhdFikGGoMMEswLajvRKhXWMIdY3DWGGRwn1E6beSWJ7iakDbk04hMZlE3KcEJygrrt4yulwBxZvAoXg161hVnxgNJIxoqrJMxUBpfrLIM4rzR24H9J3YbKL6Rw/4xf77&#x2B;HuDUQYeiEVBQRAqYaBtJ6BOwYeUN4pcPJNnJsx9JCqdGkiMkJkSVKJts8DWWAtHhwCyKwXgX70IFUvbYW&#x2B;ph8lumXFx4m7D1skx9AR9&#x2B;Kt3AFt9wzgQmcRoNAR5svXy&#x2B;FCGfx7UfevFPp3XvATXLj0ZiytqGcg&#x2B;PLAXL4n9HhRgP0hBjgwFswwFT2o1ACWOh7iWiDXw3bddjOtWvA2fXrQGQ&#x2B;JY/XFoH/5zx3MYjoXksZrvzWTBtolBfPLlh/DA&#x2B;stg01wbtDZ/wD4/6alWn4T6SIxPpfJPAVG7QVXkF0BiXl389957L3bt2onrrvs3pvqTDR&#x2B;B&#x2B;pGREbS2tmH79m1cq08BgEAggK6uvUzRpyz/jh3b8dGPfoSp&#x2B;lSzT&#x2B;r/pOBPrafnAAcBkmJs8vjjj3Ng4L//&#x2B;1Po7t6Pp59&#x2B;CldddfW8Cpho7c0PAsxWJ18KDwgcwUCesEQsFhPX73Y0NTfny1iKwbY634MPPIB169ejpqaGf1&#x2B;8TrUun6YMWyPPHASYS2BjpmOglbvMnwBAOeCPWQIBQHkBwOIgwFF5s5MgDk0Oh8Ok0Osy8Xg8pd6AVC4gbmhdcQ3dTDfU6/1upht4pkjkXJY7G2VJXU7TuafhHb/9JjZc9z0EdvfA7LJPr6kmKrpV6gQcvO8JjL&#x2B;4HUs&#x2B;dwk6PvouiBGK9D8tRaUSDyydAKKORc1IjE8iPuCFa2Ebjv/a59D3&#x2B;ycx8OBfOWPuXtrA&#x2B;LSxpQMVVbUC/0jrPr93DIEJn3wAHhLSKgp4ZCV1n8UBR0M42DWGg/rtMNmk6j4xCUwOi6z9N0otAJ1itQdFeyCn1GbTS1qAZxLuS/liYruDLAJI22GssUgyk04KJhoE&#x2B;M4R&#x2B;99k4Pd8c5hNeXu/HInGZCh7npXMgoTMomfV&#x2B;v10Jl8/T/X5RqcZzoW1sFW4UFlXLzbVhGgkiKDfjwwBQ9rEtHRGyMRSSIeTvJ3xsRgy0YQsUSCmglFxWLCbZgf7tH5x7ZM2AX8gBkgkymdvIaG&#x2B;dgn2VxCdvxG22soZF5cVyxqMBvHKxDD2T47jyfF&#x2B;9Aa9OBAnrYPYVF07AViTef71FuIcnVrbgkfO&#x2B;ij/eeHTv8Wf9m2S&#x2B;0qEJK7tpwGoaSoIRSUCSjlHrcODE11V&#x2B;NDCE3Bp&#x2B;4r8YpvsLly5aC0eHOjCcGTy2AgAcBDAisf69uD/bXsa31l7rjYa0dpRCfazioiuYr1npFcaY5D9HphsZ9BXVVXxA1G1tyseB/y9GtHmCbCI7eO/iYZfV1dXMns&#x2B;l3bffffhd7&#x2B;7m6n7tK833PBV3HHH/2L58hVYt24dbrnlu3A6XXC7PTz/yy&#x2B;/nAdSFCRYunQZlwiQUN&#x2B;qVavR0NCQX/bZZ5&#x2B;Du&#x2B;66iwH/eeedjxtvvFFsdzWaBRhbv/5M7WLUWtkxePEYe64Amu6N1157DW1tbXydvvjii/z5Y3/5Cz71T/9UMqBAE5WfTE5OcvBABd8UnKKJygcI8CuMIC5toWBYcRCgeFxfLtNfjAHmIiaotaMvAKA7jHlKvZaagPKaAkd9o9o56pDVv0lIh&#x2B;h2fr8/Rd9RJ03fU0f9essA5pLBf6MBhTcanKg6YSnecddN2Pqft6NPAHOi76u6ALmCh4vR7UTcN4ktX/0p&#x2B;h94BkuvvQx155wiI5Sx&#x2B;KFBBsW/3lJXwUyD2KAXqUAaHR&#x2B;9ALVvOx599z8J//Z9nLX3po1IChBrE&#x2B;swCXBtdTkRCk9Kyj8nzwtr6nP5pCnVshPN3ug0MqPAmvbA98JBxPuCSFfG5XyEbbNQat/1imq9knRPSocACYDlpyTSx/NSlt2ih6XRAZ1Vz2UJBNRci&#x2B;pgrrLBYrOjrrmV6/GTiTii4RCioRCXHhAl/5C7TD2gOSUokEzxulKhOJITUd6G&#x2B;EgQOtIfdFbBVuOAw&#x2B;RGPBFFLJpmVoGBxow2Ex&#x2B;zKdH9HDsLpMVyYoOTzIaYdvLygRIZ5KDsPs1P&#x2B;0fBHUdHE4v1VaxeiMpVC&#x2B;Fe3AZ7Uw1bOs7UAsk4dgigv3liCDv9o3jWN4SxaAB&#x2B;8TmIbTFNld82/3sL0XnvCU3gP3Y8i4&#x2B;0r8THFxyHZosde6NBDoyQLaU/HkGLAPpGcVwM4lycXNWAJRX1OL2mCYtc1fAUsSAmUwk8O9qD2/dvxaOD&#x2B;0SPZMYx1cw2fO&#x2B;1F3Fu4wK8q3GhNiLR2pEM9gut9zJUr0&#x2B;fkTI/ZfFJg4gG&#x2B;GTDdyTvx4EDBxg0E&#x2B;D&#x2B;7ne/i0su&#x2B;SAHAAiA3HnnHWytR1T9w2mUgackS29vD&#x2B;67734cPNiLn/3sZ/zdqaeehptu&#x2B;roA9cdjcHAYa9acgEWLpLxUV9cecfzSxIjA/fffh/PPvwDvfve7S66D6vb/8pfHxPQXFhQ0aKwhrb2BoMBsSTeDAO/9fX344x//iM9/XlpGCqDAwamW1lYG82rwr3AZ9BnpU3z6yiv5nqL7goJhg4OD2LJlC04/7TRUVFby71968UX&#x2B;7Jprr82XCsy2rXNhKc/lN1o7OhkAujl&#x2B;PlfwXywkyJO4YOZdyIiy//TqcDiMVCZAwQDSD6AAALEFKBhAET/FU7cs0J/VYqRMFG6miGSpv9/oYKXwva2hBqf/7AZUn7wCr33/LiT9IRjtBSBTzsgZbpomtnXhpU99Aw1nn4wln72Ef5cTRyUdi08DnrwepqWb4FzUhORkmAMBtqY6LPvnj2H85R3o/8PTOPjYZs5smlw2Bp6kA2B0KBl8osSbdHmnABLmyySybFVHGXDpXJBGakIA6fGomMJsYSfQAwwO45S4vbpdRG2nUnbO3Bul8CBlzMW6WKDQJEsPKLiQVSj9LAIoBiIZYhrEUtBFxG91JvFZFq4qDzw1NUyZH&#x2B;7rgXd4UCr/Z0ugcOW2onXQZHLbYGup4GX6nj2AaMCP2MAkvFt7oTMbmblgclrFuTDzsdCzMKE&#x2B;v33qNkoxPiOygQyXRRhcJknhF8c&#x2B;k0zxPnDZRaUH7gXNcC/rQNVxi1iwz9nWyA4NM7WgAKLjsTCe9w3itYlRvOofwfbJMa5fz6WT8rGg1qgTSJ0PQJVPoG7uLgM6PfziOH1961O4ZffLeGdtG85pWojLF61Bm8MNh9HCaqqVZYIhk&#x2B;JY7pgcxVg8hr5oAC96B/HUSA8OBL1Kb3SMgX/5sAPJcn5l69NYV9eulQJo7YhpBOwpUUCvNCnZ/QzpC4n3rMxHwQDVck8A6iN&#x2B;zESZyV/96pcswkcBgGAwoFjPSr2Bq676PEKhEFPw3W43du3ahZ/&#x2B;9Cf48pdvQFNT07RlEX2fmAK0HAJJXV1duOKKK/DDH/6QFfm/8IUvqLc4g/eqqkpcf/31OP300zgzSu20007HlVd&#x2B;Gvfeew/e9a7zWP1/xgG70cBBhpqa2pJOApRdJUC1Zs2aaWwLrWltNuBfPGanfylDn1Ho//Tdu847j4E8Bazy8yn1/tRIkFItG6DgAY036b4ROAN3/eY3JMQH/8QELv/4x3l&#x2B;t8fDjhZUJkNBOJWpfDjZ/LnU/2s2gEd3AEA3x&#x2B;9mq/EvDgroS8x31JYAHNaJNxr1dJNSuYAS2c8RQ4C&#x2B;i0QiSVVEUK3TKxUhLAW0Z3s/l&#x2B;XM9Fnxg6ycsGFxsEFRE8aST12MmpNWYNvNv8DY81sYuOdp7YXRT5uFlzP82MsYf34bGs49BQuueA&#x2B;qT1vFGXsW&#x2B;yvcx2w276tqFCA/6QshMTKBmlNXofrE5fC&#x2B;tJ1LA4L7BqRvvJEAbFDS8jNKPZTBIOvmCQRDZv7ZJcA0pfCvdxhgq67iIAGvUwHHku4v8Tg5BTgX1EJnMcAuBgnuykqeN5FIIBoK5h&#x2B;y&#x2B;UM3pUvK&#x2B;yCXKeYPR9H1/KvMDDCIBzwFKUgEkB7qOWNOAeo6uRzaPp1adiCuJ8roi&#x2B;2nAAKJASYGgmKKCNCvh6XNCTGOYWCfDsWQ8kcVJoQuL/nHAQYB8CmIkIlJK0GyLswhy44IuUhGAH4L7G0N8CzrRNXxS1C5ehFci1thr6uUTIgZ2sHIJA6G/Xh8tA/dAuhvEFN/eBIpoqxTJJpqKfWKOr15HmT3p3lOgun8jXYXguI1QowGnW5mQUKK9JNjAc1nMiOcSeHhwb14eGCPeJZY0GhzoMHmQp3ZAo84XilxDN0WK/pDfhbKTIr5N/tHERLry7BKZDIfVDgmgX9hM1mwcbwPv&#x2B;/bjY91rtZGJVp7yxslBFTFfTFYT1NGn2r4iSVINfyUJCCwX5DdPyLGSJQ1JLBeWVk5p/kJsH/uc1ehulq6b9hsdmYuUd/4s59JUT2fz8sWfDfccAMefvgh/pto/Dfe&#x2B;P&#x2B;mAW1S07/gApmtpzr9Bx74A375y19i0aLF&#x2B;Nd//TcG4a&#x2B;&#x2B;&#x2B;gq&#x2B;971b8P3v/xDt7e2HbA/V/j/22ONiP7LT6P7lGm2r6iDwxBNPcDaWRAVJK4DGEHQsXnzxBaxdu7bsMsiK8OWXX8pvu9bmfSCPS11UVsts4oCF3xlkQlC59vTYuWMHfvzjH6O1tRXXfuELsNpsPA&#x2B;VBtB1RQEsNRjw0EMPob2jg8sHNm3ahONPOAEfvOQS/Pr//o/LAyjAtnLlSl4WbR9pBcwk7DfXoMZMmgdaO/oCAHPJ&#x2B;OsOM2BQDP71Zb47ZqKC1NGrYjwE&#x2B;qnzJ3sen89H9Xw0ANApdoOH1fHP5eabS4BgroGH4hu/8DvVx57A4vr/&#x2B;zoO3PUodv/od4gOjsHotBdYx&#x2B;nyAJk&#x2B;JzDc/&#x2B;BfORjQeO6p6LziPag6aTmXEaRjCVnnrq6HhANJtb/WA1OlE8nxAGsE1K5bi0oKBLy8A0OPvoDwgX6BL8XD1WaFrbmSQbvRahJYyKKI3aX4wc0PXgoETANjOVbbz6m19mTzF0sKgJxiVX&#x2B;qo0&#x2B;Lv8lmz2Z3oqahSSzXzFaB5BZwcO8uxGNRabVX8qlABH&#x2B;p9G90WphOT&#x2B;uI7BtH5MAkjC6TPL4ZCSp1Fh0HUTjyazFJJ4FYio8LgXeq56eDYqyzsLAfWfoJFMgBAhYEtMqDzQ9&#x2B;qJby4n2GcKIAihaKrBhhrfHA2dkEz9IOcQ4XM&#x2B;B3djbD4nHOeK14E1H0CnC/XQDQZ8b6OOO8JehDNBGdAsesyE&#x2B;g3zy/vFGU/XMYTWzBJwX69Di5tgUnVjagw&#x2B;HBcCSILYFxvOAdYAmIQxgB4nx1OkRnXVGHiADuG3xDiFKQRAHuaXF19keD6I8EJKtgmi9kwbI4wKCT3x/roP&#x2B;QB5Yed3ZvxYfaV8Cs14S8tPa3a4XWewT2CeBTsJ&#x2B;SAJTZJzV&#x2B;pUTwiH8S/uY3v&#x2B;bXK674hznNv3PnDnziE/8gpn/E1VdfA4vFTOMdPPLIn9iC75577sPAQD8qKirZcq&#x2B;2thY33/wt3HrrD/JJBGqUtaRSAsqEqmOLu&#x2B;66WwD6k/Pz7NmzG9/61n8JUHR2SfCvttrausPe7/379&#x2B;HGG7/CgYVAYDKf6KDABukDxET/7nK5sXv3LoyNjePMM6c0Ami7fv7z27UAwDHSNrz8MoaGhnDpZZdNGx&#x2B;rY&#x2B;eZdLroWi6s63/hhRfwsY99DE89/bS4tnbz9b5j&#x2B;3YW/AsogbgzzjiD74cace8c6O5mVgAJWlJwgJwD6BqljD&#x2B;VCVCwYOnSpUjROK9o3DEbo3iuwF/L/B/dAYDDDRboZggClGMCAMdACcBcm0rro0mp6ckR9Y/EfejGpu8pYEADCNVqcCal/rnehK9HrKNcsGCmz3MK1X/xJ96LxrNOwu4f3o2DAuCnI3EYSfV92iZIT3mTEggYeOhZDD76ImpPX43Of7gQdevXcilBOpGQNnI5qZDPDgJiX6yNVTDXuJHwCnDkBRrOOpn1AXyvUCDgRYQPDopt0TEw9tTXoal9AcxUJy2WE/L7MdCzD7FwWA4q8qr&#x2B;inqqycA0ev680iYvXbGN6XgK0X4/0t1ehHaN4KB5GyxuB8xOsVyzAVldVoJvo5K91&#x2B;um3yGKeKCqG0AMgAyJBnrjyEaSyNkNMFRZYa1zwuyxwyEe5GaHDfFIFJlcSmDMtGQtMLMBeTG&#x2B;LDsbqLoAMa7l56oHtXafHAcSqXwphrnCiarFbXAv70T1CUtYod/eXAuTwzbj9fBawMuq/M8LQLtJgNX9YT8OCoDKCvQ6WQ7B2X2TZSoAUPzIKAVii7PoJYD2nOd9M1taDRQZpdNi8XqzGVzauhrL3dXMfBiJhXFOw0KsqWnC86MHUWtz4AOeGvTGQugTxyqv4F9wD1Bg4PiKOs7g7wn5ESWXA13BY1QDrW&#x2B;wJzbhFf8I9otju0KcC61p7Y3H/eQzjJh91F&#x2B;T9R5l&#x2B;qkEUP3O5XKZivtn3VE0Yu7t7Z2WOe/v72fKsZq1JOAxPj7OwnoUUKf6&#x2B;S996QY8&#x2B;OAfOABA4J9U9an2ngQAv/rVGxiYnHnmOxgk0&#x2B;9/8Ytf4jOf&#x2B;Uwe2FMjJsFf/vIoenp6MDIyjOOPPwGnnHLKtOO4bNly3H33PYdNxSeLQGIOvP/9Hyj/uBDPi9WrV/M6ly1blv&#x2B;cWAnXXnstLr/8Y7jyys/ittt&#x2B;hldeeRXt7W0caLjkkktw0kknsRuB1uZvo2ueqPoEuAlsZ5Ra/YQA8XR90XV73PHHs&#x2B;Bl8VhZpfvT/UJsTyVByPfWkiVL8PZ16xAMhfjeo2uJSk6u&#x2B;vznuQRm86ZNHACg31PQ6d577kE0FuNSgj/84Q9M/6fsv9ls5uXSOijQxpoYZUqJZxrPFwcHSjmEaYGA&#x2B;R0AmEu2fy4WgOXmO6abot6pK7TwoQEFDSa8Xi&#x2B;VChgoc0AlA5Q1KGcZWM5qZCagPtuNXS5oMJdAAtPnxSvVh5/8P/&#x2B;C9g&#x2B;di923/hYjz27hBxFZw00HUjIQYHTa&#x2B;Pux57Zi7PmtqFi9GO2XnoOmd58Ba221wFopBrnqw4yV8MUD1dpYDUuNB8mJEJLeIDMCqk87DoGd&#x2B;zHy5CsI7z0owPoQxqu64agX87rsEMM1pDNpGMzy0DMtPjd18U45/eU4my/LEOSnuYQY/HT5Yao0w1BhRmwkKPUF2IZQ1QDQK6KBOVluwFoAmbxVXjqalGUJAphnwmKfxM&#x2B;M1Rbo7QZ2QeDtsBjhrqtGhRhc0HZ6h4fgHR3k7SGMLXGwPI5kh2iCjZ0AaV3&#x2B;Tf0I7hmGpc4uliO&#x2B;EcvxLOtAxcoFqF67DJ6l7bCJY2EwlX9MUd3&#x2B;Jv8ouifH8YS3n1/3C7Af4&#x2B;y&#x2B;TgH7BjlZjNOBfTFIL9fJFH9eHBwoB/yL3x96c5Wef6bgQdH8ZnH&#x2B;3tW6BGsqG&#x2B;DQm/Cr3u3Y7R2UloM0X0Y6MfziwDbUWOyc8V/krMREKobxaBgGMc8zIz3YGvDBRxZ&#x2B;pVghOgP6xDH95rZnpAaCKn6otTfzQYtwIobtgTEtAKC1w24UpKfnbDKZzFF/TFl9lcqvZvGUWn1GxtRvz4f9drmc&#x2B;Xr6W2/9Ie6//36myH/wgx/kz7Zt2yZARpIDAJS8IDB&#x2B;xhlvYzBD6uMEkm655RauqaeselNTM5fIPf3007jssg&#x2B;zcj/NRzX8hY3oyl/4wj/j8ccfw8c//nFcdNH7So45Xk8dPgGq5557fsYAAAU4qqtr8O1v/xfuuOMOLmug/d6xYyceeuhhdhugjvyWW77P2d9rr70ar776qgBwi/HII4&#x2B;I16XaTTNPG9Xb//znP2fBPrp&#x2B;iaYfIzcr0UjT4qGHH0aFx4NVq1dPG&#x2B;cXvv7l0UfR2NTEAYJCjYx9AqzT9UQBhJWrVvG9Ud/QwPcXfb9z504G&#x2B;3RP1orfcnBOjD8I4BNLYPHixRxgI/o/3RtPPvEEuYegWXEBKFUCUAz0i0F/uWDAbIEDrR19AQDdG5ivFDNgJrcArZVpqpigWidIA45AIJCkOkE1GEBBg1LlArNR9w9XC6D4&#x2B;7nYghQNnPi17tRVqDn5Gxh6YgP2/ux&#x2B;eF99TT70CgIBuoLButFuZQBOAH7L5t3Yf9vv0XjB29By8TsYxOoEaGWdgIykRJPAHoFtcgwwV7uRmgwj6Qui6sTlqDxuCcIHh&#x2B;F9ebuYdsL3xBam3RssFvahZ50CsvejjL9BGt/TQzmblWwDEsWjbH7KH2fRQCoHoPlMVVaYK6zQOQ2KJVtO2uxRkCCTYxCfY5s2qsmmrLtRbJtdugNQGYDVJH6SZbtBPn56Xd6SUFr1pRE54EXX7mGxfB1MVjN0VoME/7StBL5JByCZ5lUkJiKcjc7y8cjCbHKh7UPvRP1pK1Fzxiq42hphncGKLyoGcnuDPmyaGMbuyTE85R3ASNiPEbLgo5pyg1KzTx2W2To7kJ8J9Je/2Er/XRxYmClYMJff5iM9uhmXScdyIBzEmDgGXRMjaLe78et1l2BSHI9XvIMIiuNNA&#x2B;AecZy6wpPYKF43iuN2d0&#x2B;WWRALnRVY7qnD&#x2B;1uWIJSM4emxPoySJoASGMqvX1d0TOfKcHgrmRBHexw7k&#x2B;JSFa1pbTawr/ZtYrCdIWBPDD0q06NyPbWkTwy0GX0aSTnuCG0kuEdTscDeXJvZbIHFYuXs/cjICH7/&#x2B;9/LYLjS32/atJFBCIF6ynxSrTKJ&#x2B;nkEALrvvntwxRWfYMs&#x2B;0gD4yle&#x2B;ihNPPPGQdah6AcXtve&#x2B;9iKe/wfhKgCM5NKdAxde&#x2B;9jVcfPH7cOGFF&#x2B;ZHIQ6Hg6n8lGX93e/uxQ9&#x2B;8D0uBaD93LevCzU11di6dSvXXm/bthX/8i//KoBhiAMD5Epw&#x2B;eWXazfS/B2fM02f7ikC2X/605/y3y1ZuhTXCLCu2l4WjpnpnlGz8RQoYIq&#x2B;2ZwPsBHIp4AAZfBPOfVUBvw0Du3u7sYd//u/fP&#x2B;Rur9OCXxRiQzV9tP20H11wgkn8P23fds2FgP840MP4aUNG/DZz32O56d7sHi8PhcxwJkCBcWYQGtHRwDgcIG&#x2B;Dq/P&#x2B;m&#x2B;2&#x2B;bQ2awds5vCgUi6QowyEuJEzVC9ENyF9T4EAxRP4sG7KctoAc7H&#x2B;KxVomOl3HH0UD7OWd52OprNPQd/Dz2LfnQ/Bt3kPXw3ECMgV0iSViYTo9GKKDQsg/ON70fPrP6N&#x2B;3Rq0vO9M1Lz9BFgqPWLZKQHSkwyeoVSWUBDAVOlCOipAuz8MtwD6riVtaHn/WawP4N&#x2B;2D4Fd3Yj0DLM1IQUSmPZPmWwW29Pls/8E6C01TvH7GjirK2GpcCAjgH08FpHWKlkFiLF2QEYq/hMdP5pkiz4KGNCxsbdVwdboQVVjE&#x2B;oaW3he/9gIxgcHSoA4Ze2UzedgQBLxoQAifT55rBNpuVzxn5GUkqs9cC1sReXxi7iGv/r05XA01sLstpc8H7F0Cr54BBsE2N8ugO1m/4gA/iPwJaJIphJKHblJAlNiNBjsR/7N8nqi0dOAf7bAt1KC8rT4fqs4NvKaEOdWAEjK1veIySKut1Orm3Bew0I8N9bLGgAD8TB&#x2B;un8zcsojrlvM3x2c4OW5zHZkpLVD6eBEqQDGTAyImfaneFmlmBjHWoBBnM&#x2B;UEpDUmtbUPku13iOQTwCfPiYGHmXxqQyPBuGFDL0jZfxCYwBSyJ&#x2B;pr//jHx8WQHULvv3t77yudZCIH9H4aV0UzA8EgnjyySfw9revY2o8CYx98YvXC9D/Uz6Wp5xyMq666ioGNZTFPxIz4USPJnBF20uA/fjjj2dNgsLTSjo6VKZArgUE8ElEkMTZiLlwzz2/g9vtYkHDVatW4StfuZHF1qidccbbcffdv&#x2B;XSgOuv/6IGjuYjqBPXNmlOUBkAaVgUlq5Q4Ii&#x2B;HxVgvV4pnSHgTdccsWGeEdcPBQAIyBM9n5wm6PekeUG1/BRMowz/po0b8ZGPfpRr/slSc&#x2B;&#x2B;ePThhzRrEolFmHNBv//D732PZ8uX5IMSu117DwYMH8ZnPfpbHwhT4o5KU41av5mXPBOJn7TpncDTQSgCOvgDAmx1AOBxngHkVAEgFIwjsPQjP4naYKhx/24MuGlkB0aCE/qZ6QxqoUMkATUo5gV4ZtOiKb/RykbvZKP2lxD9mm7&#x2B;ke4B4KBGxnbLnHRe/Ey3vPgMjT29C1x0PYHzDToid4cy/Tumcp&#x2B;272QQTCeGJZQz&#x2B;&#x2B;QXWCXAvaUfT&#x2B;aczM8CtsAKyiSSzAZhqTzegWJ7RaWVQTir3xlCMSwUq1yxHOhxFYtyPcM8gwt39CB0Y4EBDJhpDRiyHwCAJBhIAMjhImV8MHlw2VImHNKn2ExU/6PdxPb7a9DDJzLyiI0D7EdnnRXD3KCIZn1hfBJEuH7wVB2GtcCKrI5s9yRJg1f9puEzH5Q4cABAP/PhEEPHBAJyLG&#x2B;A6roGZDRUrOlGxWoD&#x2B;xW0wOR1lb6yhaAiDAow&#x2B;Nd6PLv8oq/L3hHyIUn17Jq1Qz42HZqKPlSaOgccizq3RjJw4BtF0En4SiiTavmirq5txXuMCjIrj&#x2B;KeBfUjmMmi0e3CuowI7AmOotznhcprQPxyRJRhQgLNaHiFaKK0I8cxUflDus3Ksh9l&#x2B;N9Nn5QYA5QIR5YIMxa&#x2B;zBSBmCkQcbsDhcOYX87lMmjjisdwKrfeITUdsO9F3kgWfgd7TM5s6TwLW1CjrfyTux4EDPfjtb3&#x2B;DG274yozzEYDo7j7wutcTjYbx3HPPCoAywkr9f/7zI7j44ovR0tLC3xM1v66untXxKSBAWcw3uxF4IQA1l0aK/bTPCxcunBHAkbjgxISP573mmms4u9rdvV/8bhFeE0CKnAXoeypBIBZEZ2cnZ2LJr/3d734PbxPVfxeXINDfpMpOddoaIDp6GzH/clKPq&#x2B;T3xBz51S9/iX&#x2B;57jpYiq7Nxx97DBarFeeKcSKBcAoaXXTRRRgZHkY8keCAAAH/dCbDv6VA2X/dfDOvi4Jt9Pe73vUuvpcowfS&#x2B;970PifPPx1133QWP241H//xnbHjlFSTjcZy5fj2PMSmoQLaZ73jnO7FixQreDiohULUGSgH/mWzIZxIDLP5ccwKYnwEA3Ry&#x2B;1x3mfPlgwHwRAUxMhPDEef8Kc6UDdWecgMbzTkLdqavhWtT8VkQi2WqQBi40mKGbUDxw0pTRoMAAWRBSZkNlEZTK&#x2B;M9VM6BUAKGcO0A5cRB1HUyTp4GW6Cxbzjudlf9Hn92MA799FMNPvYpkIAyjzcouAMX&#x2B;gcQiYOcA8XH4wCB2f/8u7L/jQQHol6L5ovXMDrC31nHWnkA8BwKycv0mpxUmlxQbJDG8TCwBa1M1i&#x2B;BR4IBEChO&#x2B;SSS8k4gNjiHSP4r4qADtXr/YpghCe0bg39KLbqr5FA9rg9kEA5UPWIxS8d&#x2B;gKO9ncmJ5aQ4EpCIJJL3RvJ1gSqwjFYwiPOQVnyn2hIxhpjQCmHWQkWUNBosV9o4a2GvqsfjTZ6By6SJUrV0Me0tt2c4pkIijLzKJXZPjeGa8D90BL14NjGMyFpaAibLQlN0nYEqgn94fRl38vKKcUwAkm8FXTjgLFzYvxu96dsIizuGgAPp007QJgP/02EG85B3ESCyEGosNDSYLPrPsdKypasCv9m/BNt8QNgcn4BPfyxvTVB5Y/60bM1EUq0UK6qgBiMPpoMsFD1Q7Q74nFdFM0iuA7vUFKQ43gFEqQFHuuiwZtNBhmav6MA5D7v&#x2B;zdx3wTdXf9yTp3ou2tOy991YRRBQF3AP3wL33&#x2B;osIitufiltxL1ARnKAoQ9l7Q9mrdFC6d9Pk/z03eSENGS8FFDEX8kmTvLy8/b7n3HPPDQzi/82ntlPrvYqKCjNL59Rg2EqQRpJczGrVZ1p3nuN8XbB06RL06tVbwDCzj7t37/F5fGpgoKysFJGRUU4Ewg6RGxPEakE3exrusfXd/PnzMXbsWHTt2kXam82dOw/PP/&#x2B;CAFvnrD6zlwMGDDgm67xgwXy88847uPjii4Vo0BO//fYr9uzZrb73nsdpCP6zFBjLzy8QQoOGgLyXshsBg1nYvn37orKyAp07d5W/Ccycg5led8HpaHgYiH8unt20CDe26CqePPUNmuslJiTg9KFDHe9Rms9WfCSDWFdPIM/zj9cT57OQxxbd&#x2B;xlbt2xBRkaGlIosXrxYSKQn1XnF4&#x2B;eUG2&#x2B;Uac497zwhrEgakFgjKaUpVCjxnzlzJjasX4/YuDghA&#x2B;gDwPKD04cMQaQ6f0lGsfafbv/8jib1dx2je7tW&#x2B;AL57sb/nt4LxL&#x2B;bADiSDL27rL8rmXBCjagISE1BIQqMZqNkxy/Y9tnPCI2MRXyPlkg5tRvSz&#x2B;iL&#x2B;G6tFfA8tr3ONT8AdfEItp&#x2B;8VtYvsp5RXbTMWnaDpIAvI0FvA2Jf0/ryGHAuF2CNvAU28720Qb3QUD0OrtuKXd/8jn2/LED5vhwhCUzhIfYLjcu2VwBc2uLVWnBg/hrk/rkaYakJSD65G9JGnCxGdyGJsTblAZUBIvO3zYSgnfPVWuJZFdhmtj2iaYooESzVNQLiWVpgLqtATWEJzEVlqMovEoKAREF1QYkoQKoLy2yEQmmV7XvVZls5Aqw2VUNCqK01n8HuDcALQ1iIvTsA1QVh8p2Q&#x2B;BhENU6VMySqUQoSe7ZHTOvGiG7VWLoAuKeqLdhaUoBdJflYpIAo69K3l&#x2B;ZjM93myfzapewi4w8K9g/4ucvsuk7nzlTPXRbYm/nescz6elpH1vGqxxmN2yrgXoamEbEC8N/ashSdohLQLC4JZzdsiVMbtkBudQUWHNiLA1UVqCRoULPYXVqEVlFxyCjKw6zMrQAHG0HB/&#x2B;zFyFyDvglpGN/9NCw5mKmOhX3IKMzDtvIidY6Y7ReKILvBoD/bz4oQBfif6nmGSOjLa2uQo7ZJcXWlEEwHKiuOLrnha0ChxyfC9bWlFunR8eiWkKrrWueNDPDkoOxW9eQhsxIgHI7m4SKdZ1gep7XeqyXpbfNxsYhhH0E&#x2B;FXTO5nz/pm3NTCJB&#x2B;YABJ9nIbLZtDTuUeSTAYLaQrvXOQYky65GLi0scBACNxS6//DK89tpEAbdaLFmy2OH4zyxkeHgYhg8fjiFDTj&#x2B;q&#x2B;0rvdqc3wOjRo8U40Nv3p0yZLBnQnj174UYFqm6&#x2B;&#x2B;SYhODRjwZ07dyjQ1kKk1V988QW2bMlAbm6ObIP09DQpZ7jwwosE2Gm/e&#x2B;ONNwVOrOMgmIk3&#x2B;nGeTt27GY&#x2B;vmo3ByU2PiACgiqNJ48Zickk/C5Jgn3/&#x2B;Obp36ybHCQE4zysm4AjCYXfcp5SffhmlZWWYv2ABCgsKpNPFxx99hNNPPx3nX3ABVq9ahbT0dDnXeDyTDOjbr5/TkM5iKy1Vwd/u0aOHkAL9&#x2B;/eX3xw4cKA8OB1/U3P79wbs9Wb3PSX19BAGgXvXiUEA&#x2B;AL4ej/773QBMNik30Z7H25LWQ1y/1qL7L9WYN3TnyK2lbqYnH8qWt8yElEtGv49i2Qb7MjxF2VjCR1mgjQw4sWDskcSB1prAW/u/74GwN4uND4HBRYrzGKWp26&#x2B;nVsjST3a33YxMn9dhF1T/0D&#x2B;2q0CsMUPwNWxXpKRRpgibLJ1mv/t&#x2B;fYP7J0&#x2B;V3rYJw/sjrQz&#x2B;yGuSysEx0TZwD1l9QTktZZDF7wgk8JvQbb1MNjq&#x2B;a12Iz8Ls/e8IMuzxW70Z7EBfbONOJDSA4L/SvVQF&#x2B;Pa6hqZBwkEm&#x2B;0/5LeNoSGwqumDYiJtLvNx0QhvEKfWLUSB/xQER0fKDc/gHoehoLIMawoPYFdxHn4nwCvIxtayYhQxuy81C0Y74Ge9QuiRAS5PwErvNL4M&#x2B;TwBe3ekgyuh4PodBfCklIHrLjJ7o5PB3qEscVxImHR&#x2B;KK0qh1ltoyIFZHsqULil&#x2B;ABSwpth&#x2B;qDLUKmA9PaSg/ghewceWzMXuWqbayoJdRZhZ2Up3tiyDGPWzLbNNyzy&#x2B;LgOqX2/u7JETon72vVFZPBAVMu6FGBJXibmqvVZdDALW8oKxBDPcZwYjL7wP0wk6SLj0Fttq9jgUASp78So42vUgmmYtnuD2j7/kLReL5Cvqcaw1BZI5b7ySwzhmfT09NqdUsqba7InY1W9r32VZZ1IxAKBPu9XWus93tO0en1tHZ3r9TWJtuFfvgFoGEYZ8Z9/zkP79h0QQvLbbh62b99eTJjwFA4ezFcA90uHPJ/BGv7ExIQ6AIHjgRdffFFMw5xj4cIF8l2SC3PnzpU6944dOx2V5WeWkgaCI0YMV78fres7bPNHx/VJk94X9QHbBn777Te44oorpUUf923nzl2kXzoN&#x2B;2iGxuXt3buPuKiTAKCjOokNEgBUTbCMYfDg0/Dxx58iK2u/AnpNdZcX&#x2B;A1ebeqTAAqqD&#x2B;FVU4W7Vv6GZ7oMRsPwKN3fm7xzvRqDlWFveTH6JabV&#x2B;/cJthkkjOh/ERIaKmBeez/IZBL/DQJ1SvV//uknjB83TqZl9j8nNxeVFRWiXtHq&#x2B;lMb2sb&#x2B;rOl3vpZrrbPd3Vdsx3hnebjK&#x2B;T2V89YDK7i9d/ka3weI6/8OAaAXtLvL/td3Xv/WIYrIwIOsbBNma2lXvG0f1r74CbZ&#x2B;&#x2B;CPa33MJOj5yua22/G8MVzNBqgPUTVnaDVIGSRNB&#x2B;gdwUOVpEKzHHFDPYNodsSDPrHlXIJl/h6cmoc01I9H88mE4uHwTdk/9A1nzVqA884AoBkwKSBvqSOBtEl867LNEgK/Ldmdh26TdYhwY06YJGgzshpTTeiOuc0upl3eQARZbJwG5ENcBVMRGQTZs49oKkU7/Vqu9LaAN4Nu&#x2B;bLUpDTQTP4vNXJDTcZ8b1DOJDCoBgsJDbCUEcAP41byqzNXYUVoo5nwZhTmYfWAfMkvyFchTgNRcJS7zDsAfHHrorLLW2SSH/&#x2B;0D7Pn9naMB4lxBv9Vmo8c2ekYCb8c2tm9oEjIGu8RdbeMm4dHoEZ&#x2B;CQgV4S9S2ya2sQFZFCcw1lTZwKjJ4C1JDI3BuemtsLDqAjNICrCvIxbbiArSJikV4UCiub9FVgP3nGUttXghGJ&#x2B;WEWpYqeya9nEaJpiDPXQXqC2SP5EaqlpUdG4bN/hJpYRFoGpOIvvGp6NugEXonNcKVLbqgylKL7Wq952TvxG9ZO7HoYCYKWLrA3/UE4tVnFep7Vy34DsHqmItUwIMEQKRa/yyWBfzTygffI3EFDiJwd9ve9sPaeowPZ/86rXia3pNSy9sgzpck0xOR66v9q0dfl2M4&#x2B;NNa71G2z795j6JRX2RkpMneElf8cLR6farbTphRhNN2JcClWV1xcZHI1i&#x2B;99FIMHTpU3PkZCxYskHZ0M2b8LCqBUaNG1QGh3bp1r&#x2B;O0T8B7yikDD/tNvnf33Xfhww8/RM&#x2B;ePTBmzBMORYA/QT8AkhKsp9f2DeuTf/75J79c/WloNn78eOmNznWn8dodd9yJl19&#x2B;CXl5B3H//Q8IAXDdddfjnXfexiOPPAKzuv43bJgm5n0Muq1nZWXL3wRnLGFgyQKzrq1atT4m&#x2B;&#x2B;6zzz7F4sWLpDOA9F8PhN/x&#x2B;Np5&#x2B;Hj7WrzQbYhf3&#x2B;uakIJv1fX9gLQp9j8o7SeRpBE3zO7zeB521lk4ePCgnF/0iNiSkYGevXpJyQcf9MWgTL9dhw6HEWsMyvf9AeHO12eW/&#x2B;iZTs803sC&#x2B;u7/d&#x2B;X&#x2B;5I67dvQ7EiWsC6A7Ue3pt&#x2B;G8A/7o371pLhQwzTVAgz6gehhBUHyzFijFv4cDi9Rjw4aMIS477Z3aWkzqAUVVVxVpJkgJmmh4xOMAiGcDwNvjz9p7eQa&#x2B;7iw3Bea3VRqak9O8ij7LsPGT/uRJ7f5iHgys2obqgVFrrGUOCpRTDNbWnfUbgV7RpFwrWbMH2ST8gtm1TNBjYHSmDeiK2Y3MEx0ZJZl8M96Svuw0kEJbbpPuaI//hA2ap&#x2B;a8jSVcAX5QEtrp&#x2B;6RFtFHNGmR//5j9XWVt1TQ0KFHhbWZiNNQezsVo9L1XPBxQ4KyXYJElhcgL8IZGHrW&#x2B;dl&#x2B;7&#x2B;tno5S12BP3ycrVad8/E1D/V5ggLaNMirkfZ4mmmegZYKOC&#x2B;9DeKDQzFp2yq1G2sRr4BcQnAYWsQkYV95ITYVHxTpez8F6p/pcQaeXf8nKtR8hiU1RuPYBghS2&#x2B;vlDQuxqeSgzHdzUR72q23aUwHjoWqaEAVem0cnoFgNGDLV&#x2B;yPmfoXdJflARLTLNnRVIxj1tRR0AqF1DAD1GN&#x2B;56wLgk0QwyDGyX63P/pxSLMraYc8khKKRkCTJODm5KQaQEGjWSUoaFubsxvvbV2KWeta&#x2B;744E4PFXo6ZnC0RumzxNcXK8X9bNVbi742B0jk85LNtSX&#x2B;XS0QS&#x2B;/lxffV1n9ZRmeZvG0&#x2B;DP0yDS2zxdSQlv5ATvP9p3SE4zo88sv52YlvsRn7XsvgKx//hBxywz69SvvPIqt9syM3OfAtANHZl6vUHTvbFjn8T5558nvee/&#x2B;OJzbNu2FV99NQXz5s1VAPZk1NaapZ541qxZmDr1W8nYM8P96KOPHbYPzj33PAE1vuLss8&#x2B;W&#x2B;n/es/S2DWQG9JNPPsbppw8V2TQBFNvq8b75xBNjHQQA73&#x2B;svXe9CX388UdqO&#x2B;2Xtnk0E7SoazzBOcHW999Px9VXX6NA/AbExsZJe73Zs/&#x2B;QkgS2YSPBwKBKgKUOt9xyq/r9Mpx22hCRTjNIYNx55&#x2B;346aefJAt75plnCnmiBX&#x2B;HAM62bEcn0tMbYfToG&#x2B;soMQLhPkhIP7Dyd5yZ1gIj0g4RMmxHHBJkgsHPe0uPhDQhpHMr3RMAqwtzRcHWPDL2sM&#x2B;YXV&#x2B;5YgX69e/vIABYCkMSh6U1uTk58nlRYSF69OyJM4cNc3y3szpv&#x2B;PBzHK4rceYOeHv6np57kl4SwNu13x/vsAABcGKDfV/veyMFTriw1NYgtl1ztL55OLJmr0D&#x2B;0i0oUxcOozoUjKYQhFiDsOfnebBcUYNB059BUOQ/77iudRWgOoCKAJ7QxcXFNdXV1XRLdpgJcjDmi13UO&#x2B;DV&#x2B;zmBubnWIkdMeGoiWl1yBppfPBRFGbuQ9cdS7JuxAIWbdoqxHk35jKHBLsthA0&#x2B;msGB5MBNfuHEH8ldlYNuk6Yht0xSJAzoj&#x2B;ZTuiOvUEiFJsXUNBOGjXaK27rAZIqlhKtiAgYSEZogYJJlq46GjXs3/QEUpssqL8WfeXmTQlb8gV&#x2B;rJiwn2CbDElT/YBrzEudwVZVs9oHAX1G3VCeL1vD5a89Fa4XHd1L4dnNZYAOkWZuQLc7BRbYfCygqY1Ren792MZhExGNO&#x2B;L9Jik8TgkLX6e0sLMbJVD2nT99K6P7EuPxs/79uMBzuchMdXz8ZOtX0jFOA1qAGGkC3aMqjtqo5szMnegTlWDYgbbOUDonUPtvklWJ02pd6bm6ebslrf&#x2B;JAw5JPg4P4V80VT3TIFb2UYNdWHloPHhagf7GZ8ToSJTcpvPURQmOwSfw5u1Ps7y4qk88PU3Rvl8/SIaPRMTMMpyU3xUPsBOLNhK7y4eTFyJHticG&#x2B;2p20vx8bRYRzpa5sdy8xBdQUGprbA4x1P9n0ue7g&#x2B;eRrg&#x2B;AK9rtN4es&#x2B;ThN&#x2B;XrN/ToM/fbL0/PjDetqGn6dw921vvGQn2Nad9zZXfnsmvQ1IfT0GTOWaZ//jjD2mJx3ZxbIfnHASWEydOxJNPjnNLABCsMyvvKhEnmH/hhecF&#x2B;P/ww/cK6F4lTv9PPTUOI0cOl1rktWvXYvfuXQqkNxTp/z333CseASwTYD9w1&#x2B;NRD/jXQi9o1U5bZvbZApBlCSQAKFm&#x2B;5ZabFSBPluVxDjFLU19iJp5EAQ3ODhzIU&#x2B;uyExdeeIF8/tBDD&#x2B;H88y/Arl07pd0es/R5eQcwfPjZYmTI7OrZZ4&#x2B;AWd2bCdioEhg3bqz6zdsU8D/tsOVkm77XX39D6rIHDjy1TkaeZQkTJjyNUaMuO8w7wVuwYwB9BFiiQCNF16Cvwpw5s6V2OxDeY1VBNt5YMweN1L3ImQCI4ZjH5bJC/5lpezaiU3wqOqixgLtoHhUHY3AYiqj8c4lMNSY4/89vEB0UjHmnXy33ZNf9Wl5RUed8TU1JQXGJzdw3Wf39yKOPOgitowKmvABpXx28fCkBfN0fPEn9fd0DPZkBBuLEIwAMfk7j6&#x2B;8T/iixwoLQ&#x2B;Gi0u&#x2B;cieZTtysae7/7CxpenoGx/DoJM4QgxRmPv7/Oxbvyn6P788WU2o5UAxMfHh9gHatJmkG2T1E3bbC8hMGguynqBvTf5kKfSgDoDapYHVNfY2giqQRNJlngSLTecj4J1W5E1Zzn2z1qC4q17YKmosmf/Q2wt&#x2B;ZyD2fiwEHlAIwPWZGD7B9&#x2B;LZ0Bi7w5ocHI3JPRsh7CGSTYDQTU/qxPQ1wbtAviNWpbf6FjeIC1Lb//psuoq7FMDpYziPMw7sBfbiw5gcWEuDpQXi0RTALFk90120BauA2k7p&#x2B;mt8Jx6d5f2t8Jz2t7be3rZAE8EhBVhBhOuaNZZttGkrTSuqsGP&#x2B;7Zids4utI9KQJu4Bji1QVOUKUC&#x2B;rSQfq/IyUar&#x2B;TgiPwZaCXOwqL0FSWAQGNGiMvuqRq14Pb9oBXeJSsFfd4Met/gNzDuzDQQV2sXOdLfMe7ATqtW1gDK67Oep8jsPLKDypIrwpHvharV&#x2B;vpHTMPO0K7CwtwIzMbfgxcyvWqv1fyRaDWh2&#x2B;u6y7OuZoVHh16x4YpEBshbkayaGRKFWDG/oS7CorRIbaRiRO9pUVw1xTYSsLMQW5v0zzXDAekvlnVpYjc&#x2B;9m/LB7oxiZpkTGqO1ei8Nc/b2193PX6s&#x2B;dMsKdn4O7z/S2SPTUetA51PZqE5eKjwecjyg1oJRzrT5HtB/ZDW/lUt7e89aiVc9vuk7vlweLFwWEHhdpX7&#x2B;ltd4jucz7ibqHGEksq3uN/G2/nhpc70HHY9Dk66WXXsKzzz6HhIR43HzzzXXk9VrQrOupp552ZMC///57ydjfe&#x2B;&#x2B;9AjzvueduNY9npQZdi9zcXKlXp4SfZn/8zmWXXSrz4ndoVFdQkC/H8c033yKSfTp&#x2B;a79xrIIZ9mnTvlO/VY3Ro69XAL4Kd955hwLdt0hXAoJnzXCPIP63337DypUrMWnSB3JsPPvsM9KPnEQEl5U&#x2B;BnPnzlHA/Sk8&#x2B;OCDWLZsGd57711ccsklkr1ndOjQEQ899LDUV5eWlkmLvu7duytA3xk//viDGKsRsI0Z87h0JXAH/rWgOsFdkERhb3aTyb86faoWeBw88EArKc&#x2B;g0oOqBO0QpmKBfgXDh48IACMf0TcxHX&#x2B;MuBWnpTSt836Ym3vYrct&#x2B;wQdr56FDehv8dfqVSAg5fJxEv4CE8EhU1JoP&#x2B;4zGuLvy9uGkRmpsZzwcwLO1n7Pcnn9T/t&#x2B;seXNx9l&#x2B;7Zg0K8vNx4cUXHzUCwBdJrFfOr3e8rfdeptfxvz6eXwEC4N8fegG9uxTRiU8COA00I5ulov19F6PROf0x95z/Q&#x2B;Gm3eriEYxgRGHzm9&#x2B;h5fVnIaZt4&#x2B;NzJxPMqsGY1iaJMk0O4jh4q6ioqKHNMgd0mkJAb8aqPgPkOlkqgnI1IBKoom7eSb06Ilk92t81CgVrtiJ73kpkz12O4s27UV1SrnC1Ucz3jE43esFqzmQABzo796Nw/TZRBoQr8B/frS0aXzgYqUP6OAwCTXawr60ns8sm55uVWjY6xO9WoGxZfhYWKTBKQ7n1JQW2enQNJEqmOUh8BvSdEVY/SAFv08MDorW6&#x2B;cyq8zKgg0iwqyUqjRZM2bMRwWq7tY6Kx7M9hiCrqgIb1LbKV8&#x2B;szV&#x2B;UswfVFjPaxTbAre36oHFEDGYp4BwXFIwhqc2ljn9vRQnuWP4bllG2zpuxpfYQUGRNenCof5vP26bz9JlsKotdPWB/Q/MlcBBOJmQqcP7Y6tk4r1Fb3NG2Nx7vMhBbiw9inlr2HzK3yDGSp7UQNNqJIPtmNFmsuLhxewxr3EZeT9&#x2B;zCUXVlUKKdI5JQv/ERmgRmyCTLziQiXe2rcQWtQ0dJIA3HkeIqhC5S3Hr7S8vhiPz7wl8&#x2B;9vOz9P7eqd1Rx74WjZ&#x2B;R22j9vEpmDLwYjSPjnO4KrsOZrxlR3wNbvwd9Pj6vfqSDv5cT71N62uQ6M3AUPu&#x2B;U72&#x2B;QavX52uSpHalmdXZjf94GTRSHu7a6s1dEHiyHl2rISfQIwClhJxZeGakmXXm&#x2B;hIonnHGmWKq99NPPwqI7dOnN0466WQhD9atW1eHAKBhXUlJKdLSjLj00kvEQIyAmVn5QYMGuyUajgT8c501&#x2B;by7YJaebQHZNWDfvn2S2WZZm9nu00O3/YcffkRMBimVZvA8Y7s0kh0kAtjPnCCZtfg0JOR3CeJJotx66y04cCBX3n/mmWfrqCi4L5xb/zm3GnT2Efjss8/9KrHgNn733Xek3OD666&#x2B;X5W/fvr3P73G5&#x2B;SCJQXUGD9vy8grZ/yQ73nrrLVEDXH311WJC6LxfA&#x2B;E5eL/fU5qPa3etkzK8W1v3xtCGzRGq7oPOVxu24f1qz2a0adgSG3N34&#x2B;f923BVs86HzS8mKARJIeFS7uYaI9Ja4dWTL8CQlOYId&#x2B;NbQ2Ltz3nzkBAfj8qqKiyYP18MM0eMHIk5c&#x2B;aIioQ&#x2B;FEfb2NGTMkyvIawe8sDXvU&#x2B;vak2v10wgTmwCwBeQD1BBLhHdqhF6vnQ7/hj&#x2B;kAxUjQq0VJYVYMcXv6Hb&#x2B;NH/inVgFoe1lzQRUic/B3BWNSCiOsCsBhJWSjo58LOXChjcXSy8ZZrqMxh0JgMI8Bv06YRk9ehw16VSGpDz12rkzl&#x2B;F/HXbUF1YYsvcs1RADcostbb2gBphY1LrFdu&#x2B;BaKaNkRsu2aI66j&#x2B;bp6G0HCbKQyXLkgk10YH2C9RQGPDwSzsKsrDnLx9CshmY2t5EXIJpiRDKSyFvQ1fqG/s7PrsDcTVK0l/tHT/nqZ1B/YsiFI33AbqxswseClLHFRUq/cXqxv75pJ8AcAtYhJxb/v&#x2B;aK&#x2B;eP9u&#x2B;Bk0iYxAbGqlAcC02qW26rTgPUTk7kaUAtbjYk0SR8gi7FF6XeYGvje1HqP3PjPywtBYotbcI3KnWZVNp4aHfUf/3lxXh3XV/4d3186UsYUCDdJzbqD1OS22O61p2Q54a&#x2B;Cw&#x2B;sA8/7ssQUmBbWaGjo0GVmsGI2Z/jqW6n456O/dW8ivH&#x2B;1uVIiYrDaQ0ao0V0AlpHJSJBDaL7qNfXteiKyxZOx8zMLTYywXV13V2lHWp&#x2B;4&#x2B;Fikn&#x2B;cTbX6/77aF/1SmuKzky9Eq5iEw8C/J2LRG&#x2B;DVUzfvK3vjLivjqdbSG8g&#x2B;ss15ZEauLtNZ6R9DYG&#x2B;X8hvt/jHSltbeeo&#x2B;gyXQ8jw2WLFmC5cuX4fbb73CAWE8ZPt77CALz8w8KqCeInjz5K5Hhjx8/TpzuP//8C3ELZ2ab2XuSA2PGjMGff/6J1atXS9u5iy&#x2B;&#x2B;VMC1K5hnacCrr74m7ey0tn3HKqZPny4yeoJWd8H1YpnD3XffLaCX0n0Zy0RH44MPPsSiRQtx3XXXKCB9g2N7kdTo16&#x2B;/AukjMXv2bKm5v/baa4UYad68mawjjw&#x2B;SGtyWl146SjwK6uvE7w38k5BZt26t2hcDHOdNTU21KAkoz6eJ4vTp04RYIbBzDmZ8n356vNTyd&#x2B;3aFddcc7X81kcffSz7jetG74eXX/6fAMOHHnpQ&#x2B;rOzHeOMGTOkJ3sgPEelur/dsXwmPti&#x2B;GigvsZH26r3mUQlCAIQLgW21qSlVfL5rHSZ0GYjb2/RC/5kf4M&#x2B;snW4JACZkmDDoFHs4qRWixgh3t&#x2B;ntcZk6de6M2ep4/&#x2B;ijj4Tgo7KFxzGPnUGDBnlVmRwTgKWj9t&#x2B;balYPCeDtd315BXjzDAjEiUkA1Lf&#x2B;PxAqkgd2QXSLdJTuyFR4JVgMAnNmr4b1SYtDQv6vORDsnQM1dQCDg0CyqOrGW6NuliLtpDqAxIGni44/tbW&#x2B;yQCrkAF2tgKJ3dohST3a3XYxSndmInfROuQsWIX8lRmoyD4o5n/xXVojulVjJPVoi9gOLRCZnoywpHgcNvyrtaJGgc4dlKUrkL&#x2B;lMBdzKClTwH97ZRksVRWHDPrEOT7kyLGzc5m1FfUjD7z9hrcqAT3YXzcpYYVRgf3TkpsiIq0lthQfRG51pQwCtqvt1y0xDQPb9kFiSDjWF&#x2B;bgoRWzxKyHgwCa2dVUlTmc/GkWKGSKfYCgL4UPNxvRnV4fPtgXl7/Vccp6wgsatZWMQnRwKL5XIH7T2nlCTkSq1/FqkNk2IhZtYpLk2CgyV2Jh7j7cuXAaEByGdnEpOKNhUzXoaalA/mky29UF2Zibswu7SgqQo7ZTg9BwVFhrUWupxW3t&#x2B;8rjqx1rUUyjI7VN5ufukm4GG0sLUK226W6WP7i29vN1vNWHBzL4yRe5fsdQj2PM026yITdRglzTpgcm9j4bMSFhh4F/PSC6vtl3b9c2PVl1Peopb&#x2B;VS3q6XnqT93sgFzTCRPrCclF1jSPIyo8&#x2B;HAsJGrY2sGjAHuV5BjudBISX1bAlH2T3r1VmPTjk9HeZZvz9&#x2B;/FMCApxj7do1dgIgHFu2bEVKSgratWuHv/76S4AvZfuDBw/Gr7/OFAKATvSU9Ldu3UYB&#x2B;htke2j95SmBp3eAc9C4juCYQFszsTtaQY9Fo0s5HMkGb/4ABOasx2cP8v/7v8fEf4Au/Fpwva6&#x2B;&#x2B;jqRwFMZwe2Vm5uDd999V4FlE2699TaZjuoBqgwIxCnbHzv2CemJfvHFlxzTfcz9RR8F7hctmjZthoULFwpQb9y4iex/14wuVRHPPfeMet&#x2B;EvXv3qPFMsXReoAM8ywbYG56kEfvBL1&#x2B;&#x2B;Qr1ejXvuuUdKI1544Tl0795TyIEAKLLFwrxMTN66EiObd8TQVFupyOTdG/DB&#x2B;vlor16P6DBAADtBfsc4m5IkVt3va9S1m2OEDeUlmLV/G2KadMTEjGVqLAGkKZDvKS5o1KZeLQDj1Dl3/wMPiOIlPi4OUdGHVAR/RztHPVl1veZ7/hj9uTNq9YcEqM89M0AAnLgRuOp5OhiiwhDWKA7FO/bAiGAxBizfmQNzeRWCo8L/9etHfwA&#x2B;U/ZpNpstHHzTN4CDRMrnSAaIjN5kMvgaMOslBaxeMoFmNaCT6dTFmyA/tlUTtLxqOMr356IsUwHM5ASR&#x2B;gfbsw8WpxOWA8TimkoFSPOwpiALa/NzsDA/SzL7lKpLhlar2&#x2B;fNIbQe&#x2B;89Rw&#x2B;wHMPP0uadnf0kI6CAbAP8S5wqMFqtj4YMdq9E8Kh7tYpPQKy4VVoUr2itgvKogB1MUoGXv3jKWSWgGiNr2ca71cwBbf284Vj/f01FaofY9W&#x2B;qdN3eyvEwIjUBbNZB5oNNA9E9KRzu1bmkRUYhSgxmz1YICBdg3F&#x2B;fhokbtEGwy4fHVc7BGDWw2KwA/ceNidFKDltEtu&#x2B;Gedn1wVuM2&#x2B;GXvFmRXlKJrXLJMn1VWgozsXdhXWSotkpZkbrW1KrTW2rwOpNWh9dBxWS8G5wg3qT/fseogE6xe&#x2B;Bvn86i6Eg0j4zCu&#x2B;2m4sXUP2/mvrjm&#x2B;&#x2B;ha7y&#x2B;DrBeZHGkci&#x2B;/fHSNUbeeBKYGit91japbXeowcMJftUd9k9Txyj4ePBjb&#x2B;&#x2B;BABBNrPVW7duUYP&#x2B;PJEAs982gaGzKzxl48z&#x2B;vvjii1KXzmw33fLZ1o5gsn37dgIaKAWvrq4S2bD2GwTCbD1nsTwgkngCzvHjn8SqVWtkXs5BAE1CQfv&#x2B;0QpK3lmuMGRI3ZZqISHBsnwMOvnzfn3RRRcjJiZa6v35/NZbb&#x2B;Luu&#x2B;&#x2B;1t8w7dEyRMLn33nuEFAgOPkR29&#x2B;jRU7Zpmzat1TbqJiqJKVOm4KuvJgt58tBDD6h5V9aR9x&#x2B;rkGowF4XAqlUrRc7N5adUPzo65rBrA5UaXPbRo0fLNeTDDz9AUlID2T70fKDUn8qJF154QVos0qSRxw2DBFAgbGFW59NTG/7C&#x2B;HV/AWVFmJm/H8vPuA7R6niZkbUDkWGRSFbjJhq0LlOfhat7&#x2B;6nJTTE3dw9WFeUKoTvoj8&#x2B;RVV4iZPpza&#x2B;fYDHHV97485SKPv3tLq/qbL/IcdCX&#x2B;/lbw5Ifjvzdw72s6d/cIT79dHxVBIP67BMB/nhwweDCVsVSbUX2ghE3gDt1wKGGvrD4hCIA6B35QkJE3X7tZoFUzE1SDIvlbDSYldaQGBUZ/ywK09zlg06cMsEn9a21XLekmEJGWLK2K6PRfU1Vlc/FXN6Bfs3fgt70Z&#x2B;CMvE1tKDqLCXCNt5rQ2aAJAg&#x2B;zSc1&#x2B;1zd7M05zf82SE5uyQ7m6&#x2B;3lrHeSMcfBES/pAEVjdA0urh1DcG2Z3o8w&#x2B;tj7THMx5yxdeceTWHfk/A0OCFrPClaPDlgXiYksJqW07nGWrLRiykjqPO8amYevKFaE13Yi3TZrFi8s71&#x2B;POAGtDk7cM&#x2B;NZCpqCzD//qfg6ubdRfFw7Sd69AhKR39EtLQNCoW4UEh0gqrUAHapQf3Y9y6eQiyqhutySAGimVUQFjMNnl/RJS9o4LJT3RugPf0vad6AauPnWDwg0Uy6F9cb5&#x2B;rgTjndHnzLniyxxC0ikmERQ0cLT4k/v600fM0UDoSYyU9Zk&#x2B;eQLunbL3rfL0pCuwPqzYdpfzM6NOwz17GRU8Xab0XZEdRx4s5n7t1oxSfveApZ09MTPI5D4Lss88eLv3qY2NjBNyx7rxXr15Sh8/5U7ZOafgbb7wuteIkBfg9Zug//fQTuf9QLdCtWw8FevtJRwCCWxIIbBHILPJTT02QbDFN7lJSUkVOPnXqVDzzzDOHZd8575tuukm3wRiz7cyod&#x2B;nS1et0zLYTwDKY3V64cIHU5tOwj5L8bdu2YfPmTcjIyBCwSwA0YcKz4lOwcuUqUTfk5mYrcN/LMU9um8rKCtluN9xwgwM00QuAxn6MefPm4f33J&#x2B;GOO&#x2B;5wdAR45ZXX5HePZXAduS35O0Y7EUrAzu3KkgCWV3z88cfSWjE8PMxx7hQVFaptsEWtQ6J0Fvj668l4/vkXxPvg1VdfFek/9/Po0TfIcUFywN8Wj/&#x2B;VqFH3pasWTsOUjGXo36Q9zA0aYdn&#x2B;7fg1azsuVq8f63gSBqc0w62Lf0S3Ge8ju7IUKWFROGvuZGwtzMVp6a1xZese&#x2B;Hz9fBgjY/HpgHPx2/5t2FVaiLMatUar6PgTFz/oqOX3N8PvDbB7A/q&#x2B;lAF1WmIHFC8BAuC/DPwhIDIIJdszsXniVKQO6YGY1o3FkZ6xb/p8FGfshckYXGfTGE3GE3vnq7CbCcqKam7QLBngw143SsLAYHTRKeptMeVNzlRnAM3OBtU1vEUddsEyK&#x2B;DVKioBeepmVUOvAPXYqsBqqaXWPTj3BPzdveftc2/zOpL5uiMiPBESrn3pXb/viTDwdna7IxS09nR6gZ7FE9HhB0jUW27hDtOS/FGRGh4Ni1oOnrksQyjWiCF7S8N1Bdl4ePVsPNF5IKoUQP9DDXboZBwRHIYzUlvgsQ79UaSmp0FRSpQCHGrw2CQiBg90PhWhRqMa2BTg853rsaHoANaqx5biPBxk20A1gDVbbV4CZQT&#x2B;WvmD1QP5og9C1eNzfzaiv9/1VUvgZh1JhKj175vSFGM6nozhjW01t5qLc33q5f2tgT8Soz695QLaNcz1euYrm&#x2B;9m4CfXXEr4ScQyc699ziw/3&#x2B;e1N0hLCR&#x2B;nwVp9unVTmu4cBNMpKckKwH6oAOhDdT5jFjotLd3Rlo2gPSYmBjNnzsRff80TKTrrwRkEwDTpY2ab7fj4Gevg6b4fGhoirffOO&#x2B;88aS3XpUtn3HvvfTj11FMFRBMUclq2xGPveUremRkuLS2RbD&#x2B;d7QlMnSXpzkGA2qiRd0PgWbN&#x2B;Q9u27WTf/v67TVHgiwAgsZGRsRl9&#x2B;vRVyz1RwO&#x2B;LL74kCgiSGGyN9&#x2B;yzz2PFiuV44403pO0e2xHu2LFdDP2uvvpKcblnHbQWbMf3zTdTvf4utwsfznGswf9LL72IDz74QAH4cejYsZPDoPfLL79Q&#x2B;y5NyBpuAxI13C7cH5qR4qpVq1Fba5Z1nTnzN1E/UOFx7rnnSkkHSwqeeGKsA/QHwL/n&#x2B;Hr3JszK2Y2&#x2B;6W3w5&#x2B;lXYXPxQfT46R1RA6wsyBHl3Hqa1arh3k4&#x2B;q/voLpa0qefwsEg83uEk8coZmJQuPjdDUprh3PTW/10ApaPVnx7TQF9kgbfSMk/GuQElQIAACIQD35hQmVOIJXe/jOCgSMR2a4aETq2kT3327ytgsBocGUIFRRHaMB7B0RFu51WwZgdy/1qNiv35CIqNQGyrxkjs0w4RjRv8bevD8oTaskqENjh6NYkE&#x2B;nxo6gAOQuz&#x2B;AYaysjIxldIIAb0DeXcDX39qcLVPm0bGomVsIq5o2R3VCmTsUDeqxQf348/sHViinreVFqG6psrO9th7sP9TzOeR9Kf3RDr449iu53NPn3kiUg4jDNy0pPP6W4YjoxudlQ011eiT2hR3tuktA5Aaay3CTcEoVvs/p6ocByvLsKHwADYTsKvjZF1eJq6e/x1SwiMRGRSCgQ0aoZk6nvokpiEhIhLssF1YUY7vd23EW1uWS5cIro9V3i&#x2B;zLbdI&#x2B;TUvCa1FhEFjF31L6D3V2B9Pxn71JSS4T1h6o57ZWvGudn1xUZMOCA8OkYG7VQeQ9tpq1MMAx/V64WmApec7/pIT/qoTHNdts9liL72SzUKlFa&#x2B;1BJmRkZFGOy9bh6T9N9xfCdqZtXU3AL7kklF4&#x2B;OGHBOA7O&#x2B;YzS00Q/v3308WdnRn9d955F61btxb5f8OGaQJ0meleunQplixZhoiIcMn4EgQ/&#x2B;uij2Lx5s2TSSRQMHXqGPOre00xS63755ZeLvJ3EAQ0AGVFR0QK&#x2B;j0Z8&#x2B;eVXGDbsTHHWLy8vkzp8X0GPglmzZgmp0bJlS0ybNg2ffvqpkCgffjhJHPvZuo7g/KWXXlZAeJUoHK644kppy1dYWHAYMXE026BpwY4A3Ibdu/sn4eb&#x2B;JfFHQz&#x2B;aM7788ssC&#x2B;LmvtRZ/3BeTJr2Ps88eIdPTyJD7v6Ki0rGfqNpYsGC&#x2B;dD&#x2B;geoGlHy&#x2B;88CJ27dolho70bwiAft9Ro&#x2B;5hb21Zhnva9sFvWTvwwMo/pGWtUd0T1x/MxPrcXbabkbpun6FA/V1quh0lBSitrZH7ZcfYZHSJs41xbzwCOf&#x2B;JAPr1tOLzd3o95QCeiAdvZEJAARAgAAIBWwlAsDUS1lor8pdnIG/5Bo7e1cEQoj47dOOsQTnSR/aFwSXpYqmqwerHJyHj7emoLis5dNNV349omIT0Cwag7S3nI65T82O6HgcWbsDi21&#x2B;CubAcaWf1RtcnRyMs&#x2B;ehKrzjw5GBCMxOkf4BdFWApKiqqtbeO0koFDL4uTP4MsN1d9Firba6ptuMtA9pGJ6JdXDKubdEVxdUVyCjOxwp7e7/lBVnYIu39NELAaJNmBy6E9Scv9JAN3korDPBeauH6Owb3Pe9D1WNsz9Nxd/v&#x2B;iLC3DDIrkHn1oh&#x2B;QqcB&#x2B;YnAoWsenYHBKUzzS8SQBqTmV5dhTVoQ20QmIDef5XyuGfOw/vGhLpphHbijKw87iPBvQd25FpP1tqidOdrUu8JZU96b8B9x3DTB4mLc3H0XXedaXlOC2UoPDIFMwTkpqhFsU8D&#x2B;7URvEKDBmUQP/GrtKQ8&#x2B;5rqfVqL/19f4M0tz9hq&#x2B;2TN7IBzsAEpBPwF9ZWWnhNVS6najrEWX92m&#x2B;YDqG2f&#x2B;0FillbDYTt3LlDesyfd975Iufn&#x2B;02bNhHA5kwA0Mxu6dIl0naO2XeWfhHorV69SlrPEQhSzk63&#x2B;jvuuF3q35s1aypKANat62m116xZc4wbN97xWgOVRxIWKTuyOmTsjH79&#x2B;grJccoppyjQy5r0W33Oh60ICWB37dqt1nsB5s6dK4qJnj174pdffsaGDRswdOhQac9HhcGoUZcJ2aHF0fIkoPye5okXXnih288JwLks7ggAljqwzIPGe65B1/3169dJbf4zzzwnbvzNm7cQkiI1NVWmadeuvXQFmDlzhmTzmdVPSEiso2pg/f4XX3wuCgFus4cfflgMItmxgMeC3uCysuyDv/FfjE3qHrcwezuubNZJOOvXVswEwqLx3knn4ru9GchX46gB6jo&#x2B;QoF/EuuB8E4C1IfMdncf8rc7gAtB7PF3AhEgAALhPFCjG721Uo3lQ9VNKFSeNZBhrbWoW7pVgf8yNOjYEW1vPf&#x2B;w7y&#x2B;79w1sfPsrBCMKwabIOqClPOsgNr45BTs/mYWu469D&#x2B;3suOSbDOdbNr3roPRxYvYG0Aza8PQVF63ZjyK8vwhQRdkwveFqPaJoKsiaVWSx18zfb&#x2B;QIOykx2xtHg7gLojbH0NGB3HWSLIZZ6XWWtdfSYD1MApHdiGnoThLTphYKqCmwryReDwCUH92FNQQ7Wq9fl6gbnyEabTDoM2QJRb/LAn1IM3UoI23ttopMQoQDAqgOZ&#x2B;GDbKpzUoDGaR8QIRh&#x2B;a3Axt4hqgbUyiw8gxp7IMY9bMQVZZIaLDonCwohT71LFQWlV&#x2B;SLKvGRyaXAgNdwSHHiLJehRKJNx9rteY0t/KAN3dBrRsvwWJ4dEYnNIO17bshuFpLeV8sqjPaLLmy8zP/0PryNsa&#x2B;ZOpdwfwfSiYrPRRITFaVVUlrffsgFhUVfRW4Qs7cXrCBYErtwVrumnKR1m9s6ycpm41dgKXderM7LPunll&#x2B;GrZ99tln&#x2B;Prrr6VOvWvXLnjppf8JUfLiiy9L5vdou&#x2B;9rQak&#x2B;gSnN8XzJ/LWYPHmyZLSdnfebNWsmQPWtt94RMsSJBJJ2fUOHni6Eh3PQxZ8u/DQY7NmzFzZuXC9qAB43zqQFiZPS0ob1Xkeej2Vlper33JMfNEnMytov033yyScyLdsLarwUVRIkJRhUAnB9rrvuWowYMVJaFtKv4emnJ8jnzM5zPtwe7N7Asgaa&#x2B;v3yyy8oKChQ0z0t68t6/qKiIrzyyssYO3ac1PN7JnGaqe/PEC&#x2B;HzMxMtX3qV65AxQXVBiNGjDgmSonjPQo5/lFj4GUFWZjQdTDeCY9Bl4RU3NiyO0a36IZadW0PNhgRiKM1HLLq8gTwB/j742uj9/4WIAACccIHB6axbZog9Yye2Pr&#x2B;T2q0Vmtr8ceTNDhIGFFDmAlNhpyM7s/chPDUujfL/T8vQcbb3yHEEO1oDUjSwIxKEJKSTAg1xcJcWokl972M0m1Z6PXGXUddfkMVQtnuHAH/bFkYZo1D5vwlap1&#x2B;Rru7L/zbticHuBzgkQyghJWDX5IC6iGlA6xbZf2qvR2V2&#x2B;ycr5YpnjJ6ru/XqtcVTmZwkaYg9E5oiN6J6Rjdpqc42O8uLcKGolwsOLBP6rk3qged3GnsZgOATmUDDtl2PYCer9f1BY6BEOKGxM81i75HRslBXNm8s5QBZCuAH6XOyfTwKOxUID&#x2B;jrABz9lnxV0G2&#x2B;qxcCCN6RpSzS4QhzybjNzipQrx5PrhTJ3gqe3BVQbiqIdwpJNwZS/4dx4M/4wJN4q/OFUNICPolpePcJu0V6G&#x2B;DTgkpMi&#x2B;24rQ6tfbTW1evdwDjzVzvSMkFPYSBdr2iAz&#x2B;vaTTnY70&#x2B;X/N9Anv1sBK8He/1&#x2B;hqQo4ye2WVmxX/99Vd07NhRsqqHgGONWl&#x2B;ztNfTSwDQtI4A76677pbMLsErARyBttavm/XbrANnsP67c&#x2B;dOkk0fPHiIOPPbnO0d95ljBv4ZX389RQAwzQS9BVvzUbbO7HTDhql48803cNVVV6lls5nosfUg/Qycwb8W9Cdg5ts1vvvuOyFCeOiypR3b2F1wwYVuATAf9Y2PPvpQiAVPDv&#x2B;amoImiiRwSMiQuKCKg/J6EjH8m7J7&#x2B;jb06tUT3377Lc48c5hk6tnNQDsH58yZjYEDbf4C9DCgJ0GnTh3VoxNOPvkUx75kWcF1110jmXxv4N/5OODxyrINb8oPdhGYMeMXWd/TTx8qCoQvvvgCEyY8g/T0NFEZ/BfBP6NFVByMIWGYn5eJD/uOxMkNDhFeVFUaA43C/B&#x2B;RuAHyzuDfn&#x2B;/qAe96TQYDJQABAiAQdca7tQhtEIfer9&#x2B;FqGYNsfSBV6QcgAAwLDYaAz55FNGtGyG6ZZrbAfCWd36QuWjgn98zRYSi9YWnwxgehOzfV6Foxx4EG8MQjGhseGsyguOj0e3p6&#x2B;vMqiIzD7umzEZSv46I79oSQZH&#x2B;Ze2NoSGIadcYJfv2SstCMXFXzzmzV/&#x2B;tBIDLRYm&#x2B;AQbtxkwigPLXsrKyGvoIkhBgqQAJAX8vSL4kt&#x2B;5eCyFQaz50siuwxxZ3HeKScXGzzqg21yBPgcbtChQuK8jBWgUU1xTmYE9pkcjgpG&#x2B;5OMmbDtV9u19xz4BQDxHg7nt6yIP/MklgpON&#x2B;Df5v5Sy8tXUFTibRowBpr8Q0nJOYLscBexRnqP1aoXbij/u3YU3ublt2313m6Gj7KOhVOnh7z9tveeta4Y5YcDdfT8SF63uU8Ctgj&#x2B;Aw9FBAf0hKc6kNpeIiPCRUzpPqmmo/KgYs9aqx90YaOJOCnroA&#x2B;MqieBqIEdyTyFTXMqJ8ghACfgJ/kwJ60nqP1zfHofl3NKU&#x2B;CkHJ9iuv/E/Wu3PnLgJuP/nkI9x88y11CIAff/wezz33HCZOfF2Ak7egHJ016zExsfjyyy&#x2B;xfPlyqfl/6qmnRQJeVlYu2X7GypUrRI7NFn/MIJ988skiF6cL/&#x2B;2331aHADhSAoeg1h0o1&#x2B;L660dLJpsGhm3bthVPAYJILpNz0J8gPT1dgdbRGDz4NCEz2D6QngIMAlvn8gYtCDbZjs45CPqfe&#x2B;5Z/P777/jqq69k27GTwb33PuC3JwHLJjZvzpByCU918Fu3blX7IMXxmiUazoQEyZeaGrMYMI4aNcpxTlAuf&#x2B;2114lSgdtnw4b1QgbQg2D8&#x2B;HGS0SfZ06RJEzm3ua7Lli2VY4pEwpQpk/HII48KCeCO1KDKQysF0AO0br/9Tp/TbdmyRcoVtGOIJNbPP/&#x2B;sjsU8DBw4SLwW/quREBaBJlFxOFBZjqzKUjQMi0Ig/l6SwJOqVQ8h4DrW9WSo7SuxFogAAfDfJAHMtgxV&#x2B;/suwu5pc5C7YC2CTOEoVwOgrN9WIG1YH7ffK1eg/eDyDBvgtg&#x2B;OLajBgDcfRItrz7LdaApKsWbsh9j0&#x2B;jcIIglgiMC6Zz5B8imdkXZmb8e8qgpLsfz&#x2B;t2BSQD62XRMkD&#x2B;iE5EHdkNSnHSKbpvocSRuMBrS94zzs/f0vUTVQBSCieMPxc7Jr6oCwsDATiQBeiMrKyswcSHNgwM85sOZDj3GKHumut3YptWw3aFcIGOxdBJLDI5EWEYNTGrYQOXNJdRXy1E1xQ/FBrC3MxUYFINcU52FfWbFNOkdCQdQBRs&#x2B;kgCuo8/R8pCBTD3D1BRBdwaKedoa&#x2B;ZPBH0urQLxKA&#x2B;yAEmWVFmKL215Sd68SBPyk0HJ3iGqBTbAoGJDfGtS274q52fTA/dw&#x2B;eXvcXVhTm/DvLPurTfULvMWWwt05k1wSLxVHXbwyNxKCGzTEwoSG6KsA/KLU54tQAkhJSei5UVVe5EKx1z1tvmRB356onwz9/Sgg8XS/0GPYR7GvLQQJTu3YR8Nhb74mqSZPy419cr89s/fjx47Fnzx7k5GQLSCI4Z5s8jSAIDg4SMzuqAi655CJ89tkXjrpsSryLi4ultRxB4OzZf4gT&#x2B;4IFi0TqTVf&#x2B;Bg2SBPx16NAB3377jcyHmWYG69ofeOABBf7jcNZZZ4s0nhlwOtNrGfWjEb/99qsAesrZPXEzBN5PPjlWatEJVNmycPHiRdI5ID29kZQpXHPNtejbt5&#x2B;YFbKMge7&#x2B;bGlHskOLuLh4h8LBV9Do7rLLLpe2dQTujOuuu17XdymrJ6mhZdI3btyEW265SS3bD6JOcP97UdCa&#x2B;Iwb9yTmzZuL//u/MRgyZIidpDA6yIM333wdw4adjd69e8u6c7uxlSCVCTxOKMG//vrrJKNPYufnn38SKb&#x2B;WVWdJw/nnnydkCbsyuAP/GunQokWLehM7nq4FAwYMkG2qkTHsMEEi4/XXX8fYsWPU8s74z45/I9RYsXlkLPZXliM5NDIACI4iwHe9t/jTMtAbiPdGfvtqexvI/AcIgEB4AERd/u9azB7xsJw0lO9vmvgNGp9/sgB21yjdth9VeZTq2W5ytZZqJHRug&#x2B;ZXnemYJiQ&#x2B;Cr0n3oXyfQewa9psBJsiRBK7&#x2B;pH3kXJqV5jCQuwAXg0owyNgrihH/pqtyFuzEZvfno6I1EQkdGuNZDUtlyGucwsEx7jvQtDo3JPQc8LtWDPmQ1TVFqmbdxiaX33GYdOZyyqR/cdKIRqobvgnhqyUy/JZDViCtR7XlM/yWQ00LVrWTPMP8DZQ1zMw0EMUUCFAKqgatfaRvAEhajEaRcaheXQiRjRqK5mVkpoqZFeUYUfJQWwsysNa9diqAOfO0gLkVpWjVlqe4ZArvDMxUKdfPdwbq&#x2B;l971gBSF/tDvVks13JA3ff0aOUcEcu&#x2B;OowYHTycVDT5qn9NTd7N&#x2B;Zm7cQbGUvUeRGCtmrAMyC5KWJDw93slP86I2q1ZfhZsqO2FX0UmsUk4pTEhhiU1gr9ExshRIE5dcKIm78r6NcLwt0NUnxl&#x2B;H2dy94GP55MmLTXGuAnsNfq9e2XIb5ntBubEhQZj5fBFN3laRh39dVXu/2cdfXMpuoxxuO6BAeHiGkdM7w06xs9erQAU4J/ytv5moDvmWeeUeCpoUi/aXBHoEeATKBOAoBZ8AcffABjxozBjTferADiPqlnJ8kg5Hl5uYDGG2640fH7NHKbM6eXgE4NyHoCr65BafqaNasliz1y5LkOUsFd0DjP5j1QI9vlr7/&#x2B;lMww5eHavD7//DMB9axJJ2k9YcIEtcwVsv4kNzTjO4J7khysI2fWnt0GnA35mCXnQ&#x2B;c9UcC1v8FtS&#x2B;LmyiuvFEXFsGHDZL2o2oiIiPRK&#x2B;HC61atXCxHw3XfTHevPZSGRQWKBhNCyZcvVsbQHEye&#x2B;Jtlylmgw2K6QYP7qq68RYoRqAJYF/Pjjj3j//UmO37rvvgeklIPb2J0xoD/B/UZDyK5du8l&#x2B;pnLipZdeUusahkcf/b/Dzkkea1R73Hffvbj11tuEDGCEq/GWrRxgvZhOUrXwX4208Bh1XU&#x2B;HKQAO/zYiQE8Nf308AfwlBAIRIAACoV0Iz&#x2B;qDtNP7YN9vC0QFYK4tx7qnP8GQmS8eBjgqcvJhVmAvyGQbXNWiBgm9WklXAdfoPOZqZM5YBGuVRZQAeas3Yt8PC9H0kkG2k7LWguqKUilJCEIYTEbO04KK7HzsnTlfHkFhkYht1QhJ/TsIeZB6Rm&#x2B;EubT76/zYVWg4pBcOLN0g7QxTBh/OtFvUAG7ZnRNRVViMpF4dkHxKJzQ&#x2B;/xQpPfinLpAsF6BvgO3GHG6kZwAJAfWosUuE2VmAza8NngbznpjSeuMg7g1iIavas5ZaB34PZZYiKg5tYhIwrFFbyZJWKyDEmvO9pUXYWpov7vE7ig&#x2B;qvwuQqfZrPnvEa&#x2B;UHnhQD/pq1HbYh4d7N3Z3DvF7n96NBLuidxhfhoMdA0JlccBAFahtrmE29Z1YPKjo2FObaPwu2Ewwelu&#x2B;fqsf/u8JiN8602g6C0NAI6aRxWkpTnJXWGv0U8I8ODrWRKupcrLaYBRjUp12e6zQWJwXOkZJ43ogEd&#x2B;&#x2B;x9R6N&#x2B;Aj6uRwKEEkbPnvbU2fi0XAUz4yjcGpZBZTREZ&#x2B;11fPn/yVZcmannYMZefZGv/vuexyAzTmKigoV2LM4HPAJlN57710BhQSHJD8&#x2B;&#x2B;ugjycrz99h3nuBy8uSvBAj27z8AcXFxoEiCiV7W8FMGziDIYvu7Xr16u61V528QjLkCdXdyeT3BcgW2yiM4dXcskahij3luuwsvvFiB8jhZhvnz56vtcxd69OiJd999T4AvFQIsU&#x2B;B7XG/Kxylh//PPPxXIvgKXXHKpY750qed3Jk36UF4fLQd&#x2B;vcF2gCRZCMBJmlx66SXSaWDUqEul5aBGuHgiAPjIyzug9kOoGBjS82H48BEi32cNPtsLXnzxxWq/XiHtBZndJ2jmNvn444&#x2B;kXSP3LUsXeHy8/PL/ZF9wGqo7tCAA14D3kUZ1dZW0/SMBoJ0PPXp0F98K5/s/yxNoXEgy4qGHHpZzwJkIW7RokTo/3pD3LU5eQf/FuKZFV1EBBOLYXbO9gXZfHQDczcNXSVsA7AcIgEDUI9rdfxH2zVooA/tgYzgyZy3B/lnLkXZG77qDispqWFHrhKkMCE92P4CJ79oKST3aI3vhaiEAeFru&#x2B;mq2gwCIbJqMbk&#x2B;Oxv4/lqJw9U5UlhTI/FheEKSWgUNPa6UZ&#x2B;eu3IW/9Zmx6/xv0nnAXOj52&#x2B;aGLjLlWWhQm9W0vD2/gyBQSjOriYuyfvQR7Zs9B4fqdGPjtuOOFMSXYN9h7YcOuCqhlna0CHlJ/yxpbu7zQ4IkM8Hbx01P/6xawcHkIHhQIqrY4Z6QNSA2LROOIGJyU0tSGptX7JeZq7K8oxa7SIuwvL8I6BTrZg35fWRGyKsuRW1lm71pgtYN1o61/vMHkP6isr/O7J6d3XySB1QcJUR/IdLRICF/qAxeVwGGA3xsZ4elzdyUT3pbtaJpE&#x2B;gP2a2sdxyfJj&#x2B;aRcWgTHY&#x2B;O8Snon5CGVjGJQnDFUB1BB3dm&#x2B;dXD6uSfoQeEezrHPH3HV7skX2SCp&#x2B;WSch976z2Ce03KT4DLbLNzvb6mTDqeY9u2bXjllVfwxhtvCGCmZJxmc67BzDVr7TWQTVM7mtsRDBH0v/zyS2jatJl8n0GndwK/srLuAuLWrl0rbeiY&#x2B;S4oOCgqgBtuuAHdu3dTzzdh1aqVkgFnWQCDTu&#x2B;jR18vWd5t27Zi5Mhz0LlzZ7frwGv30TRd4/q/&#x2B;upr4ghPzwHW7c&#x2B;aNUtq9rncV111hWTn7733PtlmBKuU93Mdf/llpsj92daOBnXMgH/11ZcYNGiwbOtff50p01KtsGvXTixcuABt2rSV3vXsUDBp0gdHHfjz8C0oyBdQ77qdaN63YsUKaf83ceKratmflPp6knKUsr/22qu48847pMTBW1RUVKrl/0a2FbP23303VcgNrf6ev02fB4JoloFw/s88MwFTp34r3RzoiTB27JMC7seMeQJmc40YQ7Zt6zuTbjabZfvRZ8FXC0b&#x2B;Ds9nlhFw37A94gMPPHhobBUfL2QAj3dOx&#x2B;OQ5/U333yDs846S44HZvm1eWhB5QYNKUliaZ4N/9UYmtosMPA/tmNajyBeb/bf0/v1aRd4rAxyAwRAIP71QaCfemoPZM1dLpJ91rdufH4KGg7pWSe7b1QgmhDdGe2YPEgtWaOf0LMtshautA2AFLDPW7QBlTkFCEuJR3B0BLqMvUYepTuzkLtwDbJ&#x2B;XYHcxetQsSefDe/lt00IkQeVCSQgnGPnV7OR&#x2B;fNCNBoxAEl92nuX9zPrDg7CbFJew3Ha5kVTB0RGRjrOzerqamm4XFpaWkuNLtl7ynINttB1YdNT/&#x2B;vpc/dARgElCx91Mwk0GmyhAFbb6AQbqjXYSITimiocrCrHgYoyKR3IKCnArrJC7CotxN7yYuRUV0qXAtRaDoE1TTGglRYYnBH3MXaE19sOTnfbOG873QOJYIX&#x2B;/vb1VTVY3Sy0XuWBPwoFb9O7ljq4nLduCQfX72jtEe2t&#x2B;XjcsL42OSIa3aMT0Sw2ScB&#x2B;x7gGaBgRg4bh0bbjitOq71argXZlTXU9gIvVbzLO&#x2B;3nl/fuefoPZfRKI9meD1nqPAJ9KIjsIPW4uerZWedWSifUVrMEnKCOBwbrmDz6YJO75BG4VFeXIyNgismxeBwlQCfAIxGm&#x2B;RiO0jz76APff/6CARmZBtWDbtg8//AB9&#x2B;vQWx/TQ0DAB/ATB55xzDtq3byfZfi2bf&#x2B;mll9ZZLjr80xSPgOyhhx5yOPr/XfeJdevW4dFHH1Xr97GAfmalKctnOQJ7vHNdCSDnzp2D3NwcWcfZs3&#x2B;X9aZaIjY2RuZFUEp1A4kCyssJVlnWwOB7zBhzPvwOwXd9pOM5OTlSI9&#x2B;mTRsPoPeAyNqfeOIJqbV3Du5n&#x2B;g/Qb2HJkqVirvjoo83ErK979&#x2B;4KzD&#x2B;HK664TDosOO9bTk/gTj&#x2B;GCROelvaEoaHBom545533MHDgKdKxwDkIzjWAzu3AshCSRNwOI0eOPHSfs3W58GsbsP2g67q5Cx7fcXGxomyYPn2a2i4vSnnDSSedrPZLAyl9oCrljDPOUOA/U7oo8BidOvUbKVEgGXXNNVdJ&#x2B;QaXXQuWudDgMhCB&#x2B;DuvU94AvzvyWo&#x2B;ZX31IAJ0jvwABEIj/XnS4bxRy5q0S8B9kCEP23JXInr0SDYf2ckwTnhoPkzFEppGsLUXjTi2vXCM8LVGy&#x2B;kIeKPBdkZuHos27hQBwjqjmDeXR4ophMJdXYeMLX2HNuA/VgPXQ4NAiBn9151&#x2B;xPw8ZU77Dzim/I0INWGI7N0P/SQ8iqkVd&#x2B;afmO&#x2B;AWWHiJzBlLULJlr9oGvRHTromQGv9EcGBvH5xwgE&#x2B;BAMkApieZ3bPafQMMrtk8T8zn0egl7ikI9qutarBoqa2DZ8MUGGsSEYvmkfHox7Y79t&#x2B;uMFejqKYKhdWV2F9eIuTAttJCHKgoxd6KEiEJWE7AaWp4rFlrbQZtWlmB83Od/aonNe&#x2B;rXsBwFBC2n8SDNyLiSPrbG3x8zx3R4M234eiiQX2fWWxg3Sbht9iuQXw2mRBiCkZCWBQ6K7DPThed4pPRJz4VyQrop4ZHwWgKchj8sSSCx119Bi/eTPtczzE97&#x2B;kFy5oyiOe4JuW3/77VbjYqoJ9t&#x2B;P4N95tPPvlYss9sieYrKGWnlJmAjllbAklmU&#x2B;&#x2B;77348//zz0mP9vffeF0C0adNG7NmzWwzdKN8noH/11VdlPjTaY9bb3p5VXOnvuOMOAZjbt&#x2B;8Q0EWAxXj99YmYNu07BTQf87hcXH5m4f&#x2B;J2LFjh/gR0ISOVWI08aMEvbi4RNQMzP5v3LhRgLHZXCsmhyxZuOWW26Se/PLLL5fWc1popQjMDtcZF3To4PjbOQvtb7z66itSlvDCCy95AMfxIu3XAPKPP/4gpAMBOD0GqOZg2Qe7JdCgcMyY/1PznCiEBY&#x2B;Fq666WraJtm/nzp0n0zMo4&#x2B;f60cCPZnh6g8tCgsFTaN4Bes/hqqpKWV5n9Up&#x2B;fr4QVdwfmvEjvSOoOmBQ5j9nzjxRIlAFwzKT5OQGUhJALwfW9ZMcY2afnRxIXgwa9LyQNa6dBfT4YgQiEH8nCeDP53pKAFwJBXeEQ4AECBAA/5mwcsBbXqHgcy2MVs&#x2B;7m14AKQO6I3vBSgSZwtQYuxobX5yChqf3cgz&#x2B;I5ulIiQ2ClUFJQLoKQ6vUjceTxEcHX5IMWCkC70ZxVv2IeXUbh6/U1Ncit3fzJVsvWPcX1uDsOg4pI&#x2B;s24LJGBykDuAIBBlDUZlXiJI5C1CWda2DANjx6W&#x2B;wVFUjvnvreoG2vOUbsPSJVxEb0xSxHZsh9fQe6HD/JQiO/eecY&#x2B;0Df4MaMEm5AMGAutlbKfOlZNFoqxeQbJ&#x2B;vNih65Fm&#x2B;2FU9Lq/23KyUEbh&#x2B;lz1344PDkBQSjjYKvJ2W2tyR6a1U&#x2B;71UATW2uztQWYZ95SXYXV6EfJYYyN/FyFHvkyAor6lCuRpgWtiyTVMQ1CEJDLb9b3BWEvi6F7hD3AanNfJ62/NyXzHouOfUtxzCjtb9VSZYda4&#x2B;dKy2tT7TWeuug1an75T1p5lhYmgEWsckollENKJDw8XFuUlkDLrFp6BReAziQsIQoqYj2KeBZS39KtR8eFz465eh10zT27TuTP/0nGdOrff4LFJ&#x2B;nuf2en2DvSzIcaAY/gX6xi1bMiRD37x5MzHza9GiJXbt2iX19QTTt912&#x2B;2EAKyMjQ0AdAe727dvQtGlz9OrVR4ztmKln3ffnn38hIIoEAPu18zdo7kfAxDa1dK5nUMpO1YHmhE&#x2B;ApwFO/r5znH32cHGo9yXX/qeCPeepeqDce9GixWJaFxYWKj3euX733XePeBzQZO&#x2B;22&#x2B;6QMgVKxpk1p7rh7wi2nKMpI70FaKzorWyA5BVr17kPSWBMnjxZngcOPFWOmz/&#x2B;mC37kYCYLQjffvstOT7ovk&#x2B;zRqo7WOqh7VuSHCEhwQoYd5IyCYLu&#x2B;rrtO5/PVF3YjrlPpWsDyQU9QXn&#x2B;22&#x2B;/KYoUlhFoxzdJJmb8Wb//&#x2B;ONjxPCPhAcJMhI2LDf53/9elmvZL7/MwGOPPSpKD/pccP&#x2B;SAGK5BvdtIAJxPJMAvu5/3j73Nq3r/Vfnfd7qx8jmhCUHAgTACR4hCqwyi589dw2qC4pQg3IxxXMNY5AJ7e65ANkLVsjhThVA5qzFyJ6zAqmn9ZRpIho1QEzbxshZvFYIAKP6V7otSzcwoH9AdV6x18mW3v4aDm7cjBBTtOMkptlgnxfvQ2Kvtp6uCOrGH4QgS5h0F9Ai69elyPhyOqITGqG2vAomY1Cd9fUVbFFIg8Lq4jJkL1qJ3EVr0GzUYMTGHh&#x2B;tY2wu1rZWg/YBBc29rJWVlXxmu0FBvQQLmjrAU5sxb&#x2B;DGGzjyt0&#x2B;563dr7caDNU77Evbl4pJFKTAXE6QGtuHR0uNeA8a1amBfrQZFFQrYlatHfnUFcipKkc0yg8oyHKwqk9aFmZXlyFPvFdZUoVRNU0apNx3ftUyy9ptwQxJorx3T&#x2B;HMvsB7h/cTfe47BzT3N4GGe3tQM9U33uxIPLssjpSL290R2b3&#x2B;tZfVDQsVskqRisikY6TFJ6K1AfbgC9Dxrm6j93zEuGe1jGyBKgbtQY5B99xhts1H71azmaVGPcrarBDyCb0&#x2B;DB29Gm97Mhny1&#x2B;vM2WNEy&#x2B;3JNUtcuKnrCwsKM9my/tN6zf2bQsv7HG95nttGbC70W&#x2B;fkFUpPMDOemTRmSuSYgJ0gdMOCkuuRrXp7Im2nqd8cddwqY69Chk2T7CXxatGguAJPgcOvWLQKmtGONmWaWALD&#x2B;nW7nLCEgoKLcf&#x2B;LEN3St0/HaJ52ECUE8dz/XiU7zrJFv3LgRHnnkMXHBp4kdgSnr5mlS908FSzMIxEkA2LolHO4XRLVGkyZN5TygooHrxkz5//73igB3ZsIpaac3A7seZGdniSLknnvuFdKAvgX0AaDTvrMBIMmCRx99WJQFLG9gzb6rusHfoIri5ptvFPNELg8JAD3B45UlDm&#x2B;//Y7I&#x2B;dm&#x2B;kMvKEgOWX1x44UW48cYbpERjxowZUn7BY/jee&#x2B;8W0oQkCLsKcF1Y7kHS6mhk8wN10YH4p4gAX2PGf8jUT2/K44QhBAIEwIlOAMRHY9B3z6Bkx37kLdpoM/srs7od57OtHl3y85ZvEhUAnfo3vvC1gwBgxj1tWB9kL2Zdf6iC/yHIX7EFVQeLEZoYc9hv1xSXq5&#x2B;pWyNu9eI&#x2B;u/nVqdj13e8IMR7KFJgtFWh1&#x2B;XC0uWmk3&#x2B;tuCg8V/4Cq/CKpB9ZAnNEQjIPLM7Bt0i9ocFJHRLdMhzEkyCOwMqqBuKE2DKbI4OPa/Zwgnw&#x2B;7OZA4fdNMkINjNQgRqTBXiP4BvuqqXAcJeuu4jrgrgRNg4l8W59&#x2B;trQt3Of9wNRhkX9&#x2B;UsEh0UgDR6ADtCgiI3NsiPgVUERTVVCKvqgL56lGo/i6o4usyMSbk&#x2B;wfUe8XqmUaGlIiXqgFamcWsjsFaHoj22nL7MhrqemGIHN2KusSB8/of8&#x2B;PGnzYK3uoA3L3WwD13wKG6efnY&#x2B;XyW2VoO7Ud2GyAwU89pav&#x2B;Yub/UI02B&#x2B;WbR8dKCKT4oBN3UfkuPTkCUmo5btUVkLOJDIxFC2b722woc05SvWv0ej4xKMeizHqIYvIBvb0SUHumgHv8MX/WMzp&#x2B;RqCOwp7eHGsgbNEduvseHpuBxOp8MngZPf&#x2B;cAnkCfbvFa&#x2B;zjGZ599JqZoF110kc/v9&#x2B;vXT4ApH1zuqqpqyabSj4WZdm4H1nHTjO3999&#x2B;Tum&#x2B;CPLZno7R92rSp0meere/4ezRCmzLla8nyN2/eTOrcx40bh/PPv0BqoVknTdD28MOPCLBizX592s4dT/Hiiy8owHghnnvuBan757YfNWqUtCTcvHmT1Od/8cUXmDlzJp5//oW/ZZlKS0uFgOF&#x2B;o2cC9wPl53TB15zwg4NNTiSNLdhlYPfuXSLf5/Fw1VVXCfFDcDx69HUCnLOysqXl44MPPiyu/GxH2L79oYw3a&#x2B;PdBUkQejvQ18FVCl/vsVRIiJAVPFa53bVzb8mSJeI74Ylg4DFcUFAoxoOU7Gvbge9zX82Z84e0aaSHBImFxMQEtb4PCXGVmJgk6hctjlSRQkUGyQN2fqCpoh7iLhCB&#x2B;DuIAW9mup6McvWUs3ohEfzRRZ6QESAA/iMR3SJNHs2vOB21Fe7rXwnwO9x3Kf68fKxDBZA1axly5qx2tNdrduXp2PDyZNSWVEpdbVlODnZ/PQdtbj33sPmV7c6pcyqJx7&#x2B;H7Hn&#x2B;yq1Y8&#x2B;RHCrCHOsCSubYScS2boccLN9cLQNE0sAZl6leDCHsPracxCMVb92LRjc8hNC4WMR0ao/1dF6HppacJQaGpCIzBQf/aa4DdE4AZBFlxW2alip0FrGpgVWOyFy9qJQPeMblV92d6CQS9xIFHQ5g6v8VWdziU0a8DzQ1CCsQEh4g8vEWUDXhq3hRWO4yUcgqRjFtRUlOFCgUwi6urUFpbI/4DVBoUV1eggH4E6v3cmgqUqudiNR2VBZy&#x2B;Wk1bYjajkm3j1LKU1Nh0DWWiOLDYfoxlECQPNB8DTy77Gmng7I7vSKo7F&#x2B;k7f9/Da6/3N8Phz1xWEmbyHGSfnwVxoREoNlcjVYHzqOBQAeFNw6MQFhqOSrVdWsckIUn9XVBVgQFJ6YgPj5RtyE4RzaLiZJtEK5CfEhrl8HQ0amUa9m3P96rtxI1ZTPmsh5bUS8benyy9N8LL3QCjPuUC2mt7mz2R9NsH/UY7WceBveNvd&#x2B;vjDej/ncCfmVlmHVlnzAw0gTTBOl316S7/0kt1s8wEcWzVx/ptx/U9P1/AyyOPPCQy/ZiYaAeIo4SbGVrW70&#x2B;dOhX9&#x2B;/eXzK/Wz5wgjy3a3n33bfTo0Ru33nq71LhnZWWpafth2rRpYi532223Sq03Je7MshJYNmvWVH2/sWSBT4QYN268eBUwuG0YBMwEdr179xZAd//9D0i9vtGozw6C8nPuGz0Gde6CSoTQ0BDplEDiZezYJzB58hSpd2c5xi233CIA17lenucHa/lZ&#x2B;64F1QsGw0GcccaZsk4sCXjmmeeEOKpPsOPDUR0sq2sXySsuJ7cttzUNF1mfT6k&#x2B;lS0E1&#x2B;xGwCw&#x2B;15&#x2B;kGb9zyimnICcnS0C&#x2B;plRg2cqOHduk1KRPn75ShkLlgxb1bRHp&#x2B;RplUcfFfWr7DsO8eXPk/AhEII4HwO/tvuarJMCf34LvAsejYescIAACcfyGKdwz69v4/FOQ2KMDsleuQDDC1aDcLF4AKYO6ChCIbpmGltcNw/qJnyuoHqvAVAjWTvhE6vpjOxzqy2wurUD2n6sP1fKrE5BAPKpVw8N&#x2B;01xWiaV3/A&#x2B;VRQW2LgScXIEFY2gQ&#x2B;r53P8LT63cjbHfXBQhOiMKB&#x2B;WtRtHZvnd7nNlMwE2oKy7Bv4UJEt20kBADbA64b/ykan3syynbl2MgDV1D2L73gshWYbaAVYSIwISipqKgwq2cai8GuEKijLz4SoOEsf/an3MDfLgXe1tmiAW8Ji1fGWVMVxChwG6sezFQbNZAKrduCtQ521hQKBMP8m2CfAJZt5FiawBp0Al/&#x2B;TVBbqQB0CbPX6r1cBZopez&#x2B;gADPVClUWM4oU6A1VA&#x2B;XCynKpZS&#x2B;pqbRJw&#x2B;0Sd5P60Qr1GxFqMEoCIkItJ1UL0WHh8sxWdsVqvqyVp7FivHpdYn&#x2B;uUvuY36MahtslMSxC/BNaR8Yju7IUbaLiUU6Qrn4/LSJWyijaxTZAiVr2CPVeUliUkCNUW1B1wdp6toLkViWpEuQAHHWVA9y2nFbjJSot5iM6nnwdB76y9O6m8yTPd/d9TyQXM/v27L38TfNOgn&#x2B;7lP&#x2B;w1nvO8/Q1CPongyZrmuu&#x2B;lO2oY3HChKfkuPzkk88OkyPTpC8394BkpQnC5s2bK5l9EgesVyaAItikmoDmbgsWzJfMfWbmPiEYVq1ahTvuuEvc2m&#x2B;66Sb5neuuu15czJ23DUE&#x2B;66SHDh0qnzPzr7U9I8hiS7wTLTR3fudgfTvr352OL5/z4XanIeL555&#x2B;P559/TgwRfREA3O98uGaNGzduiu&#x2B;/nyYEAEkJrbtAdXUNfv75R/Tu3UvAMFUYJGIaN24sxxH9Cnh&#x2B;8N5DEuLNN1/HmDFj5XhhWQNNDesL/o/JuMlktN1T1LWa24DbgjX4s2fPkVIVnic33XSzKCEY8&#x2B;fPF0UGCQB6XvC4pgu/tn&#x2B;4D3hM9&#x2B;rV&#x2B;5guN7c7ySEeOyzFoIkglRGBEoBAHO&#x2B;kgF53/3p2AThSsG/Fv5wgCBAAgah7kwsLwSlfjcGub2YjZ&#x2B;5qFKzYhp0zZqHNL&#x2B;cifbjtZtz5sauQ&#x2B;dNiFO/YiyBTOCoy8zDn7IfR&#x2B;YlrkDqkh4Dkdc99hoJN2xFstGUpLFYFPlIaIL7j4UY8a8Z8iKxFKxXwiXGcVmZrFbo/fANST&#x2B;tR73VJ7NNeHtX5JZjR&#x2B;1a1vPvUzdeWdWL3ghpUSHtCqg5Y768RFzumzsTuqXMQFByGYFNkndPdaDKeEPtZMxMkSGG5AAkBNaCmkaDV7qRMBYHRyWxMNyvr7aLsqd7aXTmCLwDnL2D0RShoqoJDZQcWr&#x2B;vlyJkbbCoDHhkkDux0gWN6qbuQkgH7Oljh8Dig&#x2B;sDgobWhrLMCP7I/1PRmtn9Ur0kuhJqChHQgWcDnMPtrPlepY1ueLbbp2OKOcnr6JphYZ6/AvyyPQ12gZf6tDvxuI0QMtqy8fbFq7ctRa99GXAdbtwe1bHYSRM8x4i0br&#x2B;czPeD&#x2B;SI4HX0SW9rZdym9Uz&#x2B;LKr2W0nev1&#x2B;bc3sK/nWP&#x2B;nB&#x2B;mtWrUWMFZeXiFgjcCR2dvXXnvdbS0y6&#x2B;f5GDXqUskIEwD17dtfXNppVEogQnDOjL3Wem/r1u249dbbpHaf8ySIuvbaa71uJ/7GK6&#x2B;86njtXJoQCEh/eG57d&#x2B;3qaKLI&#x2B;vxzzz0HZWVldUgDGtHRhf/MM4c5SAGWG9xww/VCHk6a9IHsI36P&#x2B;&#x2B;Scc0bim28my/6trKxASoqNKEpNTREC6Oabb5ZWgvn5B2WZSACQ1GFHAH6fBBDb/w0aNEgAdUpKsvzuP6HaWLZsGb7/frpI8DUg70ys2Mk8Wb7ly23Gi2wFye3zzTdTkZ5&#x2B;qK3gkiWL5Rjl9mzVqiX69OmjPm/kRNykCkniT/D887f9IJUzzz47AR999ImoaZo2bRoA/oE4rgC/nun0TO9NWUozXZ2gXc901hOBFAgQAIE4LGLaNEaX/7sGUI/SnVnYP2cZKnMLHZ&#x2B;zjd&#x2B;Ajx/F7LMfRHVpmQLJ4SjdnY2Fo59DRGoDWM21qMg7qMB/mAPT1KJayIGIxnVdc/f9sBCbX5&#x2B;KEIMGtA2osZQh/bR&#x2B;6PjI5UfnQhNsgkFM/2znJbsKNOjfGSmDu2L/zKXIXb9OygW0C4YJYaJssJgtjtZ/fK6tMGP5vW&#x2B;j0Yh&#x2B;SOrbXjoDePYO&#x2B;FddiA32&#x2B;mNxa2ZnAQ40Kisr6R9gsLc7cksG6K29lu3O8govWVRf8/Dn4u&#x2B;rO0F927G5uwNIVtT&#x2B;meUYmNbUuQHWWgWEV9dUyXNpTa08l9VUy&#x2B;faM7sncA1rLLZnkgbyfbrho66kXs96uyNsbM0WrIeIDZ37y9u&#x2B;9fczT8SSN6JJD3HgpFphVp/tNgXka/X6did&#x2B;TQps1CPf90Wa6ZFE/hMDd14XbMDHlq2lNPnOO&#x2B;9WAO4FBSJXY/z4p&#x2B;RzLv7KlSsExBEgUjHQpUsX6UfOOnWWElx22WVSL82YPPlrMfdLTk4J3HSPcrDk4sUXn7f7ABx&#x2B;j7KZ450ksnaCWOegbD0nJ0dq0JmZZxabJR1UC8yZM1cA&#x2B;2mnDcG6dWsVWP5eQCUB8GWXjVLAOEIdD0/L8bBq1Uq1f0MxY8ZMAdM8dpyN&#x2B;rRjuV&#x2B;//vjss8&#x2B;FJGCwPSHn7ylIPHA&#x2B;W7duFQDdpUtnXduEde8ks9gNYPPmzZg5c4Z4SbBEhCCd82WbyQ0b1os7P7PzLEOh&#x2B;SDJCPERgs0LgCUpdOSPj4/DqacOknaRvHc6B6e76KIL1Ho1Eg8EkgrOCg4qVxo1Sve4vFpLQy1I2LAsgt0CtG1XUVEuHSBIrHF&#x2B;rkGVzBtvvIWvv54ivgrsMNCsWXO7GssaOFEC8Y&#x2B;TAL7Gae7u03oSSB6Ob2eAbtUJ9nUPEf9t2z9AAATCa0Q1b4g2zQ9vG5R8Smec8vU4LLhuAspzDjiM&#x2B;yqy8wTEm4yhjnZrltoqBIdGod3dF9a9OeUUYNl9E6VFl8lkG4TUqmnDUxPR5617xMTvaATNDJ1rrC2oQVSLhug24QZ0HX89CtZuQ2253RfBZFSfmxWgq1InB9sYBkOrq&#x2B;Y1Z&#x2B;/Pf6rHPIRERaNBv044&#x2B;avHEZoUe0Ltc9YpM8tAN3KWCfBCqgZC/IMDCqtmUMZnd&#x2B;ysNzCop6WgXiDqDVjWh2Coz43L0w3I07r5Aqru1lEjTqwuJEOt/X3ttet0VjdEhbvX9SE/fG1vb8SMp/3oy9DHn/1fn&#x2B;PAufUe39dq9&#x2B;3ZfYPmq&#x2B;G0jAZ/ALurCsBXpr8&#x2B;4J&#x2B;GbGwNd6RmdwQUbLvXoUNHBWSCHLJnrj/BIwEP3fmvueYqrF&#x2B;/Xn4vK2s/1q5dg549baax3bp1R0JCvGQ633zzLURFRYqJmhaeDNwC4TkIonnc&#x2B;Gr7RkBOEsDgZFZKMFtSUqxAaAMhaDQyi676zucBs9tUY7DXPIEwOwn8&#x2B;uuvkqEn&#x2B;UMliIwB7NL24uJiIYFodMee9PR3eO&#x2B;9d&#x2B;Xx0ksvO8oyPBnO8ZjSwL&#x2B;eePrpp0TSznIRZrOdCQCSF59//pksB&#x2B;X47DxBIornDqXw7dvvknKR6dOnybFKAiMsLByDBw8WVQr9B4YPHy7TMtavXyelKtry05WfhPjIkecIKUBiw9O&#x2B;oBcA6/r5OUkCbTtowTaOztd47gPt&#x2B;kKShW0QnX002FWBCgXn6wC3wbfffoOTTjrpsOvaTz/9JKoLmmned9/9Qubs2bNHjgMSMwECIBD/NlLAl0LQj2PamxfAv17arzeMgcMtEPWN9LP64ozfX0OTEQPFrb/aUmo/IY22DBpl9rXlsKr7Y58370Zin3aHbng1Ziy98zUUbd/lAP9yEpsM6PPyXdJu8BheYmCptvekV1g2oXsbNDipk7yO79ISQ2e8ii4PXyvdASyWuhI9dkcIMoaL8uHAwg2oLiw7sS8Q9haC0dHRppiYGFNSUpIpIiKC0merAgk1asBVy4c2gNH2o&#x2B;tDL8j09F03rdM8Tqe3RaG3em9/ltPbdzzIx/1&#x2B;7el3vW0bT8SLr9/Ruw38IQ/&#x2B;n72rgK&#x2B;y/MJnwRix0Q2jU1JpKVEkFJCSBhWQ1L/SSKMgICmolIAoXQLS3V0bI1dsYzC2ERvr&#x2B;r/P2b7L3eXG992N2Hgff1d2v/t1P&#x2B;c85znG1sfc9qj53dT2mjsX9MZnDwx8kN1XXsIxSnInDW6fCYk/l3gkq1&#x2B;UjyVSboy8ayH01mb&#x2B;UYeM7K0WJOh1ckD9/oUL5&#x2B;nq1au0dOlSHpYlS7Zkwl6MPDw8mAzC&#x2B;Kxfvz6C4OfR9VdHSzfUOWP5qONGBrhYMRdux7Z6NTK8ReRDMzWBbHHezp07h0mfJUBZAZIHQqmoAXr27EGff/45KzFAXJXsMuK5iYlJ5wAy4&#x2B;hVD4DsHzp0gFq0aM7f//57FZP9Dz9Mys6XKlVaEOltHNxBoAjjw9X&#x2B;7l1fLuWAYSHa9KUG4eERdOrUyRTD7t27x&#x2B;cstk1fDo/gFwgvTCixPihVQSs9xXUf7fZwfoKQIxv/558rmIQjmABlCowQsX9nzpyha1no6enFzvwIhqEDQ4kSJTgIACCbby4Qg64AUBxAVXD69CmT42H9fv11PhN&#x2B;Ba6urmxyqY9ChQqy8gClFmvXruEWmuXLV6CpU6dxQEIJgCAQh2McExPN&#x2B;0K5L6CMB0EbeG1AmaPGK0JC4lWRfnPPPEvPP/3Auqm/DYh&#x2B;ooqAgOH4GS4oIBUAEqlCzsoluc3g/QPnyWfDIXp4wo0i/YJZqmyXNTPle68qvTO0CxX5NKWZz911R8hn40FysH0um4tPiKbyfT6jEt0&#x2B;em3bAw&#x2B;Ewi1q8ccxfw46O2weZSZn5S5D8XHRrCBA7bateMlSSgR0LyHeDyhg91l6fM2T4p5GkkNeJ3IqXZTy1qpAuaqV5n2S3gMCWbJksYPZk5OTE&#x2B;qf4R2Aeug4lAskv5jpagVMtXHR/64QEHOZXzXE02hdv8YggNpyBnMGcuZk6ObW3ZwRnZoAg6Xf1CgkUigIjHRusLTdptQgWvaF2sCD2nMB5xeIPog9ylsUEz7lfE4GKS34DI&#x2B;Fmtp9cy36tGT2U9PqD8QAJKJfv/66YZA2KyQF2WPIlmG&#x2B;9r//fc&#x2B;S5/Xr11Pv3r1ZNQBC4OPjzeQDvcdBQLZv385Zw/btO3Amf&#x2B;XKFTR9&#x2B;jRBsCpTq1af0EcfNdNJn0uWLMXGZh991JSJBnq1oxwgOvozJotaa5ffJiSXWZkdB8cP5Fw/K6wPZHYDAx9yS0TI1e3tk&#x2B;Y3ZcpkzmT//vsiQegPcscEmPKBCAL6feURuIGZIpAvX15B4Jtyr/pmzT5KoSYwBmS7ly1bJs63tGst5&#x2B;PjxfNE8AjkO2m98rEpJVo86u8bZO3RAUIxRMT5i/MQQQ1sH8gy2g7i/I2KiuZyFbTC69ixk87Ub9KkyezOj2AXABXL3LmzufShfv26NGDAQE3rD8O9sWPHi31e1uQ4UNsg4IZ1eR7AcUgRmAMQeLh16xZNmDCeg3Q41t999x39&#x2B;edScX125PV3db0ipnVkVUD9&#x2B;u9zUCY09CkHNvDM7tWrN7fPxLUqfQAk0kNgQKsSwNTfeh4AhqTe2HAyERDIUN0D5BNZIvWkMJMdFWlZlz8xj8Mo3C&#x2B;IzfQy53EmpzJFOMtuiPC7Dyi5N&#x2B;Bz8m2TiUIu3KSLI36n/O9Xozy1ylPWInlf23YlxD1vK4cyAnunzFRn3vcU5nmP7h06R1E&#x2B;j1jloAtqbDxMp/vPoGixD56buiWI/9uTfeYslPvdslSqd3Mq2flDypQzW7o/7mBLkEcrGRFkVWEiCFM0EA&#x2B;8lKHDAMbRDwiYI4Sm6vSNkTI1fWO1mgeqqTc3RzbVfDe1vuaGWQqQqO2Jq3VbrNlOLaUYah/45l4ADP9OduNnKT/fVwThV6ZT2vDp7yPDdmlanfnN1fybGzetW/1Bso0MoTLZgQP7ady4cTRt2jSuqUZWMDo6ig4ePETduvWgkJBgNipDAOD33xdyPXhwcBBdvHhREJ5DLI2eNWsmy/0Vuf6CBQtNGpHBjR7t30AsQdCU&#x2B;wJqvCVMA3JvyMzbtGlrhBxGMZlHEAf7XGn9B6CzAlQWH3/8MVe4of3ezp07adu27Xy8kpUrNGjQYHHcfhXH8hfuKQ8yfeLEMdqyZQuVKlWG5e&#x2B;5ciVlvFHvjl71yDavW7eO5fL63RSQZVeO6wsvkxYCPAhQgdhqKf04e/Ysk3hks5XrG4GNhIR48e/zQAPk7V5enrpABpQKIMtQoPj7&#x2B;3Hgy8XFhaXyOL&#x2B;RmZ8x4xdun4j6&#x2B;B49etLt27do3ry5vCx0RQAqVqxAu3bt4WUbSviNAaUXIOLKPjLVihCZesVUEB/4MGD/4Zhi3bNmzcLqBwDtMbNly86foKCHtHr1GjFOGHdKwLV4&#x2B;PBhVuKcOXNWfE5xpw0oPA4cOEALF/7G1/GaNeu4zEIxdTTWTUJC4k0i/Jae&#x2B;2qnN3ytJyPVkRZIvLnsv&#x2B;wCICGhwCGXE3/UEI1YiiCbeFuyJQeW/tvY2lPI1Tv08Ko72c1aL8h/fspTuzwVbFyDPQdyVCrBGfrXhcSEBCrYtAaV/qolVUvoQ8&#x2B;8AihLody63xHsSIgQL8eUWWyPfYp7Q2J0PD087UoPTl8kj5U7qe5vwzkgYAqhN3wp8LgrJcTEssoif4NqZGP/ZkfsQbocHR1t9F5yEvAyhFaD4GHie2JyOzSdnNraun1LfxsbZo5Qm4syG5Jsc8EFtV4GatZXC3m2tk2isQCCqX1j&#x2B;JA1t6&#x2B;sDUSoPR8UvwNk9pVhIPwg&#x2B;Mp4IP7KOuhn/a2R8Ksh6WplilrHVYsHD&#x2B;5TvXr1dEQNmfsOHTqwpBmkACRp1qw5nFFF2zIQDWRBP/igMbuVg1SATHbt2p0JIGTUyZkT1UQP5E7W9r8I7HuQLig0QESB3bt3sewcpnNxcSmzvYosHDX2Y8aM4Wx22bLlBMF10LWiA1lFjf4vv8zi41ezZk1q1KiRIKy7aMCAAYLQ3hbHegmFhDwSy/cX08RxoAAlBFBmwNQP6wQJvIL3329IU6f&#x2B;xE79ffr01ZF/EFNkldGW79133zO5nfqKE0OMGjWCWrRoyfNVC/SqR4YcNf04ZwcPHsKdI3DZo8xByZKD&#x2B;P/7779im&#x2B;/wcxeZfpy706fPZLk7CD3MDCtXrvLC&#x2B;aooLxAUgAIAAQf9IIclsozlwFCwYsVKYt/v5ONQu3Ydk&#x2B;ODuB88eJAmTpzEEn0oGxAYQXBn3bq1fHzgoxEbm1SmuHbtWu6IAfLfv/9AunLlKm3evImDNehEULp0KS4zaNmyFXXs2IHVNpinvolg2bJl5UUokW6DAObG0dIdwIDQm8v&#x2B;W/IIyBCQAQCJ14KirevRs7sBFHTmOoXe8hMvQFHE5oGCPDvYZmPTvsh7QXR3a4D4HGbiX31sH6o8rsdrXe&#x2B;4yOikG4qtDRN&#x2B;fcBLoNygduQ2dxXZx2dmM0EelxDksOeWiUSOYpvd6GDL4dR050zKU7P8C8twm/4PXZ38J6sGMuXISnGhkZSjRnF6d&#x2B;IAyt&#x2B;4avoJBjk48NuHeLHhUgG8kISHh8eDleGlTiFrigRbSys3S2Zw5gisueFqCKglsq3GoMacOaApmb3abbamLZ41wQYt&#x2B;0Htw95cJ4fkHvRsyieIRqIBqX&#x2B;h9Z65TLwlMq&#x2B;GtFs737TO/OuTRoV8IdPXqdPnLAuHLB9ZRPyO&#x2B;u2YmEh2T0dmuG/ffiylbtiwkVEJupQJawpfkWErTwAqizlzZnNpBsorhg4dSkn3xaxsyIdafRub5y00UeOOIAvq6HG84Io/ePBgQU4n8XF1ckqSgqOtXPfuPbi&#x2B;G8ORAcfykdGG1B&#x2B;lArt27WaCOGrUKA4OWWoj1717d0EkW/IyoEoA8Vdk9PB/&#x2B;PDDF8vzENR49iyMZfUXL16gTz75lNcJxLlz5y668fLkyUslS5Z84ZzFusJQD6Qby8N0IK4oU0DnCfhHQMECmTwy53iOYP1QaqC03UN2G&#x2B;74KGHAMnBeI8ihlKdA5m8M&#x2B;s79uHYUPwstwPrg&#x2B;ML0z8/PV2eCaQhsG86RcuXKi2Nbldd5&#x2B;PChNH78RMqaNRsrcBCkwDZiH&#x2B;AYnzt3jjP86HiAwAD2R&#x2B;7cebl9I46Ts3MODvoYg2HgTkIiPQcB1CoiLRgvJ5oh&#x2B;sbKA0wFBshIYMDcg0EGACQkFOSqXobqLRtFsc8i6YmrJz04epUCj16iRxfuUJR48UgQ/9mRQ5ITv3ifj416RhH&#x2B;QW/8dlX6rhP5/H2AMudzpnwNqpB9VkcK931Iwafc6Zl40c5km5Uy2WWniIdBdKbfTGp&#x2B;fCHZZ38u6/T&#x2B;ez9dHLOQqgzrRaV6NOeOCLFhz8j9l7V0oPVwqrdoBJXs1izdHW&#x2B;QNXxy5szJpF8xXxMvpDZRUVEJ6DEo/tZ1GNCSRTdGsk25wmpRAJgaLy1KClJjVGgq4m1pGyxNby5IYallnrn9qSU4oxjxgdBDMZJM5hP1A0XJmS0bY078llrwaTEbMjWNlpaSWqdLHeFOZFk/ssGQW3/77RDuu16jxrtcD4zaX2SRt2//l2X9yB7&#x2B;9dcK&#x2B;v77YdIQzEr4&#x2B;/szWTt06BBnzUHaDQFZONqxNWzYkNuwKUBmGuZ7cOEHMVeuB2STUQ8OfwUFNWpUZ1k3iCIk7EeOHGFCCSk8yPN779XkFnEBAff4WA8cOJCz3ejUkOKFT4UPA1QJWJ/58&#x2B;exez2y9lg2SDTq/AGQUxBYEOhFi/7gOnMEkRAkQKYaxoM1a9ZKMd8iRYry8M6dPxfzy0kLFizg/QJzPfSoRxZ87NgxtHTpn4Lw3uaafpDlnTt3ifEiOePdtGkTQX7bcis7BByUAAAA9358XsOzjTPspUuX4WCbcg0ndR2oqPMuQKkH1BP6jv24JtE1AQoGlOzAqwHzevfdd8V&#x2B;XUT79u2jH374gdU86HiA0hqcZxISGQUwjT19&#x2B;jR99tlnZsm82k5Dht/13gHwYwIZVwCYCwSQmWCBmqjwGwsZAJB4rcgkyG&#x2B;&#x2B;&#x2B;pX5U2VMd3rmc5&#x2B;Cz1yn&#x2B;0cuUdCxaxTm6ccZqwSKIRsrI9qvMouV1SU/fXRoDmUrlj9FnX/oTT&#x2B;6Onk5ea87SPZ2mSmTXTYKvnKD7m48SqW/bMHjxEfHkvv0tVSqXXN6b9YgOtVrOj2&#x2B;7kGFP65D1SZ&#x2B;RUVa16NTPX6mrIXzU4Em1dLtMcfxSA4IMOtAVwEEBMSLMoICcQgKiBs3u7Dru6&#x2B;bIqPWkGlj39UO0&#x2B;IPYE5mr4aYGzt3Ddv9qTEuVFMiYClIYanPrrlAgCkkt5m0SXw&#x2B;oo2eIZpSu6&#x2B;vEFGy/JqJNKYxt3&#x2B;N/W3K9d&#x2B;ST4AWX4DU3qM2btwgyGAQE0FkCyE/Xrx4EcunIeFGbT5IJqTHMP1TCNTVq65s5AdyJ6EdIPb9&#x2B;39NEydOZDm/frZbH5Csg9SBHMJrAQaMkIlD0o7MPbLOQUFJyjJkvUHwu3btxtc5AgxoV4fyDJgwgpAPHfod&#x2B;wWA6AcE&#x2B;HOwANl6kEaUgQwfPpxN3lID&#x2B;DiAdCo144UKFWIDSJQAAFu2bKIePXpxAABu9yD0GBfXLkg7AhCGbf8Q7Pjrr7&#x2B;oY8eOtG3bv7R//3769NNPORuOaxMZeMjgv/66L2fB4dgPWX6ePLlZFYF2hNg/zZp9zPNDtjytAEXalStXxHF5j68VrYCaA&#x2B;uvbANc/ydOHM8qBHQbwPUNJQj2DVQ52L/I7qNNIQIjjRs3Zr8OXMMwz0RAYOXKv3g/oGUhzi3sZwmJ9Hy/xLkPY0p9oNQJpTPNmzdP4XFiqaWusfcQla0AFQKfYPDdUqbf2PDE9EL2ZQBA4o1H9hKF&#x2B;FOiy4dsJPjY1YsCj10m/92nyd4pi3WE096O7DK/Ou&#x2B;AnFVKvjDMuUIxqr/yBwq95U&#x2B;PLt/i1ocoDfDfeoJKf9GcOwxE&#x2B;D1kX4EaM/rxNBH3ginyfggFHr1MXqv3UvOjC6jGtH50dsgc&#x2B;uTcknTfUUCPmDHRx8uk0qJNPCiYGaLDAEYBSVTM3LTWiBkbbs440Bw51krUtMjktcjoLU1nbjtN7SOtygZT&#x2B;8zMOis83yZZ7WGjtOhSsvvK&#x2B;WBIvrU65Zty79da/29KEWBuf6vZj1r8ACwBBAKZ0Dp16nIWGDJoECU4mCtu5gBqvmHIB6IIIBAgQZYCVPzSql8TDu8EEEZnZ2duoZc1a3Y2bTMlucZvN2/eouXL/2RSPHnyJNq&#x2B;fQcTf7wUQ/qtnAJJMvhAQQgbcSYeXg5YzqBBg5gAIqBz6NBhMV5Knx20fjt//hx3a0gt&#x2B;U8i/JDUT9D5OSCr7&#x2B;FxR7eNkNijdIGfbc5O7Dyvf&#x2B;6PHj2KWrX6VKxPe908HR0dacKECVSrVm3uQAEDQ6w3psmVKxf/W7BgQXJ1deNzc9iw4WKbc72SjDe8Fv7552820TQHXFdnzpzhLL5&#x2B;&#x2B;QAClvAlAHFHK00oIfbvP0g//DCaywJcXIqzGV/79p/x9QrlRuHCRal///4cOPngg6as6sB5Aal/&#x2B;fLlWa2BD/aBYUcACYn0BPiHQPGD62vmzF&#x2B;46ww6U0yZ8iPf53CPM3X/VJP9V2MKmNwFIMGA6JtSBLwVkAEAiTf35GR1wDv8qTyyO8WERqR8yRfkIZaekW28naDSpvvx2mVxoMx5BLlMDviBeEe&#x2B;hnICu8yZqNCHNSn48nVCfhO&#x2B;AI&#x2B;veVHM03ByyJmdYh6LbXHMpOt8kBgbRwXqVqOGmyfRf7X60OXRS6jhuol0feEG8tl4iEr3bpnhjnnySyQ6C9gpL8TJpQLoMJCArgIwmlKCBuYIoDnirKXVnpr5qmmRZ&#x2B;m7pXaJ1gQerDVZ1LosY3V3yO7jWKJeH8fKIGhgk6xkMCrhV0PaLRF4rTX6Woi7OVWAueOWmqCLKdSvX1/397BhwzhzC9JkZ9B9BaQOHwn1wL5EDTpKJpQXVJjsITPbq1cvJnZo9WaYNYaEfs&#x2B;ePZzhRq06ygQWLVrMRHHkyBFMpkHuEbgBaYQiA0AGed68&#x2B;XT8&#x2B;Al2na9UqRJL7fVhSP4BGDbOn78gzbYbgYolSxazmSDa52G9FMIPVUKPHt3ZzPCvv1bxcATy9FsPIgihlBuA7KPrADwK4uJi6ccfp/BwSPihLBgxYiTPH6UPKF1BJ4nXEehRji&#x2B;OHcz4UKJRtWo13TWN5w68DUBmELRBOQTGQWtAZC7xOFJUAHfv&#x2B;tLQod9TZGSE2DdJ7x1oT4iyDvwOgm&#x2B;Y0cd5gqCCfmABaNWqlbwQJd5ohIWFCVLvwUFnfRw/fpxOnTrBwS8E/xQTTtxDfvvtd/YMwTXWuXNnXQcPa96vjD2jDd&#x2B;19DwALJUBkIbfiMx3D5ABAAmJVEM8XB0MWue5dGoiHq4xFHjwCj264kHPggNStOXT3RDEgz1HlZJ07&#x2B;jZ5EigAwVfuEFeq/ZSqV7N03xVI/yDKeTcda79T4xPJMd8OcipfDFyFp9MztnouVGULcU9jWTijwAAPvA7SEh2/7XLkpkenLxEblNXUdTDx5Qldy4eXuzTBuSz8WCGDAAYu5nDTBAvpGhhhUAAiCXMBAWQScaLm23yy5uNlrpqc87&#x2B;WjP&#x2B;WrwHzH235FlgzpHf1DSGpDQ1gQVjL86YF45LMqnXZfn11sMmOYNlo5boW/qupuZfLXG3FCSwtF5q1AZaAw3WAm3P8EFbMNQMS6QEsuuoo1cM5yA9xT0EGW1jOHToALeig3wfsn0ASoqkjG8SaXxuvvj8ukOAAAS6SpXK7EiP&#x2B;viVK1dynbe3txdne1EfvnjxEg4E6L/8QrXRtWvXF9bl1q2bTDQRdNCKBw8e8DKQaVcLKB0UbwiQewSUsK0IgCBz988/q9gAECUk2Je5c&#x2B;cU2xJObm5uXLNfpEhh3fVx6dJllrtjXJhPwgsBDvgIkqALAurjlyxZQgsXLkz1Mfb3v0fHjh2hbt26G/0d2wD1AZbfvHkL/o7AhbKts2fP4nIAqDxQngCghSIMFz//vDMTfrQVxLHEc2np0qV8HqDWHwaE8NkAmT927Bhn/2GiCOD5pd9S0RjQhUNC4k2FqXcHZPMvXDhPmzdv4XOf34MjIsS1sYTvtaNGjeaSFyiJUJKGwBmCA&#x2B;vXr6W//lpptP7fVBBAjUGgqdU3&#x2B;CSQaQ8ASwGCDAEZAJBIt8heoiBVGd2LP8&#x2B;871PgyauUrVhBo&#x2B;O6dGhENxduBmPhgEBiXDyd6TuLvP7eR3bZHShn&#x2B;RJUY3p/S7cgiy/v1&#x2B;duoOtz1lGE/0NWHIgpxL&#x2B;JZO/gSM6lXbi7gb1N5uS5idURL59x4VFJLwhF85KDsxM98wmkPLUr8gh2mR3p2k&#x2B;rybm8C1X/Kal9Up73KpLv5qM8nX02x7fqmCc7vdsgKIAbvnh5T4AyAIZx8A6AQiC5/ZuNmgeDpUy5mvp8UwTcUhtBS&#x2B;ukpbZfIeKmfjf3t&#x2B;H2WYq2g&#x2B;EnS/ch4ecsvyJR1d/v&#x2B;tEYS&#x2B;Rdi8Rfa&#x2B;Zfy/y0tvIzRf7VvMy8TIBcSiTh8uWL4sUzmLOvM2ZMp2&#x2B;//Y5fSkGKYUClEHtjqFy5KtfaQ7bt7u5O77zzDrfXe/QohOvxQRqVAID&#x2B;NQOyB5k4TOmyZcsiPs5UvLgLderUiU0Z0dYO9eG4yUMabwmnTp3iWvCvvvrKqn0AeXuDBg11NfymgNp19JvHCzpKF5RtQjYfZBfbi4AJpPpoewep&#x2B;/Xr7mJbG1CFCpXYdLJbty7i04ONCfk5LfY1FBSGwHY/ffqETSvbtv2Mu1ZADqw2OIF1gtweNcVYN2Qg79zx4H1/5sxZXQAA64s2ilDF4FjBJ&#x2B;GPP/6gOnVq87FcteovDrggQILfcGzWrl3H08K0EEETyPLXrl3Dig0YPqJ14tChw2jQoIE8bwREsA7w1MC90N3djQ4ePECtW7fW&#x2B;ShISKQ3QPUCY1k8rzZs2MDBO33DWAQ6cb3cvXuXA5lxcbgXPr8HIqj3&#x2B;PFj7laBcpjJk6ewCgDXFJRr8PkYNGgIt8VEG0utz01zXYNMqAQSrCT/ROo8AmQAQELilQcDShbijykUaFyNSnRqSh4b/6PMiTnIxtaOEuMSKeDAWYqnGHLOV5SqjOuVwpEfGXjddQ738Zg4MY3pWjyPFbvo7NBZ4qJyJHtbR54mMT6BAwGJMYn05IZXUktAOwej9w8sr3Cr2nR37WEq/nkTig2LoPx1q1DOqqUE4T9GeWommR45OGelmEfhFB/x9gUADG/&#x2B;4sXbVml9pqgDIiMjE6AOwMOLWACiri2cOXJujGCrMdYzFmRQ48BvaZ7WBBBMBTUMl62/nkrrPUqu2wephx&#x2B;D3norvgw2qSX3agz5DKdTqxpILUk3F3SwNmAhkXbAOQiDQ7S6M1Q&#x2B;bN26lQkcWtjhZVR5gQXJhXletWqmDVXRag/ZYj8/P87oz5//Kx04cIBy5szBRD579mxcv5orV24xLLfe&#x2B;iQwmZw&#x2B;fQaVLFmCs8Mg1tbi8eNHbCSYP38BVeMjew0nfWThYAoJhYP&#x2B;iztq2ZG1L1eunG4Y2uxBpps5s4N42d/Esl3UtQOQq0dERNK2bds4Wz9v3hxel3/&#x2B;&#x2B;Yc6dOjA5nXA77//wXJgfXd&#x2B;U0BtOwwR9QMCau7JGAZ5PZYLY70hQ77lEgt0FMA8HBwyiX&#x2B;fKyqg3oAB5h9/LOKsPYIVS5cu46z99evX2WAQZAXPEZgZwg9g7ty5HNhAW8QmTT7gwMm8efOoVKmS7LOAQAUI//r1G1LsVwQlsH4om&#x2B;jXrx&#x2B;bNUpIpFfMmzeX731obYnAF1pd6l&#x2B;HKOdBdxMEM3FNQKGE6wmBVXjNQEmDa2/x4qVUvXp1zv4rgAkqOo3kzp2LjS&#x2B;1vt&#x2B;Yen8y5XWU7AFgqgQggV70B0ixWDPD0q1CQDYKlXhb2CLVXjSUXD5uQjEJzwSpSXJdtrfLSg42zhT9OIweXbqTYhLH3DkFYbfjrD23IoyNoGd37xudfdyzKLo5e5MYOzMb/IkJxDJiIYQmx/w5yd4JLyRJagBz94ny37anB8cvi3W5TU5li1J8ZBSVHfApPbnpTZ4rdvM4MAe0yWRDtq/Q2DBdRDPt7VkZkCNHDrtcuXLZ5MuXzyZbtmwJYli8IPBxyV4C8BFgQq8QXOWjT3ot/WZpXCVoYDjM3LytefAZ/m5pWWZUDAieIKIPrwW8THNXBpiUiWEcTEl2609BfE19jJFjw&#x2B;FqTP5MkWs17fzUkH5rlABq520p4CGROkDOD9KafG4yEUN/eEPkzZufDRLxOxz59a&#x2B;Bn36aIl5qB&#x2B;uuF9R4gzQj84v61Nu3b3EAAcfM399P/L6G&#x2B;9ZD2tq8eTPOciMA0KJFc0HQk1rkgSD37duHneHhAYDWbakh/1gv1PjD9V5thhxttWbMmMEZemTphgwZRL1792TTQQQnJk2awIZ0UDUoy4CEF5lvZOiuXbvGtegKuUUAACQAUvh8&#x2B;fLSpk2buXwBWcEffhirWy72hRryb3pbE5hAYD03b95IyUHcF4Csu5OTs9iOKUz&#x2B;ATjsK6oK/WsMwyZPnszT&#x2B;PjcZUWCUu&#x2B;PbXRxKUb58xfkFoq9evUU&#x2B;&#x2B;Q67dixnV3JQf6xPidOnKDdu/fQxo2buUMDygxwnzTWPhPLRtBFkn&#x2B;JNxW4vuKNlMsaAh1J7txJ8ivJksUxxf0F9w5k8BFMROBNuVY3bdpEc&#x2B;bM5uH//vsv30vGjfuB34fQ9lIB7kvVq1ejPn36cotR9a/yNhbVkabePci0AsBc/T&#x2B;ZIfqJKgIFb&#x2B;47s7wUJN4WZM7tRB/s&#x2B;JluzNtEHsv/o7Db/hQbH81Z&#x2B;di4cAo8fJnyN6qqGx8Zd4csTpQYGUc24kFva2NPrhP/ouylCotPIUqIiuXOBCgpCL/7gKX7dpREyuMTornmv&#x2B;asIZSzakmW66MV4M15mylQEHxbW&#x2B;OmhZim4tBOdLTjBGq8YQo55HamzHlyUKVhn5PnX7upVO/mdHfrYcpZpQRlcsoqD6rphwQnpRUzQfFiyiaCeEiJh1&#x2B;ceGDY4oEkXuBsrckOq8n46/&#x2B;tdny1y7XUFtFcxlppvYfMfnKGXyfhx/DnyXztrfBMLdOEIY/Z&#x2B;VhjzmdumNq6fv3lavFL0NqpQEI9cN0iox0S8ogzTshKoQ4bsvrx4ydy9rZSpYr09Gko&#x2B;x/oA5naTJmSXnWS/k06F69cuUwdOnQiV9crLLGHemD79u2C4OZnOTlqVCEvB&#x2B;GHCgAZb8jAkQWD8z1qXUGKAfSAV4B1y5IlGw0fPiKt7mWcVUe2HV4C5hAWFsrEGBlrlDaA7IKkt27dhtvu3bx5I7kWvREHRWBoh7IGnOcIqEyaNJGVAXCpR6YcUn8FX33VRxDk3jpzv5cBOOwj6zh69A&#x2B;0b98&#x2B;at&#x2B;&#x2B;o9H9gWAICMnYsT9QxYoVuCXh8ePHBEHfyDX6NjbPc1vYXnxAZNAyEwqHJ0&#x2B;e0tWrVzgggLaJUHJ8&#x2B;&#x2B;3/6OTJk2IfTOZ9AqCrxrRpP7GCQqnlB/r06SMvSol0CRiQogRmxoyZRu&#x2B;zO3f&#x2B;x3L8JHPSEnz/ROZevxPFf//t4PsBSmc&#x2B;&#x2B;eRTVkdB9QI0bNiAfv11nrg31tAZmP799yqaO3e&#x2B;LlgH4HpDGU1q7ouWWg8bjGOY6U8wEgiwZBCYocoAZABA4q2CrYM9vTOyC5Uf9BkFnXankMs3KdzzAVFmW8pTK2VfYedyRbl0wG/PcUHrncgO5oEXb9LeBoMpm0shiouLooZ/T6Dc1ctSfFQMJUbHJhX2c6Y1nip&#x2B;24mKfPq85jJHxeIUetufAo6dN9u1oMqYnhTu84AOfTaKas/7jjLnc6bqk/pQ8LkbdHn0UvLbfZw&#x2B;3Dr7uZeghKqAgKOjox0i1XgpBvlFtls88OKR4U5ysWaneia&#x2B;xnrGG3uoGPtu6uFkrm2ete0FjQUY9OelR/ZT/K0Y9emRXBtzWXktJNZc1l9twEAtmVdT75/WgQFryLwk/6kDZNmzZs0UpLYWBwBATKdOncoycryowkiuT5&#x2B;v2Jl&#x2B;9eq1HBBAJj9J2m2vy/jCzE6RtSO71bJlS8qRw5n9AHCMUCbQv//X1KhRQzYLhES&#x2B;d&#x2B;/enM2HI78adOnSlT9pHQCxdAqdOHGcBg8eROPGjed6esjY&#x2B;/bty8GDZs2acRYPWWtk5ZI6qdhQ0aIuyfvFll/kQbph9ocOBHXrlnnxhTENyD&#x2B;IBNZDv&#x2B;c3gg5KZh73J9TN415t6t6IdYfCAQEauInXqVOPfRqQ0cex1&#x2B;&#x2B;AARXEtm3/sswYxxUO/&#x2B;hSAI8GEJAqVZKcyeFGrrj&#x2B;K6hduxbNmTOPg0MSEukBCPQhGAZfCmOAASmMOo1dy/DEGDJkMB09epy9OWCOmZwo0b1jxMbGcelN3rx5uHvJ8OFDua3f2rXrde8iilpp9Ogx3EoU5UPo&#x2B;JHW9xIrDAGNEf0EUt8dgAzIv7FgQLoJDMgAgMRbCfvsjlSo2Xv8MXN3oepT&#x2B;1HwaXeKfhpK9nZZxI0wE8U&#x2B;gkT0FsVSBAWdusYBAGTjUY8f8/QZJb2p2ZJDrhfbNcVHx6q4qxHVXTKCrs9cR2cG/kI2DvbkVLwQRQU&#x2B;pjCf&#x2B;/TuhIFU7LMG8iCm4qGBcoFkQ0GlxRMbCcI/IPkFlX83rG03JNvGvhsOU&#x2B;MVoNXt31RtLEg&#x2B;jBCTs/sK8dePg&#x2B;j&#x2B;VaZXyJHaLL&#x2B;a7L2a8dLSDNAa4q62VZ&#x2B;WZUm8HCC7tGzZcia5IIsgqLNnz&#x2B;ZMPV48IdHGv5D0YxjGHzNmNJNgBAtQkwog&#x2B;4sacYV0tm3bhr0AMG9cJ3Da//vvv1nar8ac71UBpFY5z/bu3UOzZs2idu0&#x2B;4/7xqH2HAgGy3J9&#x2B;msrmc82afSz&#x2B;3c/E1cPjNs2cOZ2zbzDE&#x2B;/DDD9mUC2qKjh076O4dkMh7eHiy3F9pS/gyANkwHMHRYlDZpsWLF3NNP9QbWDYUFvpZfACkBeuJ44X7Wv/&#x2B;A3hbFiz4lZUNaM2H8gOQFX1vAxxXZDAxfMKESZrWtUCBgvyRkEgvyJUrJ9ffmwLKoDInl4&#x2B;ihGr9&#x2B;nXcihPGfCVKFOfr/9y5sxwAQBAUQTW8I8DnJIm421Hx4iVo1KhRfJ0imAbVDIJ2p06dpOHDh4n5jeJuKQrgrfEy3&#x2B;fMvUPpvTtZUgCQCcJvqe1f&#x2B;uVB8nKRkDCNPO&#x2B;Wo4brJtGp/tPpme89siNHsrXJRHa2mbnG/&#x2B;FxVyo/qB1lK1mQspUSJP3yDbJjl/8E8t10hEp0bWrI7VWj0sguVLzzB2wAGHrblzLlzE5FPqlHBRpW1bwduGMdD/Kl3A5Z6R3nPJK0GDxAlFaDyEIhGIAMGVoNgimjVg19BpUsuamHjDFSb81&#x2B;NhVQMHzQJZsesjmfIuVX6vwNdfymCL1aUz5T37W02zNFoo3tJ7VBBi3kX&#x2B;2LRGrmoWZ9JbQDL6wwc5s0aRJt3fovk2CY4oWGPmUyCfdp1J3C1A&#x2B;t6LDvcQ3/&#x2B;OOP/GIKCSpeaOvVe1/XCg8EEu3oKlSoSBcunKNff/2V&#x2B;7ND&#x2B;v7GvajZ27N6AbW7qK0dNGgQlwTMnDmT2rT5jE3xUD8P&#x2B;f/t23eoS5fO7OL/3Xffsvv9nDlzk&#x2B;W3NpzVNiTXAIICNWrUYOM7Y7XtpgBjRVzDyPjBlR/18whKoLbXWJASrRdhvtehQ3udqeHQoUNZrXHjxvXka8eWs/j690KUB6ClYrFiRXk6HHtkK93cXHl5UIPAhBCZRn2pMYIB&#x2B;gEBCYmMjGvX3LjtZsuWn&#x2B;iIPgCiDxUTFE&#x2B;4n0Ah9fPPU&#x2B;no0SOsnELQAMamTZo0pZUrV3BHD8xrwYLfOKiodEvBNT1v3nxWRiEokBQoyMoqLXif4NqD4uhVwlR7QP1nsrin6ZN&#x2B;Y9J/Y6qARI1BAOkBICGRkVC4RW1qvn8B3fxjM93bdZbCPO8JshUj7hBx9ODoZYoLjyT7bFkE2f&#x2B;AAi9fZiNAqAV8thyhTF/NpHID27AaIPjMdfL6ew/Z2WRSvexsxQuwJ0BqcCzIj365fop2BXhQVrtMtL1xZ/qggOwRbgpKZwHxUINPAFreJYoXTO4sEB0dDbJtq0&#x2B;utZJ5SyUEhjXoSmYfWS&#x2B;0OlSy&#x2B;yD/ycvQl&#x2B;/baK3ZT20mXk1AQC1ZV5td17ot5tr1aQl4qN0nkvynLW7evMkvsAUKJNVhw5itY8eOnPFFRr9p06ZimD9/V6SmkHavW7eOAwWQpCKLhXZzyqEBYc2duzb/HRUVzXXfqalJfdkBAHwgm0cvevgXIFjxxRdfstEggIz&#x2B;3LmzKTIygnvWo14fsn9k9BSVj7mgFdQCaqXuQUFBdPjwIV4XZOARSEG7RKgq4IFgrrUiVAsIMsBDAVl9HCdIikuVKk3Zsyep5kD&#x2B;EfDQv4ywnZ9&#x2B;2orJCPYFAkKNGzemYcOGiW2O4nplEBFA&#x2B;VfCOBAcwz6U96mMBaifYMJ369YtVgGhDSWwe/duca/4gr7//nu&#x2B;/pSyKXTvqFWrNp05c5qOHDnMJB4BQ/gEHDt2jJYvX8llNrgvODg876wBVUCjRo1TLButZ/fu3c/BQyRSXiVMPY&#x2B;NvH8lGCH9pqT/5tQBasoEZABAQiIjwKlcEao191uqNj6MHrt5sqEf2vBlKZaPTQCBsgPakPfaAxR02Z0c7LKTvW1murNiO3mt3kuZsmWj6MdPcFsSN0glKituUHCKj4t7KescFhdD31zYS397XaWE2GjBbDPTs&#x2B;gIehwTJQ&#x2B;oSiDxj4/S5xvMW7w8KU75CUrWXTxsbBXvAIX4qzWp0X9YKZ0D9LP7yZJ&#x2B;/Ux&#x2B;CoM&#x2B;LFNL5t0aGb4WXwAtbvrG9oHa8gP9/WxtwELteloyajS1XhJpcB8LC6MVK/4UhP9z&#x2B;uOP3ygw8AE7SDdrliRlR31&#x2B;dHQUFSxYiDp16sRBABBLZIz37dvPL7uWAAKLz5sGnEfI&#x2B;iOogX7c3bp14Yw7yBvc95X2e8iAf/nll2yCB5d&#x2B;mNYpQY7UAJ0QYJgHqb0&#x2B;QNh//XU&#x2B;u3cjGKAoChBsadSoETvyG1P54APjRBg6enp6MfFAAGDDhvWCyI&#x2B;g4OBgbuNoZ2fPpRsIAiiALBneBiA2aMenSJIl1AHKEQRncH7MnTuHpk79&#x2B;aUaOkpox6VLF/mcR8s8ZOBxfHC9w4gUpLtHj55mp792zZ0JPUp9oIxRAgDwBFi1ahV3I4EnBu4nUMzAcBP3x3bt2lOOHDm4Vn/69On8bgojUHQEAYoVc1G1/ggevE4YqiT1v9slyZpA6uPJfL2/ucw/kbrsf7oICsirX0JCAxxyO1GBxtX5Ywj4ADRcM5GOdPiBHl2/Iy6uLKwESIxJFC&#x2B;szyjZITDlHSMugRLU&#x2B;AJYc3GLl7JTwf4kWCoVyVmA7kc&#x2B;owTcCE0Qk1uhj2jBrbP0IDqSWhYsQV1KVKFs9pnkQU9Jnm3EAxMfPJBZHRAREQFDwTiQdGToMWqyoaBZEqhP9pOnJaVmX9&#x2B;N35Dgq5HzaxnHEiE2F0gwVwJhjau/MRWAJcKtts2fsfW2tB/U7hs1AQcJ7VCM60DoL1&#x2B;&#x2B;wq324DxdsGAB&#x2B;vrrgUw4QZAhbS1TpgxnnxYvXsQ9pseOHa&#x2B;K/L/JOHz4MG3fvo0lt&#x2B;h3j&#x2B;w3CDTKFEAIFCAAgDp6tC&#x2B;Eu7a1wL709vZm1QAcvJEpRms/Q6CMAj4JuDdhH&#x2B;tfT9On/8zZwo0bN/F3tFaEKSJUGyAVaKEHBUPZsuW4RdiSJUv4&#x2B;CKAkTdvblq27E/OICKYA8CgccuWLeKzWZCYv3XO4hKmER7&#x2B;jG7evKXrUoHjA2Ln5&#x2B;fLxpdnz56V5P8lAx0kEJg01uIuNDSUrx39TDmCmqirHzRoMAcAUNKEQBoCoGgt2q1bNx5v//59TPDh1G&#x2B;I8uXL0W&#x2B;/LWB1jXLd4vpBZh8dMFCvD/d&#x2B;dADBvXPixEk8P1zvo0aNzlDvauLeFSnezYKDgoI8vLy83E6dOuVOKbP&#x2B;8QbfjSkCyEJwgCwQ/Tc6CCDvABISaQjnCsXo40ML6NKoReS36xhFBT3V3QNylytDBZu9R55/7kkyAxQ3qfjoGIoNi3wp65LFzp7&#x2B;rteGIsTDwsHWjpodWUeRcdFGx70bHkqfHFtPnsEBYnXjafPtc7TC243Wv9&#x2B;eimR1kgfW&#x2B;EOGjQLxoE1&#x2B;AUapABQCCSAtgsgrrQb1TfkS8fAW49gohn0YbkiQDY351Mr41YybWgKt5bva4VrKENS07FO7nqmR&#x2B;avdZxLWkv8wNoqDsR2kqCAsyFLBqbpUqVIpXOT10arVJ0xOzcnQ0wsQ2FBKGtDaDx9jwAv83LnzNM8fAQOQcRjvYZ&#x2B;i9hfS32&#x2B;&#x2B;&#x2B;YaJNkg69rchQDAUk8QkIpn0jEOpxqeftuZMJFrqwWkfRMjFpTgdOLCfM9AgOvAAgFEj/BmgAvjzz&#x2B;UUFBRMFSqUp7x58/G8MI3yDo3yju&#x2B;/HyrJvyG7MBFkxv6FPwT2q0IEfXy84WvD479JBpcZEXjG79u3l1tVIruu76mBd4MBA/pTly5dqE2btrrhCP6D7Ct1&#x2B;yhHwv0O7wK9evXk9qR3796l//3vWw7UHTt2gjPueMdA6Q0UM/gOtc6pU6f5HggI8sveKJ991o4GDhzE9xMsa/369eL8WMYKnpEjR6X7fS723UPxCRLbe93V1fX2hQsX/FasWHEXhyOZ7MeRccf/BBPkXgkGEBlXASSmN8IvAwASEi8ZjgVyUv2VoynMoycFn7tO4b4PKUvhPFS0ZV2Ki4qhO0v/o5jEZ&#x2B;LicxB3l3iKeRL20talTp4i/K/702CxLNP3pt/uXCDPRw/IJrMj9ShRhe5HhdMBHzfqd3YH7WjS1aRqQCIF6bMRpMRGISbI7MNoB1I&#x2B;JdsPwq/3wmajJqNvTRbf2gBBWgxLi&#x2B;nTIhihHxgwFTCwZt7Ggg3mlBASVr6c2Gfi1m2Q9KMER4HSo90U8BL8uqWoaQW81OPzsoB6YWQXQa6Brl27cQAFMnwQ9Z9&#x2B;&#x2B;pEzhCtW/EW1atVi4gFCAsNUJUgJcqO0VoSEGWUJcA&#x2B;HdBnjQK0Ac7CPP/6YCU2DBg1pzJgxTPT1t61CBVP7oBBNnTpNXhAGQEYXMm5DwzXci9DqEWQRdd0gmbgvIXiSJ09u/tdSSZNE6oDAmo&#x2B;PD5NxQ0NNdNvYvv1fqly5cooAAAJpmTNn0h0bEHPI9VFS07fvV3wN7tmzh2bMmCmm385lOLjPIeiGen6Ux7i5XaOFCxdS06YfiuswKVhYv359OnTo8AuKj6ZNP&#x2B;DAGtajWrXq6Wr/xsbGRon94x8cHBx46dKla1evXvXbv3//PXd399Bksq//STD41zDzb&#x2B;gHkGAkEEBkuhwg3XYHkAEACYmXBKcyRfijD4f4BGq4fjzd23Oegk67UYjrLXp62&#x2B;&#x2B;lr0tcYoLJ357FxdLu&#x2B;558/6qcMz&#x2B;tqNtaDIuhGqHBtNv3Bm3xu0mdXCrKA6qZwHCrQZbnQgWgZ9SnmhhrMfRLTYBACylPTcs/S&#x2B;ugNiigZTusNUU0BUtdCyTSBshSZoQs/puMnj17cp3wlStXWHYM1&#x2B;8hQwbRxImTqUyZsvTBBx&#x2B;wjBylBwgAoLQCbuHvvvue7pyH4Z4S9ETAs3v3bnzcFi9ewt&#x2B;9vDxp8&#x2B;YtXOsvoQ76HjIgfajhrlu3niCMbfh3&#x2B;C/AfHHnzt1G738NGjSgDh06clnMrl27qEWLFhy0iYmJ5X8lXi7y589PAwYMNFpmgRamlSpVpiZNmnAmvl&#x2B;/vhzgXLBgYXKLvqSypVmzfqG2bdvSqVOn6OLFi1yvv3XrVm7Dh&#x2B;tq&#x2B;PDhPB4CAfB3QNwgKeD2PnXu3Jn0e04ZX4/8b6zpqcG1kPj06dPggIAAP19f33tHjhy5IQh/sLguHhgh9ubIv6WPIelPNEPytZQByACAhISEuCXb2VKxzxrxJy48ikIu3CRtzQHTHg&#x2B;inpHPs8e8HggAINufI1NmalqwJP0Zcp&#x2B;We7vKAEBqjnkqs/xqCKbWwICW6dIi4KB1PmrWxRgZV7OfDI0DzXk1WFvyICGRHgDiPm7cWCYO6KSAlmDffvsdHThwgJUW//67hZUYCAYAyDiCeH744Ufit63cQhGmY2XKlObf0X0AGf6SJUvyvObMmUPNm7eQ5N8CIBnHvQRKsVWr/mK5NtzX4cGwadNG7nShdDb45ZeZ3Epx9eq1JtsbIvO8a9du7qIwZcokatWqFcvRc&#x2B;fOwxlpmMFJPAdKI3AtWOqWoQX//LOKA2XNmzdPMRz7Hy06cQxg7vf06RP23YDhJuT5CMYFBgbSmTOn6PLlSzxNoUIF&#x2B;biPHTuWvLy82XEfJTQKZsyYzqU2t2/f4mutYcNG6fZYREdHRwiyHyDIvp&#x2B;7u7vfvn37PF1dXR&#x2B;LfRRBL2bx400MizcxzFy9v2EgwFgJgBrn/3QTDJABAAmJ13XxZXM0aib4qhESFUFRsTHsSVDQMZtueGmn3OJpZU/nQwLIPyKUimZ1lgfNygCAFpJviZRrJeZpuRxrggCpGVfrsi0ReFPZe0n0Jd5GrF27hoKDg9jtO6nbQBEmi0&#x2B;fPmWjv6pVq7O8GDJhAMQexoww7YM6IFu2rCzt1w8oVEjW8qMMABlMmI5JmCf/o0aNZNLv6JiZ/vjjd2rfvgP/hmz90qXL6MiRI&#x2B;ypAI8EZIb79eunM/hD9hddFL7&#x2B;uj/7NaAVHDLJ69atpb59&#x2B;3IpxuTJE1kqvnDh7&#x2B;z5ADWBRBIgyR869DuxX2dTkSJFdcMFAaUCBQpYNBJF/T2y8K1bJ6kzVq/&#x2B;h6pXr8HdSYxl3hEAwDxRYoNj0rZtO/rrrxVcstG4cRNxHPvxtQcTUzj5I6PfrVt3NnCEJ4ch0L1k584GrAoYM&#x2B;YH6t37i1fehs9aiH0QFSbg6enp4&#x2B;XldV&#x2B;c496Q8t&#x2B;6dSvcBGGPN/hbbSDAXOY/3kwgwJz5n9q/39jAgAwASEi85YiIj&#x2B;M7IBQA2e2fywPzIxhgZ08hUeHk&#x2B;eyJDACkIgBgTAWglWhqcau3tpbfGqJrrWt&#x2B;atz2rSkfsEbar2WbJSTSE2D2J168uS84CD3cwlesWM4ZfmQoN2/eRLlz52UCgnGQlVy4cAH9&#x2B;utCHck3B0yHj4R5&#x2B;Pv70/LlfzLZbNLkAy590b&#x2B;/REZGsEqjevVqnKlOcnpfSN7ePtwV4e5dH1Za1KlTRxy/FXT9ujuTT5gr4m94aKAufNGixawqQLCnUqV35I7XXQdHmez7&#x2B;fmzFP/o0WOcRZ84cYIg5quMToN2ldiXOE7wYli&#x2B;fDmbX0LS/&#x2B;OPU2j06DGkZw7MQIa/YsVKHCRDlwyoDeCJMXLkcD4eaH3Zq1dvHgZvDHhn6MMY&#x2B;QfQom/x4qX033872G8I6/CGAlL&#x2B;J2LfhYj7jeedO3cCd&#x2B;7ceffChQuPxXkdS6br8c0FAKxRBBgGBswRfzIRDCAyXiLwRhN&#x2B;GQCQkHgLYWuGsDiKBw9&#x2B;jxf3K/2xsorhPCAhgQIinxmd9k&#x2B;vq7Te25WaFCxN35avyeOVzJaTMqWhlO5tCBCYI7HWSPGtIf9qAwmW5peaQIEaEq6l5aDafax2myTxl0jvgKwcsuPY2Bg2i2vUqKEgkb7Uu3dPJvqfffYZZydRqwzpP0jRuXNnacyY0VS//vuqyL9EEmJiounZs3DKnTu3yXGcnZ3YdLFhw4Zc3w1iqBBHqC0g/YbSAll9yL4PHDjCLRGhBEDWt2rVauTiUoxN3&#x2B;D8/vjxI&#x2B;4W8cMPY7kWHe3ioOjAMgAEGt5mRESEk6Pjc7k/zm8YX8K3YvToUWxkOXjwEDbI0zcfVfDzz9NoyZLFtH37DqpSpSrVrl2bpk2byjJ&#x2B;dNLAMShatCjduHFdV7YBFQbKahRn/rx583IgAMdp9OgfaNu2rVzOAcUAvBu0wtvbi70eUHLwprQ&#x2B;jYqKihDb/djHx&#x2B;eeIPnegvQ/3LFjh/&#x2B;DBw&#x2B;i6UU3fnPkP5FezOIb&#x2B;24sCJBggfjrT2&#x2B;sK0CCEbKfLsi9DABISLzlCI6OpMCocIoXJN4mmd4bOvrndnCkzDa2hAKrmIQEvaABHpBi3MQECo013j7wkZj/fh93Ovv4Ia33dSeP0BCq4JSbZtdsQU3yu8gDQOoUANa0&#x2B;TMc3xrpvVrZv9b5aTEiNLcOatZDbYDFWIBBSwBDQiIj4PTp07R&#x2B;/Tr69dcFtG/ffiankJGj/twUUYVB4JIlS/Va80kgSIKMa44czpQrl/H9hkw9sstz585PMRzqCpRfIFOMjDzIPfZ9dHQMP3OVAAB8FlCagZ7trq6uTD7xL0zhunbtSk5OTvTgwX2eduzYcdS9e3dyds4h1ikn2dk9D8KjTeTbCkj07927RzVq1OBjMW7cD6xiUfYJzmnsTwRT0JYyT5683F0BGXlD7Nz5H506dZKDKpDsR0VFM&#x2B;kuUaIEzZ79CxN/mP5Wq1aDzp07z8vk97DgYDp06BA7&#x2B;uP44bi5uLjQyJEjuFSjc&#x2B;cuVLVqVau3Ecac69dveJ27OTFIIDm773327Fm/S5cuBR05ciSEUmbOjbXfMyTjiXqE3Jxc35jJn6lhlkoBEo38ba7u39zfMgAgISHx&#x2B;uH2JIhaHfqHijvlorhEcf8TpD4sLibFOPkcs1LeLE7kGx1BT2KjdMOjFSmZjWmbQpesTkSO2Sg0JopcI8OIbO3oUpAvdTu1jZbWbkn7H3iRd9hjalmoNPUsXY2y2WV6K8m/JfJuibyaIvyGhnZaCb&#x2B;p5ZtbZ2sl/aaWadhST816mJu/qZZ8apcjAwISGRkgGqVLl&#x2B;ZaZIXwWyKIkCyXLl1G7rxkoFwCvdzDwkLpxx&#x2B;ncqs1YwBRxL4zJP/o5Q5AZr5t2w5WAcALABljZJ2VLC5awcH9/X//&#x2B;465xfz5c&#x2B;mddypzp4WvvurL3gAzZ05nCTkCAG87njx5zOR927Z/BQmvJoh5Sfrvv//o6tXLgowv4G4W27ZtE8R7NJN97Gt3d3eaNu1nVrlAHdGxY0cO6iToJUPwN47PiRPHuaylQYNGrMr48ssv&#x2B;dgh6LJmzRrO4P/22x&#x2B;UL19eateuHQcGANT0BwTco8aNG3HpwJo167hOH8vF8tA6MzXPG1tbu1e6n5Hd9/f3D7h//37QyZMnPS5cuBAo/g0S10UMvWikZ5hNN5f9N0b&#x2B;E00Qf3NqAEvqAMNggqH8n4x8t&#x2B;QBQOktCCADABISGRiO4iUvKj6WbgX7E9k5wIGGhpzfQyeC/OjX9z4mOxtbyu2QharnKkC&#x2B;jwLoYVSEbtrHMZGc/Yc5YC4HR6Pzz4QHjyBWdrY2NLv2J1Q7TyEadHEfXRHz//ToBvGkCOd5bPd2o72Bd2lN/baUxe7tu&#x2B;1odce3lBXXJ7RaOwRYGqaFsKsl6loDDZaCEFr2tTVkXioDJDIqQPbf5oxwmrw426NeuxeTe6XmGgTxyJHD3LYN0nuY8iG77Op6laXh&#x2B;Bey8&#x2B;3btwlSuovnMX78WFZkoNxi4sSJbO6HEguQU6BHj56svnj//YZctoGSAJBK3JOQVYb7&#x2B;61bN2nevF/f&#x2B;mMC6T7aVI4YMZLLJpYvX8HDUdJSt26d5HM/F7ezdHW9Ql980Yu&#x2B;&#x2B;eZ/1KpVS9q3bx/9/fcqVsYMHDhY7F/bFB0Bzp07x4aMhQsXpQkTxonl/E4//TSV3fgzZ3YQf09jk76nT0PJ39&#x2B;XO2DA0E8BJP9oi3nt2jXuoIEAnHItNm364Ru9X8X5Hffo0aMQb29vPx8fn8A9e/Z4uLm5PRak/ym9mB1PMEKejSkAjAUDzGXjLX30gwamAgLxZFzyH29m/Sxl/9N1EEAGACQkMjBq5i5Ep1r0oYMPfOhQoDddeBRIj0JDaKPvDZrzbjOyS&#x2B;Y2rYuWFST9Krk&#x2B;DqTI&#x2B;Dgm6V5oDShebuwzZ6Hi2XIYJ0pcIpDIPgJoFVg4S3b6pHAZuhLoS/Z2RG3LvkuONna0xu8G/Svmv1WM0614JZ42NiGBDj/0oQeR4fSOcx6qlrsg2dtkPO8Ac1nntMigvwyir0WpYKkUQD9QYS4Lr3ae&#x2B;vNVQ/JTY7QoISGR8YH6bRB4SO3VAIQOTv0dO3bgtoe1atWkL7/8ggQpYvM3kEX0gZ87dw57LcB1H07/aPMGX4U9e3ZzIMDX9y61afMpZ/xR/9&#x2B;v39ccOFCAwAB8GZS/8dFfh40bN3FNe/78luv6IXGH8SO6NthmQI&#x2B;ef//dJoj8XnFcOvL2KQ78S5cu4cDAvn0HxD7Lw/tryZIlbJQ4b94c6tSpI7dNvH79GgduIPNv3749y/mhkgEQ2GnUqDF98803VK1aVUH4f2TyvnbtOt3yMf4ff/zB7fveeefFtpfwz8DnTUaCgDhPIu4JeHh4&#x2B;Lm6ut7fvXu3z40bN8KCg4NjLRB7UhEEsFQCoLUkQG1wwFSwIMHMemmR/qcb0i8DABISbwlgxlcvb1H&#x2B;jKvcgHzDn9KhQB/yEf/q86fOLpXolzzF6HaIPy28fYHaFC1HO&#x2B;/d4ex/KafcVF4QdHPArMLjYvlvOwQF4mOpWn4X2tQgqZ3Rld1B5B54l9yePCQqXonJ/9fndtJKj8vidpuUQXmvQHEa904DDiDEi3sw5pfHIUuGCwKoJdRq/1U7jprftQYQ1BBmY&#x2B;Tf2iCHsX1pKqiQmmXJQICERMYEiDA8D0DU582bR0OGDKERI4ZTt27dTAYAIAE3JM3z58&#x2B;nw4cPUYcOHejSpUtMHKdNm87GcKdPn2J3fxi/OThkYpKJjgvIJGM&#x2B;KL3o2rUbE0KUE5QqhfaKYS/0jLcEyMgNW75BkaAQ15RBDi9BhBey2RwUCRkNxYoVFeS8OpUvX56fCQjC3L59i65dcxPbXJ7l&#x2B;3Xq1KV8&#x2B;QpwVwT4LaA9IrL9IPSoxYeUf&#x2B;TIkXxuoL2eArRX3L59O7fBvHDhPC8DHRsMgbaLAwcOTDf7LDIyMiI0NPTprVu3vMUHbfj89u/fHxgQEBBlgsyTiiCA2t/V&#x2B;gFYKg3QEhgwNb4x4m9OBWDuVVgGACQkJN48uGTLQV&#x2B;UqvbCcCd7B/q9VnP65NBqGnluF02&#x2B;dpzCUQIg7mc9S1SmHJnUO8smJN8D7eFmnDwsZ/L04fFJQYKrTwJppecV9iTIliUr5XfMShcDfahdSADVylWQ4sQDvGCW7LS9Sed0rwqwRP5Nyf2tdey3RMStIfrmtkvt9NYqFKwpU7C0vpagpSWghITEmwcQYcjk4YAP0gtER0dzpr5Pnz5sDjdnzixq0OB9MV4QE0YFqL1Xsu0w4vvxx5/ot99&#x2B;Y9d2ANn72NhoatbsYzYCrFmzlpjn1zR9&#x2B;s/cxg&#x2B;mfgsX/sok0dPTi13nUet///4DypLFkSpVqsTt3tIay5YtFSS1FGe0DbF161beFwhOKB0BjAUK0itQNoGsfvbs2Xi7smXLTvfuBbBCA4Qebf7Q8g&#x2B;Ze6gxDh8&#x2B;zJ0S4MaP8gqQ&#x2B;&#x2B;bNW1Dr1m14&#x2B;lKlSuvm/fHHzenAgf18/vTp05dVGpinIYx1DXhTkJCQEP/o0aPH4poIvnTpkocg/EF79uzxhZQ/IcnwIDGVxF5LCYAp4m&#x2B;K/KspFTAXDDD0EUiwsBw1Zn&#x2B;mzP/STUmADABISEgwPixQgnZ80I3GXz1MFx/dJ0dbe&#x2B;paujoNr1DHqvkliv8SkmUGCQZy7WB4A8THiTtQJpr/bjNqW7Qszbt5jqZeO0bnHwVwYIBC7tHxh370QYH07zxtqlbfGvM7re77WrPb1i5PC2m3ROa1zEfrfLW2DJSQkEh/mDbtJzaA&#x2B;&#x2B;ijZjR16jRuxdazZw/O5jds2Ih2797F9fRFihTVycWBTZs20MCBg1gd0K5de1q/fj0bvYHQKwEAtE/08vLi&#x2B;u9Fi/7gD8ghZOIgoGi1WKlSZVYXKMQQy0DNeFoAy9&#x2B;/fx81btyYPv&#x2B;8Mw9D8GHVqlUcaDAGBCvgKQAFwrhxYwUJHsU18RkFKKNITEzgLD5M8aDIuHPnDsv/EZSJjo4SxyWeDfpKlChOM2bMZBUGACNHpWWfAn3FR5cuXbhNY2BgID16FMKqjjcdz549CwsJCXnk7e3tf/bsWe9r164Fbdu27V5YWJg&#x2B;EVZD7NMi&#x2B;29NEECtMkBLUMBwmKW6/wQTBN&#x2B;YGkCWAEhISKRfNCtYkt7PV4yuPXnIdf1VcuSnl8GH8jpmIxtB/nHHLO&#x2B;cm/JmzsolCv/4uNHd0BAaVvl9aiKI/zs582Uo8q9Vtq9Wqm9pekvz0NoJILXEWyv5tyZwonUdjPkKSEhIpE&#x2B;8/34Dzv6CtOG6/vnnqZz9XbbsTyaEyBjD9b1o0SL8O0g6ggMHDhyk7t170JYtW8jJyZn7vIMcrl79j64UoHz5cuzq/vPPM2jNmn9YRo7MMboBpEVWHeoFrJN&#x2B;YEIB1gGlB8hcQ0WA71OmTKaTJ0&#x2B;Kdd5KZcsa79ZQo0Z13obChYtwNnvo0GHp/hijnAOt/WCciGOakJDI&#x2B;6VChYrUs2cvQfbzcDDnnXfeYcVH5cqVucwDQR/9&#x2B;78h&#x2B;TcGlI18//137OiPThpZs2Z7Y/YDsvti&#x2B;wLFJ/jq1aveJ06c8Lty5UrIuXPnnqQBWVdD/NMqCKDWGyAtggTmTAnNZfspvRN/GQCQkJAwiqyC&#x2B;NfOU1jdiwoIU0KC5jtgtZz56aNCpWi/jzvNvXWeyjrlZl&#x2B;AOCjREuIpOCaSPi2ccdtOqa3RtyYwYI7spna&#x2B;ahUGasm8VgWEWpJuKdiBeRjK/KXsX0LizUZkZCTLtQsWLGRxXLirox0cZPEw7ANBRuYfRBEAUYTxH7LFmTI5MOlG1jgmJpqzvQ8fPhBEsQgNH/49jwP3eCUAMGrUGBoxYhT/rfR6TyuEhoZxNn/o0KFs9GcILHP&#x2B;/F9Zwg5JO8gtzOx69fpCkPuk5zZKGED2v/vue86CHz9&#x2B;jCXtGzZsYDUE5OsZ4V6Htn44bggA5MiRk5ycnHj4tGnTqEWL5lz6gWBAWgDnwrJly8jFpQQrP14jEp89exbuJxAQEBB07NgxT0H0H5w&#x2B;ffrR06dP49KY2GvJ/qeFaiC16gBr/1UTuDAXDEhMj8EAGQCQkJCwGjkzO1JW8YmMi6H4xATVd0C0D1xc&#x2B;xNqGR5KW7xd6XSwP2W2s6N7kc9A0cghg7gUG8v&#x2B;p1ZGr0Wir5VcayH8auX51gYYrA2eGCPzWtoYSkhIvD6gTh01&#x2B;aVLpwwAo886yDzM3las&#x2B;Muik/2VK1do0qSJnOVHfX/nzl3Y4K127Trs8h4SEiLIc2WWjsPUrW/fPpwdR2AAy1q48DduwTd16s/sLo8ggX5231onfSWIcP78eW4HB0NAfbi7XxNEfR2NHj2av6OMwcXFhbPOCkDwx479gd577z2eH8wEN27cQP7&#x2B;frRu3QbOdi9cuECsfw1au3YNXb58iYMJrq6u1KZNa/rf/74zGlxIb8A&#x2B;xP67d&#x2B;&#x2B;e2E87BOlvkfRekjOn2M62afuu85raZ8YIiHM1yMPDw9fT0xNt&#x2B;LzEcXx848aNZ/Typfpqx03UMD9z5D8tAgJqAwXWkn9jxD9dQgYAJCQkrEbT/MXpeutBdEoQ&#x2B;LyZkxz7WRUQE0WRyYZ/Rh9qCfE0w/0UhURHsA9AcFQExWJ8MdzFOTcNKPNuhtpPxshzamrrzf2rnyFPC7d/az0DtJYo6JNzZbiyLdYqBLT6AUhISLweoFb7009b02&#x2B;/LWSZ9ejRY1L8jtrtwYOHcCYeBBqkb9asX7jG//3336eoqChydMzMde337wewqzuk/HDih3y7YsVKgkRXYRn37NmzQKwE0d7I8/7mm2/p8eMnYvmfcJ92yPsRHFizZjXNmTNbzO&#x2B;&#x2B;INibU32/cHNzo127djI5HT58qCDn6198Kbe3Y0m6nZ0tk/sff5zMgYjFi5fy76GhoexHgP2B/eDiUpy2bt3GgQK0HYQsHqqAatWq0QcffEDNmn3EJQoIcowfP5HOnj1Dffv2yxDnDAI7MPSbPHkSb/P48RPS9fbECYSHhz/z9fX1v3XrFrfhE8f17u3bt8Xg8Lg0IuupkfVrDQhonVareaCWcgIyEyxQ0/LPFOlPl9l/GQCQkJBIFWzFC1HxbDn4o&#x2B;DLklUoiyBhgbFRbP6HlyZ2/4&#x2B;PY2NAAC3&#x2B;Nt29RiFR4ZRLTLuyTmtyyeZEDyPDqYJzHu5WkBHJv7Wyey3BAktBBjVk3FribE03AUvL1KpgMLduloIDEhISrxZhYWHk4XFHEOJhLM/39vZ&#x2B;ISsOwMQOWW1I37t3707Lli1hh35kuNG/HW3dVq36m&#x2B;rUqUPHjx&#x2B;nffv2cbs7ZMVr1XqP4uMTaPv2HZzN37Ztm1jecHZ&#x2B;B8qUKcMGegry5ElqewuiDpKNkoMGDRqkelsR3EA7OkjWo6KiU7jGIyCBevYkw8AkpQGW3a/f1zRt2lS6e/cuu/cj0w0FQNGixejcubM0dOh3dP36dbpx4wYTe2Sp/fz8uPMA9leHDh1Z8q/UuderVy/DnDtffPElCWLMaobevb9gX4d0du6HPX369Ik4dl7ic1&#x2B;ct/5ow2cg5beWrKdVRt/YMtT&#x2B;/apUAmqHaV0fQ6Jvye3fGN7YwIAMAEhISKQpyjnlpgnVmui&#x2B;IwjQtkg58aB&#x2B;SraURLpyOThShxKVaYn7SXocGUbjruynDwuWpo4uFTMU&#x2B;TdFYtWQeS0mgZZItzXkX8tyUrMeqQ0c6J6yZmT/aoMEEhISrwZoR4eMNYj7&#x2B;PHjqVChgizBB1E1dn2C7M&#x2B;bN5dl&#x2B;CDj/fsP4HZscLO/fPkyTZgwkd59N0k5BmKfNWsWQX7b831h9&#x2B;699Pnnn7MJHD5qDfBAnLt16252HBBQeAd07NjJaFkA1Acoa8uZM4cg7UW5Fh8mdLa2KQOSmzZt5M&#x2B;kSVO4nd3Nmzd5P0DFgPk/ePCAAwAokVi8eDFNnDiJcuXKTZs3b&#x2B;ZsP9QRvXr1Ft83sWoBPgYYlpGB/fnzz9PTxbrGxcXFhoSEBAcGBgZfuHDBQxD&#x2B;h7t3777n7u4eRq9Oqp/Wsn5z2fPUBALSyrtAbTDDHPlPNEP&#x2B;0232XwYAJCQkXjqgEphSpRENr1CXnsZG8bDAyHAaUaEO1cldiP7ydqUzQf7kFniY5rmfoE6lqtHyuq0pu71DhtkHWmvz1RBWa439tLbas7bFYGoCEub2oZoAgazxl5B4swHH9iZNPqA6deqywRpM3CBTh/Rd3&#x2B;cT7fXQwu3ixYssw58/fy4tWPArG74hm46MN&#x2B;TvxYuX0E1Tq1ZtOnbshI6Qd&#x2B;vWI1XraqoUCYDZHoITSju&#x2B;lNuYQAMHDqBWrT6hnj17ckAhX7587N5vaGaK7PW1a&#x2B;4kOCIVKlSYs/pw98&#x2B;ePTt7BYDkA2hdh0BHzZo1WT0RGRklxi&#x2B;kCzZs2LCeIiIi6euvB8iT7DUCmf2goKBgT09P/5MnT3q5ubkF79y580FsbKzabPTrMOoz97c1BFptaUBqlQbWlCoYWwdryH&#x2B;6hQwASEhIvBI4Z3LgD/DbnfO0zP0k9apYj4581ItuhYbQRt8bNOvmGdp45xLlc8xOv9VsnqG2XwuBtkbmrpXYawkUaDHn0zLMmvmmtlRBBgMkJF4f4Nru4&#x2B;PDdfuQ&#x2B;sfFxTKZBx&#x2B;GK38mfkY8f7feu3cPVa1ajcnu5593EtPHib9DOfvdokVLmjRpstGSAdtUGsnevn2bXeQhrRfEjUsGjAHrlSn5uQZSf&#x2B;PGdTFdeW7hh3sNMvdo24cAAAwHsf5QMRgqw9q2bSu2dR&#x2B;FhDzimv8qVapwsKBMmbI0bNhwXfcCBDwQNEn6Oxfp&#x2B;9LhtzVr1qEHPAcZJF4NBKmPDQwMvA9X/itXrvgcPXrU9&#x2B;rVq4/1svvpxahPa02/teTf2sBAatc1wQSxN/adyHz7P1IRCHijgwQyACAhIfHKkTOTI92PCKNlnldo7Dvvc93/&#x2B;MoNKKdDZvr2zH/0z113GlOpHhXN6pyhiL&#x2B;1BDutpPNpHViwNK45Wb4aFYGp&#x2B;aemi4CEhIT1QFu5rVu30K1btzlDDTm7GgiCRBER4STIEUv20cpu5MgR9NVXSe77Li7FxL&#x2B;F2NgNigAAAYH9&#x2B;/fRxx&#x2B;3oB49erDR361bt6h///6cVUdG/WUAPgOLFy&#x2B;idevW0&#x2B;&#x2B;//05btmyi3r17MyFXAJKN7DxKFiDnB2Au&#x2B;MMPY8S0S1gRgKz&#x2B;4MGD6aeffqLg4GC6f/8BNWrUiIMT&#x2B;fMXYLNDBSglePgwkCpWrMgBAPgSHD16PIVPgBoguGCM/KOFIrYLTvm2GaTLzutAQkJCPGr379696yvw8MiRI15nzpwJvHDhwpPo6Oh4yjhGfWpIvBZCrWZcrb&#x2B;ZmqeWbSAN5D9DSP9lAMD8QZWQkHiJaFesPE3NkZdCwp9Sn7M7aWjFulTJOS&#x2B;FxkSDxVFYXDT5RIRmiACAQkzNEWFriLEabwE1QQJlPlrc803NV9/FX5/8p6ZTgKnAgpqAgAwOSEikLW7fvkWenh7UoAEy&#x2B;ElmeWgv5&#x2B;bmyvXqq1f/TYsWLaIlS5Yxmb12zY1KlixFf/zxO1WpUpUCAgL4g6w4poNR3bRpP9Hw4SMEYc7Oxn1w&#x2B;k8mW2zoN2TIIA4OXLp0iX/v0qVrmm3P06dPBGm2Z0J/9eoVevz4MZN1fAfy58/Hy1R6zAMXLpzngMSMGTNYfYCgBboSwMQP3Qv27NnDwQ6UOTx&#x2B;/Ii7ElSvXoVq1HiPxo4dS/7&#x2B;/tSqVStWCaCm/&#x2B;TJk7x/YP4HN3sFWsm//v1x9&#x2B;7d1LhxY50xnpeXF/3&#x2B;&#x2B;0IqW7aM&#x2B;JSTJ7JKREVFRTx8&#x2B;DDo1q1bPnfu3AnctWuXt5ub2xNxrKPo5Rv1aQ0YpJVRnzkSbek3a74nWDFtWizXlOSfMjr5f1sDAJLkS0i8ZpTMnov&#x2B;rNuGvjr1L228c4E2&#x2B;t2kIlmc6GGUeOkSL2MwC3TKIB4Aal38ra3b10L4taxHamr&#x2B;tax7apahZpgk/hIS1gMkHS77BQsW5O&#x2B;ffPIpt9QLCnpIWbIktX5dsWI595pv3LgJbd26lYnvunVraOLEydzP/quvvuL2d6jjDw9/Ru7u7oLYHxMkuiedP3&#x2B;OGjZsRJ06fc7zgpM9AgEKAUapwMqVf7FCAON8//2wNN2&#x2B;cePGUaVKlfjvjRs38Pahph6ZdAAqA7TaUyT4CEqgZSGCFJky2YvtiafMmR2Z1MfGxtKjRyEcRIBr/y&#x2B;/zKb27T&#x2B;jyZN/pCNHDtOECRN4m0qUKMEmhgCCDTDt8/PzpQ0bNqXJNqHd4A8/jKaTJ0/rhsFgEC0Cz507zwEZ3BeVbZRIQkxMTHRYWFioj4&#x2B;PvzhHIeN/sGPHDj9PT8&#x2B;IBBz41NfgW5P9VzvdyzDqS0vC/jK&#x2B;p2YepOJfU3&#x2B;r4ZFvPNfMaAGAREn6JSTSBz4rWo5KN/&#x2B;SfnI/QXv9PeheWDDoGv/WvVQ1quScJ0OQfzUkVyu5VxMk0BoQULt&#x2B;WoIO5lQFaUHMtQRGJCQktAG19n379qERI0boCPrDhw/F3x3Jx8dbkNpjXKtesWIFzpgj29&#x2B;oUWPOii9YsICl/lAG9OnzFUvf/fz8WSXw7bf/S3oGfNaOCbW&#x2B;JB2yev3rd9asOTRo0BBBwl1SZOFNATX427dvZ/NA9IW3dA9AwAFu8hgPTv5Y9y1bNuteG1G3D2Kve5kU9zRk7hG0AMHOkyc3BxDwwbZCDYAM&#x2B;xdffMUmh7Vr1&#x2B;E2dQMGDDB6X4LB37Zt2yk0NFRn5jdp0gSe/4cffqQbD&#x2B;UQgp9S1qzZVBy3MG4rqE/wsa/RKg8YPXokjRs3nj0E3mY8efLkMT5ubm6e4nP/5MmTAfv373/4moz61E5n7m&#x2B;tNfPWkP/XTeBTMw5R6rL&#x2B;GYb8Z8QAgNoDIAMCEhJvAKrkyEfr67cj72dP6NKTQLofGUZFHZ3okyJlKVMGqVPUVwBoLQPQQrbVEnlrM/xqghKmav6taV2odhvVBAYkJCS0A73k582br3OgB3bs2M517cjir1mzmtq1a0/nzp1jsgon/q&#x2B;/7sekPjExgUn7ihUr2QivTZu2TEgV1YACS/XoGF9fFg/ASNBU9vrQoUNcKlC/fn0mwSDw&#x2B;nj06BGFhIQIkl6Wv4Oc&#x2B;/v7iW2sTsOGDeXMPBQPINzwHIBEv27durrpf/ttAW3atIm2bNlCY8aM4eWghADz/Oabb8U&#x2B;WUM5cjjrggJqAJm&#x2B;vlT/4sVL3AkA&#x2B;xTKAZj&#x2B;zZw5g9ejefMWuum2bdtGTk7ZqGnT54GChIR43maskxKAxbaUK1dWrNtaKlasqJjnERo1asxbdS6LcyEKUn5xLgadOXPmjiD8Qfv27Qvw8fGJJGnUl5bkn1I5TlpMRyqJv7HhqSX/6QbpPQCAg2Gj8sCpDQbI4ICExCtGyew5&#x2B;ZMRoVXiby1510q404J4a1mOluFpUQYgISGROkCuDoILoD4e3yEjh2wfpB6S/t9&#x2B;W8jjIMOM63Du3HncFq9AgQKCtM5KM8M5mA&#x2B;CtGN5DRo0YMJuDF9/3Z969epN48aNZeNBBCEUIMvesWN7Hn7gwCHOuE&#x2B;cOEEQ7Q8FMXahffv2CpJdj9zcrtLNmzeoZs13uf5/9eq1unlUr16DRo4cRe3ataPy5SvohmObx48fx6aAMDi0Fvfv34cNDlWuXJnLKvr160eLFi1mX4E6deroxvvrr5U0ZMhgHm/HjmqUN28&#x2B;9lU4c&#x2B;a0WLcOrFJA8ATdDOAxULy4C23YsI6mTp3Gmf&#x2B;MLv9/9OhRiDhHAz08PO4dPXoUbfhC9u/fH5SGZP1VyvqNkXq18v20qK&#x2B;3JiDwqoeRhuFqiL&#x2B;15D/dcMi3wQPAXFlAhjN1kJCQSB8BAbW/qXXoT62Tf1rI/tUGQAy/GyoHrAlGSEhIpPHLU2ICZ5lBto8dO0YtW7bimvwNGzZwdr158&#x2B;bUvn17KlKkGGfl//nnb1q6dAlnzTdt2pxm5P/kyRM0duwP9Mcfi7j&#x2B;vnbt2maDFrNm/SII824uAQDpR4092gX&#x2B;999/1KBBQ/YjWLToD2rb9jM6deoElzXAxwDb1L17Vw5mzJgxi5Yv/5N9DPRLD1DigI8hMM1779XkEgAEP6wFVAPocIDSgdOnT7NnAkoQnJ2ddPc7SPwFmaVDhw5TiRIlORiDAMDZs2fFsdlIbdp8RlmzZqFr167RvHlzOXiDFoFoadi69adsuGisdWJ6RXR0dFSAgJ&#x2B;fX&#x2B;ClS5d8Dh8&#x2B;7Ofq6vrYx8cnPRv1paaOPzXk31pyr8Vdn14DuU&#x2B;0wPVSS/zTHYfMiAEANYSfNBx8CQkJiVQRflOE21wZgCnybGqYNZl5rYaBWgm5VhPD1Mj8ZTBAQiJtAfIM6fnYseO5vj06Ooaz/Q0bNqSDBw9wJhzEGeUAs2fP5dZ38fEJVKFCec6UpwYg5d7e3pz1vnrVlcmsIHhsymdrm5S9PnHiBLfgq1//fd1069atpStXLnObvTx58oj1PEgHDuynbt26cYYf8wNZRpAgKQjQlpUMIO8LF/5Oly5d5Pp7tCLs2LGjpnUuVqxYqvc5OgYMHjyItwMmiQgEIOgye/YvOkk/CD9aBiIQgIAIOhnMmTOPevbsxa3&#x2B;QP7z5Mkrtqk6HysYGCKIM2PGTDpz5gx98cUX6facjBUQ2/3Uw8PjriD4gWJ7vU6fPh109erV0FSS9TfBqM9wnqkx6rNW2m/tOFpIvFZZvrXEXk2SNy2If7rkjW9LF4DEl3TAJSQkJFQFAawh8Fqk/mpIslYCr4acK/&#x2B;aMvzT6mcgyb2ExJsBZ&#x2B;cctH79RpbK7927m80As2fPynL5yZMnM8kH6SxatBhnvXGdwh/AFEBYUeuuRhlw&#x2B;vQp6ty5E/3001R24a9ZsxZ/0GHA0TEzm/3hd8zv6NFjXDOP&#x2B;vndu3dRkyZNaMmSpYLwTmdPAA&#x2B;PO4IIN2BSv23bVvruu6FM/LG&#x2B;AwYMpMjISCbJ&#x2B;F6unPUt8pCpt7Z1H1orOjhkpoIFC7FaAd0XBg7sz7X6UCBgnyUZ0RMVL16cjQbhEZA3b25au3YdD8f2lShRXBwjJ/r55&#x2B;nUsmVLDmLkypWHWwwC7777Xvp5cRd4JvBQ4Pr16163b99&#x2B;&#x2B;N9//3lfu3YtNDg4OJbS1qjP2iCAVtO&#x2B;9GDUR2RdyzytRntqMvlafrM0zcvigemSO2aUAEAiqa/3V3PSyECAhITEayH/lkh0WnkDqCX6WgMLaR20kMEBCYnXd&#x2B;9SstrDh48U5Lg8f0eGXJGQg5SrAcg/MtvIQoeEBNOpU6d4HnDeNwSy/6hfh4v&#x2B;0qVLKTw8gsaOHcsydtSug2gfPnyESwLmz5/HNe6YD9rvwcE/MPAh1atXj30ARo8eI9Z9OBsDogNBREQ4lSlTNkUNvKExoTVATT6Ievv2HVRP4&#x2B;HhIdalDPn4&#x2B;IhtbcztAffvP8ilC&#x2B;fOneVM/q1bN9lgMEeOHOwvACDIgBr/Hj2604QJE9kbAV0PsC/8/e/xfsqXL98L5olvOqKioiKeCnh5eUHCf1ccs0BB&#x2B;O8FBAREUfpvvZeejPqItDnoa83ipyXhVzuOJaJvLe9Lt3wxvQYArGn3l2gmIJAoAwASEhKvKhCghcymllhbK&#x2B;lPzd&#x2B;Gy9VXB6SGzEvyLyHxegAzvSFDvjE7DvrPR0ZGsGzdEBcunOde96tWrSRfXz82u&#x2B;vSpUuKcdBKEMNHjhxBy5b9SXv27KONGzewUR/M7FCjnyWLI658QfLvc/2&#x2B;r6&#x2B;vIL9RPD0M8dasWUeVKr3D2XC0vQN59vT0pK&#x2B;&#x2B;6sPu/mmFKVMmswcCHPqRmV&#x2B;xYgX16tWLf0PtflIngBcJ&#x2B;H//7WC1BAj9lClT6J9/VrOB4KRJU3hbz58/T4ULF2JDQQQHlHZ&#x2B;qPWvXLkKzwPqgMKFC&#x2B;vMBrFvevfuyaUP69ZtsFqF8Krf44MFxPF5JLbH8/Lly2jDd//YsWMhJI36XnYbPnMBAEvDKJXD1fymlfC/atKfrol/eg4AKM7/pjoAWJpWS3RLQkJCIs3If1p2AlBD&#x2B;lND4C0FG0xJ/i0FA7ROI8m/hMSbA2Tf0VbOWNZ81KiR1KFDR6MBANTzgzDDZX/w4CHsJ5ArVy6&#x2B;j4SGPtXVs8OYD5J9DL958ybt3buHnf1Rpw&#x2B;pPrLkkOnXrVtfEN6r9M47lcV8ktQIaH/XunUb3TKrVKlCgwYN5BIGU0FIa/DgwX26ft2dOyIgAAB5PkoIFOI9YsQwzuovWbKMWrVqlWLaZcuWMmHH/Qt1&#x2B;seOHaXdu3dziz&#x2B;08EOQ4tix47y9QUFBNHXqz5zRHzJkCLcsBJDthzJg1aq/6N69e6wWgLnh2LHj6NNPW7&#x2B;R5w2y&#x2B;/fv338QEBDw8MSJEx7Xrl0LOnDgwAOBGEp7qb406tMeACBKmxp9otRJ9tOS8Kc16c8QxP9NDwBYQ&#x2B;5NkX01tR8vnIDi5iwDARISEqkm/taSf0vBAC2eAdYEKLQSdjXL13f71/9bkn8JiTcXIKIg/vnz56PRo0dx3X/16i&#x2B;24YP7P1zwFcC4L2/ePFzXjgw86vqRpY&#x2B;MjOIs/4oVK9mZH&#x2B;Z&#x2B;kM&#x2B;D&#x2B;DZu3ITHB5mHwSA6Duzdu5cWLFjIWXNk9UGUoTQoXbo0O9&#x2B;bagmIIMXSpcvSPCN&#x2B;7tx5sb7OVKFCRbp79y53S4A8H5n64OBgsT7VmKQjK3/w4GGqWrWqblqUKkycOF7sx7G0fPkyatOmNXdSWLNmNTVr9jGVL1&#x2B;e1/v48ZOsAFDWHT4ICsqVKyuW60v9&#x2B;vXl4Ad8Evr27fvGnC8JAmI/BN27d&#x2B;/BnTt3/AXR9xLnwuPTp08/JmnUl96N&#x2B;kyNbw3Zt0TQ04LwS9KfzgIA1hwULSeUpYtCkn8JCYk0DQSoDQJoycqnhexfDclOjWpAy3SS7EtIvFmIjY2hwYMHUr169alr1260bdu/1KtX75QvWIIA29jYcs268vq0b98&#x2B;&#x2B;vzzjkxuly9fSRERkTRs2FDatWsPHTp0kC5ePE87d/5HP/88jUkz2tyhBKB9&#x2B;3Y0d&#x2B;48DgjUqlWbCTHq&#x2B;StWrMTzRQs&#x2B;KAbgZo9lTJ06leX&#x2B;pu4lL0MO/8knn3A3BGT9e/XqQZ07d6GcOXNQ9uzZOejx/vsN2aTv/PlztH37vykCAFAsdO3aXZD3flShQgXy8vJM9iaIYEPDJLLvYnb5OXPm4jaL7u7XOFiCQMFrewkXiIyMjPDz87vn6&#x2B;t7/&#x2B;LFi74HDx70hVFfcnZfGvWlf6M&#x2B;c4EALYRfrRmflnLul0H4MyzpT88BAFPKAP3hli4YIvUSGQkJCYmXRv71/1Yy4oZZcshLFfmqVpm&#x2B;teNaOz9z363xQJDBAAmJlwdI&#x2B;VG3X6OG6ZZ9IO4w7CtcuAjZ2dnqjOgUoFXgTz/9SGPGjGFCrCgADh06QOPGjaeFCxfS/v37KCAggGvxv/66H9ftw9jv8887cXu&#x2B;4OAQlsq3bNlKEGg3drcHTLXhQ3cC1L9PnjyF5fHm4Ot7N0X2XAsePXokljOXyxawbgAy/kWLFqUpUybRgAGDuJQB92jU9W/fvp3vUcjmFyxYkN36mzb9UDc/KCkmT55IderUEwR&#x2B;I3l4eNKwYcPY0A/tDbUA5ROQ/b9qREdHRz19&#x2B;vTJ7du3fby8vAIPHTrkffLkyaD/s3cfYFbVd97A/xRBVCwICgpKk6Jii1EsYANBVKJRFxWzm&#x2B;ymvLvpMT0mm2SzJZvdJJu2m91NN/3dd0ssKIIKqID0DtLLDAy9iaDAe84xww6TW865c2e4M3w&#x2B;zzMPM3fuXKaemd/3/P/fs3z58ldD4y7VV9RXuUV9DRn2DfwCgLKGAvmWqxQ6428FAHBMQoDalwsN5KVcJjDtkJ/2MYoN4qXez/APTe9Xv/pV&#x2B;M///H/hP/7j/&#x2B;W9T3xWu3fvPuGmm24K7dufGA27bY76Eyne2/8v//LPYcyYMaFLl7PDjh07wuOPPx42bKgK557bPbn83F13jY6G4Z7JmfI4DHj44Y&#x2B;Ha6&#x2B;9Ljn7HQ/WdRv54&#x2B;E6rXzDf7wn/uDBQ9HTwfCtb30z/OY3//eo18e3x6FqPHjH4qLARx99NLz3ve890m0Q78H/8Ic/GF555ZXwxBNPhpEjbwvbtm0Pjzzy2eTSgePGjYs&#x2B;3rOSwCMe9ONSvnvueXsyyD/yyCNJMBKXHdZeFSDe&#x2B;/93f/fV5DKKn/3sI&#x2B;EHP/j3ZDtE7aX9KlH0vh2MPo5dmyLz5s1buWTJkvgyfGvmz5&#x2B;/a9&#x2B;&#x2B;fQeDor7GfLlQAFDsthDKU9QXQuEz/2kH/kob9o/Lgb8lBgCFvimL/WDVf/6QbwygMYf/LIN62m0BpW4FaMjHkzUkqLuyIctgX&#x2B;gqAkDpli9fluxVzzP8hcmTJydDavv27ZJhOV5OH5/tjofrWvGl5uIhPh52r7vuuvCRj3wonHnmmclZ&#x2B;ilTJifXo49L7&#x2B;JL&#x2B;g0dOjRZ6l67iuDCCy8s&#x2B;8cUbyP4xCc&#x2B;EQYM6J/s0d&#x2B;&#x2B;fccfHIf&#x2B;/M//T7jrrrvCqFG3J7fFRYN/&#x2B;7d/He67774kAIgLCT//&#x2B;c8lAcb3v/&#x2B;v4Y47bg8f&#x2B;MD7w969e8P48eOTz8uVV14Zve6fw733/tGR0sMXXngpnHzyScmy/PriFQ6vvfZauPrqq5OtDVdddVXFfT9En7s9O3bs2L5ixYp1M2fOXD1nzpyaxx9/fMO2bdveaITBXlFf9gAghMov6qu4gT86liWPER&#x2B;7aF4BQJZl//nSqlDkh75N/QOQEkCg3CFA2mCglOCglKAgazt/Ofbxl2NlAXD0sD5jxowwffr0ZLDMN1zGg3i7dickl5SLdehw0h/8URyfwY&#x2B;b6eMz8fEQPHHic8lAG&#x2B;/TjwOAjh1PSVYFHPkjsm3bZPB/443Xk1UAmzZtTK5LHy9Pj8OFuLW/rvpbCMotPiMfdxKcdtrpyTBfd3VB7bEkXs0Qfw7irQsf&#x2B;9jDSYlg/D7HJYOx&#x2B;LJ88ZaHOAh4xzseSvbY/&#x2B;Y3v07eLi7ci0OM97///WHjxk2hU6dORx47LiXMJ368YpdRbOLvmUObN2/eFD1tnT179opo4K966aWXaqLvoR3h&#x2B;Cnqy3W/5lTUV&#x2B;rtWYb9YoN5xZ3dP/ymI4EfzTcAKBQClPpY&#x2B;X4gDwVbAIBGGP4LXU6v1H3z5bhCQJr/qyGlfaUO9YZ&#x2B;yC0exufOnRtuueXN/eUbN24Mn/nMp0Lnzl1ytvPX&#x2B;vSnP5ns&#x2B;f/nf/5&#x2B;GDZsWDLQ1/6YzZ07J8R/K8eXlfvd7/4n/PEfvzPU1NQkTfzxfb74xb9MBuTLLrsi9OjR46hQ4Sc/&#x2B;XH47ne/lwQDn/3s547p5yYOAOLhP74EYBxu1D&#x2B;MHDhwICkznDr1pWTrQvfuPcKaNauSff61JXzRQBz27NkdbrjhhmTA/8IX/jIZ&#x2B;uOywbjnoFa&#x2B;8sFKtCf6gKKvbXX0tGny5MnL58yZs3nChAk1u3fvPhgU9YXQtEV9IZR&#x2B;dr9SivoKDexNOuz7jdCyA4BCYUDty2n3&#x2B;Yd6w36ug9Qh3xpAYwYCWQbmhi77T/N29YOIUq4UUP93cZatB2nCBjhexUP&#x2B;j3/8o2iI/0z4zne&#x2B;nZTR1QYA8bXj433u8eAaN8Nff/31ye1PPvlEcsY9vrRevM89PiMe/3zdd989YcqUF5Lr0MeX24vLAL/2tb9P9q9XVVWHWbNmJo8V3/&#x2B;jH/1I8vjxZQBPPvmU5Mx3fHu8UuBzn/ts&#x2B;PWvf5mc7Y&#x2B;XtTe1&#x2B;PKAy5e/Eu6&#x2B;&#x2B;&#x2B;1J6V687z7uBYiDjXi5fVyUV/eYNHv2rKR8MP78dOrUOek0iLcsxK37jz/&#x2B;5JH79enTOzzzzDPhBz/40ZFQoDmJvp6v10TWrl1btWzZsqrx48evnD9//o65c&#x2B;fuCor6FPU106X8hv3jNwDIugogzQ/9ofC/WwAO5QgGABo88Ge5DGCx&#x2B;&#x2B;V727oDfJrtBPkG/lLO&#x2B;hcb&#x2B;EvtMADeFJfGffWrfxfe&#x2B;c53he3btx/1MxMvw4&#x2B;vS//Zz34mDB36ZjP8c889Fx588P6knX7u3AVhyZLFSSHdTTfdHH7zm9&#x2B;En//858me97/6qy&#x2B;Gq666MjkzHocMcahw552jk/3vDz30UBI09O7dOwkQ6l7OLj7b/7a3vS25fF/chl9/qX1jid/PhQsXJv//X//1V8KcObPCv/7r95NQ4oYbboo&#x2B;R19Nnu/Xr1&#x2B;yRD8u6Kv19NPjkx6CWHxFg5tvvjm8613vSu4XBxq1Kxv69eufvD4ORirdwcjevXv3RF&#x2B;ndatWraqePn36umeeeWb9okWLdu3evfuNUFlFfWkeI9dQf7wX9eUKAtK&#x2B;Lu3AX5FL&#x2B;R35BQANGfrTHjSOCgF0AADlDgLSDNillgFm6QpIO&#x2B;g3ZOg3/EP5xGfye/XqmZylj89cx2V3teLn//Ivv/D7M&#x2B;BnJLfFl&#x2B;H7&#x2B;c9/GT7&#x2B;8YeT5fsnntghKa2LA4GBAwcm&#x2B;&#x2B;QvueTSMHbsO8LSpUvDF77whWTP&#x2B;4UXXhQ6dux45LFrr0lff7l7HDrceuuI5CmfOKiI/4aPz8j/&#x2B;te/Spbe5zqjHg/1c&#x2B;bMCW95y1uOBAnx8B0fG2pfrq6uThr5a2o2JVsUvvKVvwm/&#x2B;MUvwsKFi5Kz&#x2B;HHfwIoVr4SHHhqbvP/xqoe42X/48FuP/D/xxxmvbpg2bWryunhPfnw1gniVw/btW5NtA7F4xcMdd9x5pBOgkrz66qt7os/rjiVLlqxcvnz5pmjYXzNlypTNGzduPBAU9TXGsJ81AAhBUZ9hXwDQ6MN&#x2B;/W/gVkXuE3IcpFrnCQEAmmT4z3eZv6xDddoVAGn/nyxvnyU0yPW4&#x2B;a4SAMeDeIl9PCjnE5/x7tbtnCQIaNv26OK&#x2B;H//4x6F3715h8OCrQzQUJtehnzRpcnLZuriRP94yEC/1j1vv40E57gH4&#x2B;Mc/kQzXX/rSlxvl49m3b1/Stv&#x2B;hD30odOp0Znj22YnhwQfH5rzvzJkzwuc///no/f5lEhDEZ/C/9a1/Ch/&#x2B;8EeScsM4tPjtb3&#x2B;bfI7OPvussHLlqmQP/7x588MLL0wOY8eODfff/0C4&#x2B;&#x2B;67kmLDn/3s0eRx4&#x2B;b92sv6xa644vLw8MMfC888Mz488MADyQqI2Fe&#x2B;8pUkIKkVhyCf/Wz/Y/49ES/l3xGpqqraOGfOnJULFy7c9Pjjj6&#x2B;P/t0dFPUp6mvmRX2O&#x2B;gKAUof/VnleTtMFEAoc6FoHHQBAmQb/tIV&#x2B;aYb7hpT9lRIiZPkdnbXdP2uYAM1BvPd8xYoV4YwzTk&#x2B;a39P4v//3t2H9&#x2B;vXhIx/5aHKG&#x2B;y/&#x2B;4i/C5Zdfnuxtb926VfRYnaLB/&#x2B;Qj14w/4YR2R/28vPjiC8lQG5&#x2B;1ji9pN27ck&#x2B;Gaa64Nzz//bDRIfyc5wx7v37/uuuuTUrydO3eF0047tVE/Dzt37kyG9/gQMmDAgPC1r/1jEkLkErfw/&#x2B;QnPw3f/OY3kuAgXo4fbzn48z//i/DFL34hKeibMGFCUkoYf16rq6vCn/7pu6LP7znh/e//QPjQhz6cPM64cU/9/nP15pUG6jb0x9773veGa6&#x2B;9NglFzj&#x2B;/55Hb489NXXEQUyiMaSy7du3aEX3c25YtW7b25ZdfXhMX9T322GPV&#x2B;/fvPxQU9YWgqE9RH8d9ABCKJF3FigDrnvmvffmoDoDWrVv7hgXKFgSkGc5LKfsrdcBP85hptwlkGf4N/rRU27dvS4bM1atXhYcf/nhyVvrN27cnhXT5xJed27RpU/jgBz8YfvnLX4QtWzaHf/7n74Xvfvc7yVnv&#x2B;Ix2PETHjxMP1fFZ7v79//cMdbxXP76M3cMPPxwmTZqUnEW//vqhyaX56p4Br9WYw38cZMSXEIxXF5x4YvvksoPxx/aud/1J&#x2B;MY3vpmcXa8fmMTBQFzi9/zzzyWrE&#x2B;IgY9WqleHGG4cm2xviyxLee&#x2B;8fhbPO6pIs6Y9LBzdv3pxc8aDudoW4t6CQdu3ahyuueEtFfK/EZ/c3RqLPzZaZM2eunDZt2oboaUuds/uK&#x2B;hT1lWvYb7KB37DfjP4urZSvVY4/AlvVe75Vndta13m5dZ1/6z61yfFy/ae2df496mnbtm3fjX5h9/UtApQq/uM9PpOV7&#x2B;x91tK8rOWAWZ7PVyJYruG&#x2B;1CADmov40nHjxo0LvXr1Tgrz4rPI8WX1/uzP/jR8&#x2B;9vfSYb06dOnhc9//gvh05/&#x2B;VFLIF3vssd&#x2B;FD33og2H8&#x2B;AnJwB4Ptf/wD1&#x2B;LXn46dO7cOUR/jyRnxuM97HGJ3UMPvSP07z8g2TNfSb785S9FH&#x2B;e3kksCxkP8ddddE374wx8nn4dbbx0Wfve7x6L3&#x2B;cqj3uaXv/x5GDXqjmS//cc&#x2B;9tGwdu2a8Nvf/r/wyCOfjZ5fm1xWcMeO7clVBuLegWbq8M5I9PGsX7duXc1zzz23fPbs2ZsnT568bf/&#x2B;/QdD8yjqK3R/RX25g4C0r0s78FvKn/79OvJv7d8Y8WVBK&#x2B;39O5ZaWglgsR/0kOcAcSjHE0BZlDK457pP1gE7y3Cd6/FLHfbT/N8Gf1qaU06Jz0a3Cl/72lfDT37ys&#x2B;S2eDn7jBkvh5/97Cfhc5/7fPj6178eNm/eFL73ve8mZ&#x2B;rjwX7AgIHJ2frPfObT4fTTTwtTp05NiugeffQX4ZVXloUvfelLybA/ePDgZGn/mDH3N1nrfiHxxxUv9b/llmHhhRdeCP/93/8VDeyPhBNPPDEcPPhGshQ//rjiRv7LL78i9OjxZqFgXDb4yU9&#x2B;IrmKQFz&#x2B;98ADb3YDxI39Xbp0CRs2rAu33XZbcqa/OTpw4MBr1dXVm1atWrV&#x2B;6dKlVU8&#x2B;&#x2B;eTqhQsX7li&#x2B;fPmrQVFfYwz7&#x2B;e4TQsPO&#x2B;Be7PQRn92mmWkoHQP3bDxcY9FvVez7nVgBXAQDKOfzn2lOfpVm/IcN/qVcDyBdWFPo48j1O3bcz/NNS/e53/x1&#x2B;/evfJmf33/3u94SLLroofOtb304uVXf99c&#x2B;Hq6&#x2B;&#x2B;Ohp47w//8A//EN33d&#x2B;Ff/uXNZv6bbrolPP30U&#x2B;HMMzsn5XWf&#x2B;MQnk2E4vgRfPGBXytnvn/zkJ2HEiBHRkLs/&#x2B;jjGJEv4Z8yYHebOnRPe9a4/TZr1449r6dJloWfPnuFTn/pU2LVrR7j99juSjycWhx4HDx5MrmbwxBNPJN0G8f7&#x2B;ZcuWhY9&#x2B;9OHwvve9N/q4&#x2B;4Srrro6tGvXrqK/3q&#x2B;//vqBPXv27I6G/bXR&#x2B;1/18ssvr3/qqac2RM/viV53KCjqC6FlFvWleV2aId7ZfY7N36bNdAtA7eAewtFbAOJ/29R5Oc02gLrbAWqf2uzevfsnp5xyynm&#x2B;RYAG/HGYLN/Nt9y/ocv4s94/SyFh1hAiX&#x2B;CRtn8Amrt4yfoPfvDvyZnu&#x2B;DJ88QAb79WP96s/99zzyR7/MWPebJ6PL8EXN9E/&#x2B;ujPowH/5vDe974vrFmzJnTr1i1p/C&#x2B;HeLB&#x2B;7rnnkuK7&#x2B;Kx8PvEl99IEDPGl&#x2B;C677JLk8oIrV65Ilu3HqxXibQrxXv2f/OTHSddBvNR2woSJYc6cueGTn/x4cnm9b37zn5Jwo644PHjooQeT8r644&#x2B;Bv/uZvw3XXXZccM&#x2B;PLDlbSkt1au3bt2hm9f9sXLly4fMmSJfFl&#x2B;NZNnjx5y969ew&#x2B;Gxl&#x2B;qf6yK&#x2B;goN&#x2B;Ir60r2&#x2B;0JCvqK/MbAFoWQFA/SAgVwdA/SAgVydAoQDgyPPf/e53r7r55ptvPOeccy459dRTe/jTBiglAIiLu9IM/A0JAhryfJYhX9M/5Pdf//VfYcqUSUkTfXxGe/Xq1eHxxx9L9vTHe&#x2B;Hvvvvu8NOf/jTMmjUjbN68JSn3a8w/SidOnBg&#x2B;9alPhhdffClnq300tIYPf/hDSengv/3bD46coY&#x2B;vGhCHEcuWLU16C/r163/keDZ27IPJKoZ4C8LEiROit90SFi9enJyp79atazTAD0ma&#x2B;S&#x2B;88MLfv82B5KoF&#x2B;cRbCOJgoW/fPqFt2xMq6usZL&#x2B;WPhv1tGzZs2Dh9&#x2B;vQVixYtilv510df132h9KK&#x2B;xlzW3xyL&#x2B;kIoz/L&#x2B;Qm8bgqX8LXbYFwCUprlsAci35L/u63L9W2gbQP2ng3UChEPvf//7Z0T/zj777LM7vOc97&#x2B;l/yy23XD5gwIDLO3fu3Kdt27bt/akDZJF2oM/a3t/Q&#x2B;5QSGDTkqgDQ0sTlfHGR3wUX9Avf&#x2B;973wumnnx5&#x2B;&#x2B;9v/SJbJx2ffb7zxxmhoHhx&#x2B;9atfhl//&#x2B;lfJde//6q&#x2B;&#x2B;8gd/kMZn7F999dWyrQDYtm1r2L9/35G&#x2B;gHiwj1cp9O37Zr9xvA1h5syZyfu3Zs3qIwHA7373P8mlBeOVDHVb&#x2B;&#x2B;MQIV7mv3TpknDDDTcmhYfxyoH4agdxMWG83SH&#x2B;2OsqNPzH4lUE8VMliGb9rZs3b96yZMmSNS&#x2B;&#x2B;&#x2B;OLa&#x2B;DJ8Tz/9dE04tmf0FfUp6jPwU/6/SZvJCoAQCl8JoP5qgLrbAHJtAaj//FFn/0OebQHx05gxY8697bbbBl599dVv6d69e7/oF/WZvo2AXOIzZnEJWO0xLsvy/cY&#x2B;85/2igCFAoB8Z/0t/ed4Eg/1jz76aPjpT38WFixYkFwGr1evXn9wv/hMd3x5v/j69PG16&#x2B;sHAN///vfDihXLw1e/&#x2B;vdH/cwsX748ebw0xX/x8vn48WsH&#x2B;S984fNh1qw5ycvvec&#x2B;fJasUHn/8iSSQuP/&#x2B;Pwp/93d/n&#x2B;zVj/ftDxkyJBng4z368ZaB&#x2B;j&#x2B;3hw4dDH/8x38cDf83RB9jjzB16kshGpDDz3/&#x2B;i6SroDnZv39/XNRXFT1tnj59&#x2B;qopU6asnzVr1raVK1fuC41X1FeOZf2K&#x2B;ooP7s7uH&#x2B;esAGjZAUChHoCG9gG0qTf4t83xujaDBg067e677&#x2B;41fPjwyy&#x2B;44IIBXbp06RF9g7XxowfE4r219bcApB2miwUBjR0WFPs/i93f0M/xIj5zH4d98fXsSxUHhX/xF/8nGsDPCN/4xjfD7NmzwoEDr0eDePvwN3/z1&#x2B;E//uM/iwYA8RUDPvjBD4R/&#x2B;Zd/Tc7Wz58/LzzyyCNhxoyZ4dlnJ4bHHnssLFmyODnj/rd/&#x2B;9Xwznf&#x2B;SfRHcauwe/eeJAT4xS9&#x2B;mbMLID6OPfroz5KgIy73mzx5cvjhD38YfvSjH4WPfezh8IEPfKCivz4HIzt37ty&#x2B;atWqdWvWrIn37a&#x2B;Ihv2t06ZN2x7Ku1T/eCvqCw0MAIrdFoKiPgO/AKBRNPfLABZa/t/q9we71nUOfCEcvT0g33aA2ret3RZwMNf/PX/&#x2B;/B3R07wvf/nLCzt27Nhu1KhR59xzzz2DLrnkkoHRL9M&#x2B;0R8DJ/sxBNIO11mG81K3DGR5/7K8b/XP&#x2B;td/GVqq&#x2B;A/Lhgz/sXi7QDz8Dxs2PBm4P/KRD4e3vvWqcPnll4etW7emOvvfuXOXaCD/WBg37skwb9688I53vCPZmx&#x2B;XEMarAeK9/PHZ/Z/97Kdh0qRJSQlfvN3gtttGhU9/&#x2B;jN5iwBr/3CO7x9fxvDcc7uHz3/&#x2B;C&#x2B;Hhhx8OJ51UWX/mxANR9H6&#x2B;WlVVtfGVV15Zu3DhwvgyfGuif3du3LjxQFDUF4KiPkV9&#x2B;Ju0ma0ACAUG9nylgPVXAdQtCMy1JSBfMWDap&#x2B;Sxol/apz300EMDBg8e3P/CCy8cePrpp3cO&#x2B;XsMgBYo/kM&#x2B;PrNX6Cx/1sb&#x2B;rLdnfdw0QUKxTgCDP2T3jW98PRr63xquu&#x2B;76cMstNyXPX3bZ5eHf/u1fw8SJzx1133hlUXx8qd23H3cHxCsR4oH&#x2B;y1/&#x2B;Ynj22WfDL3/562i4Hxndd1s49dRTk/3/t99&#x2B;exgyZGhYtWpVuP7665MrFcSXIWyuomF/367IihUr1ixevHjDtGnTNjz99NNVivpKOvOfdbhvTkV9xYZ1S/lbECsAiqvkFQCHiwzMh&#x2B;sEAnXvm28VwOF6z9c9gOcLFg5meF9rHy8OAQ7Nnj17e/Q0PXp&#x2B;RvSLt92f/Mmf9LrhhhsuiH6hXxT9sj2nfXwBXOC4lHaZfNoz&#x2B;lnL/xoysGcNB4Di9u/fnyyp/8xnPh2&#x2B;&#x2B;MUvJcv077vvj8K6det//8fim3/SxI37P/7xD5OBf8SIkeGOO&#x2B;5M3v6xx/4nKey7&#x2B;OJB4cYbbwpPPfV06Nq1a/jc5z4XJkx4JrzvfX&#x2B;e3O/8889PLtXXTP&#x2B;oP7x9&#x2B;/a4mH9r9PfV8kWLFtVMnDhx/aRJk7aG8i2/b4yivrTPK&#x2B;rLHQQUe12aQCBtKNDkw76BHwFAaYFAvvb/fAerugfOVjmCgCzvT&#x2B;1T63r/tqkbCOzatevQt7/97WXR0/Lo5XG33XZb15EjR/a&#x2B;4YYbLu7Zs2eP6Bd9J9&#x2B;K0HKH/VLO7KcZ6vMN5OU6u9&#x2B;Q9n8gt9/85jdJyd7o0aOTl6dOnZpcBi/er79kyZLwne98O3n9oEGXhHXr1h11tige3h94YGxSuhef1a81fvwz4Zprrk2ej1cdXXrppcnb3XvvfclTc7Rv3769cSt/fBm&#x2B;l156acX8&#x2B;fM3P/HEE1U1NTUHgqK&#x2B;xhj2890nBJfhK9vAb9inIv42reAtACGkKwLMd2WAXMWAhcoBc/2bd4l/gfvmu&#x2B;pArqc2AwYMOGXUqFE9br/99ov69&#x2B;/f65xzzuneyl/R0CLES3Tj61xnvQJAlqCg2CBfyiUA0w7/Cv&#x2B;gsLiVv0OHDslTrdGj74wG&#x2B;7Vh&#x2B;vQZyVL&#x2B;eLn/N77xT2HYsGHJy3//919Nmv/HjBmTdAv8&#x2B;te/Do8&#x2B;&#x2B;vNCA0W4/vprwymndAwdO3aMHnda&#x2B;NnPfp609TcX8VC0ZcuWmo0bN25evHjx2smTJ6&#x2B;eO3fu1ujfbUFRn6I&#x2B;RX1k&#x2B;5wf&#x2B;dcWgNyaYwlg/aX/od7LhVYB1G4BqL8tIFfYkO//bpPj3/qP3yYcvQqgblhQt4Pg4JIlS3ZGT7u&#x2B;/vWvL47&#x2B;QGg7cuTIs&#x2B;&#x2B;5556Bl19&#x2B;&#x2B;QW9e/fueeKJJ3bwowzNV6GyvCyX/8syaOcLHOL/O/4lmPYyf6UEB8Cb4isDvPOdfxze977/Ey6&#x2B;&#x2B;OLQtWu3ZKD/5Cc/FR588P7w3HPPhmuuuSYp0lu4cEG48cYbw7vf/afRy6ckwWGPHj1CTc3mMHTo0KI/76NG3R6&#x2B;&#x2B;93vhvPOOy&#x2B;5ikClD//x2f1169ZtiNRMnTp1VTToV82ePXuboj5FfUVeX2jIV9QHaf82bYYrAGr/TbsKoO5tdc&#x2B;&#x2B;1y8GTLMaoHWR&#x2B;&#x2B;W73GDrFE/1Vym0vvTSS0&#x2B;9//77&#x2B;w4ZMqTfwIEDLzjjjDM6WR0AzUe8AmDXrl1Fl/cXWiGQJRTIuh0gbchQKFBwSIL84v33bdueEL7ylS8nzfnxMeHmm28J733ve5LB/qGH3hF&#x2B;8YtfhKqqDeGee&#x2B;4NN944NJx88snh7rvfHv76r/8mWc7ftm2b5Ox&#x2B;kcEjuVpAp06dKupM1&#x2B;&#x2B;DkAPbI3FRX/S0acKECStffvnlrQsXLtwdFPU196K&#x2B;tEFAmmG/2LBuKT9pvzZH/rUCILfmtgIgVw9ArlUAoc4BtXX4w5UBdW8/GP73bP3BHMFDvoNi7dvUrihoE45eXZDr5VyhQ94QYO7cudujpxnR87M6d&#x2B;7c7u1vf3v3ESNG9H/LW97Sv1ukXbt27f2YQ/OQ9qx/viE83&#x2B;MVu3/tL8CGLvF3mT9I7&#x2B;DBg2Hbtq3hlluGhWnTpoXq6upkr/&#x2B;PfvTDJBA46aQO4R//8evJfVeuXJGU/sWN/o8//mQ4//zzQseOb&#x2B;7vP/3001MfX6K/E475x33o0KGDe/fu3bNhw4bqJUuWrFmwYMGmJ554YvWiRYt279y58/Vw7Ir6ylXal6WorynP7re0or5i92vSYd/AT4v7m7SZrQCoe1uaVQB1ny/UC5Bzf37Kl1tlfF2uHoJcIUDBf4cNG9Z59OjR8eqAAb179z7/1FNPPd23M1SW&#x2B;Gzf7t27G7SfP0twUOixGmv/P3DUkJAM/zNnzkyG/rvuuiscOHAguRzfAw88EH73u/8JZ5zRKbzzne9MBvYnn3wy/NM/fTP69&#x2B;kwaNDFze7jffXVV/fsiCxbtiwe9tdPnz69&#x2B;qmnnqpW1Keor8RhvyIGfsN&#x2B;8z8O1/5rBUBubVvK17peQJCvJyBfL0Chx811UK979r91vefbhKPP&#x2B;udaAVB3ZUChgsJ8/4ZnnnlmY/S0KXr2pZ49e3a47777eg0fPrz/oEGDLjj77LO7Rt/wrR0CoHJkaf0vdc99uS8vmPZjAd701a/&#x2B;Xdi5c0c49dTTwgUX9Etuq6qqSs7ujxx5W3j3u99z5L4f/vCHwo9//KPw0Y9&#x2B;rFkM//HZ/S1v2jpr1qzl8&#x2B;fP3zhx4sSqGTNm7AyK&#x2B;hT1KeqD5vM3aYWvAKgd4nPd1qre63NdIaB1jucLDda5ztJnfb7YMv9CfQSpVwDk&#x2B;bdV69at24wZM&#x2B;bckSNH9r366qsHnHfeeT06dOhwkm91aHp1VwDkG/Rri/nSDOjl6gUodNwtRwkhHK/&#x2B;/d//LRr2zwpTp74YHnvssXDFFVeESZMmhT/7s3eHRx75fP2BOqxduyacd975FbdvPxYdu3bXRNauXVs9ZcqU5QsWLNj65JNPVkc3HwyK&#x2B;kJQ1Keoj4pkBUDLDgDqBwG5QoB8WwHSbAkoNLy3KfH1ac72Fx3yswQD11577emjRo06/5Zbbrmwb9&#x2B;&#x2B;vTp37tzFoQGaRrwUuO4WgLrHuqxdAA0Z/vMdX7M8jj3/kN6TTz4RPvShD4Z27dqFsWMfCh//&#x2B;MdDJdf2RMeqNzZFqqurN0WD/trnn39&#x2B;zZw5c7bNnj17V1DUp6hPUR8CAAFAhQUAuQKBUq8Q0KrAEF/srH3W&#x2B;2fe958iGCh4v&#x2B;7du584fPjwbnfdddeFgwYN6tMj0jZuIwIaPQAo15DfkK0CpXQHFDk&#x2B;A3ls3749nHjiiaFDh8q6mu&#x2B;hSFzUt3bt2nVr1qzZ9OKLL66eNGnShnnz5u1S1Keor0ggUCxAOGbDvoEfAUDLDwByDf0hRQiQawVASDlkty5we77goNhZ/TT7/TMN&#x2B;SHDqoGhQ4ee&#x2B;eCDDw5461vf2qdfv359TjnllFMdNqC8AcCePXtSD//FztSXu&#x2B;AvTReA4R&#x2B;at9dee23f1siyZctWr1ixomb8&#x2B;PGrpk&#x2B;fvmX16tWvhcop6sta2qeor/jArqgPAYAAoEUHAKEBIUCrkG2JfSln6Btypr9VaMCQX&#x2B;Dfo4KPuEhw7NixfYYMGdLnsssuGxhvFWgTcRiBhgUAe/fuLThwl3oFgELHzzRn&#x2B;ktp/gcq2&#x2B;uRPXv27Fq3bl3VggUL4mb&#x2B;6scee2zdkiVL9kSvOhSaZqm&#x2B;oj5FfWUd9g38CACOvwCglBCg2KUC0wQBeYflUMaz8CUO/yUN&#x2B;SFDkeD999/fffjw4b2vv/76C8&#x2B;JnHTSSac4pEDpAUA5hv9SB/g09637i9LwD83Drl27dm6PRAP&#x2B;6jlz5qx/&#x2B;eWXN44bN25jdNypxKK&#x2B;fOFA1jP9hQZ8RX3pXl9oyFfUhwBAANAsA4Bcw3/WECAUGbxLGc7TvL51hveh1GG/pCLB4cOHX9SrV6/zu8QVx0CqACDeAlD7i6ep9v9nCRfql/sZ/qEyxWf3N2/eXLNp06Yt0aC/fN68efFl&#x2B;DYuXrx4T2jY8vumWNavqC/dUK&#x2B;oDwQAAoAiAUBDQ4C6Q3O&#x2B;53MN8IWG76xDfLEtCKUGEaUM&#x2B;0Xv37Vr1/Z33HFH99GjRw/4fZHgeW3atGnrcAPpA4AsQUDWwr5yhQbAsbVz587tVVVVG1evXl09adKkldHAv2X8&#x2B;PE1OZbyK&#x2B;or78shlLa8v1AIEMKxP7tvKT8CAAFAiwkAyhECZFkNUKg7IO1wXyxgSHv/rKsEyl4kOGzYsM733ntvv6uvvrpffJlBRYJwdAAQbwGoP8hnKfXLOrSX8rYGfzi2DkSqI&#x2B;vXr69esGDBumeeeWbN/PnzdyxdunRvOL6L&#x2B;hpr&#x2B;M93nxAU9ZVt4DfsIwAQADQkACgWArQqEAaUEgLUHaoLDf9Zg4KQcrhPe1vaEsMmKRLs16/fyXfffXfP4cOH97/44osv6Ny581mKBBEA/G8HQP2Bu9Rl/1mKAHO9rWX/cOy88cYbcVHf7lWrVq2NnjZOmTJl9XPPPVe9aNGiPfv37z8Ymraor9zL&#x2B;uv//4r6/nCoVtQHAgABQBkCgLQhQLEwINQbbluV8amUgKChKw2OWZHgySeffMLtt9/e9c477&#x2B;z31re&#x2B;tf95553Xo0OHDic5LHG8BQC1WwDSLvPPesm/YsN/ltcB5RcdA/Zs3bp1SzTgr1y2bFnNU089tebll1/eumXLltfD8VnUl2X4L&#x2B;XlrCFBCC23qC9tAGDYRwAgAKjIAKCxQoD6g36xlwutFKgfHuR6vpwrC4rdVjFFgldeeeVp99xzT&#x2B;8bbrih/4ABA/qeccYZZzpEcTwEAPW3ABQa9hs6/Bdr8y90X6DhDhw48NqOHTt2rl27dsPcuXNXz58/f9Pjjz&#x2B;&#x2B;fvny5a8GRX2VXNSXJgRIGwSkGfaLDeaW8oMAQACQMgBIEwKEkH8VQGhAEJA2JMjyfDmCgaYuEiwaJHTu3Lndfffdd/6tt97a94orrhjQrVu3c06IOGRxvAYA5QgDsp7pN/hDw23fvn1rZNuiRYtWz5gxY93LL7&#x2B;8ady4cTWh9EI9RX2K&#x2B;o7psG/gRwAgAKi0AKDcIUD9gT/X0F8sCAih&#x2B;KqAcq0eKHfXQEUUCd5xxx1njxgxotfQoUMv7Nmz53mnnnrqaQ5ftNQAIOuwX0pRYNb7AsXt37//tY2R6urqzdOmTVsxe/bsjZMnT65ZuXLlvtC8ivqynulX1Nc4w35FDPyGfQQAAoDmEAA0JARo6iAg6wqChnQPlBoMHOsiwaMee9CgQR1HjhzZI3oaGOkdrw5I&#x2B;fWGig4A6h7r6g73aYf&#x2B;NMv6S3kZyPkH2qH4zP769eur4svwPfvss/HAvzUa&#x2B;LeF8p7Rb&#x2B;wQoKHL97Ms1y9231CGAKDYbSEo6jPwIwAQABy3AUCh4b9VnvtlvYJAKFMYUHcwLxYUNHTbQLMpEjzttNPaDRs27Kx77733wssuu6xPr169erZv3/5EhzaaawBQrPwv64qAYvc1&#x2B;EO6v8f2Raoi8bA/d&#x2B;7c9ePHj1&#x2B;zYMGCHevXr9&#x2B;fcVhv6qK&#x2B;hlySr9jQrqhPUR8IAAQAFRMANCQEaEgQUP/1uQb5coQB5VgpkHbbQJoOgbSrBEoe9tPc9/LLL&#x2B;84duzY/oMHD&#x2B;570UUXXXD66ad3cpijOQYAhYb/QoFA2qHfWX/ILy7q2xV55ZVX1ixfvrxqypQp6yZOnFhdp6ivsQZ7RX3lO7uvqM&#x2B;wDwKA4zAAyBoC5BvoCwUBuQb&#x2B;fCFBOa4wkPblcl2msFkXCY4dO7bXjTfe2PvKK68ceNZZZ3VtF3HYo1IDgCxn99Ms&#x2B;2/IZQLhOPpD8HA06&#x2B;/cvHnzlgULFqxYvHhxzbhx49bMnDlzR/SzebBMw7qiPkV9TTrsG/hBAHA8BwBNHQTku39DwoAQyrNVINfrKrlIsKyrBe68886uI0eO7HXDDTdc1KNHj&#x2B;6KBKm0ACDf4F5qEJBm6b/Bn&#x2B;PNvn37Xt2&#x2B;ffu2NWvWbJgxY8bqefPm1Tz22GPrN27ceCA0zVJ9RX2K&#x2B;so&#x2B;8Bv2QQAgAChPCJDrbRojDMg1qKe9rTF6BI5lkWDaob9BRYIXXXRRxzvuuOO8kSNHXjhgwIBeXbt2PcfhkEoJAEr5N&#x2B;1tdf&#x2B;t&#x2B;4sPWurfeZvfFJ/dXz1t2rT4Mnw1eYr6Slmqr6iveRf1pR34FfWBAEAA0EwDgIYEAYWG/1ZF7l9qGBBC9lLBXPdtnSIcqIQiwVJXCTTk8oOtTj755BNGjx7dLXrqf8UVV/SLLzPYrl07RYJUXACQdpl/2v3/hn9amn379u3dsGFDdVVVVc1LL720Mhr2N77wwgubf392X1Gfoj5FfYAA4DgNAMoZBJQjDMg34Ocb6rMM/4oEMwYJ11577el33313n6FDh/bv169fH0WCNGUAUH&#x2B;wL3UFQO0Z/nxBgeGfFvCz88bWrVu3rF69esPy5curJ0yYsHLOnDnbZs2atTMo6ivH8F/qfYrdliYESBsEpBn2iw3mlvKDAEAAcBwFAJUcBuQb&#x2B;tOEAVmH/xCavkgwzW1NUSRY8DG7d&#x2B;9&#x2B;4p133tlj1KhR/S&#x2B;55JILunXrds4JEYdOmiIASHsGvyEdAbYB0BwcikQ/J/HZ/Q0rVqzYMHv27A3jx49fu2DBgp3btm17IyjqC0FRn6I&#x2B;QAAgAKioMCDf47YqEhyUslUgFBnu0wQAx3uR4B88dnRgaDNs2LAu99xzT7/Bgwf36927d89TTjmlo8Mo5QgA6g/puQb2&#x2B;JdTrrP6WVYHFHq57mPDsRQX9e2MLFu2bNWSJUuq48vwTZgwYVNVVdVrofQ9&#x2B;Ir6FPUd04HfsA8CAAFA5QYA5QgDigUAx2qrQJrhX5FgitUC/fr1O3nMmDF9brjhhgsGDRrUr0sk&#x2B;h5tHSBjALBnz54jv3iKXQGg0GX/0oYBaY6rQgCa8Gfg4PZITU3N5jlz5qxYtGjRxqeeemr9jBkzdoamW6qf9oy&#x2B;oj5FfQZ&#x2B;EAAIAFp4ANAUYUC&#x2B;x86yVSBkGPxDqOwiwdYpb8&#x2B;ySiDL0J85HGjfvn2b&#x2B;&#x2B;&#x2B;/v8ewYcP6XHPNNQPPPffcc0488cSTHGLJGgDUH9qzLPPPGgAUO6YKAWgMuyPbtm3bunLlyvXTpk1bNW/evM2PPfZYVXTzwVDaGf0s91XUl3/wzlrUl&#x2B;X2EBT1AQIAAUAzDACO&#x2B;qK0atg7VOrlBYsFAmm3CmQZ/stVJJivU&#x2B;BYFQmWdNWANPcdOnTombfddtv5w4YNuzDeKtCpU6czHW7JEgA0dMgvtlJACEATfX8frKmp2RjZMn/&#x2B;/NVTpkxZO3PmzK2K&#x2B;kpa9p91uFfUZyk/IAAQADTWF6WJw4AQFAk2pEiwHKsEUgcJPXv27HDbbbd1v&#x2B;OOOwZedNFFvXtE4j4Bh1/qBgBp9vTXDwfyvVxs0C90uLIlgIb8eozP7q9bt25D9LTphRdeWDlt2rRN0dO2nTt3NlZRX6khQCnPt4SivjSDvaI&#x2B;Az8IAAQAAoAsX5RGDAPyBQIttUgwzbaBZlUkeMIJJ7S56aabuowZM2bAFVdc0Se&#x2B;zOBJJ510skOxAKDYFoBCgUCx0CBLEFB7W76rAwgCqHXgwIH9myMrV65ct2zZsurx48evnjNnzvalS5fuCZVZ1JcvHCilqK8ph/8Qsu/3LzTYK&#x2B;oz7IMAQAAgAGjML0qFrg5QJHjsigSPPHZcJPjggw/2HTJkSN&#x2B;4SPDMM8/sbHXA8RkA1F8BUOgSgA1d8p9ruM837Be6TKAw4PjxxhtvvB59n&#x2B;5Zu3bt&#x2B;mjYXx9fhm/cuHHrFy9evHvfvn0Hg6K&#x2B;fC8fyji4K&#x2B;prwmHfwA8CAAGAAKDRvygVsDqgqYoEc93neCoSzLxqoLZI8NZbb&#x2B;179dVXDzgn0qFDB0WCx0EAkOsygPkG&#x2B;0KrArIu7a//OGkvA5h2OwHN1&#x2B;7du3fFzfxLly5dNX/&#x2B;/OoXX3xxwzPPPLOp3lL&#x2B;NMO6or7Sh3tFfYZ9QAAgAGhpXxRFgkUDgEJFgsWeb9ZFgkOGDOl0xx139Lz55psVCbbwAKBYB0C&#x2B;ICDfffMdM/O9nPUsvxUBLcvrr79&#x2B;IG7lr66urpk5c&#x2B;aKBQsWbHrqqaeqFi9evCe0vKK&#x2B;UvbxF3q7hg73ivqc3QcEAAKA4ykAOIZhQAiKBJtNkWD37t1PfNvb3tZj1KhRAy&#x2B;&#x2B;&#x2B;OI&#x2B;5557bvc2EYfwlh0A1D6fa3Cve9/4mJTrF1ehJfwNGeyL3a9QoMCxt3Pnzu01NTVbVqxYsf7FF19cNWfOnM3jxo3b9Prrrx8OivpCUNSnqA8QAAgABABN/UVRJJipKyDX/SqxSLCU1QI5H3vUqFFn33XXXRcMHjy4f58&#x2B;fXqedNJJpzicN/8AoO5xLkvTf5ol&#x2B;Wn3/Gc5/pZyNQGaVnx2vzqyYcOGmnnz5q2eNGnS&#x2B;pkzZ25T1Keor8RhvyIGfsM&#x2B;IAAQALT4L4oiwaIBQGMVCbYqMLinCQFCKPPWgPqPfemll5565513nj98&#x2B;PABkb5dItG3S&#x2B;UcxSgaAOzevfvIkJ/2UoD5XlfKwF6OZf5pVwnQeA4dOnRwV2T16tXr1qxZszEa9le99NJLm2bNmrVz//79zbGoL9/bphnisyzXP1Rk&#x2B;FbUdwyHfQM/IAAQABz3X5TjuEiwdYnhQNYiwazBQMUUCXbq1OmEkSNHdnvb294WX2bwgh6R9u3bn&#x2B;hQX7neeOONP7gMYN1fRHWX8df90Y9fX3&#x2B;pfUPP0me9QkDWY7RQoLz27dv3ak1k2bJla5YuXbpx3Lhxq&#x2B;fOnbt9/fr1&#x2B;8OxLeorV2mfor7KObuvqA8QAAgABACVQpFgpgAgS3lgvhCg2RQJXnXVVafff//9F1x33XUX9O/fv&#x2B;9pp512hsN&#x2B;5QYAdVv4cy37L3RpwIYM6PX7BLJeEjBrRwDZHThw4LXfn91fv2jRonWzZ8&#x2B;uevzxxze88sore4OiPkV9ivoABAACgOMnADiGYUAIigQrrUgw72OeddZZ7ceOHdvrpptu6nPFFVcMOPvss7u2bdv2BL8GKiMASLPPP9&#x2B;S/8Zart&#x2B;UWwY42o4dO7Zv3bp1WzTsr5w7d27VCy&#x2B;8UDVhwoTNivoatagvZAgA0gz2lVTUV2hgN&#x2B;wDAgABgACguQYATRQG5AsEFAlmCwHSBASNViR49913nzNixIieQ4YMuei8887rfsopp5zqV0JlBwDFhu/as/T175dlhUCabQX57pv1/&#x2B;JN&#x2B;/fv37d58&#x2B;YtVVVVm6ZNm7Zi3rx5Nc8880z16tWr94XKL&#x2B;rLenY/yz5&#x2B;RX3lH/abbOA37AMCAAGAAKDlBgItqUgw60qBFlEk&#x2B;Ja3vOW0ESNG9Bg5cuRF/fr163n22Wd38&#x2B;uhadQvAcx1vKv/SyntMvwsw3yaY22h0KBYSJHrMeq&#x2B;7XEUChzesmXL1pqamk3Lli1b//zzz6&#x2B;OBv4tEydO3BKabql&#x2B;cyzqy/c4pQQCpdwWgqI&#x2B;Az8gABAACACaq&#x2B;OsSLCh4UCaUsEswUDaDoFjViQ4atSouEhw4CWXXNKnZ6RdxK&#x2B;LYxcANORyf2nDgUL/b9rjcJYrARwvlxB87bXX9m3YsKFq3bp1G2fNmrX22WefXRcN/NvXrl37WlDUV8rwrqivYUV9ZRn4DfuAAEAAIAAQCOR7WZFg8b6AY1UkmCpIuOaaa864//77&#x2B;w0ePLjvgAEDLjj11FNP86ujfOItAGkuA1hseM/6cpYQIctZ/trbi60&#x2B;SHPIaW5BwOuRXbt27VixYsXalStXbnz&#x2B;&#x2B;edXvfDCCzXz58/fHZpuqb6ivuZZ1JflfqHI/1PWYd/ADwgABAACgBb&#x2B;e1CRYN6Xj/siwa5du7Z/8MEHe9988819L7/88v5dunQ5&#x2B;4SIXyUNCwBqOwCKDf75jomlFO2Veqa/1PuWcsa/7u35Viwcw98Dh6Ov255NkSVLlqxevHhxfBm&#x2B;NXPmzNmxbdu2N0J5G/gV9eUfzhX1GfYBBAACAAFAMwgD8gUClVgkWI6VAk1ZJNgkqwWiA2Wb0aNHd7399tv7XnvttQN6RDpG/FrJHgAU2gJQ/4x/KUFA1kChXAN/oaG9uV01YN&#x2B;&#x2B;fa/u3Llzx6pVq&#x2B;Il/Gtnzpy58cknn6xav379a0FRn6I&#x2B;RX0AAgABgABAIJApEGiMrQIhKBJssiLBSy&#x2B;99NTRo0f3HD58&#x2B;MD&#x2B;/fv3Puuss872K6b8AUCWwbyUgb4xLilYjtUETfk7IB6Ktm7duiV62hoN&#x2B;ytnzJhR9dJLL1VPnjx5W2i6pfqK&#x2B;hT1lXXYN/ADCAAEAAKA5hQG5AoB0m4VKDb4h6BIsKyXH&#x2B;zYsWPbt7/97d1HjRrV78orr&#x2B;zfPdKuXbv2fmpyBwC7du1KfvEUOoNeygCedj9&#x2B;Q29LGwSU4//OdZnDhtq3b9/eeCn/unXrNk2dOnXF7Nmza5599tlNGzduPBAavvxeUZ&#x2B;ivlKGe2f3AQQAAgABgECgyOsbY6tACOXpCqg/9Je7SDDfbYUG9yYrErzxxhvPHD16dO&#x2B;hQ4cO7Nu3b8/TTjvtDD8x/xsA1K4ASDsMp1kVUMpAnvbSgaVcJrDcAUGxx8/n0KFDB7ds2bJ5w4YNm5YuXbouvgxfNPBvmzZt2vZw7Ir6SgkEFPUp6jPwAwgABAACgOMyDCg28Ocb5ovd3lKKBBu6SqBBWwPq3963b9&#x2B;Tb7/99u4jR44cMGjQoL5du3Y9p03keA4A4hUA9bcAlHM4L&#x2B;UKAWnv1xhL/rNetjDf66LbD8V799etW7d&#x2B;9erV1TNnzlz3&#x2B;8vw7aqpqTkQmmdRXyln&#x2B;hX1KeoDQAAgABAANPswIF8gkCUMCEGRYNZVAqV2C/zBY3bo0KHtsGHDzrr77rv7vfWtb72gT58&#x2B;vaPbTjqeA4B8S9wLdQKkCQeKDdWFHrfUEKHcVxIo9v/v379/347IsmXLVi9fvjy&#x2B;DN&#x2B;aSZMmbV61atWrQVGfoj5FfQAIAAQAAoAWFQgoEmzcIsEsWwRK2kYwcODAU8aOHdv3uuuuu&#x2B;Diiy/ud&#x2B;aZZ3Zu1dwuBl9CALBz586cKwDqH/fSDPGFQoE0A3jat2usIb7Q/eq&#x2B;Xwcje/bs2VVVVbVx4cKFq6KnTePGjVs7d&#x2B;7cXfv37z8YFPUVe1lRXwUO&#x2B;wZ&#x2B;AAGAAEAAIAwoXxiQKwRQJFh8&#x2B;8AxKRI8&#x2B;eST244dO/a8m266qc/gwYMHdou0b9&#x2B;&#x2B;Q0sOANIO1uVs&#x2B;097icEsQUDa24v9&#x2B;Nd9fTTs796xY8f2FStWrJs9e/aamTNnbnrqqaeqtm3b9kZo/KK&#x2B;rIFBQ8r5FPUp6gNAACAAEAAIBDKGAWkCAUWCjVMk2OCtAbn&#x2B;HT58eJcRI0acf/PNN1/Us2fP884444xOLSUAiAbbnL94spb6Zb1PuVv&#x2B;y9VJEJ/d37p1a01ky9y5c1e&#x2B;/PLLG6ZOnVoTDf07Q3n24CvqU9RXaJB3dh9AACAAEAAIAJpRGJBr4Fck2DyLBHOGD3GR4KhRo8694447Lho4cGCvc845p3vrSjpylxAApB32s55ZL&#x2B;eQ31iPtXv37l0bI&#x2B;vWrat&#x2B;6aWXVs2ePXvT888/v2Xnzp1vhMZfqp/1jH4pRX1pgwBFfdleX2jIV9QHgABAACAAEAakejlrGBBCZRcJFns&#x2B;bTBQLAQ4JkWC7du3b3vrrbeede&#x2B;99w644oor&#x2B;jS3IsE4ANi&#x2B;fftRHQDlOLufJkjIVfDXWP93nY/39c2bN29au3Zt9SuvvLLh2WefjQf&#x2B;7YsWLdodmv8ZfUV9&#x2B;Qd2RX0ACAAEAAIAKi4QUCSYvkgw65UGmqRIcNCgQR3HjBnTZ8iQIf0uuuiiCzp16nRm9O1SsasD6gYA&#x2B;Qb1QkN7lmLAcocJxQKEgwcPvvHqq6/uWbNmzfpVq1ZVzZo1a/2ECRPWxcP&#x2B;3r173whNU9RXzhAg11Cfdvn&#x2B;8VjUlyskKBYMhCKvs5QfAAGAAEAAIAxosjAgVwjQEooESw0GjkWRYOpVA6eddtoJ9957b/eRI0f2u/LKKwd069ata6UVCb7&#x2B;&#x2B;utHBQB1LwdYrK2/0OCfdrAvNuxn6RGIh/24qG/p0qWrly1bVj158uS1U6ZM2VxTU3MglH&#x2B;pfiUV9RUb8Evdq6&#x2B;oz9l9AAQAAgBfFBopEKjkIsFSAoJyFwmWu0OgyYsEb7zxxjPvuuuuvkOGDOnfu3fvnqeffvoZlRYAFBvIC4UAaQf4rEN&#x2B;/dvjpwMHDry&#x2B;e/fu7dXV1Rvnz5&#x2B;fXIbvqaeeWl9nKX9zLuqr/5gNKeordWl/qfcpdluaECDf/UsZ9osN5s7uAyAAEAAIADjmYUCugb&#x2B;lFAm2DtlWCrTIIsHzzjuvwz333HP&#x2B;iBEj&#x2B;g8aNOiCrl27nnMsigTjAGDbtm1/8IsnayFfQ87ip3k5GvZ3bI2sWLFi7axZs9bMnj275plnntm0b9&#x2B;&#x2B;Q0FRXwiK&#x2B;hT1ASAAEAAIADguwoB8gYAiwcouEjzqse&#x2B;5555zRo0a1feaa64ZcP7555930kknndyUAUBDWvwbOvzXvy0u6qupqdm4adOmmnnz5q2ePn36&#x2B;pkzZ25dvHjx7tC4S/UV9Snqa7SB37APgABAACAAEAg0RiCgSLD5Fgkm//9VV111&#x2B;u23337&#x2B;LbfccmG/fv16denS5azGDgCyDu5ZXl/ovvFQtGvXrh3V1dUb1q1bt/GFF16IW/lrpk6dum3//v0HQ2UV9aV5jFxDfWMW9TVWAFDsthAU9Rn4ARAACAAEAFR8GJArBFAkmK5IsCGrBErabtC1a9cTR44c2e3OO&#x2B;8ceNlll/Xp0aPH&#x2B;SdEyhkAbN26NefAnm9wb0jLfzTU79u8eXNN3My/bNmyqokTJ65euHDh9tWrV&#x2B;9rhMFeUV/2ACAERX2GfQAEAAIAAQDNIhBQJNgyiwSP3D5kyJBOY8aM6Td48OAL&#x2B;vXr17djx46nlSMAyHWcy7pPv354ED32gb179&#x2B;5eG1m&#x2B;fPmGOXPmbJgwYcKGFStW7IledygcH0V9ue7XXIv6Qsi&#x2B;pz/NsF9sMHd2HwABgABAAIAwoIRAQJFg4xcJptki0JBVAkde17179w7veMc7eg8dOrTv5ZdfPqBz585nt2nTpm2Wb5ADBw4cCQBqG/aLHfvyvbx79&#x2B;6dO3bs2Lp06dJV0VP11KlT10&#x2B;ePHnL3r1730g5VCvqK19RXwiln91X1GfYB0AAIAAQANCCw4B8gYAiwcooEix03yNPDzzwQPcRI0b0vuaaay4699xzu5988skd0wQAW7Zs&#x2B;YPhv1gQ8Prrr7&#x2B;2c&#x2B;fObdWRuXPnrli8eHHNhAkTqletWrU3ZD&#x2B;brqhPUV&#x2B;xgd1SfgAEAAIAAQACgUYKBBQJHvsiwTRvk&#x2B;99bzV48OAzbr/99vNuvfXWi3tFunTp0rVYAJDrWFf7fDTsR3fbsjka8OPL8K2eM2fO5okTJ9akGGZLDQEU9Snqa9Rh38APgABAACAAQBiQLgzIFQIoEmycIsE0qw0KBh3dunVrf&#x2B;edd54zevToiyIXdO/evWfbtm1PqA0ANm/eXH/vflzUV70xsmDBgpXTpk1bP3v27K11ivpCgaE1y5J5RX2FP5eK&#x2B;so48Bv2ARAACAAEAAgEiocBaQIBRYLlLxIMBe6TNrTI&#x2B;fkbNmxYl/vvv3/AVVdd1f/cc8/tV1NTc2DDhg1r1q9fXxUN&#x2B;yumT59eM3PmzO15hrA0y9KbKgRQ1New27MM&#x2B;8UGc2f3AUAAIACASskDyvi2igTThQQNKRJsrOG/VYavY7EzucWG4FJDgMYo6is04CvqS/f6NN8Tx2zYL&#x2B;PjAICAQgAgAEAYkCIMyPfYjVEkWGwlQLEAoJKLBBt7&#x2B;G/VgAAgy1ntw034VOqA35jDvaK&#x2B;xhv4DfsAIAAQAECFBQLHW5Fg1m0DWTsE0gQNhT6OQp/btANX2sG31BCg/iCvqK94EJD2dWkH/opbym/gBwABgAAAmn8YkCsEaK5FguW4wkDa29L0FeTd/x/SrdooNtRl2ePe0Pb9Si/qC6FhZ/yL3R6Cs/sAgABAAAAVHAg0ZKtAvkDgeCsSzPL6Qu9vCIW7FrIMZFmG4XKHArnu19KL&#x2B;tK8Ls0Q7&#x2B;w&#x2B;ACAAEABAk4QBxQIARYLZl/lnOevfqsjnJeuglnVwznKWXlFf/oE9zeuLBTaGfQBAACAAgIoJA/I99vFcJJjlKU0QkDaEOVxkSExzOcBSSgIbY/gPoTzL&#x2B;wu9bQiW8hv2AUAA0GBtfRmg8o4NDQgEshxVWuUYglrVeblVnseuP/AeLhAA5BuaQyhfkeCh8L9n6g/VeV2&#x2B;59Oc5S&#x2B;2GqFQ0FHq1yzN1QDSDuWK&#x2B;goP75byAwDHJSsAoJn9zJbxbY/lVoEQmrZIsP4Q3zpk22qQNshI&#x2B;7lNO6Q2dDuAoj5n9wGACmELgAAAjlUgUI6tAiE07yLBrJcmTPNxNORrkmVIbooz94r6Gn/YN/ADgACgSdkCAM38OFJiGNDQrQK1tx8OhbcK5Hr7&#x2B;sP04TzDdtrhv9BjHK5330MhXcfAoZCtv6BQAJBlBUCpKwHKERCEoKjPsA8AtGhWAEAL/dku49u2xCLBWOtQ&#x2B;raDfO9jucKYYmfKs24NKBYQpH27Qm9baKgvx1L&#x2B;YsO6pfwAQEWzAgBotONLmQfSYmFBcysSjNUtD8wy8KfpOmjo163U4b9QIBBC5Rb1pQkE0oYCx2LYN/ADAM2CAACOv0CgVQPf9nDKMKB&#x2B;INCq3mPk2yoQctw/X3jQ0OLArNsPQii&#x2B;9L9VA74&#x2B;WffBl7Oor9DjhaCoz7APAAgAAGFAykAgVxgQCgz9h/MM6YdD4xQJpj3jX6j1v1XGz&#x2B;3hDM9nGcwV9ZV3UDfwAwACAKBFhQFZA4HmXiRYLCAIIf2&#x2B;/0KDf6mXAWxoABCCoj7DPgBA3T9MlQACRYb2crxtpRUJFhr&#x2B;C90vy/tX6tCZZaDOujWg0FCvqA8AoBEpAQQq&#x2B;hjVgECgORQJZhn&#x2B;C92e637lDAAKDehpQoAQjk1RX7H7NfWwb&#x2B;AHAI57AgCglOGpJRQJhiYY/luVOPiWsuw&#x2B;6xl8RX0AAAIAgIoIA3IN7uUoEqw70KcJBELIvuy/IaslslwGL&#x2B;tAr6gPAEAAAFC2wavSiwTrv65YUJB28G9V5s9lQ1cENOT1Wd4Xwz4AgAAAEAgc89UBrXK8Pl8YUH&#x2B;wb1XgY0lb&#x2B;NeqAQNs2r30ivoAABAAABUVBmQNBJqqSDDN60OeUKHYx9Yq48eXZuDOOsgr6gMAQAAAHNNA4FgXCaYJBA7nebxWRf6/VhmG2SzL78s17FfKwG/YBwAQAADCgLKEAbmG8cN5Bvw071uxYKAxP0dpBvhKHvYN/AAAAgCAY7ZVoO7zhbYMFAsGSnm/03wcaQf3wynfLs3/YdgHABAAAByTQKApVgfkGqhb5QgImnroPZzx5VKGe0v5AQAEAAAVFwZkDQRKGUxbFRmeW5Xh/cr6/pbSJWApPwAAAgCgxQQCDVkdUEoo0NAhvbGG78Z8nwz7AAACAIBmHQbkGm5bFRiwW6UMCBpz2G6K8MHADwAgAABoNmFAuQKBYsFA/bcr5//ZFMO5YR8AQAAA0KICgVZlfKzGfD9DC/h/AAAQAABURBhQq1UT/T&#x2B;V9DEDACAAADjuNFUoYMgHAEAAANCMB&#x2B;pWFfA&#x2B;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&#x2B;leydGfg&#x2B;zoAAAAASUVORK5CYII=" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>